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Flavonoids are known to interact with a number of membrane transporters, 
influencing the rate of intestinal nutrient absorption.  The transcriptional effects and 
consequences of such interactions remained to be fully elucidated.  To address this 
we carried out gene expression microarray analysis on intestinal Caco-2 cells treated 
with a flavonoid-rich berry extract (0.125 % w/v for 16 h).  This microarray analysis 
identified alterations in numerous specific nutrient pathways, three of which were 
selected for further study, namely: 1) glucose, 2) iron and 3) copper.  We then 
determined the effects of berry flavonoids on the expression and function of these 
transport pathways using qRT-PCR, Western blotting and functional assays. 
We found:  1) Chronic treatment (16 h) with flavonoids decreased the expression of 
glucose transporter genes (GLUT2 and SGLT1) and induced an acute (15 min) 
inhibitory effect on enterocytic glucose uptake. 2)  Chronic treatment (16 h) with 
berry extract modulated the expression of genes that regulate iron uptake (down-
regulation of DMT1, DCYTB and HFE; up-regulation of TfR1).  Iron transepithelial 
transport was decreased by both acute (15 min) and chronic (16 h) berry extract 
treatment.  3) Chronic berry extract treatment (16 h) decreased the expression of 
genes that coordinate copper uptake (CTR1, HAH1, ATP7A and ATP7B).  
However, copper uptake was increased by both acute (15 min) and chronic (16 h) 
berry extract treatment.  
Thus overall, there is a clear effect of flavonoids on the pathways of glucose, iron 
and copper and a possible interactive effect between these nutrients themselves.  
Further research into the functional and physiological relevance of our findings will 
aid in optimising the dietary management of conditions such as diabetes and 
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DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
ECL Electrochemiluminescence 
FBS Foetal bovine serum 
FPN Ferroportin/ iron-regulated transporter 1 
FU Fluorescence units 
GAE Gallic acid equivalence 
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GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GCOS GeneChip Operating Software 
GLUT Family of facilitative glucose transporters 
GLUT1 Glucose transporter 1 
GLUT2 Glucose transporter 2  
GLUT3 Glucose transporter 3 
GLUT4 Glucose transporter 4 
GMNN Geminin, DNA replication inhibitor 
GO Gene ontology 
GOI Gene of interest 
GPRC5A Retinoic acid-induced protein 3 
HAH1 Human antioxidant protein 1 homolog  
HbA1c Glycosylated haemoglobin 
HBSS HEPES buffered salt solution 
HDL High-density lipoprotein 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HEPH Hephaestin  
HFE Human haemochromatosis protein 
HIF Hypoxia-inducible factors  
HIF2α Endothelial PAS domain-containing protein 1 
HKG Housekeeping gene 
ICP-OES Inductively coupled plasma atomic emission spectroscopy 
IPA Ingenuity® Pathway analysis  
IRE Iron-responsive element 
IRP Iron regulatory proteins 
KCNJ8 K
+
 inwardly-rectifying channel, subfamily J, member 8 
KCNMB3 Calcium-activated potassium channel subunit beta-3 
LDL Low-density lipoprotein 
MBSS MES buffered salt solution 
MES 2-(N-morpholino)ethanesulfonic acid 
mRNA Messenger RNA 
MRS2 Magnesium transporter MRS2 homolog, mitochondrial 
MSR1 Macrophage scavenger receptor 1 
MT Metallothinein 
NCLN Nicalin 
NEAA Non-essential amino acids 
NOX1 NADPH oxidase 1 
nt Nucleotides 
ORAC Oxygen radical absorbance capacity 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PODXL Podocalyxin-like protein 1 
PROCR Endothelial protein C receptor 
PRRG1 Proline-rich gamma-carboxyglutamic acid protein 1 
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qRT-PCR Quantitative real-time polymerase chain reaction 
RHBG Rh family, B glycoprotein 
RIN RNA integrity number 
RNA Ribonucleic acid  
RNase Ribonuclease  
ROS Reactive oxygen species 
RT Room temperature 
RT buffer Reverse transcription buffer 
SDS Sodium dodecyl sulfate 
SDS software Sequence detection system software 
SEM Standard error of the mean 
SFXN3 Sideroflexin 3 
SGLT1 Sodium/glucose cotransporter 1 
SLC Solute carrier family 
SLC10A2 Ileal sodium/bile acid cotransporter 
SLC12A2 Sodium/potassium/chloride transporters 
SLC24A1 Sodium/potassium/calcium exchanger 
SLC25A37  Mitoferrin-1 
SLC26A2 Sulfate transporter 
SLC33A1 Acetyl-CoA transporter 
SLC36A1 Proton/amino acid symporter 
SLC3A1 Cystine, dibasic and neutral amino acid transporters 
SLC4A7 Sodium bicarbonate cotransporter 
SLC6A20 Proline IMINO transporter 
SLC6A4 Neurotransmitter transporter, serotonin 
SLC6A8 Neurotransmitter transporter, creatine 
SVCT1 Human vitamin C (L-ascorbic acid) transporter 
SYNGR1 Synaptogyrin 1 
TE Trolox equivalents 
TEMED Tetramethylethylenediamine 
Tf Transferrin 
TfR1 Transferrin receptor protein 1 
TfR2 Transferrin receptor protein 2 
TGN Trans-Golgi network 
TM4SF1  Transmembrane 4 L six family member 1 
TPCN1  Two pore segment channel 1 
TR Sweet taste receptor 
TRPV1 Transient receptor potential cation channel subfamily V member 1 
TSPAN7 Tetraspanin-7 
U937 Human monocyte cell line 
ZIP2 Zinc transporter 2 










1.1 Dietary flavonoids 
1.1.1 Flavonoid biochemistry 
The flavonoids are low-molecular weight polyphenolic compounds that are formed 
in plants by combining synthesised derivatives of phenylalanine and acetic acid.  The 
shikimic acid pathway is the main route by which flavonoids are synthesised, 
alongside many other products such as tryptophan and tyrosine (Knaggs, 2003).  In 
this pathway phenylalanine is synthesised from phenylpyruvate which is transformed 
into trans-cinammic acid and hydrolysed to p-coumaric acid.  Then, p-coumaric acid 
is condensed with 3 units of malonyl-Coenzyme A to form a chalcone.  Subsequent 
hydration and ring closure of p-coumaric acid and malonyl-Coenzyme A leads to the 
formation of flavonoid compounds (Aherne & O’Brien, 2002; Knaggs, 2003). 
The structure of flavonoids is based on a nucleus which is composed of three 6-
member carbon rings.  As illustrated in Figure 1.1, the benzene A-ring is condensed 
to the C-ring which can be either a pyran ring (anthocyanidins, catechins and 
flavanols) or pyrone ring (flavones, flavonols and flavanones).  The C-ring carries 
the phenyl benzene B-ring at the 2 position, which contains functional groups that 
can dictate species and biochemical properties of flavonoids (Prior & Wu, 2006; 
Xiao et al, 2011). See Figure 1.2 for functional groups that dictate structural 
classification of flavonoid species that are important in this work. 
The basic structure of flavonoids allows for conformational flexibility and a variety 
of chemical interactions and structural substitutions.  Thus, the biochemical nature 
and biological activities of flavonoid compounds will typically depend on structural 
class, hydroxylations, substitutions, the structure and positions of sugar moieties and 
their metabolites (Chen et al, 1996; Hollman et al, 1999; Prior & Wu, 2006).  The 
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basis of dividing flavonoids into structural classes is mainly on the degree of 
oxidation of the C-ring (Figure 1.3).  The main substitutions that flavonoids undergo 
during their synthesis include glycosylation, hydroxylation and hydrogenation at 
several positions.  One of the major effects of the conjugation patterns in the C- or 
B-rings is on the hydrophillicity or hydrophobicity of the flavonoid molecule (i.e. 
glycosylation increases hydrophillicity) (Sivakumar et al, 2009; Xiao et al, 2011). 
It is common for flavonoids to be found in nature as glycosylated compounds, often 
at the C-3 or C-7 positions, with D-glucose.  Glycosylation increases flavonoid 
hydrophillicity as the polarity of the flavonoid molecules increases.  This property is 
necessary for storage of flavonoids in plant cell vacuoles.  Whilst stored in plants, 
flavonoids are relatively resistant to heat, dryness and oxidation, although they are 
still photosensitive (Aherne & O’Brien, 2002; Sadilova et al, 2007). 
 
Figure 1.1. The basic flavonoid nucleus. Flavonoids consist of three 6-member 
carbon rings, identified as A, B and C.  The benzene A-ring is condensed to the C-
ring.  The C-ring can be a pyran or a pyrone ring and is also the common site for 
moieties.  At position 2, the C-ring is conjugated to the B-ring. These rings carry 
functional groups that dictate flavonoid classification and properties. (adapted from 




 R1 R2 R3 R4 R5 R6 R7 
Flavonol     -OH =O   
Quercetin -OH -OH -H -OH =O -OH -OH 
Chalcone*     =O   
Phloretin -H -OH -H -H =O -OH -OH 
Phloridzin -H -OH -H -H =O -O-glucose -OH 
Anthocyanidin†  -OH  -OH  -OH -OH 
Delphinidin -OH -OH -OH -OH -H -OH -OH 
Malvidin -OCH3 -OH -OCH3 -OH -H -OH -OH 
Cyanidin -OH -OH -H -OH -H -OH -OH 











Figure 1.2. Functional groups that distinguish the structural characteristics of 
important flavonoid species. Flavonols are characterised by presence of a hydroxyl 
group at C-3 and a pyrone C ring. *Chalcones are characterised by a pyrone C-ring, 
with an open configuration between C-9 and C-2, ring closure of a chalcone during 
biosynthesis leads to formation of other flavonoid species. †Anthocyanidins are 
characterised by 4 hydroxyl groups at C-4’, C-2, C-5 and C-7 and a pyran C-ring; 
anthocyanidins are also functionally distinguished with a positive charge on the C-
ring oxygen.  
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Figure 1.3. Major flavonoid structural classes. The structural classification of a 
flavonoid will depend largely on the degree of hydroxylation of the C-ring.  Note 
the pyrone C-ring configuration for flavones, flavonols, flavanones and 
isoflavones, whilst for anthocyanidins and catechins the C-ring is a pyran (adapted 
from Aherne & O’Brien, 2002). 
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1.1.2 Flavonoid intake 
The main dietary sources of flavonoids in the western world are fruits, vegetables, 
red wine and tea (Hertog et al, 1993; Johannot & Somerset, 2006; Song & Chun, 
2008).  The flavonoid content of fruits and vegetables will depend very much on 
cultivar, skin to volume ratio of the fruit and other factors (Nyman & Kumpulainen, 
2001; Chira et al, 2009). 
Nutritional data regarding the intake of flavonoids is mainly based on quantifying the 
flavonols quercitin, myrictin and kaempferol and the flavones apigenin and luteolin.  
As flavonoid species consumed in the diet are much more diverse than those 
typically measured it can be assumed that the reported intakes may be 
underestimates (Aherne & O’Brien, 2002).  There have been numerous studies 
estimating varied levels of intake in several countries; see Table 1.1 for a brief 
summary. 
Table 1.1 demonstrates the very high variability in flavonoid intakes, both between 
and within countries and over time. Variations have been attributed to the multiple 
quantification approaches that can be applied. Quantification of flavonoid intake will 
start with estimating consumption using food frequency questionnaires, diet records 
or food balance sheets; which may give different results (Mullie et al, 2008). 
Following this, the determination of flavonoid content in food is problematic. This is 
because different standards are used as estimates of flavonoid content (e.g. United 
States Department of Agriculture, Food and Agricultural Organisation).Furthermore; 
very few flavonoid species are included for quantification. Typically 5-10 flavonoids 
are included in intake estimates; these include flavonols (quercetin, myricetin, 
kaempferol) and flavones (apigenin, luteolin). However there are more than 5000 
species of flavonoids that are ubiquitously distributed in the human diet. 
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Belgium F 166-203 - Mullie et al, 
2008 
Fiji M & F 18 - Lako et al, 2006 
Finland M 131 - Mursu et al, 
2008 
Greece M 16 Vegetables, fruits, 
tea, wine 
Hertog et al, 
1995 
Holland M & F 23  Tea, onions Hertog  et al, 
1993 
Ireland  177 - Beking & 
Vieira, 2011 
Italy M 23-34 Vegetables, fruits, 
tea, wine 
Hertog et al, 
1995 
Italy M & F 134 - Tavani  et al, 
2006 
Italy M 153 - Bosetti et al, 
2009 
Spain M & F 313 Fruits, red wine Zamore-Ros et 
al, 2010 
UK M & F 182 - Beking & 
Vieira, 2011 
USA M 13 Vegetables, fruits, 
tea, wine 




14 Tea, apples, 
broccoli 
Yochum et al, 
1999 
USA M & F 190 Tea, wine Song & Chun, 
2008 
USA M & F 60 - Cui et al, 2008 
USA M & F 190 Tea, citrus fruit 
juices, wine  
 
Chun et al, 2007 
USA M & F  
(13-15 y) 




1.1.3 Flavonoid bioavailability and intestinal metabolism 
The metabolism of flavonoids has been extensively studied both in-vivo and in-vitro.  
Flavonoid absorption through the intestinal epithelium has been demonstrated by 
several lines of evidence, however there is still confusion regarding whether there is 
preferential absorption of aglycone or glycosidic forms (Aziz et al, 1998; Manach et 
al, 1998; Hollman et al, 1999; Arts et al, 2002).  With respect to glycosidic forms, 
Hollman et al (1995, 1999), demonstrated that the absorption of flavonoid glycosides 
was largely dependent on the nature of the sugar moiety.  For example, quercitin 
rutinoside has only 20% of the bioavailability of quercitin glucoside.  Thus 
conjugation to a glucose molecule enhances absorption of flavonoids (Hollman et al, 
1995; Hollman et al, 1999). Conjugation to a monosaccharide (i.e. to glucose, not to 
a disaccharide such as rutinose as is the case with rutin) implies the recruitment of 
active glucose transporters in the transport or cotransport of flavonoid glycosides 
(Johnston et al, 2005). Conversely, aglycones can be absorbed by facilitative 
diffusion, whereas conjugation to disaccharides will require further metabolism (e.g. 
deglycosylation, glucuronidation) prior to complete absorption. Therefore the 
bioavailability of flavonoids that are conjugated in a complex manner may be 
hindered due to further steps in preabsorptive metabolism (Hollman et al, 1999; 
Spencer et al, 1999; Johnston et al, 2005). 
It has been speculated that absorption of glycosides or aglycones will occur through 
different pathways, i.e. by active or diffusive mechanisms, respectively.  The 
hydrophobic nature of flavonoid aglycones allows them to be absorbed passively by 
diffusion or facilitated diffusion across cell membranes.  Conversely, for the more 
polar glycosylated flavonoids an active transporter is required.  The sodium/glucose 
cotransporter (SGLT1) and bilitransclocase have been implicated in the cotransport 
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or transport of flavonoid glycosides; and aglycones are suggested to diffuse through 
the facilitative glucose transporter (GLUT2) (Walgren et al, 2000; Passamonti et al, 
2002).  In light of this, aglycone forms of flavonoids are made readily available by 
intestinal enzymatic action (Day et al, 1998; Day et al, 2000).  Therefore, the effects 
of glycosylation on flavonoid absorption may be negligible. 
For a schematic overview of the intestinal cellular metabolism of flavonoids see 
Figure 1.4a.  Typically the first stage in flavonoid intestinal metabolism is the 
deglycosylation of the flavonoid glycosidic forms.  Lactase-phlorizin hydrolase and 
1-β-glucosidase are two enzymes localised in the intestinal brush border that have 
been shown to deglycosylate flavonoids within the gut lumen (Day et al, 1998; Day 
et al, 2000). Parent compounds may also be absorbed unaltered, cellular metabolism 
involved several other reactions including: hydroxylation, methylation and 
conjugation (Spencer et al, 1999). Following these reactions flavonoids can be 
effluxed back into the lumen or are released into circulation. For the estimated 
proportions of flavonoids that undergo metabolism or are directly release into the 
lumen or into circulation see Figure 1.4b.  
Jejunal tissues have been found to have the highest transport efficiencies for 
flavonoids (Talavera et al, 2004; Matuschek et al, 2006). Flavonoids that have not 
been metabolised by luminal enzymes nor absorbed in the small intestine undergo 
bacterial degradation in the colon.  Colonic microbacter metabolise flavonoid 
glycosides to aglycones and phenolic acids which are easily reabsorbed 
(Bokkenheuser et al, 1987; Hollman et al, 1995; Walle et al, 2000).  The final step in 
flavonoid metabolism is the excretory pathway.  When in polar forms flavonoids are 
excreted in urine or secreted in bile. Flavonoids secreted in bile will undergo further 




Figure 1.4b. Proportions of flavonoids that undergo 
metabolism. ~ 75% of luminal flavonoids will be absorbed, the 
majority undergoing cellular metabolism. > 50% of the initial dose 
will be metabolised and rereleased back into the lumen. ~ 20% will 
be glucuronidated or sulfonated and released into circulation. ~ 
1.5% of the parent compound reaches circulation. Various sources, 



























Figure 1.4a. Enterocyte flavonoid metabolism. 1) Luminal flavonoids enter cells unaltered or undergo 
deglycosylation by bacterial or endogenous enzymes, influx will be either carrier mediated or by endocytosis 
2) intracellular flavonoids are destined for immediate efflux or for downstream metabolism prior to efflux 3) 
metabolism involves hydroxylation, sulfonylation or glucuronidation 4) flavonoids can reach circulation by 
transporter mediated basolateral release or by paracellular diffusion  5) flavonoids can also be release back into 














Figure 1.5. Schematic overview of flavonoid digestion & absorption. 1) 
Flavonoids enter the stomach mainly as glycosylated compounds from dietary 
sources. 2) In the small intestine is the highest efficiency of flavonoid absorption, in 
the digestive tract flavonoids will undergo deglycosylation, glucuronidation, 
oxidation among other enzymatic reactions. 3) After systemic distribution 
flavonoids are metabolised by the liver, undergoing hepatic phase 2 metabolism, 
flavonoids can be secreted in bile. 4) Flavonoids that are not absorbed/ metabolised 
in the small intestine, as well as flavonoids that are secreted in bile will undergo 
bacterial degradation in the large intestine to a final product of easily absorbable 
aglycones or phenolic acids. 5) Polar flavonoids can also be excreted in urine 
following metabolism. Various sources, e.g. Das & Sothy, 1971; Bokkenheuser et 
al, 1987; Hollman et al, 1995 
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1.1.4 Health effects of flavonoids 
There have been numerous reports on the health promoting and protective effects of 
flavonoids on lipid metabolism, neurodegenerative decline, cancer cell proliferation, 
nutrient bioavailability, cardiovascular health and glycaemic control among many 
other effects (Vuorela et al, 2005; Mursu et al, 2008; Renis et al, 2008).  This 
section will briefly review some of the current research into the health promoting 
and protective effects of flavonoids in-vitro and in-vivo.  Further sections will 
specifically discuss the effects of flavonoids on intestinal tissues and nutrient 
interactions which pertain to the subject of this thesis. 
1.1.4.1 In-vitro studies on the health effects of flavonoids 
The flavonoids have a number of mechanisms that can lead to their antioxidant 
effects; namely these are the chelation of metal ions and the direct interaction with 
reactive oxygen species (ROS). When chelating metal ions, flavonoids decrease the 
abundance of reactive metals which catalyse Haber-Weiss-Fenton reactions. When 
interacting directly with ROS, flavonoids are capable of donating hydrogen from a 
hydroxyl group, thus decreasing ROS reactivity (Nijveldt et al, 2001). The above 










 Presence of a metal ion will provide a destination for the electron to be 




; which is then donated from the metal to catalyse H2O2 
degradation. Flavonoids will chelate metal ions, preventing the electron exchange.  
2) Flavonoid–OH + R– → Flavonoid–O– + RH 
In the above reaction flavonoids will donate a hydrogen from reactive hydroxyl 
groups to an ROS (annotated R above) forming more stable products. This 
36 
 
antioxidant effect is physiologically important in preventing the oxidation of 
biological substrates which are potentially damaging; e.g. low-density lipoprotein 
(LDL) oxidation (Nijveldt et al, 2001).  The in-vitro investigations on flavonoids 
have generally focused on these antioxidant properties and the molecular reactions 
they can induce; this is discussed in the ensuing section. 
 A series of preclinical studies using extracts from raspberry, rapeseed and pinebark 
found multiple properties that were of putative benefit for health (Vuorela et al, 
2005).  For example, rapeseed and pinebark phenolic compounds and raspberry 
anthocyanins had antioxidant properties towards liposomal membranes (Vuorela et 
al, 2005).  Rapeseed phenolic compounds are effective free radical scavengers in 
diphenylpicryl-hydrazyl tests (Vuorela et al, 2005).  Furthermore, raspberry and 
pinebark phenolic compounds are effective inhibitors of LDL oxidation (Vuorela et 
al, 2005).  These phenolic compounds also inhibited the formation of pro-
inflammatory mediators and the growth of some bacterial strains (Vuorela et al, 
2005).  
A study by Renis et al (2008) investigated the molecular effects of anthocyanin 
glycosides and aglycones on cell growth, formation of ROS, cell-cycle/stress protein 
modifications and DNA fragmentation in Caco-2 cells.  Aglycone anthocyanins 
decreased ROS formation at all concentrations (25, 50, 100 and 200 µmol/l), whilst 
the glycosides had the same effect only at the lower concentration tested (25 µmol/l) 
(Renis et al, 2008).  The studies by Renis et al (2008) showed that both aglycone and 
glycosides counteract oxidative stress, with the latter being more effective.  It was 
concluded that anthocyanin aglycones exert their chemoprotective effects by a ROS-
dependent mechanism.  Conversely, when anthocyanins are conjugated to a sugar 
moiety the interaction is ROS-independent (Renis et al, 2008).  
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Renis et al (2008) suggested that flavonoids will mediate their antioxidant effects 
through separate mechanisms, depending on their glycosylation. The aglycone 
mediates a cytoprotective effect by directly modulating ROS levels and through the 
induction of DNA-repair pathways (e.g. P53, Ataxia telangiectasia mutated genes). 
Whereas the glycoside derivative was cytoprotective without modulating ROS 
levels, and had a more direct protective effect on DNA. This was observed after 
inducing stress to naked DNA and observing a protective effect against 
fragmentation. This can be attributed to intercalation capabilities of flavonoids, 
providing direct protection from radicals, as well as increased stability and cross-
linking of DNA structures (Renis et al, 2008; Kanakis et al, 2007). 
1.1.4.2 In-vivo animal studies of the health effects of flavonoids 
The in-vivo animal studies with flavonoids are commonly focused on investigating 
the metabolic and systemic potential of flavonoids, such as the cardiovascular and 
glycaemic effects.  This section presents a few recent studies that investigated such 
related themes. 
Studies have compared the effects of berry anthocyanins on markers of metabolic 
syndrome in experimental C57BL/6J mouse models (Prior et al, 2008; Hsu et al, 
2009).  Prior et al (2008) used a murine model of obesity based on high-fat feeding.  
They showed that the addition of purified anthocyanins to the high-fat diets reduced 
weight gain, body fat and fasting plasma glucose relative to high-fat fed controls 
(Prior et al, 2008). The aforementioned study did not address the mechanisms behind 
their findings; however another study in adipocyte cell lines found that anthocyanins 
induce adiponectin expression (Tsuda et al, 2006). High adiponectin expression 
prevents adipocyte differentiation and increases energy expenditure thus contributing 
to the decreased weight gain (Bauche et al, 2007). 
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Similar effects were reported by Hsu et al (2009), where mice were fed a high-fat 
diet with or without rutin and o-coumaric acid.  Supplementation with the phenolic 
compounds resulted in less weight gain and decreased serum lipid profiles, insulin 
and leptin concentrations (Hsu et al, 2009).  In addition, hepatic biomarkers and 
antioxidant capacity were beneficially altered, i.e. decreased malondialdehyde from 
lipid peroxidation, trolox equivalent antioxidant capacity was increased, increased 
glutathione, with increased ratio to glutathione disulfide, increased activity of hepatic 
antioxidant enzymes glutathione peroxidase, glutathione S-transferase and 
superoxide dismutase (Hsu et al, 2009).  Thus, the results indicated anthocyanin 
suppression of dyslipideamia, hepatosteatosis and oxidative stress induced by a high-
fat diet (Hsu et al, 2009).  Other studies investigating the cardiovascular effects of 
flavonoids in diabetic conditions found proanthocyanidins reduced markers of 
glycation damage (advanced glycation end products and their receptors) and 
decrease the number of degenerated mitochondria whilst maintaining myocardium 
fine structure (Cheng et al, 2007). The general metabolic effects associated with 
flavonoid intake were attributed to their abilities to act as antioxidants and to their 
involvement in pathway activation. The above studies have demonstrated the 
modulation of antioxidant enzyme levels, adipocytokine expression, glycation, 
glycation products and receptors; all of which had a measurable and physiologically 
relevant response in animal models. 
1.1.4.3 In-vivo human studies of the health effects of flavonoids 
Similarly to the in-vivo animal studies on the effects of flavonoids, experiments in 
humans tend to focus on the metabolic and systemic effects of flavonoids.  Such 
studies have included a variety of tissues and conditions, e.g. cardiovascular disease, 
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osteoporosis, oxidative stress, inflammation, diabetes and cancer (Scheiber et al, 
2001; Chambers & Camire, 2003; Di Giacomo et al, 2009; Holt et al, 2009).  
Flavonoids have been beneficially linked to oxidative capacity both in athletes who 
are expected to encounter oxidative stress, and in normal subjects (Di Giacomo et al, 
2009; Holt et al, 2009).  Consumption of fruits and vegetables, rich in antioxidants 
such as isoflavones and lycopene, is correlated with decreased markers of 
inflammation and oxidative stress (Holt et al, 2009).  In athletes, supplementation 
with lycopene and isoflavonoids increases plasma antioxidant capacity, decreases 
lipid peroxidation and improves plasma non-proteic antioxidant defence (Di 
Giacomo et al, 2009).  
Beneficial effects of flavonoids on the cardiovascular and skeletal systems have been 
reported in a prospective clinical trial involving a twelve week supplementation with 
isoflavone-rich soy (Scheiber et al, 2001).  Mean lag time of LDL oxidation 
increased and correlated with serum phytoestrogen concentrations (Scheiber et al, 
2001).  In the same study, plasma high-density lipoprotein (HDL) cholesterol and 
serum osteocalcin were both significantly increased.  The ratio of total cholesterol to 
HDL cholesterol was decreased and negatively correlated with the urinary excretion 
of isoflavones (Scheiber et al, 2001).  
Although numerous in-vitro studies have found evidence of flavonoid and dietary 
sugar interactions, few studies in humans have investigated the effects of flavonoids 
on glycaemic regulation.  For example, a small study by Chambers & Camire (2003) 
investigated the effects of cranberry-extract in patients with type-II diabetes who 
have good control of their blood sugar with diet alone.  No differences were 
observed in fasting serum glucose, HbA1c, fructosamine or blood lipids after 6 or 12 
weeks of supplementation.  However, insulin levels in the cranberry supplemented 
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group were significantly decreased.  Differences in some biomarkers may not have 
been significant due to small sample size (control n=13 and treated n=14), low 
dosage and an already good level of glycaemic control among subjects prior to 
participation (Chambers & Camire, 2003).  Prospective studies with interventions at 
different stages of the disease, such as during insulin resistance rather than after the 
development of diabetes, may yield more significant or meaningful results. 
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1.2 Dietary glucose 
1.2.1 The roles of SGLT1 and GLUT2 
Intestinal glucose transport is the primary step in glucose metabolism. It is adaptable 
to luminal and systemic factors in-vivo, thus maintaining the metabolic milieu of the 
tissue and thus the whole organism (Gouyon et al, 2003; Tobin et al, 2008).  
Classical mechanisms of intestinal glucose transport state that apical uptake is 
initially by the sodium/glucose cotransporter member 1, SGLT1.  This occurs 
through a downhill sodium ion gradient which is maintained by a sodium-potassium 
ATPase at the basolateral membrane of enterocytes.  SGLT1 is capable of 
transporting glucose against its concentration gradient when luminal glucose 
concentrations are higher than blood glucose concentrations (Debnam & Levin, 
1975; Díez-Sampedro et al, 2004).  Following entry into the enterocyte, glucose 
undergoes basolateral release at the high-capacity low-affinity facilitative glucose 
transporter member 2 (GLUT2).  GLUT2 transports glucose, as well as fructose and 
galactose (Cheeseman, 1993; Helliwell et al, 2000) (reviewed by Kellet et al, 2008). 
The apical SGLT1 uptake pathway is saturable and phloridzin-sensitive. A diffusive 
component of apical glucose uptake also exists which has been attributed to apically 
localised GLUT2 (Kellet & Helliwell, 2000).  Current models suggest that GLUT2 
translocates to the apical membrane under conditions of high luminal glucose to 
increase uptake by up to 3-fold more than SGLT1-mediated transport alone (Corpe et 
al, 1996; Kellet & Helliwell, 2000; Gouyon et al, 2003).  Under healthy conditions, 
GLUT2 is retracted from the apical membrane in response to insulin signaling after 
plasma glucose increases (Tobin et al, 2008).  However, in insulin-resistant states, 
GLUT2 is permanently localised at the apical membrane and does not respond to 
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insulin signaling.  Therefore glucose influx is greatly increased with the permanent 
apical localisation of GLUT2 (Corpe et al, 1996; Tobin et al, 2008).  In fact, this 
permanent apical presence of GLUT2 is popularly used as an experimental model of 
insulin resistance in mice (reviewed by Kellet et al, 2008; Tobin et al, 2008; Ait-
Omar et al, 2011). 
Typically, low concentrations of glucose are absorbed efficiently by SGLT1.  When 
luminal concentrations of monosacharides are above the saturation limits of SGLT1, 
then any GLUT2 that is not saturated is recruited to the apical membrane to aid in 
uptake (Kellet & Helliwell, 2000; Gouyon et al, 2003; Chaudhry et al, 2012).  The 
translocation of GLUT2 occurs rapidly, within 1-2 minutes of sugar sensing.  This 
occurs following a signaling cascade from sweet taste receptors and the voltage 
gated calcium channel, (Cav1.3).  Cav1.3 induces an accessible cytoskeleton for the 
trafficking of proteins (Mace et al, 2007; Mace et al, 2009).  After the uptake of 
sugar, GLUT2 is internalised by insulin-dependent mechanisms (Kellet et al, 2008; 
Tobin et al, 2008).  The ability of GLUT2 to translocate and the kinetics involved 
with the apical GLUT2 pathway are factors that make it a candidate for the 
previously unexplained diffusive component of glucose uptake (Kellet & Helliwell, 
2000; Kellet et al, 2008). 
1.2.2 Importance and regulation of the GLUT2 transporter 
As well as the intestine, GLUT2 is localised to several other tissues including the 
liver, pancreas, kidney and brain (Gould & Holman, 1993; Goestemeyer et al, 2007).  
In these aforementioned tissues, GLUT2 has similar capabilities to process high 
concentrations of glucose in a bidirectional flux owing to its high-capacity, low-
affinity, and translocation properties.  The regulation of GLUT2 is complex; it 
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responds to calcium, sweet-taste receptors, glycaemia, insulineamia, and paracrine 
and endocrine signaling (reviewed by Kellet et al, 2008; Leturque et al, 2009). 
The capability of GLUT2 to traffic between membranes facilitates a considerable 
bidirectional flux of glucose.  The importance of this transporter protein and its 
influx and efflux capabilities is demonstrated by its redundancy in Fanconi-Bickel 
syndrome.  Fanconi-Bickel syndrome results in sugar intolerance, growth 
retardation, hepatomegaly and nephropathy, among other effects (Santer et al, 1997; 
Leturque et al, 2009).  Furthermore, the deletion of the GLUT2 gene in mouse 
models is fatal (Guillam et al, 1997).  
The initial phases of enterocytic glucose uptake occur through SGLT1 (Figure 1.6).  
When SGLT1 activity increases, under conditions of high glucose (also detected by 
apically localised sweet taste receptors) there is an increased intracellular ATP: ADP 
ratio. This increase causes closure of the basolateral ATPase, which initially 
maintains SGLT1 activity, and depolarisation of the apical membrane.  This 
depolarisation activates Cav1.3, in-turn causing an influx of calcium ions into the 
cell.  The increased intracellular calcium content causes a rearrangement of the 
cytoskeleton, making it accessible to protein trafficking, and a terminal web that is 
available for GLUT2 insertion (Mace et al, 2007; Morgan et al, 2007; Mace et al, 
2009).  This rearrangement allows for GLUT2 to attain its apical localisation when 
stimulated (Figure 1.7).  Following translocation, flux of dietary glucose greatly 
increases and this in turn increases plasma glucose which activates insulin signaling.  
Under normal conditions, GLUT2 is retracted from the apical membrane in response 
to insulin signaling (Tobin et al, 2008) (Figure 1.8). 
The response of GLUT2 is an example of the molecular adaptability of enterocytes 
to the local environment (i.e. the luminal contents). When GLUT2 is apically 
44 
 
localised, the enhanced glucose accumulation affects downstream molecular events 
(Uyeda & Repa, 2006). These include the transcription rates of genes with 
carbohydrate response elements, such as L-type pyruvate kinase (Yamashita et al, 
2001). These regions associate with carbohydrate response element-binding proteins 
(Noordeen et al, 2010).  
Figure 1.6. SGLT1 and GLUT2 mediated glucose transport under normal 
conditions of low luminal glucose.  1) Under states of low luminal glucose (e.g. 
between meals) SGLT1 adequately co-transports glucose and 2 sodium ions along 
a downhill sodium gradient. 2) The downhill sodium gradient is maintained by a 
sodium/potassium ATPase at the basolateral membrane of enterocytes. 3) 
Intracellular glucose can be utilised for cellular metabolism or is effluxed via 
basolateral GLUT2. Under these conditions, apical GLUT2 is localised to 
subapical vesicles and does not function to influx glucose. SGLT1: sodium/glucose 
cotransporter; GLUT2: facilitative glucose transporter 2; Cav1.3: voltage dependent 
calcium channel; T1R2/T1R3: taste receptors 2 & 3. Adapted from various sources 





Figure 1.7. Activation of the apical GLUT2 pathway of glucose transport 
across enterocytes.  1) A high luminal glucose concentration (e.g. following a 
sugary meal) will increase SGLT1–mediated glucose and sodium influx. 2) The 
resulting high intracellular glucose and sodium content closes the basolateral 
sodium/potassium ATPase, in turn activating the Cav1.3. 3) High intracellular 
calcium and sodium cause the cytoskeleton to rearrange, allowing protein 
trafficking. The apical membrane depolarises and is prepared for GLUT2 insertion 
from the subapical vesicles, insertion of GLUT2 is signaled by apical sweet taste 
receptors. 4) High influx of glucose results from apical GLUT2 recruitment and 
therefore there is a higher rate of glucose release into circulation from basolateral 
GLUT2. SGLT1: sodium/glucose cotransporter; GLUT2:  facilitative glucose 
transporter 2; Cav1.3: voltage dependent calcium channel; T1R2/T1R3: taste 
receptors 2 & 3. Blue dashed lines represent activation; red dashed lines represent 








Figure 1.8. Retraction of the apical GLUT2 pathway of glucose transport 
across enterocytes.  1) Following the apical recruitment of GLUT2, the increased 
circulating glucose stimulates the secretion of insulin from the pancreas. 2) 
Secreted insulin acts on insulin receptors in enterocytes. 3) Insulin causes the 
retraction of GLUT2 from the apical membrane back to subapical vesicles, GLUT2 
can undergo degradation. SGLT1: sodium/glucose cotransporter; GLUT2:  
facilitative glucose transporter 2; Cav1.3: voltage dependent calcium channel; 
T1R2/T1R3: taste receptors 2 & 3; IR: insulin receptor; INS: insulin. Blue dashed 
lines represent activation; red dashed lines represent inhibition. Adapted from 
various sources. (e.g. Tobin et al, 2008) 
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1.3 Dietary iron  
Iron is an essential element in the human body as it is an integral component of 
several enzymes and proteins.  These include, most importantly, the role of iron in 
haemoglobin as the oxygen carrying protein in blood.  Iron deficiency causes 
anaemia and insufficient oxygen delivery to cells and tissues, whereas iron excess 
can cause haemochromatosis.  The latter can lead to several conditions such as 
cirrhosis and cardiomyopathy.  The uptake of iron from the human intestine is 
mediated by complex interactions between several proteins localised in cells of the 
intestinal epithelium.  The uptake mechanisms of dietary haem iron are different 
from those of dietary ionic iron (i.e. non-haem iron) (reviewed by Wang & 
Pantopoulos, 2011).  Our focus is on the intestinal uptake of non-haem iron and the 
ensuing discussion reflects this.  
1.3.1 Iron uptake and transepithelial transport 
A number of important genes and proteins are involved in transepithelial transport of 
ionic iron in enterocytes.  These include the apically localised uptake proteins 
duodenal cytochrome B reductase (DCYTB) and the divalent metal ion transporter 
(DMT1) (Canonne-Hergaux et al, 1999; McKie et al, 2001).  Localised basolaterally 
is the regulatory complex denoted as HFE-β2m-TfR1 (Figure 1.9). This complex is 
comprised of the haemochromatosis protein (HFE), transferrin receptor 1 (TfR1) and 
β-2-microglobulin (β2m), it is typically expressed in crypt enterocytes and in mature 
enterocyte cell lines.  This complex is a putative regulator for DMT1-mediated iron 
uptake and for the interaction between transferrin (Tf) and its receptors (TfR1/TfR2) 
(Feder et al, 1998; Arredondo et al, 2001; Arredondo et al, 2006).  The proteins 
responsible for basolateral efflux of iron are the iron channel ferroportin (FPN) and 
the ferroxidase hephaestin (HEPH) (McKie et al, 2000; Anderson et al, 2002a).   
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When dietary ferric iron (Fe
3+
) enters the intestine it is reduced to ferrous iron (Fe
2+
) 
by DCYTB at the apical membrane of enterocytes (McKie et al, 2001).  Iron can 
then be easily imported into the cell by DMT1 (Han et al, 1995).  A transcytotic step 
is necessary prior to the transfer of iron across the basolateral membrane.  FPN is the 
exporter of intracellular ferrous iron at the enterocyte basolateral membrane.  HEPH 
oxidises ferrous iron to its ferric form before iron is bound to Tf and then circulated 
systemically (De Domenico et al, 2007a).  A schematic representation of the overall 






Figure 1.9. Structure of the regulatory HFE-β2m-TfR1 complex.  TfR1: 
transferrin receptor 1; HFE; haemochromatosis protein; β2m: β-2-microglobulin.  























Figure 1.10. Transepithelial transport of dietary non-haem iron across 
enterocytes.  1) Luminal Fe
3+
 is reduced by luminal reductants or by apical 
reductase DCYTB.  2) Fe
2+
 is influxed as a substrate for DMT1.  3) Fe
2+
 will 
become part of the intracellular pool of iron. 4) Fe
2+
 is effluxed via FPN and 
oxidised by HEPH. 5) Fe
3+
 is bound to Tf for systemic distribution. 6) The HFE—
TfR1-β2m complex is thought to inhibit Fe absorption by re-routing Fe from Tf or 
by inhibiting apical DMT1-mediated uptake. DCYTB: duodenal cytochrome B 
reductase; DMT1: divalent metal ion transporter 1; HFE: haemochromatosis protein; 
FPN: ferroportin; HEPH: hephaestin; Tf: transferrin; TfR: transferrin receptor; FT: 
ferritin; LIP: labile iron pool. Adapted from various sources (e.g. Han et al, 1995; 
McKie et al, 2001; De Domenico et al, 2007a). 
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1.3.2 Maintaining iron homeostasis 
Several factors are involved in the regulation of iron uptake, such as the interaction 
with other metals, vitamins and flavonoids.  Molecular factors such as protein 
interactions and systemic factors such as feedback signals from body iron stores also 
contribute to this homeostatic control.  The effects of ascorbate and flavonoids on 
iron uptake are discussed in Section 1.5.2 and in Chapter 5.  This section reviews 
briefly the systemic and molecular factors that influence iron homeostasis to 
maintain body levels and distribution as in Figure 1.11. 
Figure 1.11. Typical distribution and use of total body iron.  FT: ferritin; HS: haemosiderin 
(Geissler & Powers, 2005). 
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The systemic regulation of iron is very much dependent on increasing or restricting 
iron uptake and absorption (Yamaji et al, 2004; Wang & Pantopoulos, 2011).  
Hepcidin, a hepatically expressed peptide, negatively regulates enterocytic iron 
transport into the body by inhibition of DMT1-mediated uptake or by inducing the 
internalisation and degradation of FPN (Nemeth et al; 2004; De Domenico et al, 
2007b).  Hepcidin also acts on macrophages.  When levels of hepcidin are high 
macrophages retain iron, as FPN is not available to release cellular iron. Low 
hepcidin levels will cause macrophages to readily release iron (Chaston et al, 2008).  
Hepcidin is abundantly expressed following iron intake and during inflammation.  In 
contrast, hepcidin levels decrease in states of iron deficiency, anaemia and hypoxia 
(Wang & Pantopoulos, 2011).  HFE and TfR2 are proteins also thought to be 
necessary for the iron dependent activation of hepcidin.  However, their mode of 
action remains unclear (reviewed by Lee & Beutler, 2009). See Figure 1.12 for a 
summary of the systemic regulation of body iron and the involvement of hepcidin. 
Other molecules involved in the cellular regulation of enterocytic iron uptake include 
HFE and TfR1; both of these are highly expressed in crypt cells (Anderson et al, 
1990; Parkkila et al, 1997).  The precise mechanism through which HFE regulates 
iron absorption has not been thoroughly characterised.  However, it is thought to be 
mediated through formation of the HFE-β2m-TfR1 complex.  Formation of this 
complex either decreases the affinity of Tf for TfR1, or reduces TfR1 cycling-time 
(Feder et al, 1998; Ikuta et al, 2000).  The formation of the HFE-β2m-TfR1 complex 
is sensitive to the whole body iron pool in a feedback loop between hepatic hepcidin 
and the intestinal epithelium (Brissot et al, 2004).  
HFE may also be a direct negative regulator of DMT1, by a hypothesised interaction 
between DMT1 and the HFE-β2m-TfR1 complex causing decreases in apical iron 
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uptake (Arredondo et al, 2001; Arredondo et al, 2006).  It has been found that HFE 
transfected Caco-2 cells have a decreased labile iron pool and cellular iron content, 
whilst apical iron uptake is decreased independently of DMT1 expression.  
Furthermore, DMT1 expression increases in Caco-2 cells transfected with HFE, 
therefore making HFE as a primary rate-limiting protein of iron uptake (Arredondo 
et al, 2001).   
Transcriptome analysis of differentiating Caco-2 cells indicates variability in several 
of the genes mentioned above during stages of differentiation (Bédrine-Ferran et al, 
2004).  As HFE is expressed in crypt cells, which are undifferentiated epithelial 
tissue, it was hypothesised that HFE expression (among other genes) will be 
responsive to body iron stores throughout the differentiation process (Bédrine-Ferran 
et al, 2004).  Indeed in the study by Bédrine-Ferran et al (2004), HEPH, DMT1, 
FPN, and Tf were all up-regulated during differentiation.  It is possible therefore that 
HFE may be part of a signal transduction cascade that will dictate the iron uptake 
capacity of mature villi enterocytes (Bédrine-Ferran et al, 2004).  
Given the regulatory mechanisms in place for the absorption of iron, there are no 
known mechanisms for the regulated disposal of excess body stores of iron. The only 
known processes are the unregulated exfoliation of cells, such as intestinal epithelial 
cells, and through menstrual bleeding. Therefore, regulating the iron absorption 






















Figure 1.12. The systemic regulation of iron homeostasis. Hepcidin is a key 
regulator of iron homeostasis. During states of high iron, hepcidin levels increase; 
this signals the degradation of macrophage ferroportin and limits the intestinal 
release of iron from what is absorbed from the diet. When sates of iron are low this 
signals a decrease in hepcidin levels thus increasing intestinal release of iron into the 
body and allowing macrophages to readily release iron. 
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1.4 Dietary copper 
Copper is an essential trace element in the human body and has multiple functions 
for example forming parts of proteins and enzymes (e.g. Cu-Zn superoxide 
dismutase, ceruloplasmin, hephaestin).  Copper deficiency can have detrimental 
effects including iron anaemia, impaired growth and osteoporosis.  Copper overload 
can be toxic and is often a consequence of genetic abnormalities such as Wilson’s or 
Menke’s disease.  Both uptake and excretion of copper is tightly regulated, mainly 
through the hepatointestinal pathways.  This section discusses the enterocytic role in 
copper uptake and the main regulatory mechanisms in maintaining body copper 
levels.  Dietary copper can also interact with other nutrient such as flavonoids; this is 
discussed in more detail in Section 1.5.2 and in Chapter 6. 
1.4.1 Copper uptake and transepithelial transport 
Copper can be apically absorbed into enterocytes via copper transporter1 (CTR1) in 
its reduced form. Alternatively, both cupric and cuprous copper might be substrates 
for DMT1 (Gunshin et al, 1997, Lee et al, 2002; Arredondo et al, 2003).  Copper is 
reduced through interaction with the Steap proteins, DCYTB or other reducing 
agents (Wyman et al, 2008; Ohgami et al, 2006).  Cellular copper must then be 
bound to a chaperone molecule, such as antioxidant protein 1 (HAH1) (Walker et al, 
2002).  HAH1 delivers copper to the copper transporting ATPase ATP7A which can 
export copper or utilise it in the trans-Golgi network, the site of enzyme cupration 
(Petris & Mercer, 1999; Hamza et al, 2003).  Another copper transporting ATPase 
found in enterocytes is ATP7B (Yamaguchi et al, 1996).  The role of ATP7B in 
intestinal cells is unclear, though it is thought to be involved in copper delivery to 
HEPH, cupration of other metalloenzymes and copper efflux (Walker et al, 2002; 
Lörinczi et al, 2008).  A schematic representation of the transport pathway of copper 




























Figure 1.13. Intestinal transport of dietary copper through enterocytes.  1) Cu
2+
 is 
reduced by luminal reductants or by apical reductase activity (e.g. DCYTB) and influxed 
by CTR1 and bound to an intracellular chaperone.  2) Copper bound to CCS is delivered 
to Cu/Zn-SOD.  3) Copper bound to HAH1 is delivered to ATP7A or ATP7B which will 
function to cuprate metalloenzymes in the TGN. 4) ATP7A (and possibly ATP7B) will 
efflux copper at the basolateral membrane. 5) Effluxed copper is bound to histidine (Hist) 
for systemic distribution. 6) Copper that is bound to COX17 will enter the mitochondria 
and is incorporated into CcO. 7) DMT1 has been shown to influx copper, however with 
an unknown destination; such excess copper can be reversibly bound by MT. DMT1: 
divalent metal ion transporter 1; CTR1: copper transporter 1; HAH1: antioxidant protein 
1; ATP7A and ATP7B: copper transporting ATPases, α and β polypeptides, respectively. 
TGN: trans-Golgi network.  ER: Endoplasmic reticulum; Cu/Zn-SOD: Copper/Zinc-
superoxide dismutase; CCS: Copper chaperone for superoxide dismutase. CcO: 
cytochrome C oxidase; COX17: CcO copper chaperone; Cu-Hist: copper histidine; MT: 
metallothionein. Adapted from various sources. (e.g. Yamaguchi et al, 1996; Gunshin et 
al, 1997; Lee et al, 2002) 
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1.4.2 Maintaining copper homeostasis 
The general homeostatic regulation of copper balance is well known, for example 
intestinal copper absorption is not only influenced by total body copper status but 
also by the copper content of the meal. For example, in-vitro copper depletion of 
Caco-2 enterocytes resulted in higher transport, whereas high oral doses in rat pups 
result in decreased absorption and increased intestinal retention (Zerounian et al, 
2003; Bauerly et al, 2005; Lönnerdal, 2008).  The more molecular events and 
mechanisms that coordinate copper balance are complex and are described below. 
1.4.2.1 Copper uptake, storage and toxicity 
The enterocytic regulation of copper uptake is the first step in limiting dietary copper 
availability.  Important regulatory proteins include CTR1, ATP7A, ATP7B and 
HAH1 (Lönnerdal, 2008).  For example, CTR1 knockout mice exhibit neonatal 
defects with peripheral tissue copper accumulation, cardiac hypertrophy; impaired 
growth and hepatic iron overload (Nose et al, 2006). Hepatic iron overload is a 
consequence of CTR1 knockout because ferroxidases (hephaestin or ceruloplasmin) 
are cuproenzymes necessary for iron efflux; thus a cellular deficiency in copper will 
impede the formation and function of these ferroxidases. In CTR1 knock-out mice 
there is still some accumulation of copper, which indicates alternative uptake 
pathways. These pathways include DMT1-mediated uptake, paracellular uptake and 
pinocytosis (Arredondo et al, 2003; Nose et al, 2006).  HAH1 knockout mice show 
poor survival, growth failure and high levels of intracellular copper, indicating 
defects in copper efflux and impaired delivery to secretory pathways (Hamza et al, 
2001).  
Copper loading in Caco-2 cells causes no change in the expression of CTR1.  CTR1 
is however endocytosed whilst metallothionein (MT) expression is increased.  MT is 
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a metal-binding protein heavily involved in the regulation of metal-induced oxidative 
stress.  Although the regulation of MT can be independent of copper status, the 
increased expression at higher levels of copper treatment is a mechanism of 
enterocytic copper retention, thus preventing systemic copper toxicity (reviewed by 
Lönnerdal, 2008).  
1.4.2.2 Copper handling and efflux: the copper transporting ATPases 
Other essential genes in the cellular metabolism of copper are ATP7A and ATP7B; 
both of which encode the copper transporting ATPases.  They are particularly 
important for the cupration of membrane bound and/or secreted proteins.  ATPases 
utilise energy from ATP hydrolysis to carry out their role in transporting copper 
from the cytosol to the lumen of intracellular compartments such as the endoplasmic 
reticulum or Golgi network.  It is within these compartments that cupration of 
enzymes occur (reviewed by Lutsenko et al, 2007).   
Copper transporting ATPases are found mainly within the apical membranes of 
polarised cells or in the trans-Golgi network.  However, they are also localised in 
small amounts along the secretory pathway for subsequent remetallation and 
phosphorylation of secreted enzymes (Veldhuis et al, 2009; White et al, 2009).  
Some cells will contain both ATP7A and ATP7B, indicating another level of 
homeostatic regulation.  It is not known whether the same biochemical factors 
regulate both ATPases, or whether different forms of copper will bind preferentially 
to either one.  Some studies have suggested that ATP7B is a slower transporter of 
copper than ATP7A (reviewed by Lutsenko et al, 2007). 
ATP7A is required for the formation of numerous enzymes including tyrosinase, 
peptidyl-α-monooxygenase, superoxide dismutase and lysyl oxidase (Petris et al, 
2000; Tchaparian et al, 2000; Qin et al, 2006).  ATP7B is required for the formation 
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of the copper-dependant ferroxidase holoceruloplasmin (Terada et al, 1998).  ATP7B 
expression is tissue specific to some degree.  For example, the main role of ATP7B 
in hepatocytes is to facilitate the export of copper.  This function of ATP7B is of 
crucial importance as the liver is the primary organ responsible for copper 
homeostasis, for example transporting excess copper into bile for subsequent faecal 
excretion (Tao et al, 2003).  
Studies into the cellular responses to copper depletion have found that the copper 
transporting ATPases will relocalise to the site of enzyme metallation (Petris et al, 
1996).  Indeed expression of these ATPases will increase, decrease or relocalise in 
response to copper supply, hormonal signaling or other unknown events (Schlief et 
al, 2005; Kelleher & Lönnerdal, 2006).  Very little is known regarding the molecular 
regulation of the proteins and genes involved in the copper uptake pathway.  
However, it is known that degradation of some of these proteins is copper dependent 
whereas their mRNA expression appears to be copper independent (Bertinato & 




1.5 Flavonoids and nutrient interactions 
As flavonoids are abundant in the human diet and are known to interact with 
nutrients, the modulatory effects of flavonoids on nutrient availability are proposed 
to be a major physiological consequence of their consumption (Park, 1999; Cermak 
et al, 2004; Ma et al, 2010).  The following sections will briefly discuss the 
interaction of polyphenolic flavonoids with the nutrients that are the focus of this 
thesis, namely glucose, iron and copper.  
1.5.1 Dietary glucose and flavonoid interactions 
In diabetic states pharmacologic interventions to modulate glucose homeostasis are 
mainly used in conjunction with optimised lifestyle and dietary management.  
Regarding the latter, establishing the therapeutic properties of naturally occurring 
flavonoids will potentially reduce the reliance on pharmacological interventions 
which are often characterised by unwanted side effects (Cheng & Fantus, 2005; 
Martinuea et al, 2006). 
The glycosylated flavonoid phloridzin, abundantly found in apples, is the classic and 
specific inhibitor of SGLT1-mediated glucose uptake (Alvarado & Crane, 1962; 
Alvarado, 1967).  Studies using Caco-2 cells have found that other glycosylated 
flavonoids such as neohesperidin and quercitin glucosides also elicit a similar and 
SGLT1-specific inhibition of glucose uptake (Gee et al, 1998; Wolffram et al, 2002; 
Johnston et al, 2005).  In contrast, aglycone flavonoids are known to selectively 
inhibit GLUT-mediated transport of glucose.  The classical inhibitor of GLUT2 is 
phloretin, the aglycone counterpart of phloridzin (Johnston et al, 2005; Kwon et al, 
2007).  Flavonols, flavones, isoflavones and anthocyanidins (e.g. quercetin, 
apigenin, daidzein and cyanidin, respectively) have all also been shown to modulate 
glucose uptake in U937 monocytes (Park, 1999).  
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Through numerous studies, the structural characteristics of flavonoids that potently 
inhibit glucose uptake have been identified.  These appear to be flavones or flavonols 
with hydroxylation of the C-5 and/or C-7 positions.  Furthermore, there have been 
attempts to distinguish mechanisms of inhibition.  Inhibition of glucose uptake in a 
U937 model was shown to be mainly sodium-independent and competitive for 
GLUT-mediated transport (Park, 1999).  Inhibition of GLUT2-mediated glucose 
uptake has been shown to be specific, reversible and non-competitive in other studies 
investigating the effects of quercetin and isoquercetin (Kwon et al, 2007).  These 
aforementioned studies investigated glucose uptake in transfected Xenopus laevis 
oocytes, GLUT2 over-expressing pituitary cells and Caco-2 cells (Kwon et al, 2007).  
In adipocytes and myoblasts, blueberry root and fruit, stem and leaf extracts were 
shown to enhance basal and insulin-stimulated glucose uptake.  Interestingly, the 
fruit extract from blueberries was the only part of the plant to contain anthocyanins, 
which had specific inhibitory properties on glucose uptake (Martineau et al, 2006).  
Several mechanisms have been proposed to explain the inhibitory effects of 
flavonoids on glucose uptake.  These include, for example, competitive inhibition 
and steric hindrance due to the structural similarities between monosacharides and 
flavonoid functional groups.  For example, glucose moieties on flavonoids may bind 
to hexose binding sites on glucose transporters thus inhibiting monosaccharide 
influx. Conversely, a separate binding site for flavonoids may be present on a 
glucose transporter, preventing glucose binding due to steric hindrance. 
Alternatively, there may be molecular interactions of flavonoids directly with cell 
membranes, affecting transporter function (Nakayama et al, 2000).  Furthermore, 
flavonoids may influence the redox state of certain nutrients such as copper and iron; 
the latter of which influences glucose uptake (Ren et al, 2008; Lekka et al, 2009).  It 
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is well known that flavonoids are powerful reducing agents, this will reduce iron and 
copper, and these reduced forms of the metals are preferentially absorbed due to their 
solubility. In light of this, solubility of iron, and therefore its absorption, can be 
dependent on the proportion of monosacharides present in the diet, e.g. fructose 
lowers the solubility of dietary iron relative to glucose (Brouwer et al, 1993). 
Finally, interactions between flavonoids and metals, may initiate the competitive 
inhibition of glucose transporters. The formation of metal polyphenol complexes 
have been shown to initiate the use of a GLUT-type transporter for metal shuttling 
out of epithelial cells (Vlachodimitropoulou et al, 2010b). There is also the 
possibility that flavonoids may cause transcriptional and/or translational effects that 
influence glucose transport, though this has not been investigated in detail 
(Miyamoto et al, 1993; Oliveira et al, 2008). Given these numerous interactions 
between dietary flavonoids, metals and glucose it is not surprising to assume a much 
more important role of flavonoids may be in modifying the absorption of nutrients, 
rather than a main role strictly as a systemic antioxidant. 
1.5.2 Interactions of flavonoids, iron and copper 
There have been numerous studies investigating the interaction between dietary 
metal bioavailability, cellular metabolism and interactions with polyphenols.  These 
studies have included epidemiological data, in-vivo and in-vitro investigations in 
both man and animals.  For example, dietary iron is significantly influenced by 
vitamin C, flavonoids and presence of other dietary metals such as zinc, manganese, 
lead and, of relevance to this thesis, copper (Mira et al, 2002; Teucher et al, 2004; 
Reeves et al, 2005; Thumser et al, 2010).  
With regards to vitamin C, this reducing agent increases iron uptake by forming 
transportable iron-ascorbate complexes (Thumser et al, 2010).  Flavonoids will also 
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influence the bioavailability of iron through the formation of polyphenol-metal 
complexes (Kim et al, 2008; Ren et al, 2008; Vlachodimitropoulo et al, 2010b). 
Specifically, green tea flavonoids have been shown to decrease enterocyte 
transepithelial iron transport by limiting basolateral release (Kim et al, 2008).   
Dietary factors that affect copper status are similar to those for iron, such as the 
presence of vitamin C (Kuo et al, 2004). Furthermore, copper can form a complex 
with flavonoids, similar to that formed by iron (Lekka et al, 2009). In light of this, it 
cannot be ruled out that these interactions will induce similar effects on the transport 
of copper as they do to iron, if inhibitory mechanisms are to be based on the 
structural interactions.  Whilst numerous studies have investigated the physiological 
basis of copper transport, many molecular mechanisms remain to be elucidated. 
Copper and iron metabolism are also known to be intertwined.  The genes that are 
integral to copper transport are not overtly regulated by their substrate (Tennant et al, 
2002; Nose et al, 2010).  Their transcription is more sensitive to the presence of iron 
(Collins, 2006; Collins et al, 2009).  However, copper is able to induce post-
translational modifications of the proteins involved in its uptake (Tallkvist et al, 
2000; Bertinato & L’Abbé, 2004).  
Furthermore, iron homeostasis can essentially be regulated by copper in three ways.  
Firstly, copper is a constituent of key iron regulatory proteins such as HEPH and 
ceruloplasmin (Eisentstein, 2000).  Thus copper deficiency can lead to iron 
deficiency anaemia. Secondly, copper presents competition for iron at the DMT1 
iron binding site (Tennant et al, 2002, Arredondo et al, 2003).  Thirdly, copper 
loading is known to influence expression of DMT1 and FPN, proteins that 
coordinate iron uptake and release, respectively (Tennant et al, 2002). 
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1.6 Hypothesis and aims of this thesis 
We hypothesised that dietary berry flavonoids are capable of modulating intestinal 
transport of glucose, iron and copper via functional, transcriptional and translational 
mechanisms.    
To address this we investigated the effects of dietary flavonoids in the form a 
flavonoid-rich berry extract on intestinal epithelial Caco-2 cells.   
This thesis is divided into four parts with the following aims: 
1. To evaluate the effects of dietary berry flavonoids on the global gene 
expression profile of enterocytes.  From this study we identified areas of interest for 
further investigation. 
2. To characterise the transcriptional, translational and functional effects of 
dietary berry flavonoids on glucose uptake processes in human intestinal epithelial 
Caco-2 cells. 
3. To characterise the transcriptional, translational and functional effects of 
dietary berry flavonoids on iron transport processes in human intestinal epithelial 
Caco-2 cells. 
4. To characterise the transcriptional, translational and functional effects of 









2 Materials and methods 
2.1 Materials 
The following sections will list the reagents, equipment, software and commercial 
suppliers. 
2.1.1 Materials used in Caco-2 cell culturing and flavonoid treatments 
The Caco-2 TC7 cell line expresses the necessary proteins for transport of glucose, 
iron and copper, has been previously characterised and applied as a successful model 
of the intestinal epithelium (Mahraoui et al, 1994; Bédrine-Ferran et al, 2004; Sun et 
al, 2008).  The Caco-2 cells and many of the ensuing protocols were provided by the 
laboratory of Dr. Paul Sharp (Diabetes and Nutritional Sciences Division, King’s 
College London, UK).  For reagents and composition of cell culture media see Table 
2.1.  For reagents and composition of treatments see Table 2.2.  For reagents used in 
cell subculturing and viability testing see Table 2.3.  For consumables and 
equipment used in cell culture see Table 2.4. 
Table 2.1.  Reagents, composition and suppliers of Caco-2 cell culture media. 
Reagent Concentration  
in complete 
media (% v/v) 
Concentration  
in serum- free 
media (% v/v) 
Product details/ Supplier 
Antibiotics 1 1 15140122, Invitrogen Life 
Technologies, Paisley UK 
DMEM 86.8 97 41965062, Invitrogen Life 
Technologies, Paisley UK 
FBS 10 - F9665-500ML, Sigma, Dorset, 
UK 
L-glutamine 1 1 25030024, Invitrogen Life 
Technologies, Paisley UK 
NEAA 1 1 11140035, Invitrogen Life 
Technologies, Paisley UK 
Plasmocin™ 0.2 - Source BioScience 
LifeSciences, Nottingham, UK 
DMEM: Dulbecco’s modified Eagle medium; FBS: Foetal bovine serum; NEAA: 




Table 2.2.  Reagents, composition and suppliers for Caco-2 cell treatments. 
Reagent Final 
concentration  
Product details/ Supplier 
Berry extract 0.125 % (w/v) Optiberry®, InterHealth Nutraceuticals, USA 
Quercetin 100 µM Q4951-10G, Sigma, Dorset, UK 
Phloretin 100 µM P7912-250MG, Sigma, Dorset, UK 
Phloridzin 100 µM 274313-5G, Sigma, Dorset, UK 
DMSO 0.05 % (v/v) D1435-500ML, Sigma, Dorset, UK 
All reagents were diluted in DMEM for gene expression, or protein abundance analysis, or were diluted 
into relevant buffers for functional investigations.  DMSO: dimethyl sulfoxide. DMEM: Dulbecco’s 
modified Eagle medium. 
 
 
Table 2.3.  Reagents used for Caco-2 cell subculturing and viability testing. 
Reagent Product details/ Supplier 
Trypan blue dye T6146-100G, Sigma, Dorset, UK 
PBS BR0014G,  Oxoid, Hants, UK 
TrypLE™ 0040090DG, Invitrogen Life technologies, Paisley UK 
PBS: phosphate buffered saline. 
 
 
Table 2.4.  Consumables and equipment used in Caco-2 cell culture. 
Consumables/Equipment Product details/Supplier  
Air cabinet Airtech Class2, Howorth, Bolton, UK 
Glass pipettes (5-10 ml) CLS4487, CLS4488, Sigma, Dorset, UK 
Cell scraper CLS3010, Sigma, Dorset, UK 
Centrifuge 5810R, Eppendorf, Cambridge, UK 
CO2 incubator MCO-36AC, Sanyo, CA, USA 
Cover slips 631-1566, VWR, PA, USA 
Disposable filters (0.2 µM) Minisart®, Sartorius Stedim Biotech, France 
Falcon tubes (15-50 ml) 210261, Grenier Bio One, Gloucestershire, UK 
Flasks (T-25/T-75) 690/658175, Grenier Bio One, Gloucestershire, UK 
Haemocytometer CM175-20, Sigma, Dorset, UK 
Needles 305115, BD, NJ, USA 
Pipette controller E4866-0021, Starlab UK Ltd, Milton Keynes, UK 
Plates (6-12 well) CLS3516, Sigma, Dorset, UK 
Syringes (20-50 ml) 309628, BD, NJ, USA 
Upright light microscope Eclipse TS100, Nikon Instruments Inc., NY, USA 
Waterbath W14, Grant, Cambridgeshire, UK 




2.1.2 Materials used in Caco-2 cell RNA isolation and quantification 
This section lists materials used for RNA isolation, integrity analysis and 
quantification protocols.  For reagents used in RNA isolation see Table 2.5.  RNA 
was quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific, 
Leicestershire, UK).  RNA integrity was quantified using the 2100 BioAnalyzer 
(Agilent, Cheshire, UK) with the RNA 6000 Nano Kit (Agilent, Cheshire, UK).  For 
consumables and equipment used in RNA integrity and quantification see Table 2.6. 
 
Table 2.5. Reagents, consumables and equipment for Caco-2 cell RNA isolation, 
quantification and integrity analysis. 
Reagents/Consumables Product details/Supplier 
Ethanol 34963-2.5L, Sigma, Dorset, UK 
Chloroform 25668, Sigma, Dorset, UK 
Nuclease-free water AM9937, Applied Biosystems, Cheshire, UK 
Propan-2-ol P/7509/17, Fisher Scientific, Leicestershire, UK  
TRIzol® reagent 15596026, Invitrogen Life Technologies, Paisley UK 
 
 
Table 2.6. Consumables and equipment for RNA isolation and integrity 
analysis. 
Consumables/Equipment Product details/Supplier 
Temperature controlled centrifuge Microlite RF, ThermoFisher, 
Hampshire, UK 
Nuclease-free, extended-length, filtered tips I1402-4300, Starlab UK Ltd, 
Milton Keynes, UK 
Nuclease-free tubes (1.5-2 ml) S1615-5510, Starlab UK Ltd, 





2.1.3 Materials used in gene expression experiments 
This section lists materials used for gene expression analysis.  RNA was reverse 
transcribed using a high-capacity reverse transcription kit (Applied Biosystems, 
Cheshire, UK) in a thermal cycler (DNA Engine Tetrad PTC-225, Bio-Rad, 
Hertfordshire, UK).  Global gene expression was quantified using Affymetrix HGU-
133A GeneChip arrays (Affymetrix Inc., CA, USA).  Affymetrix GeneChip arrays 
are a high-throughput platform for the analysis of global gene expression or 
transcriptome variation in samples.  They are constructed of thousands of hybridised 
oligonucleotide probes and labeled with fluorescent tags.  Such arrays allow the 
quantification of gene expression through template cDNA adherence to the probes 
and the concomitant detection of fluorescence.  The specific expression of genes was 
quantified using quantitative real-time polymerase chain reaction (qRT-PCR).  For 
qRT-PCR analysis, SYBR green was used as a DNA-binding dye with sequence 
specific primers.  For reagents used in specific gene expression analysis and their 
suppliers see Table 2.7.  For consumables and equipment used in gene expression 
analysis see Table 2.8. 
 
 
Table 2.7.  Reagents used for gene expression analysis 
Reagent Product details/Supplier 
SYBR green DNA binding dye 4367659, Applied Biosystems, Cheshire, UK 
Sequence specific primers MWG Eurofins, London, UK 
Nuclease-free water AM9937, Applied Biosystems, Cheshire, UK 






Table 2.8.  Consumables and equipment used in gene expression analysis 
Consumables/Equipment Product details/Supplier 
96-well PCR plates N8010560, Applied Biosystems, Cheshire, UK 
Adhesive film applicator 4313663, Applied Biosystems, Cheshire, UK 
Optical adhesive film 4360954, Applied Biosystems, Cheshire, UK 
Optical compression pads 4313663, Applied Biosystems, Cheshire, UK 
96-well plate-adaptable centrifuge 5804R, Eppendorf, Cambridge, UK 
Nuclease-free, extended-length, 
filtered tips 
3810, Starlab UK Ltd, Milton Keynes, UK 
Nuclease-free microtubes (0.2 ml) I1402-4300, Starlab UK Ltd, Milton Keynes, UK 
Nuclease free tubes (1.5-2.0 ml) S1615-5510, Starlab UK Ltd, Milton Keynes, UK 
Sequence detection system ABI Prism® 7700 sequence detection system, 
Applied Biosystems, Cheshire, UK 
Thermal cycler DNA engine tetrad PTC-225, Bio-Rad, 
Hertfordshire, UK 
 
2.1.4 Materials used in Caco-2 cell protein isolation and quantification 
This section lists materials used in protein isolation and quantification.  For a list of 
the reagents used, see Table 2.9.  For the composition of the cell lysis buffer and 
sample loading buffer, see Table 2.10 and Table 2.11, respectively.  For sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer, 
see Table 2.12 and for the nitrocellulose membrane semi-dry transfer buffer, see 
Table 2.13.  For the polyacrylamide gel composition, see Table 2.14.  For the 
composition of washing, blocking and stripping solutions, see Table 2.15, Table 
2.16 and Table 2.17, respectively.  For the consumables and equipment used in 
protein isolation and quantification, see Table 2.18.  Western blot membranes were 
excited using the Novex® ECL chemiluminescent substrate reagent kit (WP20005, 
Invitrogen life technologies, Paisley, UK) then developed on Kodak light film 
(Z370398-50EA, Sigma, Dorset, UK) with standard developing and fixing reagents 
(product numbers P7042 and P7167, Sigma, Dorset, UK).   
70 
 
Table 2.9.  Reagents used in Caco-2 cell protein isolation and quantification 
Reagent Product details/Supplier  
Acrylamide A4058-100ML, Sigma, Dorset, UK 
APS 215589-500G, Sigma, Dorset, UK 
Bromophenol blue B0126-25G, Sigma, Dorset, UK 
Chemiluminescence agent WP20005, Invitrogen Life Technologies, Paisley, UK 
Developer P7042, Sigma, Dorset, UK 
Fixer P7167, Sigma, Dorset, UK 
Glycerol G9012-100ML, Sigma, Dorset, UK 
Glycine 94119-10G, Sigma, Dorset, UK 
Non-fat powdered milk Premier Foods, Windsor, UK 
PBS BR0014G, Oxoid, Hants, UK 
Protease inhibitor P8340-1ML, Sigma, Dorset, UK 
Protein weight marker SM0441, Fermentas Life Sciences, North Yorkshire, UK 
SDS ELR-428-010N, Fisher Scientific, Leicestershire, UK 
TEMED T9281-50ML, Sigma, Dorset, UK 
Tris-base 648310-500GM, Merck chemicals Ltd.  Nottingham, UK 
Tween 20 P5927-500ML, Sigma, Dorset, UK 
β-mercaptoethanol 436024C, VWR international Ltd.  Leicestershire, UK 
PBS: phosphate buffered saline; SDS: sodium dodecyl sulphate; APS: ammonium 
persulphate; TEMED: tetramethylethylenediamine. 
 
Table 2.10.  Composition of Caco-2 cell lysis buffer 
Reagent Concentration  
PBS 50 mM 
Protease inhibitor 1% (v/v) 
SDS* 0.1% (w/v)  
*SDS was excluded from cell lysis buffer when isolating membrane bound protein.  
PBS: phosphate buffered saline; SDS: sodium dodecyl sulphate. 
 
Table 2.11.  Composition of 5X protein sample loading buffer 
Reagent Concentration 
Bromophenol blue 0.1% (v/v) 
Glycerol 25% (w/v) 
SDS 2% (v/v) 
β-mercaptoethanol 5% (v/v) 
SDS: sodium dodecyl sulphate. 
 
Table 2.12.  Composition of 10X SDS-PAGE running buffer 




SDS: sodium dodecyl sulphate; SDS-PAGE: sodium dodecyl sulphate-




Table 2.13.  Composition of 10X SDS-PAGE-membrane semi-dry transfer 
buffer* 




*10X transfer buffer in Table 2.13 was diluted into a 20% (v/v) methanol solution to 
make the 1X transfer buffer.  SDS: sodium dodecyl sulphate; SDS-PAGE: sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis. 
 
Table 2.14.  Composition of polyacrylamide gels for protein electrophoresis 







Distilled water 4.40 ml 3.75 ml 3.10 ml 
Tris (pH 8.8) 2.15 ml 2.15 ml 2.15 ml 
40 % (w/v) acrylamide 1.65 ml 2.25 ml 2.85 ml 
10 % (w/v) APS 82.5 µl 82.5 µl 82.5 µl 
10 % (w/v) SDS 82.5 µl 82.5 µl 82.5 µl 
TEMED 11.0 µl 11.0 µl 11.0 µl 
APS: ammonium persulphate; SDS: sodium dodecyl sulphate; TEMED: 
tetramethylethylenediamine. 
 
Table 2.15.  Composition of washing solution and antibody incubation solution. 
Reagent Concentration 
Non-fat powdered milk 1% (w/v) 
PBS 1X 
Tween 20 0.1 % (v/v) 
PBS: Phosphate buffered saline. 
 
Table 2.16.  Composition of nitrocellulose membrane blocking solution. 
Reagent Concentration 
Non-fat powdered milk 5% (w/v) 
PBS 1X 
Tween 20 0.1 % (v/v) 
PBS: Phosphate buffered saline. 
 
Table 2.17.  Composition of nitrocellulose membrane stripping buffer. 
Reagent Concentration (% v/v) 
10% (w/v) SDS 20 
Distilled water 69.22  
Tris (pH 6.8) 10 
β-mercaptoethanol 0.78 




Table 2.18.  Consumables and equipment for protein isolation and 
quantification. 
Consumables/Equipment Product details/Supplier 
Disposable gel cassettes NC2015, Invitrogen Life Technologies, Paisley, UK 
Exposure cassette  Molecular Dynamics, Fisher Scientific, Leicestershire, UK 
Falcon tubes (50 ml) 210261, Grenier Bio One, Gloucestershire, UK 
Homogeniser  Ultra Turrax T8, Sartorius Mechatronics Ltd., Epsom, UK 
Light film Z370398-50EA, Sigma, Dorset, UK 
Needles  305115, BD, NJ, USA 
Platform shaker Innova 2100, 444-0541, VWR, PA, USA 
Powerpack Labosi Power 300, Fisher Scientific, Leicestershire, UK 
Roller-mixer Mixer SRT2, MIX1990, SLS, Nottingham, UK  
Calibrated densitometer GS-800™, BioRad Laboratories, Hertfordshire, UK 
Semi-dry transfer blotter TE77PWR, GE Healthcare, Buckinghamshire, UK  
Syringes (1 ml) 309628, BD, NJ, USA 
Well-combs NC3510, Invitrogen Life Technologies, Paisley, UK 
Microplate reader Synergy HT, PJB-290-040A, Fisher Scientific, 
Leicestershire, UK 
Safelight Photax A safelight, Paterson photographic limited, West 
Midlands, UK 










2.1.5 Materials used in nutrient uptake and transport studies 
This section lists materials used in uptake and transport studies.  For a list of 
reagents used, see Table 2.19.  For the radionuclides and their suppliers, see Table 
2.20.  For the composition of the HEPES-buffered salt solution (HBSS) used for the 
glucose uptake experiments, see Table 2.21; this was made glucose-free and 
supplemented with D-glucose to initiate uptake.  A sodium-free HBSS was also 
prepared with equimolar potassium salts for D-glucose uptake studies of sodium-
independent glucose uptake pathways.  For the composition of MES-buffered salt 
solution (MBSS) and HBSS used in iron transport experiments see Table 2.22 and 
Table 2.23, respectively.  The same HBSS buffer used for iron transport experiments 
was used for our copper uptake experiments.  For consumables and equipment used 
in uptake and transport studies see Table 2.24. 
 
Table 2.19.  Reagents used in substrate uptake and transport studies. 
Reagent Product details/Supplier  
Sodium chloride 424290010, Acros Organics, Geel, Belgium 
Potassium chloride P4504-500G, Sigma, Dorset, UK 
Sodium phosphate 342483-500G, Sigma, Dorset, UK 
Calcium chloride 06991-1KG-F, Sigma, Dorset, UK 
Magnesium chloride M8266-100G, Sigma, Dorset, UK 
HEPES-salt S11-001, Fisher Scientific, Leicestershire, UK 
BSA B6917-5X100MG, Sigma, Dorset, UK 
D-glucose 15023021, Invitrogen Life Technologies, Paisley UK 
Ascorbate  A4034-500G, Sigma, Dorset, UK 
Ferrous sulphate F8048-500G, Sigma, Dorset, UK 
Copper chloride 203149, Sigma, Dorset, UK 
Nitric acid 68 % (w/v) 225711, Sigma, Dorset, UK 
Nitric acid (1 M) 35315, Sigma, Dorset, UK 
MES-salt M3058-100G, Sigma, Dorset, UK 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; BSA: bovine serum 





Table 2.20.  Radionuclides used in uptake and transport studies. 
Radioisotopes Chemical form Product details/Supplier  
55
Fe* Ferric Chloride NEZ043001MC, Perkin-Elmer, Bucks, UK 
3H† D-glucose NET100C001MC, Perkin-Elmer, Bucks, UK 
*Diluted into FeSO4: Ascorbate in a 1:10 molar ratio to give a final concentration of 
1 µM:10 µM and activity of ~500,000 DPM/well.  †Diluted into 20 mM D-glucose 
to give a final concentration of 1 mM glucose and activity of ~500,000 DPM/well. 
 
 
Table 2.21.  Composition of glucose free HEPES-buffered salt solution (HBSS) 
used in glucose uptake studies. 
Reagent Concentration (mM) 
Sodium chloride* 140 
Potassium chloride 5 
Sodium phosphate* 1 
Calcium chloride 1 
Magnesium chloride 0.5 
HEPES-salt 10 
BSA 0.2% (w/v) 
*Sodium-free buffer was made by replacing sodium salts with equimolar potassium 
salts.  Buffered to pH 7.5; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid; BSA: bovine serum albumin. 
 
Table 2.22. Composition of MES-buffered salt solution (MBSS) used in copper 
uptake and iron transport studies. 
Reagent Concentration (mM) 
Sodium chloride 140 
Potassium chloride 5 
Sodium phosphate 1 
Calcium chloride 1 
Magnesium chloride 0.5 
MES-salt 10 
D-glucose 5 
Buffered to pH 6.5; MES: 2-(N-morpholino) ethanesulfonic acid; BSA: bovine 
serum albumin. 
 
Table 2.23. Composition of HEPES-buffered salt solution (HBSS) used in iron 
uptake and transport studies. 
Reagent Concentration (mM) 
Sodium chloride 140 
Potassium chloride 5 
Sodium phosphate 1 
Calcium chloride 1 
Magnesium chloride 0.5 
HBSS-salt 10 
D-glucose 5 
BSA 0.2 % (w/v) 
Buffered to pH 7.5; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 
BSA: bovine serum albumin. 
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Table 2.24.  Consumables and equipment used in radiolabelled substrate uptake 
and transport studies. 
Consumables/Equipment Product details/Supplier 
Cell scraper CLS3010, Sigma, Dorset, UK 
Falcon tubes (15-50 ml) 210261, Grenier Bio One, Gloucestershire, UK 
Needles  305115, BD, NJ, USA 
Plate reader Optima, Promega, CA, USA 
Scintillation counter LS6500, Beckman-Coulter, High Wycombe, UK 
Scintillation vials BOT15, KCL Central Stores, London, UK 
Syringes (1 ml) 309628, BD, NJ, USA 
Transwell® inserts TKT-526-010M, Fisher Scientific, Leicestershire, UK 
Tubes (1.5-2.0 ml) S1615-5510, Starlab UK Ltd, Milton Keynes, UK 
 
 
2.1.6 Analysis software 
This section lists the software used for the experiments in this thesis Table 2.25. 
 
Table 2.25.  Software applied in research. 
Software Application/s Source/references 
GCOS Microarray normalisation and filtering Affymetrix Inc.  CA, USA 
GraphPad Prism® 5 Data analysis and figures GraphPad software, CA, USA 
Primer3 Primer design Rozen & Skaletsky, 2000 
IPA Pathway analysis Maaser & Borlak, 2008; 
Ingenuity® systems Inc.  CA, 
USA 
DAVID Clustering and gene ontology Huang da et al, 2009; Dennis et al, 
2003 
QuantityOne® Densitometry BioRad Laboratories, 
Hertfordshire, UK 




Word processing, data analysis and 
formatting 
Microsoft corporation, WA, USA 
DAVID: Database for annotation, visualisation and integrated discovery; GCOS: GeneChip 









2.2.1 General study design 
Global gene expression microarray analysis was initially carried out to identify genes 
and pathways of interest for further investigation.  Two groups (i.e. control and 
treated) were used to identify effects of a flavonoid-rich berry extract on 
transcriptome variation in Caco-2 cells.  Six RNA samples from each of the separate 
groups were pooled for use on two separate microarray chips (Figure 2.1). 
Following microarray analysis, target genes and pathways of interest were selected 
for further investigation by qRT-PCR and Western blotting.  Finally, functional 
effects were quantified with nutrient uptake and transport assays (Figure 2.2). 
 
 
Figure 2.1. Study design. Caco-2 cells were treated with a flavonoid-rich berry 
extract at 0.125 % (w/v) for 16 h. Following treatment, RNA was isolated, pooled 
per group, and applied to microarray chips. Informatic analysis of microarray data 
identified areas of interest for subsequent validation and further investigation. GO: 
gene ontology. 
GO, clustering and pathway analysis 
RNA isolation and pooling on 
control microarray chip 
Control cells: growth media for 16 
hours n = 6 
Treated cells: 0.125 % (w/v) berry 
extract for 16 hours n = 6 
 
Identify areas of interest for further 
investigation 
Caco-2 cells cultured until confluence and 
differentiation 
RNA isolation and pooling on 






Figure 2.2. Validation of gene expression and further investigations. 
Following microarray analysis areas of interest were further investigated 
through gene expression analysis, protein abundance analysis and 
functional assays. qRT-PCR: quantitative real-time polymerase chain 
reaction. 
Caco-2 cells cultured until 
confluence and differentiation 
Quantify gene expression by 
qRT-PCR 
Quantify effects on function by 
uptake and transport assays 
Control group: growth media 
for 16 h 
Treated group: 0.125 % (w/v) 
berry extract or 100 µM 
flavonoids for 16 h 
 




2.2.2 Human intestinal Caco-2 cell cultures and treatments 
The human intestinal Caco-2 cell line TC-7 strain was used in all of the following 
studies.  This cell line has been previously used as an adequate model of the human 
intestinal epithelium (Mahraoui et al, 1994).  Caco-2 cells were cultured until 
confluence (i.e. adhered to at least 90% of the growth surface) and differentiation 
(i.e. exhibited morphological characteristics of mature enterocytes such as thickened 
membranes) (Figure 2.3).  Cells were only treated once differentiated, this typically 
occurred during the third week of growth.  For cell seeding densities and media 
volumes used see Table 2.26. 
 
Figure 2.3. Newly seeded and fully differentiated Caco-2 cells. A. Newly seeded 
Caco-2 cells at X10 magnification and B. Newly seeded Caco-2 cells at X100 
magnification; C. Confluent and differentiated Caco-2 cells at X10 magnification; D. 
Confluent and differentiated Caco-2 cells at X100. Note in panels A and B Caco-2 
cells are not adherent and do not resemble enterocytic cells. In panels C and D note a 
monolayer has developed of tightly packed cells with thickened membranes, at this 




Table 2.26.  Standard conditions for Caco-2 cell seeding and culture. 





number of cells  
Volume of media 
used (ml) 
6-well plates 9.6 40,000 2 
12-well plates 3.8 20,000 1 
T-25 flasks 25.0 150,000 4 
T-75 flasks 75.0 450,000 12 
6-well plates with 
Transwell® inserts 
4.7 50,000 2.5 (basolateral) 
1.5 (apical) 
 
The complete cell growth media consisted of Dulbecco’s modified Eagle media 
supplemented with 10 % (v/v) foetal bovine serum filtered through a 0.2 µm pore 
filter, with 1 % (v/v) non-essential amino acids, 1 % (v/v) penicillin-streptomycin 
antibiotic solution, 1 % (v/v) L-glutamine and 0.2 % (v/v) plasmocin micoplasma 
inhibitor.  Serum-free media was prepared with the same components, with the 
exclusion of foetal bovine serum and Plasmocin™ micoplasma inhibitor.  Serum-
free media was used 24 h prior to cell treatment in order to arrest cell growth, 
synchronising cells at the G0/G1 restriction point (Pardee, 1974; Pardee, 1989; 
Cooper; 2003). For suppliers of cell culture media components see Section 2.1.1. 
2.2.2.1 Caco-2 cell passaging and viability testing 
Caco-2 cells were subcultured for 40-43 passages and then experiments were 
performed on passages 44-47.  Caco-2 cells were seeded in T-25 or T-75 cell culture 
flasks, allowed to reach confluence after approximately one week of growth and then 
detached using TrypLE™, a trypsin-like enzyme.  Monolayers in each T-25 or T-75 
flask were gently washed once with 3-5 ml PBS.  TrypLE™ was then applied; 1.5 
ml was added into the T-25 flasks (or 4.5 ml in T-75 flasks) and allowed to act on 
the monolayers at 37°C for 5-10 min.  After detaching the cells, a suspension was 
made up to a volume of 10-15 ml with complete cell growth media and centrifuged 
at 600 rpm for 5 min at room temperature.  The media was discarded and the cell 
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pellet was dispersed by gentle tapping.  The cells were then resuspended in 10-15 ml 
of complete cell growth media.  From the resulting cell suspension 15 µl was used 
for haemocytometry in order to determine the volume required to seed experimental 
plates and further flasks for passaging.   
Cell viability was routinely tested during passaging and during the optimisation of 
treatment conditions using the trypan blue dye-exclusion method (Thanou et al, 
2000).  After detaching the Caco-2 cell monolayer, centrifugation and resuspension 
of the pellet, 10 µl of the cell suspension was mixed with 10 µl of 2 X trypan blue 
dye.  Then 15 µl of this cell suspension was used for counting and determination of 
cell viability. 
2.2.2.2 Caco-2 cell treatments 
To investigate the response of Caco-2 cells, our primary treatments used a flavonoid-
rich berry extract at a final concentration of 0.125 % (w/v).  Our further studies 
included the following synthetic flavonoids: quercetin (marker flavonol, most 
abundant flavonoids in the human diet), phloridzin (specific SGLT1 inhibitor) and 
phloretin (specific GLUT2 inhibitor) at final concentrations of 100 µM dissolved in 
DMSO, the final concentration of DMSO in treatment media was 0.05 % (w/v).  
Berry extract treatments and synthetic flavonoid treatments had separate flavonoid-
free controls.  Thus, controls for the berry extract treated cells were treated with 
media only, whereas controls for isolated flavonoid treated cells were treated with 
media including 0.05 % (w/v) of the DMSO solvent.  All media used during the 
treatments were serum-free DMEM supplemented with 0.2 % (w/v) BSA, filtered 
through a 0.2 µm filter.  For the composition of treatment solutions, stock and final 
concentrations of compounds, see Table 2.27.  For a typical analysis of the 
commercial berry extract used throughout the studies in this thesis see Table 2.28. 
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Final treatment composition 
Control  
 
- - DMEM 
+ 0.2 % (w/v) BSA 
Berry extract 0.25 % (w/v) 0.125 % (w/v) DMEM  
+ 0.2 % (w/v) BSA 
+ 0.125 % (w/v) berry extract 
Control  
(with DMSO) 
100 % (v/v) 0.05 % (v/v) DMEM  
+ 0.2 % (w/v) BSA 
+ 0.05 % (v/v) DMSO 
Quercetin 200 mM  100 µM DMEM  
+ 0.2 % (w/v) BSA  
+ 0.05 % (v/v) DMSO  
+ 100 µM quercetin 
Phloretin 200 mM 100 µM DMEM  
+ 0.2 % (w/v) BSA  
+ 0.05 % (v/v) DMSO 
+ 100 µM phloretin 
Phloridzin 200 mM 100 µM DMEM 
+ 0.2 % (w/v) BSA  
+ 0.05 % (v/v) DMSO  
+ 100 µM phloridzin 






Table 2.28.  Typical analysis of the berry extract. 
Analysis/analyte Quantity  
ORAC  ≥3700 µmol TE/g 
Polyphenolic content  6.50 GAE-mg/g 
Total anthocyanin contents 3.60 mg/g 
Malvidin  0.32 mg/g 
Cyanidin  1.60 mg/g 
Delphinidin  0.94 mg/g 
Petunidin  0.52 mg/g 
pH (1 g/100 ml in water) 2.5-3.5 
Recommended dose for human consumption is 30 mg taken twice a day.  ORAC: 
Oxygen radical absorbance capacity; GAE: Gallic acid equivalence; TE: trolox 
equivalents.   
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2.2.3 Gene expression analysis 
Gene expression was quantified through the use of qRT-PCR with transcript specific 
primers and SYBR green as a fluorescent cDNA binding dye.  The following 
sections describe the process of gene expression analysis. 
2.2.3.1 RNA isolation 
Following treatment, total RNA was isolated using TRIzol® reagent according to the 
manufacturer’s protocol which consisted of five steps: 
1. Homogenisation: cells were washed once with ice-cold PBS and 
homogenised by adding TRIzol® directly to wells in a reagent to surface area 
ratio of 1 ml: 10 cm
2
.  Cells were scraped with a pipette tip and incubated at 
room temperature (RT) for 5 min 
2. Phase separation: 0.2 ml of chloroform, per 1 ml of TRIzol®, was added 
and samples were transferred to tubes, vortexed for 15 s and incubated at RT 
for 2-3 min.  Samples were then centrifuged for 15 min at 12,000 g at 4 °C.  
The colourless aqueous phase was retained for RNA isolation.   
3. RNA precipitation: 0.5 ml of isopropanol, per 1 ml of TRIzol®, was added 
to the aqueous phase and incubated at RT for 10 min.  Samples were then 
centrifuged for 10 min at 12,000 g at 4 °C.  The RNA pellet formed at the 
bottom of the tube. 
4. RNA wash: the supernatant was removed and the RNA pellet washed with 1 
ml 75 % (v/v) ethanol in nuclease-free water, per 1 ml of TRIzol®.  Samples 
were vortexed and centrifuged for 5 min at 7,500 g at 4 °C. 
5. Redissolving the RNA: the supernatant was removed and tubes were then 
inverted in a fume hood allowing the pellet to dry for 15-20 min.  Pellets 
were then redissolved in 50 µl nuclease-free water by repeated pipetting.   
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2.2.3.2 RNA integrity, purity and quantification 
Immediately following RNA isolation, sample concentrations and purity were 
quantified using the NanoDrop spectrophotometer.  For this, 1.2 µl of RNA sample 
was used to quantify RNA concentrations.  A blank of nuclease-free water was used 
to optimise the instrument. Sample pedestals were first cleaned with nuclease-free 
water and ethanol prior to use.  The purity of RNA was indicated by the 260/280 
ratio.  According to the manufacturer’s protocol, a 260/280 ratio of ~ 2.0 was 
considered optimal. 
RNA integrity was quantified using BioAnalyzer chips.  An RNA integrity number 
(RIN) of isolated RNA was obtained.  RIN of approximately ~10 was considered 
optimal. The chips were run according to the manufacturer’s protocol.  
2.2.3.3 Reverse transcription of complimentary DNA 
Following RNA isolation and quantification, RNA was reverse transcribed into 
cDNA using a High Capacity Reverse Transcription Kit, producing cDNA suitable 
for use with qRT-PCR.  Reverse transcription reactions were prepared as a 
mastermix and aliquoted for immediate use, then reverse transcription was carried 
out.  The resulting cDNA was stored at -20 °C until use.  See Table 2.29 for reverse 
transcription reaction components and Table 2.30 for thermal cycling conditions. 
Table 2.29.  Reverse transcription reagents and 2X reaction composition. 
Reagent Volume per 2X reaction mix (µl)* 
10X RT buffer 2.0 
25X dNTP mix (100 mM) 0.8 
10X random primers 2.0 
MultiScribe™ reverse transcriptase 1.0 
RNase inhibitor 1.0 
Nuclease-free water 3.2 
*2 µg of total RNA is added to the reaction and diluted with nuclease free water to 















Setting HOLD HOLD HOLD HOLD 
Temperature 
(°C) 
25 37 85 4 
Time (min) 10 120 5 ∞ 
“∞” denotes short-term (up to 24 h) storage prior to transferring samples to -20 °C.  
“HOLD” denotes a setting where temperature is constant. 
 
2.2.3.4 Real-time quantitative polymerase chain reaction 
Following cDNA synthesis samples were used with transcript-specific primers to 
amplify regions of mRNA for quantification of gene expression.  A SYBR® Green 
Mastermix was used as the polymerase enzyme and DNA-binding dye in qRT-PCR 
experiments.  On each qRT-PCR plate target genes and housekeeping genes were 
run together.  The housekeeping genes used were 18S ribosomal RNA and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  For detection of 18S, 
samples were diluted 10-fold due to the high abundance of the mRNA sequence.  
Standards were run for every gene amplified at five consecutive 10-fold dilutions 
from the sample concentration as 1 to the lowest concentration as 1/10,000 to 
quantify efficiency of amplification using the slope [Efficiency = ((10
(-1/slope)
)-1)100].  
Two non-template controls not containing any sample material and standards were 
run on every plate.  See Table 2.31 for qRT-PCR reaction components, Table 2.32  
for the thermal cycling programme, Figure 2.4 for the programme interface and 
thermal cycler settings and Table 2.33 for housekeeping gene primer sequences.  All 
primers were either previously reported in literature or designed with the online 
primer design tool Primer3 (http://frodo.wi.mit.edu/; Rozen and Skaletsky, 2000).  
Target gene primer sequences are listed in each chapter. See Section 9.1 for details 
of primer design and specificity. 
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Table 2.31.  Quantitative RT-PCR reaction composition 
Reagent Volume per 20 µl reaction (µl) 
SYBR green PCR Mastermix 10 
Forward primer 0.8 
Reverse primer 0.8 
cDNA template* 0.8 
Nuclease-free water 7.6 
The quantity of the template cDNA strand was varied, depending on the desired 
amplicon.  Between 25-250 ng cDNA was typically used per reaction. 
 
 
Table 2.32.  Quantitative RT-PCR thermal cycling procedure. 





Setting HOLD CYCLE (40-55) HOLD 
Temp.  (°C) 50 95 95 60 95 60 95 
Time (min) 2:00 10:00 0:15 1:00 0:15 0.:20 0:15 
*data is collected during the annealing/extension phase of the qRT-PCR run.  
“HOLD” denotes a setting where temperature is constant.  “CYCLE” denotes a setting 
















Table 2.33.  Housekeeping gene primer sequences. 
Gene 
symbol 
Forward sequence (5’-3’) Reverse sequence (5’-3’) 
18S AAC TTT CGA TGG TAG TCG CCG CCT TGG ATG TGG TAG CCG TTT 
GAPDH CTG TTG CTG TAG CCA AAT TCG T ACC CAC TCC TCC ACC TTT GA 
18S: ribosomal RNA 18S; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 
 
 
Figure 2.4. Sequence detection software thermal cycling protocol. Stage 1: 
heating. Stage 2: enzyme activation. Stage 3: denaturation and annealing/extension. 
Stage 4: Dissociation. “Reps” indicates the number of cycles the stages are repeated 
for. On the temperature indication line, the top box represents temperature in °C and 
lower box represents time in minutes. The Section highlighted in yellow is the data 
collection stage of the stage 3 cycle. 
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2.2.3.5 Quality control and gene expression data analysis 
A standard curve for each gene was included to ensure the efficiency of PCR 
amplification was within 90-110 %, according to the manufacturers’ protocol.  See 
Figure 2.5 for an example of standard curve demonstrating acceptable efficiency of 
amplification.  A dissociation stage at the end of each qRT-PCR run was included to 
ensure primer specificity through melting curve analysis.  Figure 2.6 shows a typical 
melting curve indicating a single and specific product of amplification. Standard and 
melting curves from qRT-PCR analysis and their calculated efficiency of the 















Figure 2.5. Example of sequence detection system generated standard curve. 
 
Figure 2.6. Example of sequence detection system generated results of dissociation 
stage for melting curve analysis. 















After inspection of the quality controls mentioned above, expression data was 
derived by the 2
(-ΔΔCt) 
(Livak) method (Livak & Schmittgen, 2001; Schmittgen & 
Livak, 2008).  The Livak method of gene expression analysis is in 3-steps, as 
follows: 
1. Normalisation of the gene of interest per sample  
ΔCT(sample) = CT (sample GOI) – CT (sample HKG)  
2. Normalisation per treatment group 
ΔΔCT = ΔCT (treated sample) – ΔCT (control sample) 
3. Calculating a normalised expression ratio 
2
(-ΔΔCt) 
Where, CT: threshold cycle at which amplicon fluorescence passes above background.  GOI: gene of 
interest.  HKG: housekeeping gene. 
 
The Livak method of gene expression analysis assumes efficiency of amplification is 
perfect or equal between all genes in the equation. The threshold cycle (CT) value is 
derived from the linear exponential phase of PCR amplification (above low level 
background, and below the high level plateau). The equation is based on the fact that 
during the linear exponential phase of amplification, the levels of all amplicons are 
directly proportional to their starting amounts. As the increase in amplicon 
abundance during replication is exponential, the data are initially handled as logged 
values. Thus the CT is normalised for each gene and expressed as a ratio for each 
sample, the efficiency of amplification is then raised to the power of the derived 





2.2.4 Protein abundance analysis 
Protein abundance levels were quantified through the use of Western blotting and 
band-specific densitometry.  The following sections describe the process of protein 
isolation and quantification.  For buffer and gel compositions see Section 2.1.4. 
2.2.4.1 Protein isolation and quantification 
Total protein was isolated from Caco-2 cells, immediately following treatments, by 
adding a SDS lysis buffer directly into cell culture wells/flasks after washing with 
ice-cold PBS.  Proteins were then prepared for Western blotting as follows.  In 6-
well plates 50-100 µl of lysis buffer (see Section 2.1.4, Table 2.10 for composition) 
was used per well depending on the cell density.  When using T-25 flasks, 150-300 
µl of lysis buffer was added per flask depending on the cell density.  If cell density 
was high, i.e. covering the entire growth surface in a thick layer, more lysis buffer 
was used.  Caco-2 cell monolayers were then removed thoroughly using a cell 
scraper and the entire cell lysate was transferred to 2 ml tubes.  Cells were lysed and 
homogenised over ice by repeatedly passing through a 1 ml syringe and needle.  Cell 
lysates were then centrifuged at 600 rpm at 4 °C for 10 min until the supernatant was 
transparent.  From the supernatant, 6µl was then taken for quantification using a 
Bradford spectrophotometric assay (Protein quantification kit-rapid, 51254-1KT, 
Sigma, Dorset, UK) based on a BSA standard curve ranging from 0 to 2000 µg/ml.  
Following quantification, samples were made into 40 µg aliquots and stored with 
sample loading buffer at -20 °C. 
2.2.4.2 Western blotting 
For the first step of Western blotting, gels were prepared for electrophoresis.  
Sodium dodecyl sulphate-polyacrylamide gels consisted of 10 % (w/v) acrylamide.  
After setting, gels were then placed into electrophoresis tanks which were then filled 
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with SDS running buffer.  The electrophoresis tanks were operated at a constant 
voltage of 180 V and a variable current from 0-5 mA.  Gels were run for 
approximately 40 min.   
After electrophoresis, the proteins in the gel were then blotted onto a nitrocellulose 
membrane using a semi-dry transfer cell.  The transfer was made by creating a 
layered stack in the following order, from top to bottom: Filter paper – gel – 
nitrocellulose membrane – filter paper.  It was important to ensure that the filter 
paper, gel and membrane were of the same size.  Stacked components were soaked 
in transfer buffer for at least 5 min, then placed on a moistened transfer cell surface, 
membrane-side down and gel-side up.  Transfer was run at 35 mA per gel-membrane 
for 60-90 min. Following transfer, reversible Ponceau S staining (P7170, Sigma-
Aldrich, Dorset, UK) was carried out to ensure efficiency of transfer. For an example 









Figure 2.7. Ponceau S reversible protein staining. Ponceau S was used as a 




After destaining (by immersion in 0.1 M NaOH for 30 s and rinsing with distilled 
water) the membranes were placed in blocking solution for 30-60 min at room 
temperature with constant agitation at 60 rpm.  After blocking, membranes were 
incubated with the primary antibody diluted into 3 ml of washing solution contained 
in a 50 ml falcon tube.  Primary antibody incubation was carried out overnight at 4 
°C on a roller-mixer to ensure even distribution of the antibody solution over the 
membrane.  After the primary antibody incubation, membranes were washed at room 
temperature, 3 times for 10 min each, with washing solution.  Membranes were then 
incubated with the appropriate secondary antibody, diluted into 3 ml of washing 
solution, for 60-90 min at room temperature.  After the secondary antibody 
incubation, membranes were washed at room temperature, 3 times for 10 min each, 
with washing solution and were then ready for detection.  All washes were done with 
constant agitation at 60 rpm, by placing membranes on a rocker. See Table 2.34 for 
primary antibodies and concentrations used, secondary antibodies were used at the 
same dilution as the primary antibodies. Working antibody dilutions were 
determined by initially carrying out smaller scale Western blots with varying 
concentrations (1:2000, 1:1000, 1:500). 
Table 2.34. Antibodies and working concentrations applied in Western blotting. 
Antibodies were diluted in PBST and 1 % (w/v) non-fat powdered milk. 
Primary antibody Working dilution Supplier 
Anti-SGLT1 1:500 Millipore, Consett, UK 
Anti-GLUT2 1:500 Millipore, Consett, UK 
Anti-DMT1 1:1000 Alpha Diagnostics, TX, USA 
Anti-FPN 1:1000 Alpha Diagnostics, TX, USA 
Anti-CTR1 1:1000 Novus Biologicals, Cambridge, UK 
Anti-ATP7A 1:1000 Abcam, Cambridge, UK 
Anti-β-Actin 1:2000 Sigma-Aldrich, Dorset, UK 
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2.2.4.3 Detection, densitometry and data analysis 
After the incubations with primary and secondary antibodies were complete, 
membranes were briefly removed from the washing solution and placed on a clean, 
dry and flat surface ready for application of the detection reagents.  The detection 
reagent components were mixed in a 1:1 ratio with a final volume of 1 ml per 
blotting membrane.  Detection reagents (Novex® ECL chemiluminescent substrate 
reagent kit, WP20005, Invitrogen life technologies, Paisley, UK) were then gently 
and evenly pipetted onto the surface of the membranes before dripping off excess 
reagent.  Membranes were then placed in a dark exposure cassette and covered with 
clear plastic.  The photosensitive light-films were exposed to the membranes in a 
dark room for 5-15 min then developed and fixed with film processing solutions.See 
Section 2.1.4 for materials and reagents. 
The fixed films were manually digitised on a densitometer (BioRad Laboratories, 
Hertfordshire, UK) with film-specific settings.  QuantityOne 1-D analysis software 
(BioRad Laboratories, Hertfordshire, UK) allowed autocorrection of the image, lane-
specific background reduction and automated band-detection.  Specific band density 
was quantified for each of the proteins to be detected.  Normalisation was to the 
amount of protein loaded per well and to the housekeeping protein β-actin.   
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2.2.5 Functional uptake and transport experiments 
Three experiments were carried out to quantify nutrient transport, one in each 
chapter, to investigate glucose, iron and copper absorption. Iron and glucose 
experiments were carried out with radiolabelled substrates, copper uptake 
experiments were carried out using inductively coupled plasma optical emission 
spectroscopy (ICP-OES). Each experiment was performed acutely (co-incubation of 
flavonoids and substrate for transport) or chronically (pre-treatment with flavonoids 
followed by separate functional experiment). The acute experiments were designed 
to investigate the effects when both compounds are present, i.e. structural, 
competitive, interactive effects. The chronic experiments were designed to 
investigate effects that may have arisen due to a transcriptional or translational effect 
only, i.e. could flavonoids induce an effect on gene or protein expression that has a 
functional consequence. The following section describes the protocols of the 
functional studies in each chapter. 
2.2.5.1 Glucose uptake experiments 
Glucose uptake experiments were carried out in the presence and absence of sodium, 
to identify differences between GLUT-mediated transport (active under both 
conditions) and SGLT-mediated transport (only active in the presence of sodium). 
Cells for this experiment were grown in 6 well plates. 
Glucose free HBSS was used for the glucose uptake experiments; see Section 2.1.5, 
Table 2.21 for composition of the uptake buffer. After loading buffers and 
treatments, cells were incubated at 37 °C for 15 min prior to initiating experiments. 
Radiolabelled glucose, D-[
3
H]-glucose, was diluted into a stock solution of 20 mM 





glucose was diluted to give an activity of ~ 500,000 DPM/well, and the final glucose 
concentration was 1 mM.  
Uptake was terminated after 2 minutes by aspirating uptake buffer and washing the 
cells 3 times with ice cold HBSS. After washing, 0.5 ml of 200 mM NaOH was 
added to each well; plates were then covered in cling film and cells were allowed to 
dissolve overnight at 4 °C. Cell lysate was then scraped and passed repeatedly 
through a 1 ml pipette, 20 µl of lysate was used for protein quantification and 200 µl 
was added to 5 ml of scintillation liquid (Ecoscint A, National Diagnostics, USA). 
Other control vials were also prepared, including the starting amount of glucose and 
a NaOH blank. All samples were subjected to scintillation counting. 
2.2.5.2 Iron transport experiments 
Iron transport experiments were carried out acutely and chronically, similar to the 
glucose uptake experiments above. For these experiments Caco-2 cells were grown 
on Transwell supports in 6-well plates. Two components of transport were measured 
for each experiment; the first being apical iron uptake and cellular retention, the 
second was the basolateral release of iron. 
For all experiments, the apical compartment of the Transwell supports was loaded 
with 1.5 ml pH 6.5 MES buffer and the basolateral compartment was loaded with 2.5 
ml pH 7.5 HBSS; see Section 2.1.5, Tables 2.22 and 2.23 for composition of these 
buffers. After loading buffers, cells were incubated at 37 °C for 20 min prior to 
initiating experiments. 
The source of iron was made by diluting the radioisotope 
55
FeCl3 into a stock 
solution of FeSO4 and ascorbate. Trace amounts of the radioisotopes were added to 
give ~ 500,000 DPM/well; the final concentrations of FeSO4 and ascorbate in the 
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apical compartments were 1 and 10 µM, respectively. Uptake was allowed to 
progress for 20 min, whereas measurements of cellular retention and transport were 
allowed to progress for 120 min.  
After 20 minutes or 120 minutes, the incubation was terminated by dipping each 
Transwell insert into ice cold HBSS 3 times; basolateral compartment media was not 
discarded. Transwell membranes were then drip dried briefly and cut away. 
Membranes were left overnight in 0.5 ml 200mM NaOH at 4 °C to dissolve cells. 
Membranes were then thoroughly scraped and the resulting cell lysate was passed 
through a 1 ml syringe. The following components were included for scintillation 
counting in 50 ml of scintillant:  150 µl cell lysate; 250 µl basolateral media; starting 
amount of the radiolabelled iron isotope and blanks for NaOH and basolateral media. 
2.2.5.3 Copper uptake experiments 
The experiments for copper uptake were carried out based on previous work in the 
laboratory of Dr. Paul Sharp, and were optimised in previous experiments by Dr. 
Katayoun Pourvali at Diabetes and Nutritional Sciences Division, King’s College 
London. Copper uptake experiments were carried out with an acute treatment or 
following a chronic treatment on cells grown in T-25 flasks. Copper uptake was 
carried out in MES buffer pH 6.5 with and without the inclusion of 100 µM 
ascorbate as a reducing agent; see Section 2.1.5, Tables 2.22 for the composition of 
the uptake buffer. To initiate uptake, CuCl2 was added into the cell culture flasks that 
had been preequilibrated in with uptake buffer for 15 min, to give a final 
concentration of 10 µM. 
Uptake was terminated after 120 min by washing cells with ice cold PBS. Cells were 
harvested (in 2 ml PBS; of which 20 µl was used for protein quantification) and 
dissolved (in 3 ml of 1 M nitric acid and 5 ml of 70 % (v/v) nitric acid). The 10 ml 
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solution of cell lysate was heated at 90 °C of 90 min, and then centrifuged at 5000 
rpm for 10 min to remove any remaining cell debris.  
Solubilised samples were analysed by ICP-OES (iCAP 6000 series; Thermo 
Scientific, UK). A multi element standard, with a copper content of 1006 ± 10 mg/L, 
was used for quantification. The specific wavelength for quantification of copper 
was 324.754 nm. Data were normalised to protein content and expressed as copper 
uptake per 120 min. 
2.2.6 Statistical analysis 
Statistical approaches and algorithms applied in microarray analysis are detailed in 
Section 9.3. Bioinformatics analysis.  Each data set, for qRT-PCR, Western 
blotting and uptake and transport studies was normalised prior to statistical testing.  
Gene expression data were normalised to both 18S and GAPDH as housekeeping 
genes. In this regard, normalisation to multiple housekeeping genes is recommended 
by Vandesompele et al (2002) and Caradec et al (2010).  Protein abundance data 
were normalised to both the amount of protein loaded and to the density of 
corresponding β-actin bands.  Uptake and transport studies were normalised to total 
protein content.  All data was tested using a non-paired Student’s t-test, ANOVA 
with Dunnet’s post-hoc test, ANOVA with post test for linear trend or Kruskal-
Wallis with Dunn’s post-hoc test.  In all cases significance was indicated at p ≤ 0.05.  
Other statistical tests are as indicated in the methods section of each chapter or in the 









3 Effects of berry extract on the transcriptome of Caco-2 
enterocytes 
3.1 Introduction: The transcriptomic effects of flavonoids 
Flavonoids are known to have wide ranging beneficial effects including antioxidant 
actions and reducing the risk of cancer, cardiovascular disease and diabetes 
(previously reviewed by Bravo, 1998 and Crozier et al, 2009).  However, the precise 
mechanisms by which flavonoids influence health remain unknown.  One powerful 
tool to investigate the therapeutic range and transcriptional mechanisms of such 
biologically active compounds is the application of genome wide arrays.  Essentially, 
they identify the relative change in global mRNA expression and thus help to define 
novel testable hypotheses for future research.  The transcriptomic effects of 
flavonoids have however only been investigated by a few groups which are briefly 
reviewed below. 
Lefevre et al (2008) applied microarray technology as a “hypothesis generating 
paradigm”.  They found that anthocyanin supplementation of a proatherogenic diet 
down-regulated gene clusters associated with the response to inflammation and 
oxidative stress in murine liver.  Their resulting gene-lists were highly enriched with 
pathways related to cellular defense and energy metabolism (Lefevre et al, 2008). 
In another study, Tsuda et al (2006) investigated the effects of anthocyanin 
aglycones and glycosides on the expression of genes relating to adipocytokine 
expression in human adipocytes.  Both aglycone and glycosides resulted in the 
alteration of 33 and 142 distinct genes, respectively.  The unique gene expression 
profiles were attributed to differences in membrane permeability of the flavonoid 
treatments (Tsuda et al, 2006).  
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In contrast to the above study by Tsuda et al (2006), Natsume et al (2009) suggested 
that the effects of sugar moieties on quercetin-induced changes in gene expression 
were negligible.  However, dosage was found to be a more significant determinant, 
as mice on a low flavonoid dose had a significantly different expression profile 
whereas there was no effect of the high dose (Natsume et al, 2009).  
To our knowledge, few other groups have investigated the effects of flavonoids on 
transcriptome variation, particularly in cells of the intestinal epithelium with the use 
of diet derived flavonoids.  We addressed this by examining the transcriptomic 
effects of berry flavonoids on enterocytes.  A well characterised model of human 
intestinal epithelial cells was used, i.e. Caco-2 cells (Sun et al, 2008); and treated 
with a documented flavonoid-rich berry extract; i.e. Optiberry
®
 (InterHealth 
Nutraceuticals, CA, USA) (Zafra-Stone et al, 2007).  Gene expression microarray 





Presented here is a brief description of the methods used in this chapter.  For full 
details of reagents, buffer/media compositions and methods used see Chapter 2. 
3.2.1 Experimental design 
This study was designed to generate testable hypotheses with the application of 
transcriptome analysis.  Human intestinal Caco-2 cells were treated with a flavonoid-
rich berry extract.  Following treatment, RNA was isolated and transcriptome 
variation measured using Affymetrix
®
 microarray chips.  Microarray data was 
analysed to identify areas of further investigation.  We then validated microarray-
detected gene expression values by qRT-PCR. 
3.2.2 Cell line, culturing and treatments 
Caco-2 cells between the passages of 44 and 47 were seeded into 6-well plates at a 
density of approximately 40,000 cells per well (4,000 cells per cm
2
) and cultured for 
19 days prior to treatment.  Details of the maintenance of the cells and composition 
of cell culture medium have been previously described (see Chapter 2 and Johnston 
et al, 2005).  The treatment used was a flavonoid-rich berry extract (derived from 
blueberry, bilberry, cranberry, elderberry, raspberry seeds and strawberry; rich in the 
anthocyanins delphinidin, cyanidin, petunidin and malvidin, OptiBerry®, 
InterHealth Nutraceuticals, CA, USA) for 16 h at a final concentration of 0.125 % 
(w/v) prepared in DMEM.  An identical medium, without berry extract, was used to 
treat control cells.  There were 6 samples in each group. 
Effects of berry extract treatment on cell viability and RNA content were tested.  




3.2.3 RNA sample preparation 
Following treatment, RNA was isolated using TRIzol® reagent (Invitrogen™ life 
technologies, Paisley, UK) according to the manufacturer’s protocol.  RNA 
concentration was quantified with a NanoDrop spectrophotometer (Thermo Fisher 
Scientific, Leicestershire, UK) and RNA integrity was quantified with the 2100 
BioAnalyzer (Agilent, Cheshire, UK) using the RNA 6000 Nano Kit (Agilent, 
Cheshire, UK) according to the manufacturer’s protocols (Fleet et al, 2003; Brand et 
al, 2008).  RNA was pooled from the 6 samples in each treatment group and applied 
to the microarray chips for global gene expression analysis.  Reverse transcription 
was carried out according to the manufacturer’s protocol using the High Capacity 
Reverse Transcription kit (Applied Biosystems™ Cheshire, UK).    
3.2.4 Transcriptome analysis 
Transcriptome analysis was carried out through the application of Affymetrix® 
GeneChip® Microarray systems.  Two HGU-133A gene chips (Affymetrix Inc., CA, 
USA) were prepared, with a single chip for each treatment condition: i.e. berry 
extract and control.  Following normalisation and filtering, resulting gene lists were 
subjected to ontological and pathway analysis. See Section 9.3 for details of the 
informatics analyses applied to global gene expression data. 
3.2.5 Gene ontology and pathway analysis 
Genes that passed the normalisation and filtering were then subjected to gene 
ontological clustering and pathway analysis.  Gene ontology (GO) clustering was 
performed on the Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) bioinformatics resource (www.david.abcc.ncifcrf.gov) using the default 
analysis settings (Dennis et al, 2003; Huang da et al, 2009).  Pathway analysis was 
performed on Ingenuity® Pathway Analysis (IPA) software (Ingenuity® Systems, 
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CA, USA; Maaser & Borlak, 2008).  Multiple pathway analyses were performed 
with the following filters: 
Analysis 1: all molecules and/or relationships 
Analysis 2: molecules and/or relationships where species = human 
Analysis 3: molecules and/or relationships were cell lines = colon cancer 
Analysis 4: molecules and/or relationships were species = human and cell lines 
= colon cancer 
3.2.6 Real-time PCR 
Genes were selected for validation using a candidate gene approach and on the basis 
of functional similarity.  The DAVID functional classification tool was utilised to 
determine a similarity score (Kappa statistic) of genes relative to an initial candidate 
gene (also called “bait” gene).  This was by a modified Fisher’s exact test based on 
overlapping GO terms between the bait gene and other genes in the gene-list (Dennis 
et al, 2003).  For the statistical approach of gene functional similarity clustering see 
Section 9.3.3. Functional similarity clustering and the Kappa score.  Genes 
selected for validation by qRT-PCR were related to nutrient transport; namely, 
glucose or metal transport.  The facilitative glucose transporter, GLUT2, was 
selected by a candidate gene approach.  Metal transport genes were chosen by 
functional similarity to the divalent metal ion transporter DMT1.     
Total RNA was isolated from cultured cells using TRIzol® (Invitrogen™ life 
technologies, Paisley, UK) according to the manufacturer’s protocol.  Following first 
strand cDNA synthesis (using the High Capacity Reverse Transcription kit; Applied 
Biosystems™ Cheshire, UK), gene expression levels were analysed by qRT-PCR 
using an ABI Prism 7700HT Sequence Detection System and a Power SYBR® 
Green PCR master mix kit (Applied Biosystems™ Cheshire, UK).  Primers were 
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designed using the online design tool Primer3 (Rozen & Skaletsky, 2000) and 
sourced from MWG Eurofins (London, UK).  Quantitative measurement of gene 
expression was derived from the 2
(-ΔΔCt)
 method, also known as the
 
Livak method 
(Livak & Schmittgen, 2001; Schmittgen & Livak, 2008).  Data were expressed as 
ratios to the control and normalised to the housekeeping genes 18S and GAPDH. 
The primer sequences used for each gene are in Table 3.1.  







GLUT2 AGT TAG ATG AGG AAG TCA AAG CAA TAG GCT GTC GGT AGC TGG 
DMT1 AGT GGT TTA TGT CCG GGA CC TTT AAC GTA GCC ACG GGT GG 
HFE CAC ACC ATC CAC TTT CAT GC GCA TGG ACA TGG TCA GTC AC 
ATP7B CCA CAT GAA GCC CCT GAC GAC CAC TTG TCC CCA TCA TC 
ZIP2 GTG CAG AAC AGA TCA GCA AGT GA CAA TGC CAG CGA CTC CAA A 
ZNT10 ACT AAC TCC TTT CCA TTC CCC TAT CCG CAG CTA TTG AGC C 
MRS2 CAT ACC CAA CAC TGC TGA C TTA CCC CAT CTT TTC CCT CC 
CACNA1D TGG TAG GAA CAG GTC CCA AG GGG AGA AGC AGA CTC CAC AG 
GLUT1 TCC ACG AGC ATC TTC GAG A ATA CTG GAA GCA CAT GCC C 
GMNN TGT CCA AAA GGA AAC ATC GGA ACT CCT GGG TGA CTC CTC CAA 
CDKN1A CTG CCC AAG CTC TAC CTT CC CAG GTC CAC ATG GTC TTC CT 
BUB1 AGG ATC TGC CCG CTT CCC GTC GTC TGA TAG GTT ACT GG 
18S AAC TTT CGA TGG TAG TCG CCG CCT TGG ATG TGG TAG CCG TTT 
GAPDH CTG TTG CTG TAG CCA AAT TCG T ACC CAC TCC TCC ACC TTT GA 
GLUT2: facilitative glucose transporter member 2; DMT1: divalent metal ion transporter 1; HFE: 
haemochromatosis protein; ATP7B: copper transporting ATPase β-polypeptide; ZIP2: zinc influx 
transporter member 2; ZNT10: zinc efflux transporter member 10; MRS2: magnesium homeostasis 
factor; CACNA1D: voltage-gated calcium channel; GLUT1: facilitative glucose transporter member 
1: GMNN: geminin; CDKN1A: cyclin dependent kinase inhibitor 1A: BUB1: budding uninhibited by 




3.2.7 Data and statistical analysis 
Microarray data were normalised with the use of GeneChip® Operating Software 
(GCOS; Affymetrix Inc., CA, USA) by MAS 5.0 linear normalisation with standard 
default settings applied (Traka et al, 2005).  Only genes with a fold-change of 1.9 or 
more and with a probe-set detection p-value of ≤ 0.05 were accepted as being 
differentially expressed; as dictated by GCOS default settings.  Resulting gene lists 
(up-regulated and down-regulated) were then subjected to pathway analysis, GO 
clustering and functional similarity clustering.  For details of informatics analysis see 
Section 9.3. Bioinformatics analysis.  Note, in bioinformatics, the term 
“enrichment” refers to a statistically significant high proportion of genes, from a 
given category, occurring in the experimental gene-list.  The category could mean a 
pathway or could mean a “term”; a term refers to a specific category of a larger 
database (e.g. apical membrane is a term from the GO category of cellular 
components) (Dennis et al, 2003). 
Real time PCR data are expressed as means + SEM of 6 observations per group.  
Statistical analysis was carried out using GraphPad Prism 5 (San Diego, CA, USA), 
A Student’s unpaired t-test was used to compare means; significance was indicated 





3.3.1 Effects of berry extract on cell viability, RNA content and integrity 
The effects of treatments on cell viability, RNA content and integrity were tested to 
ensure effects of berry extract were not due to pathological changes, but as 
normative responses.  There was no effect of berry extract on cell viability (Figure 
3.1), RNA content (Figure 3.2) nor RNA integrity for those samples used for either 
qRT-PCR or microarray analysis (Figure 3.3).  For an example of representative 
traces of BioAnalyzer charts indicating RNA integrity see Figure 3.4.   
Figure 3.1. Caco-2 cell viability after berry extract treatment. Caco-2 cells were 
treated with berry extract at 0.125 % (w/v) for 16 h. Cell viability was quantified 
with the trypan blue dye-exclusion method. Data is presented as mean percentage 
viable cells ± SEM, n = 6, Student’s t-test showed there was no significant 






















Figure 3.2. RNA concentration from Caco-2 cells after berry extract treatment. 
Caco-2 cells were treated with berry extract at 0.125 % (w/v) for 16 h. RNA 
concentration in the extracts of Caco-2 cells was quantified with the NanoDrop 
spectrophotometer. Data is presented as mean RNA concentration ± SEM, n = 6, 
Student’s t-test showed there was no significant difference between groups. 
Figure 3.3. Integrity of Caco-2 cell RNA samples. Caco-2 cells were treated with 
berry extract at 0.125 % (w/v) for 16 h. RNA integrity was quantified with 
BioAnalyzer chips. Data is presented as mean RIN ± SEM, n = 6, ANOVA showed 
there was no significant difference between groups. RIN: RNA integrity number; 




Figure 3.4. Example BioAnalyzer traces of Caco-2 cell RNA samples. Following 
RNA isolation, samples were tested with the BioAnalyzer to ensure high quality 
sample material with clearly defined peaks of 18S and 28S RNA (trace A for sample 
applied to microarray chips, and trace B for sample applied to qRT-PCR). Any 
degraded RNA samples (trace C) were not used in experiments. 18S/28S: ribosomal 
RNAs 18S and 28S. qRT-PCR: quantitative real-time polymerase chain reaction. 






3.3.2 Effects of berry extract on Caco-2 cell transcriptome 
Affymetrix chip .CEL file images of the fluorescent probes for each chip are shown 
in Figure 3.5.  Visual inspection of these chips indicated there was no uneven 
hybridisation, with a uniform balance of signals.  A total of ~22’000 genes showed 
positive signals, i.e. expressed in either control or treated samples.  Following 
normalisation and filtering, 2557 genes were accepted as altered by the berry extract, 
with a fold-change of 1.9 or more and a detection p-value of ≤ 0.05 (Figure 3.6).  Of 
these, the expression of 761 genes was increased and 1796 decreased relative to the 
control samples.  For a full set of the gene list, see Section 9.4. 
Chip for RNA  
from control cells 
Chip for RNA from  
berry extract treated cells 
  
Figure 3.5.  Graphic .CEL files generated from global gene expression analysis.  
Caco-2 cells were treated with berry extract at 0.125 % (w/v) for 16 h.  RNA was 
isolated and applied to microarray chips.  Each chip, one for control cells and the 
other for cells treated with berry extract, had 6 pooled RNA samples.  Each spot on 
the graphic file represents a gene; each gene is represented by 11 probe-sets from 
along the gene’s whole transcript. The microarray chips contain both positive 
controls as a set of 100 housekeeping genes, as well as pre-determined ranges of 
acceptable fluorescence. Negative controls are present for each probe-set in the form 
of mismatched probes to correct for cross- and random- fluorescence. Visual 
inspection shows a uniform balance of staining and signals across the chips. 




Figure 3.6. Gene expression fluorescence intensity between the control and 
berry extract treated cells. Caco-2 cells were treated with berry extract at 0.125 
% (w/v) for 16 h. RNA was isolated and applied to global gene expression 
microarray chips, fluorescence intensity from the chip was quantified, data was 
then normalised and filtered. A) Microarray fluorescence intensity signals prior to 
normalisation and filtering; and B) after normalisation and filtering. Lines and red 
numbers indicate fold-changes of 2, 3, 10 and 30 respectively from centre.  Red • - 
Present signal on both chips; Blue • - Present signal on one chip only; Yellow • - 
Absent signal on both chips. 

















































































3.3.3 Pathways affected by berry extract in Caco-2 cells  
Pathway analysis indicated there were a large number of processes affected by the 
berry extract.  Significance of enrichment of networks decreased considerably with 
increasing stringency of filtering.  For a tabulated summary of the highest scoring 
pathways resulting from each filtering condition see Table 3.2.  A number of 
associated functions of these pathways were common throughout the filtering 
process which included: cell cycle, gastrointestinal disease, gene expression, 
molecular transport, and small molecule biochemistry. For a description of the 
bioinformatics method for pathway analysis see Appendix 9.3.1. 
 
3.3.4 Gene ontological and functional similarity clustering 
GO term clustering analysis revealed a large number of enriched terms in our gene-
list; a sample of these is presented in Table 3.3.  GO terms enriched in our down-
regulated gene-list include: ion transport and carbohydrate metabolism; see Section 
9.5.1 Down-regulated genes for a complete list.  GO terms enriched in our up-
regulated gene-list were for transport and protein localisation; see Section 9.5.2 Up-
regulated genes for a complete list.  Gene functional similarity clustering, to DMT1, 
indentified 27 other genes related in nutrient and metal transport (Figure 3.7).   
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Table 3.2.  Gene networks affected by berry extract in Caco-2 cells.  Caco-2 cells 
were treated with berry extract at 0.125 % (w/v) for 16 h.  RNA was isolated and 
applied to microarray chips.  Microarray data was subjected to pathway analysis 
under 4 different filters with increasing analysis stringency. * Network score is -log10 












100 Cell Cycle, Cellular Assembly and Organisation, DNA 
Replication, Recombination, and Repair. 
40 
Developmental Disorder, Genetic Disorder, 
Neurological Disease. 
40 
Cellular Function and Maintenance, Skeletal and 
Muscular System Development and Function, Organ 
Development. 
40 
Cell Cycle, Cancer, Gastrointestinal Disease. 37 
RNA Post-Transcriptional Modification, Endocrine 





were species = 
human 
70 Cell Death, Inflammatory Disease, Hematological 
Disease. 
30 
Cell Cycle, DNA Replication, Recombination, and 
Repair, Cellular Movement. 
30 
Cell Death, Cellular Growth and Proliferation, Cell 
Cycle. 
30 
Cancer, Cellular Movement, Reproductive System 
Disease. 
13 





were cell lines 
= colon cancer 
cell lines 
16 Cell Death, Cancer, Respiratory Disease 10 
Cancer, Gastrointestinal Disease, Reproductive System 
Disease  
6 
Cancer, Cell Death, Reproductive System Disease 5 
Cell Death, Cancer, Cell Cycle 5 






= human) & 
(cell lines = 
colon cancer 
cell lines)  
19 Cell Death, Cancer, Cell Cycle 7 
Cancer, Cell Death, Connective Tissue Disorders 7 
Gene Expression, Cell Cycle, Cancer 4 
Cancer, Cell Death, Gastrointestinal Disease 3 
Cell Death, Cancer, Reproductive System Disease 2 
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Table 3.3.  Highly enriched GO terms in berry extract treated Caco-2 cells.  
Caco-2 cells were treated with berry extract at 0.125 % (w/v) for 16 h.  RNA was 
isolated and applied to microarray chips.  Microarray data was subjected to GO 








Metal ion binding ↓ 
Iron ion binding ↓ 
Zinc ion binding ↓ 
Transmembrane transporter activity ↑ 
Substrate specific transmembrane transporter 
activity 
↑ 
Sugar: hydrogen ion transporter activity ↑ 
Carbohydrate transmembrane transporter 
activity 
↑ 
ATPase activity coupled to transmembrane 
movement of substances 
↑ 
Glucose transmembrane transporter activity ↑ 
Passive transmembrane transporter activity ↑ 
Biological 
Process 
Carbohydrate metabolic processes ↓ 
Metal ion homeostasis ↓ 
Calcium ion homeostasis ↓ 
Metal ion transport ↓ 
Glucose metabolic process ↓ 
Iron ion transport ↓ 
Transport  ↑ 
Intracellular transport ↑ 
Vesicle mediated transport ↑ 
Regulation of intracellular transport ↑ 
Metal ion transport ↑ 
Cellular 
component 
Brush border ↓ 
Integral to Golgi membrane ↓ 
Apical plasma membrane ↓ 
Basolateral plasma membrane ↑ 
Membrane-bound vesicle ↑ 




Figure 3.7. Differentially expressed genes with functional similarity to DMT1 in berry extract treated Caco-2 cells. Caco-2 cells were 
treated with berry extract at 0.125 % (w/v) for 16 h. RNA was isolated and applied to microarray chips. Microarray data was analysed by gene 
functional similarity to DMT1, the initial ‘bait’ gene. Gene functional similarity (Kappa score) is determined by the overlap of gene ontology 
terms between all genes in the submitted gene list and the initial bait gene. From this list, some genes specifically relating to nutrient transport 
were chosen for further investigation. DMT1: Divalent metal ion transporter 1; HFE: Human haemochromatosis gene; ATP7B: Copper 









































































































































































































































































3.3.5 Preliminary validation of microarray detected gene expression 
Expression of DMT1, 7 functionally related genes and 4 randomly chosen genes 
were quantified by qRT-PCR as validation of microarray data.  In terms of 
directionality, microarray-detected changes were similar to data obtained by qRT-
PCR.  There was a significant correlation between microarray-detected and qRT-
PCR-detected changes in gene expression (r
2






















































Figure 3.8. Quantitative PCR validation of microarray detected fold-changes 
from berry extract treated Caco-2 cells. Caco-2 cells were treated with berry 
extract at 0.125 % (w/v) for 16 h. RNA was isolated and applied to global gene 
expression microarray chips. A number of genes were chosen for validation of 
microarray data. Validation of gene expression changes was done using qRT-PCR. 
The microarray and qRT-PCR data are significantly correlated (solid line: r
2
 = 0.45; 
p ≤ 0.05; dashed lines are 95% confidence intervals). DMT1: divalent metal ion 
transporter 1. ATP7B: copper transporting ATPase β-polypeptide, HFE: 
haemochromatosis protein; GLUT2: facilitative glucose transporter 2. All others 
were arbitrarily chosen for purposes of validation; their biological roles are not 
pertinent to the subject of this thesis 
r
2
 = 0.45 









After consumption, flavonoids are known to be present at high concentrations in the 
intestinal lumen, up to 50 or 100 fold higher than those levels found in the 
circulation (Manach et al, 2005; Kwon et al, 2007).  In this anatomical region the 
flavonoids have direct interaction with the absorptive enterocytes (Talavera et al, 
2004; Matuschek et al, 2006).  Although flavonoids are known to have a broad 
therapeutic spectrum, their precise transcriptional effects are unknown.  We therefore 
tested the supposition that dietary flavonoids are capable of altering the human 
intestinal Caco-2 cell transcriptome.  This was addressed by use of microarrays and 
bioinformatic analysis.  Transcriptome analysis generated gene-lists that were later 
subjected to pathway analysis, GO analysis and functional similarity clustering.  
Finally, a number of genes were selected for validation, and to generate areas for 
further research.   
Bioinformatic analysis revealed that flavonoids affected the expression of genes 
relating to gastrointestinal conditions, inflammation and nutrient transport.  
Functional similarity clustering, around our initial gene of interest DMT1, identified 
genes related to the transport of dietary metals (iron: HFE; copper: ATP7B) and 
glucose (GLUT2).  Microarray data must be validated, to some degree, with the use 
of more sensitive and specific methods of gene expression analysis such as qRT-
PCR. The expression of the above genes and other randomly chosen ones was 
validated as such, with qRT-PCR, thus lending support to the validity of our array.  
The following discussion focuses on our microarray analysis in the context of other 




3.4.1 Effects of flavonoids on transcriptome variation  
The term ‘enrichment’ refers to the high proportions of co-functioning genes in a 
given gene-list.  In other words, if an experimental gene-list is enriched, it will have 
a higher proportion of co-functioning genes than the background gene-list (e.g. 
human genome).  Furthermore, term refers to detailed items in a given database; e.g. 
oxygen binding is a term from a database that encompasses molecular functions 
(Huang da et al, 2008). Term, is often used synonymously with the word cluster.  
However, comparison of results between microarray-based studies remains 
problematic due to inconsistent ways of reporting and due to different bioinformatic 
and statistical approaches. 
In a study by Tsuda et al (2006), where adipocytes were treated with an anthocyanin 
extract, GO terms such as carbohydrate metabolism, lipid metabolism, ion transport 
and cell cycle processes were shown to be enriched. Our gene-list was also enriched 
with such terms.  On a gene-by-gene basis Tsuda et al (2006) reported decreased 
expression of GLUT3 and ATP7A.  These genes are isoforms of GLUT2 and 
ATP7B, respectively, both of which had decreased expression in our study.  This 
indicates a common feature of flavonoid-induced ATPase and GLUT mRNA 
regulation between cell types.  Lefevre et al (2008) found that grape-anthocyanins 
downregulated mitochondrial function, energy metabolism and acute inflammatory 
response GO clusters in hepatocytes.  These were similarly enriched in our findings 
and are possibly attributed to the general antioxidant effects of flavonoids.  In 
another study, conducted in humans (Boomgaarden et al, 2010), quercetin 
administration enriched GO clusters relating to nucleic acid metabolism and 
apoptosis in monocytes.  This also agrees with our findings.  However, the affected 
pathways (as opposed to ontological clusters) reported in the aforementioned study 
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were very different to the ones we identified.  Therefore pathway activation may be 
more of a cell- or tissue-type specific phenomenon than GO term enrichment.   
3.4.2 Transcriptomic evidence of flavonoids and nutrient interactions 
Our array findings emphasise that flavonoids induce differential expression of genes 
that coordinate transport of metals and glucose.  In this section there is a discussion 
of the evidence which supports the putative interactions between flavonoids and 
these nutrients.   
3.4.2.1 Putative interactions of glucose and flavonoids 
There have been reports of the putative anti-diabetic properties of flavonoids in other 
microarray-based studies (Suzuki et al, 2011; Viduranga et al, 2011).  For example, 
the flavone baicalin has been found to reduce oxidative stress induced by 
hyperglycaemia.  This was through the increased hepatic expression of antioxidant 
enzymes in Goto-Kakizaki rats fed baicalin (Viduranga et al, 2011).  Furthermore, 
anthocyanidin treatments have been found to strongly inhibit adipocyte 
differentiation mediated via the insulin pathway (Suzuki et al, 2011). 
In our study, berry extract treatment decreased the expression of GLUT2 mRNA, a 
major monosaccharide transporter.  Furthermore, our gene-list, of berry extract 
treated cells, was enriched with the following ontology terms: glucose 
transmembrane transporter activity, apical plasma membrane and basolateral 
plasma membrane.  These findings support the putative anti-diabetic properties of 
flavonoids, as GLUT2 is a major apical and basolateral channel for intestinal glucose 
transport.  In-fact, permanent apical localisation of GLUT2 is a major characteristic 
of insulin resistant states and a popular animal model of diabetes (i.e. the ob/ob 
mouse) (Tobin et al, 2008; Ait-Omar et al, 2011).  Therefore, differential expression 
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of GO terms related to glucose transporters and their cellular membrane localisations 
provide strong support for the beneficial anti-diabetic properties of flavonoids.   
3.4.2.2 Putative interactions of dietary metals and flavonoids 
Flavonoids are known to form complexes with metal ions; these interactions are 
known to influence the dietary metal transport processes (Kim et al, 2008; Lekka et 
al, 2009).  In light of this, it is not surprising that the berry extract caused differential 
expression of a number of genes relating to dietary metal transport.  Furthermore, 
enriched GO terms were related directly to dietary metal metabolism, these include: 
metal ion binding, iron ion binding, zinc ion binding, metal ion transport, metal ion 
homeostasis and iron ion transport.  The differentially expressed genes in our array 
are specifically involved in the transport of dietary iron (HFE and DMT1), copper 
(ATP7B, and DMT1 is also known to transport copper), zinc (the zinc influx and 
efflux genes ZIP2 and ZNT10, respectively) and magnesium (the magnesium 
homeostasis factor MRS2).   
Other array based studies have reported findings supporting flavonoid interactions 
with metal metabolism.  Zhao et al (2011) reported that flavonoids induced 
differential expression of phase 2 enzymes and the ATP-binding cassette (ABC) 
transporter superfamily in rat livers.  These groups of enzymes are involved in the 
metabolism, biotransformation and biliary excretion of quercetin.  As well as the site 
of flavonoid metabolism and excretion, the liver is the main site of copper 
metabolism and excretion in the body. Thus, there are clear effects of flavonoids at 
the sites of copper absorption, metabolism and excretion; i.e. intestinal and hepatic 
tissues (Tsuda et al, 2006; Natsume et al, 2009; Zhao et al¸ 2011).  Furthermore, 
specific genes involved in copper homeostasis are affected by flavonoids, (i.e. 
ATP7B and DMT1). In light of our findings and those from Tsuda et al (2006), 
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Natsume et al (2009) and Zhao et al (2011) there is transcriptomic evidence that  
flavonoids affect copper metabolism/excretion.   
In the study by Natsume et al (2009) a 2 week administration of quercitin and its 
derivatives caused a decrease in expression of iron transport-related genes (e.g.  
FPN, MT, ferritin heavy chain) and several ATPases in mouse intestine.  This is 
consistent with our in-vitro findings of the berry extract causing down-regulation of 
metal transport-related genes in enterocytes.  Although different genes are reported 
by Natsume et al (2009), they are part of a single pathway, which is the intestinal 
transport of iron.  The longer duration of treatment by Natsume et al (2009) may 
have activated pathways of crypt cell programming; in turn dictating the absorptive 
capacity of enterocytes (Parkkila et al, 1997; Bédrine-Ferran et al, 2004).     
3.4.2.3 Flavonoids, metals, glucose and oxidative stress 
It is well known that cellular glucose and metal homeostasis are tightly regulated, as 
an increase in either one will induce cellular oxidative stress (Núñez et al, 2001; Han 
& Park, 2011; Ogawa et al, 2011).  Furthermore, nutrient transport is known to be 
sensitive to cellular oxidative states. In light of this, it is not surprising that flavonoid 
antioxidants may reverse the effects of such oxidative stress on transport processes 
(Han & Park, 2011; Jagetia & Reddy, 2011; Dhar et al, 2012).   
Previous researchers have consistently reported GO terms relating directly to 
oxidative stress, antioxidants or cellular oxidative state following flavonoid 
treatments (Viduranga et al, 2011; Zhao et al, 2011).  However, we did not find any 
GO terms relating directly to antioxidant potential, this may be due to the treatment 
durations, the sources of flavonoids, the cell line under investigation or the general 
study designs. Inasmuch as inclusion of a treatment condition to induce oxidative 
stress co-incubated with the flavonoids may result in enrichment of the 
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aforementioned GO terms; or given the volatile nature of redox reactions and 
responses, shorter durations may cause enrichment or oxidative stress related GO 
terms.  However, the co-regulation of metal and glucose transport related genes, in 
our study, suggests there is an antioxidant role of flavonoids mediated through their 
nutrient interactions; i.e. preventing oxidative stress induced by high cellular metal 
or glucose concentrations. 
3.5 Conclusions and implications for next chapters 
In this study, microarray analysis was applied to derive biological themes arising 
from the effects of flavonoids on cells of the intestinal epithelium.  Gene expression 
arrays are typically used as screening tools or to generate testable hypotheses.   
Following Caco-2 cell treatment with berry flavonoids, informatic analysis identified 
a large number of pathways and ontological clusters of genes that were affected.  
Pathway analysis revealed networks with functions relating to cell cycle, gene 
expression, post-translational modification and molecular transport, among others.  
Numerous GO terms were enriched, including: metal ion binding, glucose 
transmembrane transporter activity, transport, brush border and late endosome 
membrane. The GO findings are consistent with previous findings from other 
groups.  This indicates there are common mechanisms to regulate mRNA of these 
co-functioning genes.   
We also applied functional similarity clustering around DMT1 as a bait gene. We 
found genes relating to metal transport, namely iron transport (HFE) and copper 
transport (ATP7B). Furthermore, the major glucose transporter, GLUT2, was also 
down-regulated. In the remainder of this thesis, we focused on these candidate genes. 
We investigated the effects of flavonoids on intestinal uptake of glucose, iron and 




Effects of flavonoids on the expression and function of intestinal glucose 





4 Effects of flavonoids on the expression and function of intestinal 
glucose transporters in Caco-2 enterocytes 
4.1 Introduction: Intestinal glucose uptake and dietary flavonoids 
The primary step in glucose metabolism is intestinal glucose absorption; it is 
adaptable to luminal and systemic factors to maintain glucose homeostasis (Cui et al, 
2003; Tobin et al, 2008).  The classical mechanisms of intestinal glucose transport 
state that apical uptake is mediated via the sodium/glucose co-transporter member 1, 
SGLT1, and that basolateral release is mediated via the facilitative glucose 
transporter member 2, GLUT2.  However, the apical uptake of glucose can occur 
through both a saturable component and a non-saturable diffusive component.  The 
phloridzin-sensitive SGLT1 pathway accounts for saturable uptake.  The diffusive 
component, however, is suggested to be mediated via GLUT2 at an apical 
localisation (Debnam & Levin, 1975; Kellet & Helliwell, 2000).   
Current models suggest that under conditions of high luminal glucose, GLUT2 
translocates to the apical membrane, which increases glucose uptake by up to 3-fold 
more than SGLT1 alone (Gouyon et al, 2003).  Under healthy conditions, GLUT2 is 
then retracted from the apical membrane in response to insulin signaling after plasma 
glucose levels increase (Tobin et al, 2008).  However, in insulin-resistant states, 
GLUT2 is permanently localised at the apical membrane. It does not respond to 
insulin signaling, thereby chronically increasing glucose influx (Corpe et al, 1996; 
Tobin et al, 2008).  This high transport capacity of GLUT2, its translocation 
properties and its permanent apical presence during insulin resistance, makes it a 
major candidate for the control of glucose absorption.  Although pharmacological 
regimes are currently used to maintain plasma glucose, they have numerous side-
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effects (for example, hypoglycaemia, weight gain, diarrhea).  Furthermore, 
pharmacological intervention remains supplementary to rigorous dietary and lifestyle 
management.  In light of this, there has been an emergence of interest in the putative 
therapeutic properties of polyphenolics in order to optimise dietary management of 
this disease (Cheng & Fantus, 2005; Martinuea et al, 2006).    
It is currently well known that intestinal glucose uptake is sensitive to polyphenols, 
exemplified by the inhibitory effects of apple polyphenol phloridzin and apple tree 
leaf polyphenol phloretin, on SGLT1 and GLUT2 mediated uptake, respectively 
(Alvarado, 1967).  Other flavonoids have been confirmed to inhibit glucose uptake, 
such as quercetin, cyanidin and catechins (Park, 1999).  The most potent inhibitors of 
glucose uptake are flavones or flavonols with hydroxylation of the C5 and/or C7 
positions (Park, 1999).  Furthermore, past research has established selective 
interaction of glycosylated compounds such as neohesperidin and phloridzin with 
SGLT1 (Gee et al, 1998; Walgren et al, 1998; Walgren et al, 2000; Wolfram et al, 
2002; Walle & Walle, 2003).  In contrast, aglycone flavonoids, like phloretin, target 
GLUT2 (Johnston et al, 2005; Kwon et al, 2007).  In light of this, quercetin, its 
derivatives and structurally similar flavonoids, may be effective regulators for both 
absorptive components of intestinal glucose uptake.   
Previous studies of the modulatory effects of flavonoids on glucose uptake were 
conducted with acute treatments of 1 h or less (for example Gee et al, 1998; 
Wolfram et al, 2002; Johnston et al, 2005). Such short durations would not have 
allowed transcriptional or translational events to have fully taken place; therefore the 
measurement of such a response would not have been possible.  Furthermore, studies 
used isolated synthetic flavonoids, i.e. not from a food matrix, thus disregarding the 
potential synergistic effects of a heterogeneous mixture of polyphenolics.     
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The aim of this study was to address the issues raised above and in particular the 
hypothesis that dietary polyphenolics modulate glucose uptake and the expression of 
intestinal glucose transporters.  Berries are a rich source of flavonoids, and quercetin 
is the most abundant polyphenol in the diet.  Therefore in this study we have used a 
flavonoid-rich berry extract, (i.e. Optiberry®), quercetin and the well documented 




Presented here is a brief description of the methods used in this chapter.  For full 
details of reagents, buffer/media compositions and methods used see Chapter 2. 
4.2.1 Cell culture 
Caco-2 TC7 cells between the passages of 44 and 47 were seeded into 6-well plates 
at a density of approximately 40,000 cells per well (4,000 cells per cm
2
) and cultured 
for 19 days prior to treatment.  Details of the maintenance of the cells and 
composition of cell culture medium have been previously described (see Chapter 2 
and Johnston et al, 2005). 
The treatment used was a flavonoid-rich berry extract (derived from blueberry, 
bilberry, cranberry, elderberry, raspberry seeds and strawberry; rich in the 
anthocyanins delphinidin, cyanidin, petunidin and malvidin, OptiBerry®, 
InterHealth Nutraceuticals, CA, USA) at a final concentration of 0.125 % (w/v).  
Isolated flavonoids used were quercetin, phloretin and phloridzin at a final 
concentration of 100 µM.  Isolated flavonoids were dissolved in DMSO, which was 
then diluted into the treatment media or buffer to give a final DMSO concentration 
of 0.05 % (v/v).  All treatments were prepared in DMEM for gene expression, 
protein abundance studies and chronic-exposure glucose-uptake experiments.  
Treatments for acute-exposure glucose-uptake experiments were prepared in HBSS.  
Controls for the berry extract cells were treated with identical medium without the 
berry extract.  Controls for isolated flavonoid-treated cells were treated with identical 
medium, containing 0.05 % (v/v) DMSO, without the flavonoids. All treatments 
were added followed by gentle mixing. 
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The effect of flavonoid and solvent treatments on cell viability, RNA and protein 
content of the cells were tested.  There were no effects of any treatments on cell 
viability, RNA or protein content (see Results, Section 4.3.1). 
4.2.2 Real-time qPCR 
Total RNA was isolated from cultured cells using TRIzol® (Invitrogen™ life 
technologies, Paisley, UK) according to the manufacturer’s protocol.   Following 
first strand cDNA synthesis (using a high-capacity cDNA reverse transcription kit, 
Applied Biosystems™ Cheshire, UK), expression levels of GLUT2 and SGLT1 
mRNA and of 18S and GAPDH mRNA (used as housekeeping genes) were analysed 
by real-time PCR using an ABI Prism 7700HT Sequence Detection System and a 
Power SYBR® Green PCR master mix kit (Applied Biosystems™ Cheshire, UK).  
Primers were designed using the online design tool Primer3 (Rozen & Skaletsky, 
2000) and sourced from MWG Eurofins (London, UK).  Quantitative measurement 
of gene expression was derived from the 2
(-ΔΔCt)
 method, also known as the
 
Livak 
method (Livak & Schmittgen, 2001; Schmittgen & Livak, 2008).  Data were 
expressed as ratios to the control and normalised to the housekeeping genes 18S and 
GAPDH. The primer sequences used for each gene are in Table 4.1. 







GLUT2 AGT TAG ATG AGG AAG TCA AAG CAA TAG GCT GTC GGT AGC TGG 
SGLT1 TCT TCG ATT ACA TCC AGT CCA TCT CCT CTT CCT CAG TCA TC 
18S AAC TTT CGA TGG TAG TCG CCG CCT TGG ATG TGG TAG CCG TTT 
GAPDH CTG TTG CTG TAG CCA AAT TCG T ACC CAC TCC TCC ACC TTT GA 
GLUT2: facilitative glucose transporter member 2; SGLT1: sodium-glucose cotransporter member 1; 
18S: ribosomal RNA18S; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 
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4.2.3 Western blotting 
Total protein from Caco-2 cells was prepared as described previously (Chaston et al., 
2008).  Total proteins (40 μg) were solubilised in loading buffer and subjected to 
SDS-PAGE.  Following transfer to nitrocellulose, membranes were exposed to 
GLU2 or SGLT1 antibodies; β-actin levels were used to normalise.  Proteins were 
visualised using a horseradish peroxidase-linked secondary antibody and Novex® 
ECL chemiluminescent substrate reagent kit (Invitrogen™ Life Technologies, 
Paisley UK).  Band densities were quantified on a densitometer (GS-800™) and 
Quantity One software (Bio-Rad Laboratories, Hertfordshire, UK). For antibody 
concentrations and reagents see Section 2.2.4. Protein abundance analysis. 
4.2.4 Glucose uptake assays 
For full description of glucose uptake assays see Section 2.2.5.1. Glucose uptake 
experiments, for buffer composition, radionuclides and suppliers see Section 2.1.5. 
Materials used in nutrient uptake and transport studies; this section only briefly 
describes the protocol applied. Glucose uptake assays were performed with D-[
3
H]-
glucose and designed to identify interactive and transcriptional/translational effects 
of flavonoids on glucose uptake.  Caco-2 cells were exposed to flavonoid treatments 
acutely (15 min) or chronically (16 h).   For acute incubations, D-[
3
H]-glucose was 
added into the treatment solution. In chronic incubation studies, treatment solutions 
were replaced with uptake buffer containing only D-[
3
H]-glucose. Uptake carried out 
in the presence and absence of sodium allowed differentiation between effects on 
sodium-dependant (mediated by GLUT2 and SGLT1) and sodium-independent 
(mediated by GLUT2) pathways.  The difference between the two, when sodium-
dependent was greater than sodium-independent uptake, the difference indicated 
SGLT1-mediated uptake.  
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4.2.5 Data and statistical analysis 
Data are expressed as means + SEM of 4, 6 or 12 observations per group depending 
on the experiment.  Statistical analysis was carried out using GraphPad Prism 5 (San 
Diego, CA, USA).  In studies containing 2 experimental groups Student’s unpaired t-
test was used to compare means.  Differences between multiple groups were 
calculated using a 1-way ANOVA with Dunnett’s post-hoc test.  For data that was 
not normally distributed a Kruskal-Wallis test was used with Dunn’s post-hoc test.  





4.3.1 Effects of flavonoids on cell viability, RNA and protein content 
The effects of treatments on cell viability, RNA content and protein content were 
examined to ensure effects were not due to pathological changes, but as normative 
responses.  There was no effect of flavonoids or solvent on cell viability (Figure 
















Figure 4.1. Caco-2 cell viability after flavonoid treatments. Caco-2 cells were 
treated with berry extract at a concentration of 0.125 % (w/v), phloretin, phloridzin 
or quercetin at 100 µM, or DMSO at a concentration of 0.05 % (w/v) for 16 h. Cell 
viability was quantified by the trypan blue dye-exclusion method. Data is presented 
as mean percentage viable cells ± SEM, n = 4. ANOVA and Dunnet’s post-hoc test 





Figure 4.2. RNA concentration from Caco-2 cells after flavonoid treatment. 
Caco-2 cells were treated with berry extract at a concentration of 0.125 % (w/v), 
phloretin, phloridzin or quercetin at 100 µM, or DMSO at a concentration of 0.05 % 
(w/v) for 16 h. RNA concentration in the extracts of Caco-2 cells was quantified with 
the NanoDrop spectrophotometer. Data is presented as mean RNA concentration ± 
SEM, n = 6. ANOVA and Dunnet’s post-hoc test showed there was no significant 
difference between groups. DMSO: dimethyl sulfoxide. 
Figure 4.3. Protein concentration from Caco-2 cells after flavonoid treatment. 
Caco-2 cells were treated with berry extract at a concentration of 0.125 % (w/v), 
phloretin, phloridzin or quercetin at 100 µM, or DMSO at a concentration of 0.05 % 
(w/v) for 16 h. Protein concentration was quantified by the Bradford 
spectrophotometric assay. Data is presented as mean protein concentration ± SEM, n 
= 6. ANOVA and Dunnet’s post-hoc test showed there was no significant difference 





4.3.2 Effects of flavonoids on glucose transporter gene expression 
Expression of GLUT2 and SGLT1, the main glucose transport genes, was quantified 
across a number of concentrations of the berry extract and across different treatment 
durations.  Significant inhibitory effects were observed on GLUT2 gene expression 
at 0.0125 % (w/v) (p < 0.001) and at 0.25 % (w/v) (p < 0.05; Figure 4.4, panel A). 
The expression of GLUT2 at the 0.016 % (w/v) dose (0.79 ± 0.1) was only slightly 
higher than that at 0.25 % (w/v) dose (0.72 ± 0.2); this slight difference in expression 
level caused the expression at 0.016 % (w/v) to be just out of the significance 
threshold, whereas the 0.25 % (w/v) dose expression level was borderline significant 
(p ≤ 0.05).  As for SGLT1, there was significant inhibition of gene expression at 0.25 
% (w/v) (p < 0.05; Figure 4.5, panel B).  As for the effects of treatment duration (all 
with 0.125 % (w/v)), significant effects on GLUT2 gene expression were between 12 
h (p < 0.01) and 16 h (p < 0.001) of treatment (Figure 4.5, panel A).  There was a 
slight linear trend of the effects of treatment duration on GLUT2 expression, 
indicating decreased expression with increasing duration of treatment (slope= -0.1; r
2
 
= 0.1; p < 0.05; Figure 4.5).  
Flavonoid treatments were tested on GLUT2 and SGLT1 expression at 0.125 % 
(w/v) berry extract or at 100 µM of quercetin, phloretin or phloridzin; all treatments 
were for 16 h. GLUT2 mRNA decreased significantly with the berry extract (p < 
0.001), quercetin (p < 0.001), phloretin (p < 0.01) and phloridzin (p < 0.001; Figure 
4.6, panel A). SGLT1 mRNA also decreased significantly with the berry extract (p < 
0.01), quercetin (p < 0.001) and phloridzin (p < 0.05; Figure 4.6, panel B).  
Note that multiple comparison tests account for overall data variability, and not just 
variability between 2 groups. This explains disparity between ANOVA findings 







Figure 4.4. Dose-dependent effects of berry extract on GLUT2 and SGLT1 
mRNA expression. Caco-2 cells were treated for 16 h with a berry extract at 
different doses from 0.25 % (w/v) in 2-fold dilutions until 0.016 % (w/v). Levels of  
GLUT2 (A) and SGLT1 (B) mRNA were quantified by qRT-PCR and normalised 
against 18S and GAPDH as housekeeping genes. Data are presented as mean 
normalised expression ratio ± SEM, n = 6, statistical significance was determined by 
an ANOVA and Dunnet’s post-hoc test against the 0 % (w/v) concentration. (*) p ≤ 
0.05, (***) p ≤ 0.001. GLUT2: facilitative glucose transporter 2. SGLT1: 
sodium/glucose cotransporter 1. 18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 







Figure 4.5. Time-dependent effects of berry extract on GLUT2 and SGLT1 
mRNA expression. Caco-2 cells were treated with berry extract at 0.125 % (w/v) 
from 4 h to 24 h. Levels of GLUT2 (A) and SGLT1 (B) mRNA were quantified by 
qRT-PCR and normalised against 18S and GAPDH as housekeeping genes. Values 
are mean normalised expression ratio ± SEM, n = 6, statistical significance was 
determined by an ANOVA and Dunnet’s post-hoc test against the 0 h time-point. 
(**) p ≤ 0.01, (***) p ≤ 0.001. ANOVA indicated SGLT1 gene expression as 
significantly different across the treatment durations (p ≤ 0.05). There was a 
significant linear trend for GLUT2 expression (slope= -0.1; r
2
 = 0.1; p ≤ 0.05). 
GLUT2: facilitative glucose transporter 2; SGLT1: sodium/glucose cotransporter 1. 
18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 





















Figure 4.6. Effects of flavonoids on GLUT2 and SGLT1 mRNA expression. Caco-2 
cells were treated with berry extract at a concentration of 0.125 % (w/v), phloretin, 
phloridzin or quercetin at 100 µM, or DMSO at a concentration of 0.05 % (w/v) for 16 h. 
Expression of GLUT2 (A) and SGLT1 (B) was quantified by qRT-PCR and normalised to 
18S and GAPDH as housekeeping genes. Data is presented as mean normalised expression 
ratio relative to the control ± SEM; n = 6. Statistical significance was determined by an 
unpaired t-test or ANOVA with Dunnet’s post-hoc test against the relevant control.  (*) p ≤ 
0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. GLUT2: facilitative glucose transporter 2. SGLT1: 
sodium/glucose cotransporter 1. 18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. DMSO: dimethyl sulfoxide. qRT-PCR: quantitative real-time 
polymerase chain reaction. 
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4.3.3 Effects of the flavonoids on glucose transporter protein expression 
Expression of GLUT2 transporter protein decreased significantly in response to the 
berry extract treatment (p < 0.05; Figure 4.7, panel A).  There was no effect on the 
expression of SGLT1 transporter protein (Figure 4.7, panel B) 
Figure 4.7. Effects of flavonoids on GLUT2 and SGLT1 protein expression. 
Caco-2 cells were treated with berry extract at a concentration of 0.125 % (w/v) for 
16 h. Levels of GLUT2 (A) and SGLT1 (B) protein were quantified by Western 
blotting and normalised to β-actin as a housekeeping protein. Data is presented as 
mean normalised protein density expressed relative to the control ± SEM, n = 4. 
Statistical significance was determined by an unpaired t-test. (*) p ≤ 0.05. GLUT2: 




4.3.4 Effects of flavonoids on glucose uptake 
In this section, our interest was in 1) the acute inhibitory effects of flavonoids on 
glucose uptake and 2) the chronic inhibitory effects of flavonoids on glucose uptake.  
Differences between transport systems, i.e. total uptake, GLUT-mediated uptake or 
SGLT-mediated uptake, were not investigated.  We investigated the inhibitory 
potential of flavonoids on these components of uptake. 
Acutely, total glucose uptake, GLUT-mediated and SGLT-mediated glucose uptake 
were significantly decreased by the berry extract (p < 0.01; Figure 4.8, panel A).  
Quercetin and phloretin decreased total, GLUT-mediated and SGLT-mediated 
glucose uptake (p < 0.05; Figure 4.8, panel B). Phloridzin significantly decreased 
SGLT-mediated glucose uptake only (p < 0.05; Figure 4.8, panel B). 
Following chronic treatment with berry extract there was no significant effects on 
total glucose uptake, GLUT-mediated uptake or SGLT-mediated uptake (Figure 4.9, 
panel A).  Chronic treatment with quercetin, phloretin or phloridzin also had no 














Figure 4.8. Acute effects of flavonoids on total, GLUT2-mediated and SGLT1-mediated glucose uptake. Total glucose uptake, GLUT2-
mediated glucose uptake and SGLT1 mediated glucose uptake were measured in Caco-2 cells treated acutely, 15 min, with (A) 0.125 % (w/v) 
berry extract (white bars) or with (B) 100 µM isolated flavonoids quercetin (white bars), phloretin (light grey bars) or phloridzin (dark grey bars); 
control bars are black. Data are presented as the mean ± SEM, n = 12. (*) p ≤ 0.05. To determine significance, an unpaired t-test was used for the 





Figure 4.9.Chronic effects of flavonoids on total, GLUT2-mediated and SGLT1-mediated glucose uptake. Total glucose uptake, GLUT2-
mediated glucose uptake and SGLT1 mediated glucose uptake were measured in Caco-2 cells treated acutely, 15 min, with (A) 0.125 % (w/v) 
berry extract (white bars) or with (B) 100 µM isolated flavonoids quercetin (white bars), phloretin (light grey bars) or phloridzin (dark grey bars); 
control bars are black. Data are presented as the mean ± SEM, n = 12. (*) p ≤ 0.05. To determine significance, an unpaired t-test was used for the 





There are 366 million people worldwide affected with diabetes, 90 % of these cases 
are type II diabetes (Diabetes UK, 2009). This disease is managed through rigorous 
lifestyle modification and/or pharmaceutical interventions to maintain optimal 
glucose homeostasis and thus prevent complications, such as cardiovascular disease.  
A failure to maintain glucose balance leads to the development of type II diabetes. 
Given that current pharmaceutical options cause undesirable side-effects (e.g. 
hypoglycaemia, weight gain, nausea), there has been an emergence of interest in the 
use of naturally occurring glucose modulatory substances, such as flavonoids.  The 
acute effects of flavonoids on glucose uptake have been reported by numerous 
studies (e.g.  Park, 1999; Johnston et al, 2005).  However, there has been little 
research into the chronic effects of these compounds.   
We addressed the hypothesis that dietary flavonoids chronically and acutely 
modulate glucose uptake processes in enterocytes.  This was done by treating Caco-2 
cells with a flavonoid-rich berry extract, quercetin, phloretin and phloridzin, then 
quantifying transporter expression and function. 
We demonstrated that chronic treatment with flavonoids decreased glucose 
transporter gene expression, with concomitant decreases in GLUT2 protein 
abundance.  However, radiolabelled studies showed there was no affect on glucose 
uptake.  In contrast, acute flavonoid treatments markedly inhibited both GLUT2 and 
SGLT1 mediated glucose uptake.   
4.4.1 Flavonoids and glucose transporter gene expression 
GLUT2 gene expression decreased in a dose- and time-dependent manner when 
treated with the berry extract.  The strongest effects on GLUT2 gene expression were 
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at 16 h with 0.125 % (w/v); the remainder of our experiments was based on this 
finding.  GLUT2 mRNA also decreased when Caco-2 cells were treated with 
quercetin, phloretin or phloridzin.  The common effect of flavonoid treatments on 
GLUT2 mRNA expression indicates a similar underlying mechanism.   
Typically, GLUT2 mRNA is regulated by the presence of substrates and by 
hormonal cues, such as insulin (Cui et al, 2003, Goestemeyer et al, 2007; Tobin et 
al, 2008).  GLUT2 mRNA expression correlates directly to glucose availability. 
Thus a decreased intracellular or extracellular availability of glucose, decreases 
GLUT2 gene expression (Inagaki et al, 1992; Mahraoui et al, 1994; Cui et al, 2003).  
Although GLUT2 is regulated by glucose, it is not known to contain a glucose or 
carbohydrate responsive element in its mRNA transcript (Rencurel et al, 1996).  
Therefore GLUT2 may be responding to other cues.  However, the inhibitory effects 
of flavonoids on glucose uptake are the likely cause of low intracellular glucose and 
in-turn decreased GLUT2 mRNA expression. 
As for SGLT1 mRNA levels, significant inhibitory effects were observed at 16 h of 
treatment with 0.125 % (w/v) of the berry extract, with quercetin or with phloridzin.  
Previous research has similarly reported decreased SGLT1 mRNA in the intestine in 
response to polyphenolic extracts (Oliveira et al, 2008). Furthermore, phloridzin is a 
classical inhibitor of SGLT1-mediated glucose uptake and is known to reverse the 
over-expression of SGLT1 mRNA that occurs in diabetes (Alvarado & Crane, 1962; 
Masumoto et al, 2009; Walle & Walle, 2003).  Quercetin and its derivatives are also 
known inhibitors of SGLT1-mediated uptake (Kwon et al, 2007).   
SGLT1 mRNA regulation is known to be independent of glucose. However, there is 
a degree of correlation with GLUT2 mRNA expression throughout cellular 
differentiation (Mahraoui et al, 1994).  SGLT1 mRNA increases under conditions of 
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oxidative stress or when treated with metal compounds (Miyamoto et al, 1993; 
Blumenthal et al, 1998). Its expression decreases during hypertension, sodium 
loading or in response to polyphenol-rich plant extracts (Mate et al, 2006; Oliveira et 
al, 2008). It is consistently reported that mRNA fluctuation is not always in line with 
protein abundance nor does it affect transport function (Smith et al, 1992; Lescale-
Matys et al, 1993; Mate et al, 2006).  As flavonoids are known antioxidants, and 
SGLT1 mRNA is known to be sensitive to oxidative states (Aherne & O’Brien, 
1999; Myhrstad et al, 2002; Han et al, 2005), the decreased SGLT1 mRNA is 
possibly a response to changes in cellular oxidative balance with the increase in 
antioxidant capacity with the flavonoid treatments (Li et al, 2004).   
4.4.2 Flavonoids and glucose transporter protein expression 
The GLUT2 protein is primarily localised at the basolateral membrane and rapidly 
translocates to the apical membrane when monosaccharide demand is high.  GLUT2 
is endocytosed and degraded in response to insulin signaling following a rise in 
plasma glucose (Corpe et al, 1996; Tobin et al, 2008).   
We found there was decreased abundance of GLUT2 protein in response to treatment 
with the berry extract.  This is a result of either increased protein degradation and/or 
decreased translation.  Decreased translation would arise following the decreased 
expression of GLUT2 mRNA as discussed above.  However, noting that there is no 
significant effect on GLUT2-mediated glucose uptake, it is likely that degradation 
may be site-specific.  In other words, GLUT2 that is not localised for apical uptake is 
subjected to degradation.  Rather, the basolaterally or intracellularly localised 
GLUT2 would have been targeted.  Alternatively, another glucose uptake route may 
have been made available, or that the apical presence of GLUT2 is not the rate-
limiting factor for glucose uptake.  Further experiments to characterise the migration 
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and degradation patterns of GLUT2 will enable a better understanding of our current 
observations to be obtained. 
4.4.3 Acute effects of flavonoids on glucose uptake 
Other studies have demonstrated the acute inhibitory effects of flavonoids on glucose 
uptake (Park, 1999; Song et al, 2002; Kwon et al, 2007; Johnston et al, 2005).  We 
carried out an acute treatment, in line with this previous research, to ensure the 
inhibitory potential of our treatment compounds was similar to those previously 
reported.  Furthermore, acute treatments indicate mechanisms that require 
simultaneous presence of both the substrate and inhibitor compounds.   
Phloretin, and its glucoside phloridzin, were included as known inhibitors of 
GLUT2- and SGLT1-mediated glucose uptake, respectively (Alvarado, 1967).  Our 
experiments with phloretin and phloridzin confirmed the presence and activity of 
both transporters. 
Flavanols are known as the most potent flavonoid inhibitors of glucose uptake, thus 
quercetin was included as a marker flavonol (Park, 1999).  In our experiments, 
quercetin significantly inhibited GLUT2- and SGLT1-mediated glucose uptake.  
Other studies have shown similar results (Song et al, 2002; Kwon et al, 2007).   
The berry extract used in this work for the thesis is rich in delphinidin, malvidin, 
cyanidin and petunidin (InterHealth Nutraceuticals).  These anthocyanins are all 
hydroxylated at the C-5 and C-7 positions.  Hydroxylation at these positions has 
been previously identified as a structural feature that increases inhibitory potential of 
flavonoids towards glucose uptake (Park, 1999).  The berry extract also, as expected, 
acutely inhibited both GLUT2- and SGLT1-mediated uptake.  
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There are currently a number of hypotheses regarding the flavonoid inhibition of 
glucose uptake. The study by Park (1999) is of particular importance as he 
investigated 10 different flavonoid species, the structural classes of which spanned 
flavones, flavonols, flavanones, isoflavones, anthocyanidins and catechins. As well 
as a number of structural classes, he investigated different hydroxylation patterns, 
presence of double bonds on the 6-member rings, orientation of the B-ring, presence 
of a ketone group and moiety effects on the inhibitory properties of these 
compounds. Park (1999) found that hydroxylation at certain positions was important 
for inhibition (namely: C-5 and C-7 are necessary, but hydroxylation at C-3 and C-3’ 
had no effect). Orientation of the B-ring is important; i.e. flavonoids have a higher 
inhibitory capacity than isoflavonoids that have the B-ring conjugated at C-3 rather 
than C-2; presence of a double bond between C-2 and C-3 also increased inhibitory 
capacity. Finally, no single component of the flavonoid backbone structure induced 
an inhibition of glucose uptake, e.g. chromone, coumarin and catechol all failed to 
inhibit glucose uptake; furthermore the backbone structure without C-5 and C-7 
hydroxylation did not have inhibitory potential. Other studies have implied that 
glucose moieties will bind to the same transporter binding site as hexoses, thus 
competitively impeding monosaccharide transport, possible by steric hindrance 
preventing transport of the glucose alone (Johnston et al, 2005; Kwon et al, 2007). 
Alternatively, both aglycone and glycoside flavonoids may bind to a separate 
binding site or to membranes, affecting both membrane integrity and transporter 
function (Nakayama et al, 2000; Johnston et al, 2005).  However, despite the 
possibility of non-specific polyphenol interactions with any glucose binding site, or 
with any membrane (potentially affecting other nutrient transporters); this inhibition 
has been observed in many cell lines, in transfected cells and in Xenopus oocytes, the 
effect appears to be glucose transporter specific (Kwon et al, 2007).  
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The study by Martineau et al (2006) is one of only a few groups to have investigated 
the mechanisms whereby polyphenolic plant extracts may aid in the maintenance of 
circulating glucose.  They investigated effects of blueberry plant extracts on 3T3-L1 
adipocytes and C2C12 muscle cells, expressing GLUT1 and GLUT4 facilitative 
transporters (Martineau et al, 2006).  These have similar properties to GLUT2 in 
enterocytes and hepatocytes (Klip & Paquet, 1990).  The treatment compounds in the 
aforementioned study consisted of lyophilised ethanolic extracts from blueberry 
plant and fruits.  In their study, the root, stem and leaf extracts contained numerous 
phenolic compounds, whereas anthocyanins were only found in the fruit.  All the 
extracts increased glucose uptake in myocytes and adipocytes, except for the 
anthocyanin containing fruit extract.  The blueberry fruit extract inhibited both basal 
and insulin-stimulated glucose uptake in myocytes (GLUT4) and adipocytes 
(GLUT1) (Martineau et al, 2006).  Thus, in line with our findings, there is a specific 
and potent inhibition of GLUT-type transporters by anthocyanin flavonoids.  
4.4.4 Chronic effects of flavonoids on glucose uptake 
Quantifying the relative amount of protein provides information on the potential 
functional capacity. On the other hand quantifying mRNA allows one to ascribe 
mechanisms to the changes observed in function. Thus, a glucose uptake assay 
following chronic flavonoid treatment is the only reliable way to evaluate the chronic 
effects on glucose uptake function. Furthermore, chronic treatments allow time for 
any compensatory mechanisms to develop. 
In our studies, chronic treatments had no significant effect on glucose uptake, despite 
decreased GLUT2 protein abundance. This suggests that the apical availability of 
GLUT2 was probably not affected by the decreased abundance of the protein.  
However, this must be confirmed by localisation experiments, or by studies of total 
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transepithelial transport of glucose.  Alternatively, a different transport route may 
have been recruited for glucose uptake. 
Regarding SGLT1, there was no effect of chronic flavonoid treatment on the protein 
or on SGLT1-mediated glucose uptake. 
4.5 Conclusions 
We have reported, for the first time, the effects of berry flavonoids on glucose 
transporter expression and function in a model of human enterocytes.  A flavonoid-
rich berry extract induced a decrease in the mRNA expression of two key glucose 
transporters; quercetin, phloretin and phloridzin induce a similar response.  There is 
a concomitant decrease in expression of the GLUT2 protein. These changes in 
expression do not affect cellular glucose uptake.  However, when applied acutely, 
flavonoids inhibited glucose uptake. These acute inhibitory effects did not affect 
longer term function (i.e. presence of flavonoid compounds is necessary to exert 
inhibition) although they are likely to have caused the observed changes in 
transporter expression.   
Overall, these findings indicate dietary flavonoids are effective acute inhibitors of 
intestinal glucose uptake. Given this property, other health benefits and the high 
safety profile of flavonoids, they are likely candidates for the non-pharmacological 
management of type II diabetic conditions. Further research is required to 
characterise protein trafficking, the response patterns of GLUT2 and to characterise 
the transepithelial flux of glucose.  
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4.6 Future work 
Our results, together with previous research, leave a number of questions to be 
answered. These are mainly related to the chronic effects we have observed. The 
resulting effects and questions are summarised schematically in Figure 4.10. Most 
important are the translational effects on GLUT2 and the transcriptional effects on 
SGLT1. Following the chronic treatments, GLUT2 protein abundance decreased, 
without a functional consequence (i.e. no significant change in glucose uptake). Our 
studies could not distinguish between apical, basolateral and intracellular GLUT2 
pools and it is possible that the actions of berry flavonoids are specific to one of 
these sites. Alternatively, presence of the protein per se is not the rate limiting step 
with regards to its function. In support of this possibility, studies by Helliwell et al 
(2000) show that both transporter protein abundance and the intrinsic activity of 
sugar transporters are important determinants of overall rates of transport. 
 Furthermore, flavonoids have been reported to possess insulin-like properties 
(Anderson et al,2004; Martineau et al, 2006; Su et al, 2006); insulin is known to 
affect the apical presence of GLUT2 and thus its glucose importing functions (Tobin 
et al, 2008).  
SGLT1 is also know to traffic between intracellular pools and the apical membrane 
(Khoursandi et al, 2004) and it is possible that berry polyphenols influence cellular 
distribution of transporter protein without altering overall SGLT1 protein levels. 
However, polyphenols have been reported to previously alter SGLT1 mRNA 
expression; albeit through unknown the mechanisms (Oliviera et al, 2008). Finally, 
the roles of other flavonoid importers, and their effects on basolateral glucose 
release, or the roles of basolateral GLUT2 in flavonoid efflux, require investigation. 




















Figure 4.10. Future work into the chronic effects of flavonoids on glucose 
transport. Following chronic flavonoid treatment of Caco-2 cell monolayers a 
number of observations were made that require further investigation. 1) There was a 
decrease in GLUT2 mRNA and protein, with no effect on GLUT-mediated glucose 
uptake. This may be due to site targeted degradation of the GLUT2 protein, to a site 
that is not related to its apical uptake role, there may be other unknown compensatory 
routes of glucose uptake, or merely that apical presence of the transporter is not the 
rate limiting step of its function, i.e. a non-saturable capacity. 2) Cellular distribution, 
but not total, SGLT1 protein may also change following exposure to flavonoids. The 
down-regulation of GLUT2 and SGLT1 mRNA are likely to be a flavonoid effect, or 
a downstream effect of high cellular flavonoids as previous research has found 
polyphenolic compounds to decrease SGLT1 mRNA as well; it is also likely that the 
electrochemical or oxidative balance within the cell will have the modulatory effect 
on SGLT1 mRNA. 3) Whether basolateral GLUT2 will provide an efflux route for 
flavonoids that have accumulated, this is also assuming that flavonoids will not have 
induced the degradation or basolateral GLUT2. Furthermore, it is not known if the 




4.6.1 Elucidating the mechanisms of inhibition  
Previous researchers have attempted to establish modes of flavonoid inhibition. This 
has resulted in divergent findings due to the diversity of flavonoid structures, the 
various metabolic fates of these compounds and the various tissues and cell lines 
they have been tested in (Park, 1999; Cermak et al, 2004; Johnston et al, 2005; 
Kwon et al, 2007). It has however been a general assumption that aglycones 
preferentially inhibit GLUT2 and glycosides preferentially inhibit SGLT1 (Figure 
4.11); however the modes of inhibition have been inconsistently reported. 
Figure 4.11. Flavonoid inhibition of glucose transporters. Inhibition of glucose 
transporters will cause intracellular accumulation of mixed flavonoid species and a 
decrease in cellular glucose. The nature of inhibition (competitive, non-competitive) 
has not been fully elucidated. 1) Aglycone flavonoids are expected to inhibit GLUT2; 
2) Glycosides are expected to inhibit SGLT1. GLUT2: facilitative glucose transporter 
member 2; sodium-glucose cotransporter 1. 
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To determine the modes of inhibition of the compounds we used, firstly the active 
components of the berry extract need to be identified. A subsequent series of kinetic 
analysis studies must be carried out in Caco-2 cells. When the enzyme reaction 
constants are determined, if the maximum rate of transport (Vmax) does not change 
then inhibition is competitive, whereas decreasing Vmax means the inhibition is non-
competitive. Determining effects on the Michaelis and dissociation constants (Km & 
Kd) will also aid in determining the mode of inhibition. Parallel alterations in these 
constants will dictate that inhibition is competitive. When Km, Kd and Vmax are 
altered, this indicates mixed type inhibition (Park, 1999; Ader et al, 2000; Manzano 
& Williamson, 2010). Previous reports state that inhibition of apical uptake is of 
mixed type, with GLUT2 beifng inhibited non-competitively and SGLT1 being 
inhibited competitively; whereas basolateral release of glucose is inhibited in a non-
competitive manner, indicating an effect on GLUT2 only (Manzano & Williamson, 
2010). From a mechanistic perspective it is important to determine these parameters, 
both with the acute treatment conditions and following the chronic exposure, 
particularly with regards to our findings of decreased GLUT2 protein abundance, 
with no apparent effect on function. In addition, selective interaction of individual 
polyphenols with SGLT1 and / or GLUT2 could be assessed by expressing each 
transporter in Xenopus oocytes and determining the effect on glucose uptake (e.g. 
Kwon et al 2007). 
4.6.2 Localisation and contribution of glucose transporters: 
It is of particular importance to determine the cellular localisation of the transporters 
we have investigated and to determine whether other hexose transporters are affected 
or recruited to compensate loss of GLUT2 or SGLT1 activity. As GLUT2 
translocates in response to its substrates (Kellet & Helliwell, 2000; Chaudhry et al, 
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2011), it is important to determine its localisation at the appropriate area to be 
inhibited, and to determine the location of its degraded units (after 16 h). Although, 
the function and orientation for inhibition of GLUT2 is partially resolved as we have 
shown glucose uptake in the absence of sodium, and other researchers have shown 
GLUT2 to appear at the correct membrane (Kwon et al, 2007). Furthermore, despite 
the decrease in GLUT2 protein following chronic treatment, there is no effect on 
transport capacity, this may be due to targeted degradation of GLUT2 protein either 
basolaterally or from the subapical vesicles, which can also be resolved by 
localisation of the transporters with confocal microscopy.  
It is also worth determining the contribution of GLUT1 and GLUT5 to the hexose 
and/or flavonoid uptake, although GLUT5 is a fructose transporter and therefore may 
not directly affect glucose metabolism. Nonetheless, the contribution of other 
transporters (not GLUT2 or SGLT1) can be quantified either by inclusion of 
flooding doses of phloretin, phloridzin, cytochalasin B and disruption of the 
electrochemical gradient, expressing transporters in Xenopus oocytes or targeted 
deletion of GLUT2 and SGLT1 with siRNA.  
4.6.3 Determining effects on basolateral glucose flux: 
An important mechanistic and physiological question remains as to whether 
flavonoids inhibit both components of absorption; i.e. apical uptake from the lumen 
and basolateral release into circulation. This component is physiologically important 
when determining if effects seen are truly acute, as flavonoid metabolism will 
involve, the apical reflux of flavonoids as well as the biliary excretion back into 
intestinal lumen (Walle, 2004; Lotito et al, 2011; Planas et al, 2012). Therefore if 
flavonoids are present or are reabsorbed prior to the introduction of dietary glucose 
into the intestinal lumen, there may be a persistent intracellular inhibitor of glucose 
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transport. This can be determined initially by applying confocal microscopy or 
membrane separation Western blotting to ensure GLUT2 is remains localised at the 
basolateral membrane following longer treatment with flavonoids and that it is at the 
expected position for intracellular inhibition by flavonoids. Furthermore, we can 
determine if other routes are available for basolateral glucose or flavonoid release by 





Effects of berry extract on the expression and function of intestinal iron 
transport pathway in Caco-2 enterocytes 
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5 Effects of berry extract on the expression and function of 
intestinal iron transport pathway in Caco-2 enterocytes 
5.1 Introduction: Intestinal iron transport and dietary flavonoids 
Iron is an essential element with diverse biological roles, e.g. as a prosthetic group in 
redox reactions and as an essential part of haem, serving to transport and store 
oxygen (Noyes et al, 1964; Lopes et al, 2010).  As a consequence of its essentiality, 
even small changes in its metabolic homeostasis can cause a number of diseases, 
such as anaemia in states of low iron and haemochromatosis in high iron states 
(Kaplan et al, 2011).   
Humans lack regulated mechanisms for the disposal of excess iron. The only way 
that iron can be excreted is through the unregulated exfoliation of epithelial cells and 
through bleeding. Therefore, body iron levels must be maintained at the site of 
absorption, at the intestinal epithelium.   
Intestinal epithelial cells express a number of specialised proteins to absorb and 
handle iron from the diet.  Intestinal iron absorption is regulated systemically in 
response to the hepatically expressed peptide hepcidin.  It is also regulated locally by 
dietary factors and the iron responsive element / iron regulatory protein (IRE/IRP) 
system (Anderson et al, 2002b; Sharp & Srai, 2007; Hentze et al, 2011).  
Furthermore, the bioavailability of dietary iron is also dependent on the presence of 
other dietary constituents, such as flavonoids, that can either impede or enhance its 
absorption (Kim et al, 2008; Thumser et al, 2010). 
Non-haem iron is the most abundant form of iron in the diet.  It is ingested in its 
ferric form, which must be reduced to its ferrous form in the intestine before 
absorption (Han et al, 1995).  This reduction is mediated by the apical membrane 
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reductase activity of duodenal cytochrome B reductase (DCYTB) or by luminal 
dietary reducing agents (McKie et al, 2001).  Following reduction, ferrous iron 
becomes a substrate for the apical divalent metal ion transporter (DMT1) which 
mediates influx of iron into the enterocyte (Han et al, 1995; Gunshin et al, 1997).  
Iron then joins the intracellular iron pool by binding to ferritin, or is effluxed from 
the basolateral membrane via ferroportin (FPN) (McKie et al, 2000).  After efflux, 
ferrous iron is oxidised by the basolateral ferroxidase hephaestin (HEPH) (Vulpe et 
al, 1999).  Ferric iron can then be bound by plasma transferrin for distribution 
throughout the body (Núñez & Tapia, 1999).  The haemochromatosis protein, HFE, 
is also expressed in duodenal enterocytes.  HFE is assumed to act as an intracellular 
inhibitor of DMT1-mediated iron uptake or as a regulatory protein for the interaction 
of transferrin (Tf) and its receptors (TfR1/ TfR2) (Arredondo et al, 2006). 
The absorption of iron is greatly influenced by the presence of dietary compounds 
such as vitamin C and flavonoids (Teucher et al, 2004; Thumser et al, 2010; Ma et 
al, 2011).  Vitamin C is known as a chelator or as a reducing agent which enhances 
the uptake of iron (Thumser et al, 2010).  Flavonoids are also known for their 
reducing capacity and their ability to chelate dietary metals. Both these properties are 
affect the transport and bioavailability of iron (Ren et al, 2008; Vlachodimitropoulo 
et al, 2010a; Vlachodimitropoulo et al, 2010b).  However, little is known about the 
concordant regulation of related mRNA levels and iron absorption per se in response 
to flavonoids.  To address this we investigated the effects of a flavonoid-rich berry 
extract on iron transport and DCYTB, DMT1, HFE, TfR1, FPN and HEPH 




Presented here is a brief description of the methods used in this chapter. For full 
details of reagents, buffer/media compositions and methods used see Chapter 2. 
 
5.2.1 Cell culture 
Caco-2 TC7 cells between the passages of 44 and 47 were seeded into 6-well plates 
at a density of approximately 40,000 cells per well (4,000 cells per cm
2
) and cultured 
for 19 days prior to treatment.  For iron transport experiments, cells were seeded on 
Transwell® inserts in 6-well plates.  Details of the maintenance of the cells and 
composition of cell culture medium have been previously described (see Chapter 2 
and Johnston et al, 2005).   
The treatment used was a flavonoid-rich berry extract (derived from blueberry, 
bilberry, cranberry, elderberry, raspberry seeds and strawberry; rich in the 
anthocyanins delphinidin, cyanidin, petunidin and malvidin, OptiBerry®, 
InterHealth Nutraceuticals, CA, USA) at a final concentration of 0.125 % (w/v).  
Treatment was prepared in DMEM for gene and protein expression and chronic-
exposure iron transport studies.  Treatments for acute-exposure iron transport 
experiments were prepared in HBSS.   An identical medium or buffer, without the 
berry extract, was used for the control cells.   
The effects of berry extract treatments on cell viability, RNA content and protein 
content of the cells were tested.  There were no effects of any treatments on cell 





5.2.2 Real-time qPCR 
Total RNA was isolated from the cultured cells using TRIzol® (Invitrogen™ Life 
Technologies, Paisley, UK) according to the manufacturer’s instructions.   Following 
first strand cDNA synthesis (using a high-capacity cDNA reverse transcription kit, 
Applied Biosystems™ Cheshire, UK), expression levels of iron transport-related 
gene mRNA, 18S mRNA and GAPDH mRNA were analysed by qRT-PCR using an 
ABI Prism 7700HT Sequence Detection System and a Power SYBR® Green PCR 
master mix kit (Applied Biosystems™ Cheshire, UK).  Primers were designed using 
the online design tool Primer3 (Rozen & Skaletsky, 2000) and sourced from MWG 
Eurofins (London, UK).  Quantitative measurement of gene expression was derived 
from the 2
(-ΔΔCt)
 method, also known as the
 
Livak method (Livak & Schmittgen, 
2001; Schmittgen & Livak, 2008).  Data were expressed as ratios to the control and 
normalised to the housekeeping genes 18S and GAPDH. The primer sequences used 
for each gene are in Table 5.1. 
 







DCYTB TCA TCC AGG GCA TCG CCA TC CGG AGC CCA TGG AAG CAG AA 
DMT1 AGT GGT TTA TGT CCG GGA CC TTT AAC GTA GCC ACG GGT GG 
HFE CAC ACC ATC CAC TTT CAT GC GCA TGG ACA TGG TCA GTC AC 
TfR1 TGA GAA AAC AAT GCA AAA TGT GA CCC AGT TGC TGT CCT GAT ATA GA 
FPN GGG GTC GCG TAG TGT CAT CAG GTA GTC GGC CAA GGA T 
HEPH CAC ACC ATC CAC TTT CAT GC GCA TGG ACA TGG TAC GTC AC 
18S AAC TTT CGA TGG TAG TCG CCG CCT TGG ATG TGG TAG CCG TTT 
GAPDH CTG TTG CTG TAG CCA AAT TCG T ACC CAC TCC TCC ACC TTT GA 
DCYTB: duodenal cytochrome B reductase; DMT1: divalent metal ion transporter 1; HFE: 
haemochromatosis protein; TfR1: transferrin receptor 1; FPN: ferroportin; HEPH: hephaestin; 18S: 




5.2.3 Protein abundance analysis 
Total protein from Caco-2 cells was prepared as described previously (Chaston et al., 
2008).  Total proteins (40 μg) were solubilised in sample loading buffer and 
subjected to SDS-PAGE.  Following immobilisation on nitrocellulose, the proteins 
were exposed to anti-DMT1 or anti-FPN antibodies (1:1000 dilution, Source 
Bioscience, Nottingham, UK).  Blotted membranes were visualised using a 
horseradish peroxidase-linked secondary antibody and Novex® ECL 
chemiluminescent substrate reagent kit (Invitrogen™ Life Technologies, Paisley 
UK).  Band densities were quantified using a densitometer (GS-800™) and Quantity 
One software (Bio-Rad Laboratories, Hertfordshire, UK).  Protein levels of β-actin 
were also measured (anti-actin antibody, 1:2000 dilution, Sigma-Aldrich).  Protein 
density data were normalised to β-actin as the housekeeping protein. For antibody 
concentrations and reagents see Section 2.2.4. Protein abundance analysis. 
 
5.2.4 Iron uptake and transport assays 
This section contains a brief description (for further details see Section 2.2.5 
Functional uptake and transport experiments) of the iron uptake and transport 
assays, similar to those previously described (Johnston et al, 2005; Kim et al, 2008).  
Iron uptake and transepithelial transport were carried out using [
55
Fe]-ferric chloride 
(Perkin-Elmer, Bucks, UK).  Cells for these experiments were grown on Transwell® 
inserts to allow loading into the apical compartments and transport to the basolateral 
compartments.  See Figure 5.1 for an illustration of how Transwell® inserts work to 





Figure 5.1.Transwell® insert system applied in 
55
Fe uptake experiments. The Transwell® insert system allows the compartmentalisation of 
two components of nutrient transport; both apical uptake and basolateral release. 1) The inserts fit into standard 6-well cell culture plates 2) Inserts 
allow cells to become confluent and polarise on a semipermeable membrane, where both apical and basolateral sides of the cells are exposed to 
media 3) Apical chamber media or buffer is in contact with the apical surface of the Caco-2 cells and represents conditions within the intestinal 
lumen 4) The semipermeable membrane allows a physical barrier for cells to grow on, as well as separating the apical media or buffer from the 
basolateral media or buffer, thus allowing the quantification of apical to basolateral transport, as opposed to cellular uptake alone 5) The 
basolateral chamber carries media or buffer in contact with the basolateral side of the Caco-2 cells and represents conditions in circulation, 
analytical substrates (e.g. 
55
Fe) detected in this area represents substrates that have completely passed through the cell monolayer. 
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Uptake and transport assays were designed to identify the acute interactive effects of 
berry extract treatment or the chronic transcriptional or translational effect of a 16 h 
berry extract treatment.  During acute effects 
55
Fe was added to the apical buffer 
compartment with the flavonoid treatments, whereas for the chronic effects the 
treatment media was replaced with buffer containing 
55
Fe and no flavonoids.   
To quantify iron uptake, after 20 min of exposure to the radioisotope, the buffer was 
removed, and inserts were washed 3 times in ice-cold PBS and drip dried briefly 
before dissolving cells in 500 µL of 200 mM NaOH overnight at 4 °C.  An aliquot of 
this cell lysate was subjected to scintillation counting. To quantify 
55
Fe 
transepithelial transport, the cells were exposed to the radioisotope for 2 h at 37 °C.  
Transport was then terminated by washing and dissolving as above.  Two hours were 
allowed for the measurement of transepithelial transport as the time frame for 
cellular accumulation and basolateral release is longer than that required simply to 
measure apical uptake (20 min). 
An aliquot of the cell lysate and basolateral media were then subjected to 
scintillation counting. Background of scintillant only and starting amount of 
55
Fe 
were also subjected to scintillation counting.  Aliquots of cell lysate from each 
experiment were also taken to quantify protein concentration for normalisation 
purposes.  
Data from functional studies was expressed as follows: (1) iron uptake into Caco-2 
cell monolayer within 20 min of exposure to iron; (2) iron retention in Caco-2 cell 
monolayer following 120 min of exposure to iron; (3) iron released into basolateral 
compartment following 120 min of exposure to iron; (4) percentage of effluxed iron 
relative to total iron uptake (i.e. iron retention + iron release) in the Caco-2 cell 
monolayer following 120 min of exposure to iron. 
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5.2.5 Data and statistical analysis 
Data are expressed as means + SEM of 4 or 6 observations per group depending on 
the experiment.  Statistical analysis was carried out using GraphPad Prism 5 (San 
Diego, CA, USA).  In studies containing 2 experimental groups Student’s unpaired t-
test or a Mann-Whitney test was used to compare means.  Differences between 
multiple groups were calculated using a 1-way ANOVA with Dunnett’s post-hoc 




5.3.1 Effects of berry extract on cell viability, RNA and protein content 
Indices of cell viability, RNA and protein content were tested to ensure effects of 
berry extract were not due to pathological changes, but as normative responses.  
There was no effect of berry extract on cell viability (Figure 5.2), RNA content 
(Figure 5.3), or protein content (Figure 5.4). 
 
Figure 5.2 Caco-2 cell viability after berry extract treatment. Caco-2 
cells were treated with berry extract at 0.125 % (w/v) for 16 h. Cell 
viability was quantified with the trypan blue dye-exclusion method. Data 
is presented as mean percentage viable cells ± SEM, n = 6. Student’s t-test 

















Figure 5.3. RNA concentration from Caco-2 cells after berry extract 
treatment. Caco-2 cells were treated with berry extract at 0.125 % (w/v) 
for 16 h. RNA concentration in the extracts of Caco-2 cells was quantified 
with the NanoDrop spectrophotometer. Data is presented as mean RNA 
concentration ± SEM, n = 6. Student’s t-test showed there was no 
significant difference between groups. 
Figure 5.4. Protein concentration from Caco-2 cells after berry 
extract treatment. Caco-2 cells were treated with berry extract at 0.125 
% (w/v) for 16 h. Protein concentration was quantified by the Bradford 
spectrophotometric assay. Data is presented as mean protein concentration 




5.3.2 Effects of berry extract on iron transport-related gene expression 
Varying concentrations of berry extract were tested on DMT1 and FPN gene 
expression, from 0.25 % (w/v) in 4 consecutive two-fold dilutions until 0.016 % 
(w/v).  Inhibitory effects on DMT1 expression were observed at 0.125 % (w/v) (p < 
0.05; Figure 5.5, panel A).  FPN first increased in expression at 0.031 % (w/v), then 
there was a decrease at 0.25 % (w/v) (p < 0.05; Figure 5.5, panel B).  The effects on 
gene expression of different incubation times with the berry extract were also tested 
on DMT1 and FPN expression.  Inhibitory effects on DMT1 gene expression were 
observed at 4 h and persisted until 24 h, there was a  significant linear trend with 
increased treatment duration (r
2 
= 0.03; p < 0.01; Figure 5.6, panel A).   
The effects of the berry extract 16 h treatment at 0.125 % (w/v) were tested on the 
genes that coordinate the enterocytic iron transport pathway.  DMT1 and DCYTB 
mRNA were decreased in response to the berry extract (p < 0.05; Figure 5.7, panel 
A for DMT1; panel B for DCYTB).  Expression of HFE was decreased, whereas 
TfR1 was increased (p < 0.01, Figure 5.7, panel C for HFE; panel D for TfR1).  
The levels of significance at the same treatment conditions vary. For example: 
DMT1 expression at 0.125 % (w/v) dose in Figure 5.4, 16 h time point in Figure 5.5 
and in Figure 5.6,  all have the same treatment time, dose and condition. However, 
biological variation and, more importantly, the different statistical approaches, result 
in varying levels of significance. A multivariate test, for the dose-response or time 
course, will give a lower level of significance than the bivariate test applied in the 2-
condition analysis. This is because a multivariate test takes into account overall 
variability over a number of conditions, whereas the bivariate will only account for 
variability within the two conditions being tested. 
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Figure 5.5. Dose-dependent effects of berry extract on DMT1 and FPN mRNA 
expression. Caco-2 cells were treated with a berry extract for 16 h at different doses 
from 0.25 % (w/v) in 2-fold dilutions until 0.016 % (w/v). DMT1 (A) and FPN (B) 
mRNA were quantified by qRT-PCR and normalised against 18S and GAPDH as 
housekeeping genes. Data are presented as mean normalised expression ratio ± 
SEM, n = 6, statistical significance was determined by an ANOVA and Dunnet’s 
post-hoc test against the 0% (w/v) concentration. (*) p≤0.05, (***) p≤0.001. DMT1: 
divalent metal ion transporter 1. FPN: ferroportin. 18S: ribosomal RNA 18S. 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase. qRT-PCR: quantitative real-






Figure 5.6. Time-dependent effects of berry extract on DMT1 and FPN mRNA 
expression. Caco-2 cells were treated with berry extract at 0.125 % (w/v) from 4 h 
to 24 h. Levels of DMT1 (A) and FPN (B) mRNA were quantified by qRT-PCR and 
normalised against 18S and GAPDH as housekeeping genes. Values are mean 
normalised expression ratio ± SEM, n = 6, statistical significance was determined by 
an ANOVA and Dunnet’s post-hoc test against the 0 h time-point. (**) p ≤ 0.01, 
(***) p ≤ 0.001. DMT1 expression had a significant linear trend (***) p ≤ 0.001. 
DMT1: divalent metal ion transporter 1. FPN: ferroportin. 18S: ribosomal RNA 18S. 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase. qRT-PCR: quantitative real-





Figure 5.7. Effect of berry extract on mRNA expression of iron transport-related genes. Caco-2 cells were treated with 0.125 % 
(w/v) of berry extract for 16 h. Levels of DMT1 (A), DCYTB (B), HFE (C), TfR1 (D), FPN (E) and HEPH (F) were quantified and 
normalised to 18S and GAPDH as housekeeping genes. mRNA data are presented as the mean (relative to the control) ± SEM, n = 6. (*) p 
≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001. Student’s t-test was used to determine statistical significance. DMT1: divalent metal iron 
transporter 1. DCYTB: duodenal cytochrome B reductase. HFE: haemochromatosis protein. TfR1: transferrin receptor 1. FPN: 
ferroportin. HEPH: hephaestin. 18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. qRT-PCR: quantitative 









5.3.3 Effects of berry extract on DMT1 and FPN protein expression 
Following a 16 h treatment with the berry extract at 0.125 % (w/v) protein 
abundance of DMT1 and FPN was quantified by Western blot.  There was no effect 





Figure 5.8. Effect of berry extract on DMT1 and FPN protein expression. Total 
protein was prepared from Caco-2 cells treated with 0.125 % (w/v) berry extract for 
16 h. Levels of DMT1 or FPN protein were normalised to β-actin as a housekeeping 
protein. Representative blots for DMT1 (A) and β-actin are shown in the lower left 
panel, with semiquantitative densitometry data in the upper left panel. 
Representative blots for FPN (B) and β-actin are shown in the lower right panel, 
with semiquantitative densitometry data in the upper right panel. Expression levels 
of the housekeeper protein β-actin were not altered by berry extract treatment. 
Densitometry data are presented as the mean (relative to the control) ± SEM, n = 4. 




5.3.4 Effects of berry extract on iron transport 
In this section our interest was in the acute and chronic effects of flavonoids on the 
transepithelial transport of iron. We investigated: 1) the apical uptake of iron, within 
20 min of iron loading; 2) the cellular retention and the basolateral release of iron, 
within 120 min of iron loading; and 3) the rate of effluxed iron relative to total 
uptake (expressed as a percentage) within 120 min of iron loading. 
Under acute treatment conditions, the berry extract treatment increased apical iron 
uptake (p < 0.05; Figure 5.9, panel A).  At 120 min, there was a significant decrease 
of cellular retention and basolateral release of iron (p < 0.05; Figure 5.9, panel A 
and panel B, respectively).   
Following chronic berry extract treatment, apical iron uptake was decreased (p < 
0.05; Figure 5.10, panel A).  After 120 min there were no significant effects on 
cellular retention or basolateral release of iron (Figure 5.10, panels B and C). 
As for the transepithelial flux of iron, the percentage of effluxed iron decreased after 
both acute (p < 0.05; Figure 5.11, panel A) and chronic (p < 0.05; Figure 5.11, 
panel B) treatments. 
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Figure 5.9. Acute effects of berry extract on iron uptake and release. Caco-
2 cells cultured on membrane supports were treated acutely (20 min) with 
0.125 % (w/v) berry extract and iron uptake was initiated. Apical uptake of iron 
was measured following 20 min (A), the cellular retention of iron was 
measured following 120 min (B); and the basolateral release of iron was 
measured after 120 min (C). Data are presented as the mean ± SEM, n = 6,  
Mann-Whitney or Student’s t-test was used to determine statistical 








Figure 5.10. Chronic effects of berry extract on iron uptake and release. 
Caco-2 cells cultured on membrane supports were treated chronically (16 h) 
with 0.125 % (w/v) berry extract then iron uptake was initiated. Apical uptake 
of iron was measured following 20 min (A), the cellular retention of iron was 
measured following 120 min (B); and the basolateral release of iron was 
measured after 120 min (C). Data are presented as the mean ± SEM, n = 6, 
Mann-Whitney or Student’s t-test was used to determine statistical 








Figure 5.11. Effects of berry extract on transepithelial flux of iron. Caco-2 cells 
cultured on membrane supports were treated acutely for 20 min (A) or chronically 
for 16 h (B) with 0.125 % (w/v) berry extract then iron transport was initiated. 
55
Fe 
effluxed into the basolateral compartment was expressed as a percentage of all the 
55
Fe that was effluxed and that was remaining in cell lysate. Data are presented as 
the mean ± SEM, n = 6, Mann-Whitney test was used to determine statistical 





In order to prevent the development of iron overload or anemia, total body iron must 
be tightly regulated at the stage of intestinal absorption, i.e. enterocytes. This is 
essential as humans are not equipped with a regulated excretory mechanism for 
excess iron. The transepithelial transport process of iron is coordinated by a number 
of genes that respond to systemic, local and luminal stimuli. The luminal stimuli are 
largely under our dietary control and depend on the presence of substances, such as 
ascorbate and flavonoids, which influence iron availability. Effects of dietary, 
luminal contents on the iron transport process are, in turn, likely to influence the 
function and expression of the transport pathway. However, the chronic effect of 
dietary flavonoids on iron transport and transporter expression hitherto remains to be 
elucidated. 
We addressed the hypothesis that a flavonoid-rich berry extract will alter the 
expression of the genes and proteins that regulate intestinal iron transport and will in 
turn influence iron transport in Caco-2 cells.  Caco-2 cells are an established model 
of human intestinal epithelial cells expressing the necessary proteins for the transport 
of dietary iron (Sharp et al, 2002).  We demonstrated that berry extract treatment 
decreases expression of those genes responsible for the apical uptake of iron, 
DCYTB and DMT1.  The expression of HFE and TfR1 decreased and increased, 
respectively. HFE, transfected into Caco-2 cells, is known to inhibit apical uptake of 
iron; TfR1 and HFE in crypt cells, form a complex to cycle iron from circulation 
back into the cell; thus HFE and TfR1 work cooperatively, putatively, to lower 
systemic iron levels (Feder et al, 1998; Arredondo et al, 2001; Trinder et al, 2002; 
Arredondo et al, 2006). In terms of function, iron uptake was increased with acute 
berry extract treatment. Following chronic treatment, iron uptake was decreased. The 
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transepithelial flux of iron was decreased with berry extract, following both acute 
and chronic treatments. 
Our results thus indicate berry extract flavonoids can elicit a transcriptional response 
from iron-transport related genes. Furthermore, chronic treatment with the berry 
extract decreases the transepithelial flux of iron.  Under acute settings, the flavonoids 
in our experiment replicate other findings from other studies. These indicate 
structural interactions with flavonoids or transporters that enhance apical uptake and 
diminish basolateral release (i.e.  Kim et al, 2008).   
5.4.1 Effects of berry extract on gene and protein expression 
5.4.1.1 DCYTB expression 
In our experiments the expression of DCYTB mRNA was decreased following berry 
extract treatment.  In-vivo DCYTB expression is dependent on iron requirement, 
increasing in conditions favouring iron influx and decreasing in states of high 
cellular iron status (Frazer et al, 2002; Frazer et al, 2003; Zoller et al, 2003).  In our 
study, the decreased expression of DCYTB, following berry extract treatment, 
indicates Caco-2 cells are replete with iron.   
It must be noted that Caco-2 cells are not known to highly express the DCYTB 
protein.  To resolve this, other studies use transfected Caco-2 cells (Latunde-Dada et 
al, 2008).  Alternatively, other metalloreductase activity is in place to compensate 
for a lack of DCYTB protein.  This notion is supported by studies in DCYTB-null 
mice which do not develop iron-deficiency (Gunshin et al, 2005).  However we 
resolved this by adding ascorbate, a well known dietary reductant, to the iron prior to 




5.4.1.2 DMT1 expression 
DMT1 gene expression decreased in response to treatment with the berry extract.  
DMT1 is typically expressed in at least two transcript variants, one with an IRE 
region in its transcript (DMT1+IRE) and one without (DMT1-IRE) (Lee et al, 1998).  
In enterocytes the DMT1+IRE isoform is predominant and responds strongly to iron.  
Its expression increases in response to low iron and decreases in response to high 
iron (Canonne-Hergaux, 1999; Gunshin et al¸ 2001).  Regarding our findings, DMT1 
mRNA expression may have decreased as a response to iron accumulation in the 
enterocyte.  Accumulation of iron is strongly reflected by the time-course of DMT1 
mRNA expression in this study, in which there was an immediate and persistent 
inhibition of gene expression.   
5.4.1.3 HFE expression 
The precise role of HFE in the intestine remains unclear.  One proposed role of HFE 
is its function as an intracellular inhibitor of DMT1-mediated iron uptake.  This is 
supported by experiments showing decreased apical iron uptake when HFE, β2m and 
TfR1 co-localise with DMT1 at the apical membrane; (Griffiths et al, 2000; 
Arredondo et al, 2001; Arredondo et al, 2006).  Furthermore, defects in the HFE 
gene cause iron overload haemochromatosis and mice lacking this gene have 
increased DMT1-mediated iron uptake (Fleming et al, 1999).   
The regulators of HFE are unknown. There is evidence to support reciprocal 
regulation to DMT1 or as a negative regulator of DMT1 (Han et al, 1999).  In-vitro 
HFE expression has been found to be dependent on the presence of serum, and not 
iron (Tallkvist et al, 2000).  This negates a correlation of HFE expression to a major 
transcript variant of DMT1. Others suggest HFE expression is regulated by 
alternative splicing, and acts as a signaling peptide (Martins et al, 2011).   
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5.4.1.4 TfR1 expression 
Systemically, TfR1 is known to bind to Tf to facilitate cellular iron absorption; 
whereas in enterocytes TfR1 and HFE interact to regulate iron transport.  TfR1’s 
transcript contains an IRE region thus its expression is strongly induced by iron 
(Brookes et al, 2006; Lee et al, 1998; Tallkvist et al, 2000).  It is reciprocally 
regulated to HFE, and is expressed only in the presence of serum.  (Tallkvist et al, 
2000).  The expression profile we have observed following treatment with the berry 
extract supports the reciprocal regulation to HFE and the intracellular accumulation 
of iron. 
TfR1 is known to form a complex with HFE and β2m.  This complex is suggested to 
be an inhibitory component for apical DMT1-mediated uptake.  Furthermore, HFE 
binding decreases TfR1 cycling time. This results in blocked Tf binding sites and 
therefore decreased efflux capacity thus impeding basolateral iron release (Griffiths 
et al, 2000; Ikuta et al, 2000; Tallkvist et al, 2000).   
5.4.2 Effects of berry extract on functional iron transport 
5.4.2.1 Acute effects of berry extract on iron transport 
Functional studies were carried out acutely to characterise the effects of co-
incubating iron with flavonoids.  Initially, the uptake of iron was increased in the 
presence of the berry extract flavonoids.  This is consistent with previous findings 
(Kim et al, 2008).   
Proposed mechanisms for the initial increase in uptake include more available 
ferrous iron as a result of flavonoid reducing capacity.  However, excess ascorbate 
was added as a reductant to ensure availability of ferrous iron.  Alternatively, metal-
polyphenol complexes are formed and transported across the apical membrane via a 
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different transporter to DMT1 (Kim et al, 2008; Ren et al, 2008; 
Vlachodimitropoulo et al, 2010b).   
Following 120 minutes, the berry extract treatment caused the rate of iron efflux to 
decrease relative to the control. The cellular retention and basolateral release of iron 
were both decreased. The decreased cellular retention of iron is likely to be the result 
of cellular feedback mechanisms to limit the initial increase in iron uptake.  This 
could be mediated by rapid redistribution of DMT1 away from absorptive 
membranes (Sharp et al, 2002).  Alternatively, there may be an efflux of iron from 
the apical route via an unknown transporter. An adaptive mechanism, such as this, is 
necessary for cell survival, as basolateral release of iron was diminished.  Previous 
research suggests that the metal-polyphenol complex transported into the cell is too 
large to be effluxed by FPN (Kim et al, 2008). 
5.4.2.2 Chronic effects of berry extract on iron transport 
Chronic incubations were carried out to characterise the functional relevance of the 
effects of the berry extract on mRNA or protein expression.  Chronic berry extract 
treatment initially decreased the apical uptake of iron. This is consistent with the 
decrease in expression of the genes that coordinate apical iron uptake, i.e. DCYTB 
and DMT1.  Following 120 minutes of exposure to iron, the cellular retention and 
basolateral release of iron returned to the control levels. However, the percentage of 
effluxed iron was significantly decreased in the cells treated with the berry extract.  
The dietary reductant ascorbate is known to increase iron uptake and has been 
reported to negate the inhibitory effects of flavonoids on iron absorption (Ma et al, 
2011).  In our studies, the inclusion of ascorbate does not appear to have affected the 
inhibitory effect of flavonoids on iron absorption. The mechanisms for these 




Our findings indicate that flavonoids acutely stimulate the uptake and impede the 
basolateral release of iron, thus causing intracellular iron accumulation. Over a 
prolonged period (as with our chronic studies) the cellular responses would be that of 
iron overload; i.e. a cellular adaptation to limit influx and maintain efflux of iron. 
This is reflected in the expression profiles of those genes that coordinate iron uptake 
and in our functional studies following chronic treatment. There are no previous 
studies, to our knowledge, that have investigated the chronic effects of flavonoid 
treatments on intestinal iron transport.  Our research has thus contributed to the 
understanding of nutrient interactions and the effects that these have on the function 
of the intestinal epithelium with respect to transport.  Further studies are required to 
understand the mechanisms behind the observed effects and their application to 




5.6 Future work 
5.6.1 Acute interactions of flavonoids and iron 
Our findings regarding the effects of flavonoids on iron absorption leave a number of 
questions that remain to be answered. Figure 5.12 gives an outline of the acute 
effects of flavonoids on cellular iron metabolism with resulting points of future 
investigation. Briefly, given previous work in the area, several mechanisms might 
contribute to increased iron uptake following acute exposure to berry flavonoids; 
including: increased iron reducing capacity in the presence of flavonoids (Kim et al, 
2008) or through flavonoids acting as substrates for DCYTB (Vlachodimitropoulou 
et al, 2010a). Polyphenol-iron complexes formed at the apical pole of enterocytes 
could be imported via GLUT transporters (as transporters of flavonoids) or via other 
unknown routes (Vlachodimitropoulou et al, 2010b). Polyphenols, might also form 
chelates of iron intracellularly, and these are too large to exit via FPN, the only 
known basolateral release route for iron (McKie et al, 2000). Furthermore, 
intracellular flavonoids may have a direct inhibitory action on FPN-mediated efflux 
by interacting directly with the basolateral transporters or membranes. The fate of 
the iron-polyphenol complex remains unknown, it may undergo further metabolism, 
or may be recycled back into the apical medium. The latter supposition is credible 
since following 120 min, despite an initial increase in iron uptake, cellular retention 
as well as the transepithelial flux of iron decrease below control levels. 
Efflux of polyphenol-iron complexes into the basolateral medium could be addressed 
by adding phloretin or cytochalasin-B, which will inhibit GLUT-mediated transport 
to the basolateral medium. The metabolic fates of these complexes could also 
potentially be monitored with confocal fluorescence microscopy, as flavonoids do 
emit at specific wavelengths. Determining the exchange of iron distribution between 
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ferritin pools, labile iron pools and flavonoids will also aid in determining the 
cooperation between these compounds and the modulation of cellular iron stores. If 
metals affect the fluorescence of the flavonoid compounds, tritiated flavonoids as 
well as iron-55 can be applied to determine redistribution between cellular pools and 
the subcellular activity of flavonoids; i.e. mitochondrial or nuclear accumulation etc. 






Figure 5.12. Model of the acute effects on flavonoid treatment. Acute flavonoid treatment 
increases the uptake of iron and decreases the cellular retention and basolateral release of iron; 
this results in an overall decrease in iron transport through enterocytes. 1) Several mechanisms 
contribute to higher iron uptake, including the direct extracellular reduction of Fe
3+ 
by flavonoids; 
alternatively cellular flavonoids can be substrates for DCYTB, catalysing the apical reductase 
step. 2) Flavonoids will form chelates with iron, either intracellularly or extracellularly, 
extracellular chelates enter the cell via GLUT2 or other unknown routes. 3) Cellular flavonoids 
may also interact with the LIP or FT to bind iron. 4) Cellular destination or metabolism of iron-
flavonoid chelates is unknown. 5) There may be an apical efflux route for chelates, as GLUT-type 
transporters have been shown to carry out this function. 6) There is no known efflux route for 
such complexes, causing the decreased trans-epithelial flux of iron. DCYTB: duodenal 
cytochrome B reductase; DMT1: divalent metal ion transporter 1; GLUT2: facilitative glucose 
transporter 2; FT: ferritin; LIP: labile iron pool; FPN: ferroportin; HEPH: hephaestin. 
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5.6.2 Chronic effects of flavonoids on iron metabolism 
From the chronic studies with flavonoids, we have seen that chronic exposure to 
flavonoids causes a decrease in the transepithelial flux of iron. Unlike the acute 
studies, in which the flavonoids are present at the same time as the iron substrate, the 
rate-limiting step of transport can be determined here. Following chronic treatment, 
clearly apical uptake is the rate-limiting step. The results of the Western blotting of 
uptake proteins did not present an overt explanation as to why this may be the case, 
as levels of the apical uptake protein, DMT1, appeared slightly lower but did not 
change significantly. Uptake via DMT1 can be endogenously modified by re-
distribution of transporter proteins away from the cell surface to 
endosomal/lysosomal compartments within the cell (Johnson et al, 2005). Exposure 
to berry flavonoids could affect cellular distribution of DMT1 without modifying 
total transporter protein levels. This hypothesis should be addressed, as with the gene 
expression array results in Chapter 3, several gene ontology terms relate to late 
endosomal/lysosomal compartments (Section 9.5). We can test this supposition by 
confocal microscopy investigating transporter distribution as well as subcellular 
fractionation following exposure to berry flavonoids to determine whether 
transporter protein levels change within specific cellular compartments.  
We can also hypothesise that there may be a significant contribution of flavonoid-
iron chelates to total iron uptake, and that this uptake could be mediated via GLUT2. 
As the decrease in uptake, coincides with a decrease in GLUT2 protein abundance 
(Chapter 5). Again, inhibition of GLUT2 transport with phloretin and inhibition of 
DMT1 by disrupting the pH gradient will determine the relative contribution of these 
transporters.  




Figure 5.13. Effects of flavonoids on iron absorption. 1) flavonoid-iron complexes 
may be transported into the cell via a separate route, GLUT2, other flavonoid 
transporters or unknown routes. 2) Intracellularly, it is not known if the chelate will 
interact with the cellular iron pools or will undergo separate metabolism. 3) It is not 
known if a basolateral efflux route exists for these chelates, or if downstream 
metabolism will liberate any iron for transport via ferroportin. 4) Finally, the role of 
flavonoids, if metabolised or bound to iron is known, will this complex undergo 




5.6.3 Effects of flavonoids on iron-transport related genes  
The molecular effects we observed of flavonoids on gene expression are perhaps the 
most worthy of further investigation. As the expression profile we have seen does 
not completely adhere to what is expected as a response to a single substrate. There 
are other possibilities, such as the influence of flavonoids on oxidative state, and the 
downstream events that arise from this. Future work to investigate the effects of 
flavonoids on gene expression is discussed in the following section. 
5.6.3.1 The iron effect 
When investigating any area of iron metabolism, the local regulatory potential must 
be taken into account. This is mediated by the IRE/IRP system. Of the genes we 
have tested, DMT1 and TfR1 contain IRE regions in their 3’UTR, whereas FPN 
contains an IRE region in the 5’UTR end of its transcript. IRP levels and / or activity 
increase when there is a lack of iron; if IRP binds to the 3’UTR, they stabilise and 
protect mRNA species, whereas binding to the 5’UTR end prevents translation of the 
gene product (reviewed by Sharp & Srai, 2007). Therefore with regards to our 
findings, the decrease in DMT1 mRNA following prolonged treatment with 
flavonoids would be consistent with cellular iron loading, decreased activity of IRP 
and as a result a decreased DMT1 mRNA stability. However, the response of TfR1 
mRNA is not consistent with this mechanism. We must confirm the presence or 
absence of an iron effect on these genes. Quantifying the presence of IRP proteins 
with Western blotting will confirm their contribution to the observed effects. 
Quantifying the effects that flavonoids have on cellular iron pools is also important, 
for both acute and chronic investigations, as well as intermediate exposure times. 
Measuring ferritin as a surrogate marker for iron levels and Phen-Green fluorescence 
to indicate the abundance of the labile iron pool would help to address this. 
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5.6.3.2 The effect of hypoxia-inducible factors 
Hypoxia-inducible factor 2α (HIF-2α) is known to be expressed under hypoxic 
conditions and to induce the expression of components of the iron uptake pathway 
(Mastrogiannaki et al, 2009; Hu et al, 2010). HIF-2α interacts directly with the 
DMT1 and FPN promoter regions to induce their expression (Mastrogiannaki et al, 
2009; Taylor et al, 2011). Knockout of HIF-2α has been shown to decrease 
expression of DMT1, DCYTB and FPN; these findings are very similar to the gene 
expression profile we have found following a chronic treatment with flavonoid 
compounds.   
Flavonoids have been shown to induce accumulation of HIFs through chelating iron, 
thus making iron unavailable as a cofactor for HIF prolyl hydroxylases; enzymes 
which label HIF subunits for rapid proteasomal degradation (Park et al, 2008).  
However, HIF-2α contains an IRE in its 5’UTR sequence which means under iron 
deficient conditions, translation would be decreased. The effect of berry flavonoids 
on HIF-2α mRNA and protein levels should therefore be measured to determine 
whether it plays a role in iron transporter regulation. 
5.6.3.3 The crypt-villus axis and co-culture models  
One of the most controversial elements of iron metabolism surrounds the function 
and expression of HFE. The leading assumptions with HFE are that this gene is 
primarily expressed basolaterally in crypt enterocytes. Its assumed functions are: 1) 
HFE binds to TfR1 and aid in the internalisation of Tf-bound iron from the 
circulation back into intestinal epithelial layers; and 2) in transfected Caco-2 cells, 
HFE inhibits apical DMT1-mediated iron uptake (Fleming et al, 1999; Arredondo et 
al, 2001; Arredondo et al, 2006; Martins et al, 2011). The most reasonable approach 
for determining the effects of flavonoids on this gene, and elucidating the functional 
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consequences would be to investigate the effects of feeding flavonoids on the 
expression and distribution of HFE along the crypt-villus axis in animal models and 
in Caco-2 cells. These studies could be carried out at various stages of cell 
differentiation; Caco-2 cells have previously been applied in differentiation studies 
and as models of the crypt-villus maturation process (Tremblay et al, 2006; Bedrine-
Ferran et al, 2009). In light of this, it would be preferable to investigate the 
differentiation and maturation through an in-vivo model. Knockdown of HFE in 
Caco-2 cells using siRNA and the use of HFE-knockout mice would be useful 
models to further study the role of this gene in flavonoid-mediated regulation of 
intestinal iron transport. 
The other important peptide in iron metabolism, which we have not investigated in 
this system, is hepcidin. To investigate the effects of this decrease in iron flux on 
hepcidin expression we can apply a co-culture model of enterocytes and hepatocytes 
(Chaston et al, 2008). As well as allowing the response and feedback of hepcidin to 
be measured (giving a more physiological context to our results), the co-culture 
system will allow us to determine transport efficiencies and effects of hepatic phase 
2 metabolism on flavonoids, or the effects of systemic polyphenolics on iron 
metabolism in hepatocytes. Hepcidin knockout mice will be useful to further test the 







Effects of berry extract on the expression and function of intestinal copper 
transport pathway in Caco-2 enterocytes 
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6 Effects of berry extract on the expression and function of 
intestinal copper transport pathway in Caco-2 enterocytes 
6.1 Introduction: Intestinal copper transport and dietary flavonoids 
The trace element copper is essential for life, as an integral part of several redox 
enzymes; e.g. hephaestin and ceruloplasmin (Vulpe et al, 1999; Eisenstein, 2000; de 
Romaña et al, 2011).  However, in excess copper generates free radicals through the 
Fenton reaction (Speisky et al, 2009).  In light of this, the maintenance of copper 
homeostasis must be tightly regulated.  The intestine is important in maintaining 
copper balance, via absorption from dietary sources or reabsorption from bile, 
pancreatic juices, gastric juices and saliva (Owen, 1964; Turnlund et al, 1999).  
Several factors influence intestinal copper absorption including age, gender, dietary 
copper content and the presence of other nutrients (Johnson, 1989).  Imbalances in 
copper homeostasis are rare, though they occur in two major diseases: Menke’s 
disease and Wilson’s disease.  These diseases result from genetic mutations in the 
two copper transporting ATPases, ATP7A and ATP7B, respectively (Cox & Moore, 
2002; Lutsenko, 2008).   
The primary step in copper metabolism is the transport of ingested copper across the 
intestinal epithelium.  Following this, copper is transported and distributed via the 
portal venous system (Puig & Thiele, 2002).  The first step in intestinal copper 
absorption is the reduction of cupric copper.  This occurs through dietary reductants 
such as ascorbate and candidate reductases such as DCYTB and the Steap proteins 
(Kuo et al, 2004; Ohgami et al, 2006; Wyman et al, 2008).  Once reduced, cuprous 
copper can be transported into the enterocyte via the apical importer CTR1 (Lee et 
al, 2000).  Once in the enterocyte, copper can be bound by any one of a number of 
chaperone proteins, such as the HAH1 or CCS.  Each chaperone has its specific 
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destination for intracellular copper delivery (Harrison et al, 2000). Copper that is 
bound to HAH1 is delivered to ATP7A or ATP7B (Hamza et al, 2003).  ATP7A is 
necessary for the efflux of copper from the basolateral membrane of enterocytes 
(Yamaguchi et al, 1996; La Fontaine et al, 1998).  The role of intestinal ATP7B 
(highly expressed in hepatocytes as a copper efflux protein) remains unclear.  Both 
ATPases are implicated in the cupration of metalloenzymes at the trans-Golgi 
network (Nyasae et al, 2007; Weiss et al, 2008). 
Copper is known to interact with other nutrients.  For example, adequate copper 
status is necessary for the metabolism of iron (Tennant et al, 2002).  Additionally, 
copper and iron are both substrates for DMT1, thus presenting competition for each 
other (Arredondo et al, 2003).  Both of these metals are influenced by the presence 
of ascorbate and by polyphenolic compounds (Kuo et al, 2004; Ren et al, 2008; 
Lekka et al, 2009; Thumser et al, 2010).  However, the effects of flavonoids on 
copper absorption and on the genes and proteins that coordinate copper absorption 
remain unknown. To address this we investigated the effects of a flavonoid-rich 
berry extract on copper uptake and on the expression of copper transport-related 




Presented here is a brief description of the methods used in this chapter. For full 
details of reagents, buffer/media compositions and methods used see Chapter 2. 
6.2.1 Cell culture 
Caco-2 TC7 cells between the passages of 44 and 47 were seeded into 6-well plates 
at a density of 40,000 cells per well (4,000 cells per cm
2
) and cultured for 19 days 
prior to treatment.  For copper uptake studies, cells were grown on T-25 flasks at a 
density of 100,000 cells per flask.  Details of the maintenance of the cells and 
composition of cell culture medium have been previously described (see Chapter 2 
and Johnston et al, 2005). 
The treatment used was a flavonoid-rich berry extract (derived from blueberry, 
bilberry, cranberry, elderberry, raspberry seeds and strawberry; rich in the 
anthocyanins delphinidin, cyanidin, petunidin and malvidin, OptiBerry®, 
InterHealth Nutraceuticals, CA, USA) at a final concentration of 0.125 % (w/v).  
Treatment was prepared in Dulbecco’s modified Eagle’s medium for gene and 
protein expression and chronic-exposure copper-uptake studies.  Treatments for 
acute-exposure copper-uptake experiments were prepared in 2-(N-morpholino) 
ethanesulfonic acid buffered salt solution (MBSS).  An identical medium, without 
the berry extract, was used for the control cells.   
The effect of berry extract treatments on cell viability, RNA and protein content of 
the cells were tested.  There were no effects of any treatments on cell viability, RNA 





6.2.2 Real-time qPCR 
Total RNA was isolated from the cultured cells using TRIzol® (Invitrogen™ Life 
Technologies, Paisley, UK) according to the manufacturer’s instructions.   Following 
first strand cDNA synthesis (using a high-capacity cDNA reverse transcription kit, 
Applied Biosystems™ Cheshire, UK), expression levels of copper transport-related 
gene mRNA and 18S and GAPDH mRNA (used as housekeeping genes) were 
analysed by real-time PCR using an ABI Prism 7700HT Sequence Detection System 
and a Power SYBR® Green PCR master mix kit (Applied Biosystems™ Cheshire, 
UK).  Primers were designed using the online design tool Primer3 (Rozen & 
Skaletsky, 2000) and sourced from MWG Eurofins (London, UK).  Quantitative 
measurement of gene expression was derived from the 2
(-ΔΔCt)
 method, also known as 
the
 
Livak method (Livak & Schmittgen, 2001; Schmittgen & Livak, 2008).  Data 
were expressed as ratios to the control and normalised to the housekeeping genes 
18S and GAPDH. The primer sequences used for each gene are in Table 6.1.  







CTR1 GCC ACC CAT GAG ATG TCT TT CCA TCA ATC CTG GCT GAA GT 
HAH1 CAC AGC ATG GAC ACT CTG CT AAG TCC CAG GTC TGT CTG GA 
ATP7A TCC TTC TTC CCG CCT TAA AT GAA ATG CCG CTT CTG ACT TC 
ATP7B CCA CAT GAA GCC CCT GAC GAC CAC TTG TCC CCA TCA TC 
18S AAC TTT CGA TGG TAG TCG CCG CCT TGG ATG TGG TAG CCG TTT 
GAPDH CTG TTG CTG TAG CCA AAT TCG T ACC CAC TCC TCC ACC TTT GA 
CTR1: copper transporter 1; HAH1: human antioxidant protein homologue 1; ATP7A: copper 
transporting ATPase α polypeptide; ATP7B: copper transporting ATPase β-polypeptide; 18S: 





6.2.3 Western blotting 
Total protein from Caco-2 cells was prepared as described previously (Chaston et al., 
2008).  Total proteins (40 μg) were solubilised in sample loading buffer and 
subjected to SDS-PAGE.  Following immobilisation on nitrocellulose, the proteins 
were exposed to anti-CTR1 or anti-ATP7A antibodies (1:1000 dilution, Source 
Bioscience, Nottingham, UK).  Blotted membranes were visualised using a 
horseradish peroxidase-linked secondary antibody and Novex® ECL 
chemiluminescent substrate reagent kit (Invitrogen™ Life Technologies, Paisley 
UK).  Band densities were quantified using a densitometer (GS-800™) and Quantity 
One software (Bio-Rad Laboratories, Hertfordshire, UK).  Actin protein levels were 
also measured (anti-actin antibody, 1:2000 dilution, Sigma-Aldrich).  Protein density 
data were expressed normalised to actin as the housekeeping protein. For antibody 
concentrations and reagents see Section 2.2.4. Protein abundance analysis. 
6.2.4 Copper uptake assays 
This section contains a brief description (for further details see Section 2.2.5 
Functional uptake and transport experiments) Uptake was carried out in MBSS, 
both in the presence and absence of 100 µM ascorbate as a reducing agent.  Caco-2 
cells, grown in T-25 flasks to allow for a higher cell density, were treated with berry 
extract acutely or chronically.  For the acute studies, Caco-2 cells were pre-
equilibrated with berry extract for 15 min and 10 µM copper chloride was added to 
initiate uptake.  In the chronic studies, cells were exposed to berry extract for 16 h. 
At the end of this incubation period the treatment solutions were removed and the 
cells were washed in uptake buffer.  Fresh berry extract-free MBSS uptake buffer 
containing 10 µM copper chloride was added to initiate uptake.   
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Copper uptake was terminated after 120 min by washing cells in ice cold PBS.  Cells 
were harvested in 2 ml PBS, dissolved in 3 ml 1M nitric acid and 5 ml 68-70% nitric 
acid.  Cell lysate was further digested at 90°C for 90 min and the remaining cell 
debris was removed by centrifugation at 5000 rpm for 10 min.  These samples were 
run through inductively coupled plasma optical emission spectroscopy (ICP-OES; 
iCAP 6000 series; Thermo Scientific, UK) for mineral analysis.  A multi element 
standard (Merck, Germany, Cat No.  11335), containing 1006±10 mg/L copper, was 
used to construct a calibration curve.  The optimum specific wavelength for 
measurement of copper concentrations was 324.754 nm.  Data were normalised to 
amounts of total protein, quantified using the protein quantification kit-rapid (Fluka, 
from Sigma-Aldrich).  Data were expressed as total copper uptake per 120 minutes. 
6.2.5 Data and statistical analysis 
Data are expressed as means + SEM.  Statistical analysis was carried out using 
GraphPad Prism 5 (San Diego, CA, USA).  In studies containing 2 experimental 
groups Student’s unpaired t-test was used to compare means.  Differences between 
multiple groups were calculated using a 1-way ANOVA with Dunnett’s post-hoc 




6.3.1 Effects of berry extract on cell viability, RNA and protein content 
The effects of treatments on cell viability, RNA content and protein content were 
tested to ensure effects of berry extract were not due to pathological changes, but as 
normative responses.  There was no effect of berry extract on cell viability (Figure 
6.1), RNA content (Figure 6.2), or protein content (Figure 6.3). 
Figure 6.1. Caco-2 cell viability after berry extract treatment. Caco-2 
cells were treated with berry extract at 0.125 % (w/v) for 16 h. Cell 
viability was quantified with the trypan blue dye-exclusion method. Data 
is presented as mean percentage viable cells ± SEM, n = 6. Student’s t-test 
showed there was no significant difference between groups. 
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Figure 6.2. RNA concentration from Caco-2 cells after berry extract 
treatment. Caco-2 cells were treated with berry extract at 0.125 % (w/v) 
for 16 h. RNA concentration in the extracts of Caco-2 cells was quantified 
with the NanoDrop spectrophotometer. Data is presented as mean RNA 
concentration ± SEM, n = 6. Student’s t-test showed there was no 
significant difference between groups. 
Figure 6.3. Protein concentration from Caco-2 cells after berry 
extract treatment. Caco-2 cells were treated with berry extract at a 
concentration of 0.125 % (w/v) for 16 h. Protein concentration was 
quantified by a Bradford spectrophotometric assay. Data is presented as 
mean protein concentration ± SEM; n = 6. Student’s t-test showed there 




6.3.2 Effects of berry extract on copper-transport related gene expression 
Expression of CTR1 and ATP7A, the main genes involved in apical influx and 
basolateral efflux of copper, respectively, was quantified across a number of 
concentrations of the berry extract and across different treatment durations.  CTR1 
expression decreased with increasing concentration; a significant decrease in 
expression started at 0.031 % (w/v) (p < 0.05) and continued to decrease until the 
highest concentration 0.25 % (w/v) (p < 0.001; Figure 6.4, panel A).  ATP7A 
expression decreased at 0.125% (w/v) and continued to decrease at a higher 
concentration (p < 0.01; Figure 6.4, panel B).   
As for the time-dependent effects, CTR1 had an initial increase in expression at 4 h 
(p < 0.001) and decrease in expression at 16 h (p < 0.05; Figure 6.5, panel A).  
ATP7A, decreased at the 16 h time point (p < 0.05; Figure 6.5, panel B). 
When treated with the berry extract for 16 h at a concentration of 0.125% (w/v) the 
expression of all the genes tested was significantly decreased (Figure 6.6).  These 
were CTR1 (p < 0.01; panel A), HAH1 (p < 0.05; panel B), ATP7A (p < 0.05; 




Figure 6.4. Dose-dependent effects of berry extract on CTR1 and ATP7A 
mRNA expression. Caco-2 cells were treated with a berry extract at different doses 
from 0.25 % (w/v) in 2-fold dilutions until 0.016 % (w/v). CTR11 (A) and ATP7A 
(B) mRNA were quantified by qRT-PCR and normalised against 18S and GAPDH 
as housekeeping genes. Data are presented as mean normalised expression ratio ± 
SEM, n = 6, statistical significance was determined by an ANOVA and Dunnet’s 
post-hoc test against the 0 % (w/v) concentration. (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p 
≤ 0.001. CTR1: copper transporter 1. ATP7A: copper transporting ATPase α-
polypeptide. 18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 3-phosphate 






Figure 6.5. Time-dependent effects of berry extract on CTR1 and ATP7A 
mRNA expression. Caco-2 cells were treated with berry extract at 0.125 % (w/v) 
from 4 h to 24 h. Levels of CTR1 (A) and ATP7A (B) mRNA were quantified by 
qRT-PCR and normalised against 18S and GAPDH as housekeeping genes. Values 
are mean normalised expression ratio ± SEM, n = 6. Statistical significance was 
determined by an ANOVA and Dunnet’s post-hoc test against the 0 h time-point. (*) 
p ≤ 0.05. CTR1 expression had a significant linear trend (*) p ≤ 0.05. CTR1: copper 
transporter 1. ATP7A: copper transporting ATPase α-polypeptide. 18S: ribosomal 
RNA 18S. GAPDH: glyceraldehyde 3-phosphate dehydrogenase. qRT-PCR: 






Figure 6.6. Effect of berry extract on mRNA expression of copper transport-
related genes Caco-2 cells were treated with 0.125 % (w/v) of berry extract for 16 
h. Levels of CTR1 (A), HAH1 (B), ATP7A (C) and ATP7B (D) were quantified and 
normalised to 18S and GAPDH as housekeeping genes. mRNA data are presented as 
the mean (relative to the control) ± SEM, n = 6, (*) p ≤ 0.05, (**) p ≤ 0.01. To 
determine significance an unpaired t-test was used against the control group. CTR1: 
Copper transporter 1. HAH1: human antioxidant homolog 1. ATP7A: copper 
transporting ATPase α-polypeptide. ATP7B: copper transporting ATPase β-
polypeptide. 18S: ribosomal RNA 18S. GAPDH: glyceraldehyde 3-phosphate 







6.3.3 Effects of berry extract on CTR1 and ATP7A protein expression 
The effects of the berry extract on those proteins that are important for apical uptake 
(CTR1) and basolateral release (ATP7A) of copper was quantified.  There was no 
significant effect on the abundance of either protein following 16 h treatment with 
the berry extract (Figure 6.7).  
Figure 6.7. Effect of berry extract on CTR1 and ATP7A protein expression. 
Total protein was prepared from Caco-2 cells treated with 0.125 % (w/v) berry 
extract for 16 h. Levels of CTR1 or ATP7A protein were normalised to β-actin as a 
housekeeping protein. Representative blots for CTR1 (A) and β-actin are shown in 
the lower left panel, with semiquantitative densitometry data in the upper left panel. 
Representative blots for ATP7A (B) and β-actin are shown in the lower right panel, 
with semiquantitative densitometry data in the upper right panel. Expression levels 
of the housekeeper protein β-actin were not altered by berry extract treatment. 
Densitometry data are presented as the mean (relative to the control) ± SEM, n = 4 
(*) p ≤ 0.05. Student’s t-test showed there was no significant difference between 









6.3.4 Effects of berry extract on copper uptake  
The functional effects of berry extract on intestinal copper uptake were measured 
both in the presence and absence of ascorbate.  We therefore investigated whether 
berry extract, at a final concentration of 0.125 % (w/v), can acutely (following 15 
min exposure) or chronically (following a 16 h exposure) influence copper uptake.   
Only in the presence of ascorbate (higher reducing capacity, i.e. transport of cuprous 
copper) was the increase rate of copper uptake significant under both acute 
treatments (p < 0.01; Figure 6.8, panel A) and chronic treatments (p < 0.001; 





















Figure 6.8. Acute effects of berry extract and ascorbate on copper uptake. 
Caco-2 cells were treated acutely, for 15 min, with 0.125 % (w/v) berry extract and 
subjected to copper uptake in the presence (A) or absence (B) of ascorbate as a 
reducing agent. Data are presented as the mean ± SEM, n = 6. Unpaired t-test was 
used to determine significance against the control (**) p ≤ 0.01. 
Figure 6.9. Chronic effects of berry extract and ascorbate on copper uptake. 
Caco-2 cells were treated chronically, for 16 h, with 0.125 % (w/v) berry extract and 
subjected to copper uptake in the presence (A) or absence (B) of ascorbate as a 
reducing agent. Data are presented as the mean ± SEM, n = 6. Unpaired t-test was 




The intestinal absorption of dietary copper is coordinated by a number of genes and 
proteins mediating apical uptake (i.e. CTR1), intracellular binding (i.e. HAH1) and 
the distribution and basolateral efflux of copper (i.e. ATP7A and ATP7B).  The 
intestine is the main site responsible for maintaining copper balance, and the 
absorption of copper is greatly influenced by the presence of other dietary 
constituents.  In this regard, dietary flavonoids and ascorbate have been 
demonstrated to influence the absorption of copper as well as other dietary metals 
(Kim et al, 2008; Lekka et al, 2009).  Although the structural interactions between 
flavonoids and copper have been characterised, the functional, transcriptional and 
translational implications remain unknown.     
To address this we investigated the effects of a flavonoid-rich berry extract on the 
expression of genes and proteins related to copper uptake in Caco-2 cells.  Further to 
this we investigated the chronic and acute effects of berry extract on copper 
absorption.  We found decreased abundance of CTR1, HAH1, ATP7A and ATP7B 
mRNA following chronic berry extract treatment. There was no concomitant effect 
on the abundance of either CTR1 or ATP7A proteins.  In functional experiments, the 
berry extract enhanced the uptake of copper with both chronic and acute treatments, 
albeit only in the presence of ascorbate. 
6.4.1 Regulating copper transport-related gene and protein expression 
The intestinal absorption of copper is tightly regulated.  It has been demonstrated 
that prolonged exposure to high copper causes accumulation in enterocytes, whilst 
maintaining plasma copper status (Arredondo et al, 2000; Bauerly et al, 2004).  
Furthermore, the responses of enterocytes to low and high copper are presumed to be 
different, i.e. different genes, proteins or mechanisms (Arredondo et al, 2000).   
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Expression of the genes that mediate enterocytic copper metabolism is regulated by 
iron or other factors, but not by the presence of their substrate, copper.  Instead, post-
translational mechanisms are in place to respond to local copper balance.  
Degradation and trafficking of copper transport-related proteins between intracellular 
and membrane compartments is the main response to copper load (Bauerly et al, 
2004; Nyasae et al, 2007; Weiss et al, 2008).  In light of this, the effects of our 
flavonoid treatment on gene expression cannot be attributed to copper content per se 
(as is the case with other dietary metals such as iron).  Rather, flavonoids may 
interact with other mechanisms or regulatory pathways that indirectly influence the 
expression of these genes.   
6.4.2 Effects of berry extract on gene and protein expression 
6.4.2.1 Berry extract and CTR1 expression 
Following berry extract treatment, we found a decrease in CTR1 mRNA expression, 
but no effect on CTR1 protein.  CTR1 is the primary importer of copper into 
enterocytes.  Although mammalian CTR1 mRNA responds to copper status during 
early development, this responsiveness is lost in adulthood and thus CTR1 mRNA 
expression becomes independent of its substrate (Lee et al, 2000; Lee et al, 2001; 
Sharp, 2003; Bauerly et al, 2005).  In Caco-2 cells there is a copper-dependent 
relocalisation and degradation of the CTR1 protein, but no effect on mRNA, 
following copper loading (Bauerly et al, 2004; Nose et al, 2010).   
Miyayama et al (2011) reported that CTR1 mRNA expression decreases in response 
to silencing or knockout of copper chaperones.  Despite previous reports, this effect 
on CTR1 gene expression was attributed to excess copper.  Presumably any copper-
related effects on CTR1 mRNA expression would, in that case, be related to 
unbound copper, chaperone abundance or chaperone properties (Miyayama et al, 
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2011).  Furthermore, in drosophila, the induction of CTR1 by copper starvation is a 
normal transcriptional response. However, a recent study has found that in HAH-
knockouts, CTR1 expression is not induced (Hua et al, 2011).  In light of the 
aforementioned studies, the decrease in CTR1 mRNA we observed may be induced 
by the concomitant decrease in HAH1 expression.  Alternatively, it may be a 
response to high intracellular copper, chelated to flavonoids, rather than to the 
typical chaperone molecules.   
6.4.2.2 Berry extract and HAH1 expression 
HAH1 delivers copper to ATP7A and ATP7B and maintains copper cellular 
distribution in enterocytes and hepatocytes (Larin et al, 1999; Strausak et al, 2003; 
McRae et al, 2010).  In our study, there was a decrease in mRNA expression of 
HAH1 following treatment with the berry extract.   
Little is known regarding the regulation of mammalian HAH1 mRNA.  In-vivo 
expression profiles of HAH1 are highest in tissues with high metal content. This 
indicates the importance of metal binding and maintaining functionality of 
metalloenzymes (Naeve et al, 1999). In light of this, copper chaperone expression is 
likely to be in accordance with the need for copper binding or distribution.  
Expression of copper chaperones is also known to increase when another copper 
chaperone has been silenced or knocked down (Miyayama et al, 2011).   
With regards to our findings, the decreased expression of HAH1 indicates either: 1) 
decreased requirement for copper binding as it may be bound to flavonoids; or 2) the 
regulation of HAH1 mRNA may be concordant with the expression of the target 




6.4.2.3 Berry extract and ATP7B expression 
The role of intestinally expressed ATP7B has not been fully characterised, though it 
is assumed to be involved in copper efflux, enzyme metallation and copper 
sequestration (Terada et al, 1999; Weiss et al, 2008).  The copper-dependent 
regulation of ATP7B is through post-translational mechanisms, e.g. high copper 
induces ATP7B translocation to dispersed vesicles (Weiss et al, 2008).    
The transcriptional regulation of ATP7B is independent of copper status.  However, 
transcriptome variation studies have shown that ATP7B mRNA expression decreases 
with iron loading (Bédrine-Ferran et al, 2004).  Therefore, from the expression 
profile seen in our study, we can speculate that there may be an increase in 
intracellular iron in response to berry extract.  Indeed, this is supported by our 
findings in Chapter 5. 
6.4.2.4 Berry extract and ATP7A expression 
ATP7A is involved in the efflux of copper and in enzyme metallation (Petris & 
Mercer, 1999). This protein is also known to be post-translationally regulated by 
copper (Petris et al¸ 1996). In Caco-2 cells, copper loading decreases ATP7A 
activity, without affecting mRNA or total protein levels (Bauerly et al, 2004).  This 
decrease in enterocytic efflux is a protective mechanism, as copper accumulation at 
the epithelium prevents high plasma levels and accumulation in other organs. 
Intestinal ATP7A expression responds to systemic signals, e.g. mice with cardiac 
specific CTR1-knockout have increased intestinal ATP7A activity, leading to 
elevated serum copper levels and decreased hepatic copper stores (Kim et al, 2010).  
Furthermore, the silencing or knockout of copper chaperones induces the expression 
of ATP7A, promoting copper efflux to maintain cellular homeostasis (Miyayama et 
al, 2011).  In light of this, ATP7A expression may coincide with copper chaperone 
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properties; this is similar to CTR1. ATP7A is expressed in at least three splice 
variants that are strongly induced in rat enterocytes in response to iron deprivation 
(Collins et al, 2009).  This supposes that high iron will reduce ATP7A expression.   
Indeed this was observed, i.e. increased iron (in Chapter 5) and reduced ATP7A 
(this section). 
6.4.3 Effects of berry extract on functional copper uptake 
Chronic and acute berry extract treatment both increased copper uptake, albeit only 
in the presence of ascorbate. Ascorbate, as a reducing agent, allows more cuprous 
copper to be available. Cuprous copper is transported exclusively by CTR1. This 
indicates that the enhancing effects of berry flavonoids on copper uptake are 
mediated via CTR1 alone.  Alternatively, a separate transport route may be recruited. 
Furthermore, flavonoids are effective metal chelators (Ren et al, 2008; Lekka et al, 
2009).  Chelators, such as triethylenetetramine, are often applied in research to 
deprive cells of copper (Zerounian et al, 2003).  Following treatment with chelators 
copper uptake is typically increased. Therefore, the higher rate of copper uptake in 
the chronic berry extract study may have simply been a consequence of prior copper 
deprivation. Following the chronic treatments, there is also a markedly higher rate of 
copper uptake relative to the acutely treated cells, which would not have had 
chelators present beforehand (i.e. 1.5-3.0 pmol Cu/ µg protein/ 120 min following 
chronic treatment and ~0.5 pmol Cu/ µg protein/ 120 min following acute treatment). 
In light of the above, the increase in copper uptake during acute and chronic 
treatments may be mediated via separate mechanisms.  The mechanism from chronic 
studies may have been due to chelation-mediated copper depletion.  In contrast, the 
increased uptake from acute studies is more likely due to redox or structural 
interactions which increase availability of transportable copper. 
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6.5 Conclusions  
We have investigated the effects of dietary berry flavonoids on the expression and 
function of the copper uptake pathway in enterocytes. We found that a flavonoid-rich 
berry extract decreases expression of the genes that modulate copper transport, with 
a concomitant increase in copper uptake in the presence of ascorbate. This indicates 
increased CTR1 activity. Our findings contribute to the knowledgebase regarding 
nutrient interactions and will aid in optimising dietary management in conditions of 
copper or iron imbalance.  The metabolism of iron is dependent on maintaining 
adequate copper levels. If copper status varies, iron status will vary and vice versa in 




6.6 Future work 
Flavonoids, in the presence of additional reducing capacity in the form of ascorbate, 
significantly increase copper uptake. Given that the transcriptional regulation of 
copper transport-related genes has not been fully elucidated, our findings raised 
numerous points for future investigation, mainly related to the functional 
implications of flavonoid treatments. These are discussed in the following section, 
for a summary of the flavonoid effects and the areas for future work see Figure 6.10.  
6.6.1 Enhancement of copper uptake 
During both acute and chronic treatments there was an increased uptake of copper 
into Caco-2 monolayers; the mechanism for this increased uptake is unknown. The 
leading hypotheses regarding these changes are an enhanced reducing capacity or the 
formation of polyphenol complexes that will be transported by other means. 
Flavonoids and ascorbate are known to be powerful reductants; as well as providing 
substrates for apical reductase activity (Vlachodimitropoulo et al, 2010a). 
Furthermore, the complexation of copper to flavonoids has previously been 
demonstrated (Lekka et al, 2009). Polyphenol-metal complexes that contain iron are 
thought to flux via GLUT-type transporters, or possibly through other flavonoid 
influx routes (Vlachodimitropoulo et al, 2010b).  The formation of polyphenol-metal 
chelates has been shown to increase iron uptake as well as ascorbate being a well 
known enhancer of iron uptake. Thus the increase in copper uptake may be attributed 
to a similar synergy between increased reducing capacity and the availability of more 
transportable substrates, in the form of chelates. 
To address the above hypotheses regarding copper absorption a series of studies can 
be carried out to elucidate the contributing transporter proteins. The current 
candidate transporters that will contribute to the copper influx by CTR1 are DMT1 
207 
 
or GLUT2. Targeted deletion of DMT1 by siRNA and inhibition of GLUT2 by 
phloretin will allow us to determine if CTR1 is the only contributing protein to the 
increased influx of copper. Furthermore, localising each of these proteins to the 
apical membrane will confirm their correct location for influx.  
6.6.2 Effects on copper efflux 
In these experiments we could not assess the effects of flavonoids on the second 
component of absorption, that being basolateral efflux. This can be easily quantified 
by applying a Transwell® system, as in Chapter 5, using radiolabelled copper-64. 
This will allow us to quantify effects on basolateral transfer of copper, and therefore 
also the function of ATP7A. Specific deletion of ATP7A by siRNA will allow us to 
elucidate if another efflux route for copper is recruited in this process.  
6.6.3 Effects of flavonoids on chaperones and gene expression 
Given that copper may be bound by flavonoids, either extracellularly and imported, 
or may be bound intracellularly after apical influx, the question remains whether 
these forms of chelated copper are metabolically accessible to classical copper 
chaperones or if they have a separate metabolic route. This can be elucidated by 
Western blot protein analysis of specific forms of the copper chaperone proteins; i.e. 
the apo-proteins versus the holo-proteins.  
Previous research has found that flavonoids will inhibit the degradation of HIFs by 
binding to iron, preventing the correct function of prolyl hydroxylase. In which case, 
HIFs will accumulate intracellularly. ATP7A and CTR1 have been shown to be 
induced by HIF-2α, and knockout or silencing of HIF-2α results in decreased 
expression of these genes (Xie & Collins, 2011; Pourvali et al, 2012).  
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In light of the above, the expression effects of flavonoids may be largely due to their 
effects on the hypoxia response pathway. Quantifying expression of HIFs and the 
metabolic availability of copper bound to flavonoids will give a better understanding 
to the downstream events that coordinate copper transport. 
Figure 6.10.Model of effects of flavonoids on copper uptake. 1) Higher copper 
uptake may have been due to increased reducing capacity by flavonoids, reducing 
copper extracellularly or providing more substrate for apical reductase activity. 2) An 
alternative source of copper influx may be the uptake of copper-flavonoid complexes 
via GLUT-type transporter or other routes. 3) The destination of copper imported via 
DMT1, GLUT or other transporters (aside from CTR1) is unknown; this source of 
copper may not be metabolically accessible. Copper that is imported via CTR1 will 
bind to a chaperone molecule (COX17, HAH1 or CCS), each with a specific 
destination 4) Flavonoids may also act as extracellular copper chelators, “leaching” 
copper from cellular compartments or providing an intra- to extracellular copper 
shuttle. 5) The effects of flavonoids on COX17 and on CcO expression are unknown. 
6) The effects of flavonoids on CCS and on Cu/Zn-SOD expression are unknown. 7) 
Although we have quantified the expression of ATP7A and ATP7B, the effects that 




Summary of the thesis 
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7 Summary of the thesis and general discussion 
We investigated the effects of dietary berry flavonoids on the human intestinal Caco-
2 cells.  Initially we carried out a microarray study where several pathways related to 
nutrient transport were identified to have been altered.  These pathways pertained to 
the transport of glucose, iron and copper.  From the aforementioned study, work was 
focused to identify the processes whereby berry flavonoids modulate nutrient 
transport.  For brevity, only the most significant findings are discussed in this 
section.   
7.1 Transcriptomic effects of berry extract on Caco-2 enterocytes 
The initial investigation of the Caco-2 cell transcriptome following berry extract 
treatment revealed differential expression of 2557 genes.  Of these, 761 genes had 
increased expression whereas 1796 decreased.  Pathway analysis identified a large 
number of pathways that were significantly affected.  These included pathways 
related to the cell cycle, gene expression, molecular transport and small molecule 
biochemistry.  GO analysis revealed clusters relating to metal ion transport and 
carbohydrate metabolism, as well as several others such as ATPase activity and 
brush border cellular components.   
Following traditionally applied pathway analysis and GO clustering, we carried out 
functional similarity clustering with DMT1 as the bait gene, a bait gene forms the 
basis around which other genes are clustered for similar function (for details of 
informatics approaches with the gene expression array see Section 9.3 
Bioinformatics analysis).  There were 27 other genes functionally related to DMT1, 
including those pertaining to glucose (GLUT2), iron (HFE) and copper (ATP7B) 
transport.  We then investigated the expression and function of each pathway 
involved in the transport of the aforementioned nutrients.   
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7.2 Effects of flavonoids on intestinal glucose uptake 
In Chapter 4 we addressed the hypothesis that dietary flavonoids influence glucose 
uptake processes in human intestine epithelial cells.  This was investigated by 
treating Caco-2 cells with a flavonoid-rich berry extract, or with the synthetic 
flavonoids quercetin, phloretin or phloridzin.   
Treatment of Caco-2 cells with either the berry extract or with quercetin decreased 
mRNA expression of both GLUT2 and SGLT1, the main enterocyte glucose 
transporters. With concomitant decrease in abundance of the GLUT2 following berry 
extract treatment.  Further to this, we investigated the functional effects of flavonoid 
treatments, both chronically and acutely, using radiolabelled glucose.  Chronic 
treatments were used to characterise the transcriptional and translational effects on 
function of GLUT2 and SGLT1.  Acute treatments were used to characterise the 
interactive or competitive effects of flavonoids, i.e.  co-incubation of flavonoids and 
glucose.  Chronic treatment did not induce an inhibitory effect on glucose uptake.  
However, acute treatment with the berry extract and quercetin decreased glucose 
uptake mediated by GLUT2 and by SGLT1.  The acute inhibitory effects of phloretin 
and phloridzin confirmed the presence and function of both glucose transporters in 
this cell line. As phloretin and phloridzin are specific inhibitors of GLUT2 and 
SGLT1 mediated uptake, respectively.   
Our findings indicated that, in line with previous research, there is an acute 
inhibitory effect of flavonoids on glucose uptake and that flavonols (i.e. quercetin) 
are particularly potent inhibitors (Park, 1999; Kwon et al, 2007).  Furthermore, 
although chronic flavonoid treatment inhibited the expression of glucose 
transporters, their function was not affected.  Put simply, this suggests that the 
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molecular events that occurred from chronic flavonoid treatments are not rate-
limiting factors for glucose uptake.   
It seems that flavonoids must be present to cause an inhibitory effect on glucose 
uptake, as we have noted in our acute experiments.  Therefore, the effects we 
observed on gene and protein expression are more likely to be a consequence of the 
acute inhibition of glucose uptake.  Further research is required to characterise the 
effects of flavonoids on protein trafficking or downstream events such as activation 
of carbohydrate response elements.   
7.3 Effects of berry extract on intestinal iron transport 
In Chapter 5 we addressed the hypothesis that dietary berry flavonoids influence 
intestinal iron transport processes in Caco-2 cells.  Following treatment with the 
berry extract there was decreased expression of DMT1, DCYTB and HFE, and a 
concomitant increase in TfR1 expression.  These genes coordinate and regulate the 
apical uptake of iron. The gene expression profile indicated high intracellular iron 
content.   
We then investigated the acute and chronic effects of berry extract on iron transport.  
Acute treatment resulted in increased iron uptake, with decreased cellular retention 
and basolateral release of iron. In contrast, chronic treatment decreased iron uptake 
with but did not affect the cellular retention or basolateral release. However, both 
acute and chronic treatments with berry extract resulted in decreased transepithelial 
flux of iron and thus cellular iron accumulation. 
In light of the above, the gene expression profile we have observed may have arisen 
due to a high cellular iron content resulting from initial acute interactions with 
flavonoids. High levels of cellular iron retention following flavonoid treatments have 
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been previously ascribed to increased apical uptake and impeded basolateral release 
(Kim et al, 2008).  Several mechanisms have been suggested for this, including: 1) 
flavonoid reducing capacity provides more Fe
2+
 as a substrate for DMT1 (Mira et al, 
2002); 2) formation of metal-polyphenol complexes that are transportable into cells 
through other routes such as SVCT1 or GLUT2 (Song et al, 2002; 
Vlachodimitropoulou et al, 2010b); 3) complexed iron accumulates because it cannot 
be effluxed via the FPN route (Kim et al, 2008).  
These findings highlight the role of flavonoids in the management of iron anaemia or 
overload. With the administration of flavonoids, there is an accumulation of iron at 
the intestinal epithelium.  Potentially, this may decrease plasma peaks in iron, and 
reduce systemic accumulation in tissues. This is important in light of the fact that 
current treatment regimens for dysregulated iron status have side effects such as 
gastrointestinal distress and infection risks.  Further research is required to 
characterise the full potential of flavonoids in correcting iron imbalances. 
7.4 Effects of berry extract on intestinal copper uptake 
In Chapter 6 we addressed the hypothesis that dietary berry flavonoids influence 
intestinal copper uptake processes in Caco-2 cells.  Components of the copper uptake 
pathway that were investigated were the apical copper importer, CTR1 and the 
intracellular chaperone, HAH1.  The targets of the HAH1 protein, ATP7A and 
ATP7B, were also investigated.  Berry extract treatment decreased expression of all 
these genes.  Unlike iron or glucose metabolism, the genes involved in copper uptake 
are not regulated by their substrate.  Instead they are regulated by iron, and the 
expression profile seen following berry extract treatment reflects high intracellular 
iron, i.e. decreased expression of ATP7A and ATP7B.   
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Copper uptake was investigated in the presence or absence of ascorbate, as a dietary 
reductant, following acute and chronic berry extract treatment.  With ascorbate 
cuprous copper is available, and is only transportable via CTR1.  In these functional 
studies there was an increase in copper transport under both acute and chronic 
treatment conditions, only in the presence of ascorbate.  This suggests that increased 
copper influx is mediated via the CTR1 transporter. Alternatively, separate transport 
routes may be recruited. Furthermore, following chronic treatments, copper 
deprivation due to chelation reactions may have caused an increase in influx when 
copper uptake was initiated. Our findings indicate that berry flavonoids, acutely and 
chronically, enhance CTR1-mediated intestinal copper uptake.  The transcriptional 
and translational events that occur following treatment are indicative of high 
intracellular iron.  With these findings we can confirm that flavonoids are a dietary 
means of enhancing copper uptake.  Enhancing copper uptake should ensure efficient 
iron absorption, given that the complete transepithelial flux of iron is dependent on 
the cuproenzymes HEPH. However our findings from the preceding chapter indicate 
iron transport is decreased. Further research is required to characterise the 
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9.1 Primer design and specificity 
All primer sequences were designed by Primer3 (Rozen & Skaletsky, 2000) and 
sequences were subjected to Basic Local Alignment Search Tool (BLAST) analysis 
to ensure specificity of the amplicon (McGinnis & Madden, 2004). 
The first step of designing primers for qRT-PCR was to find the transcript of the 
gene of interest for investigation. The gene was first located in the The Reference 
Sequence (Refseq) database, provided by the National Centre of Biotechnology 
Information (NCBI) (Pruitt et al, 2012). The mRNA sequence was selected based on 
accession number (e.g. NM_001859) and the transcript was used in its FASTA 
format (a standardised bioinformatics format containing sequence information; 
Pearson & Lipman, 1988). 
FASTA sequence was applied to the Primer3 web interface; primers were picked 
directly from this sequence. Selection criteria for primer and amplicon designed were 
as follows: 
 Amplicon length between 75-200 bases 
 Avoid repeats in amplicon of more than 4 of the same base 
 Amplicon and primer GC content between 50 and 60 % each 
 Primer melting temperature between 50 and 65 °C 
 Avoid secondary structures of primers and of amplicons 
Once selected, amplicons were subjected to BLAST and melting curve analysis to 




9.2 Efficiency of gene expression analysis 
Gene expression analysis was carried out using quantitative real-time polymerase 
chain reaction (qRT-PCR). With every experiment a number of quality controls were 
in place. These were: 1) inclusion of genes of interest and housekeeping genes in the 
same plate for every experiment, to decrease variation between plates and runs; 2) 
inclusion of a standard curve for every set of samples run on every plate, this was to 
ensure the efficiency of PCR amplification; 3) inclusion of a dissociation step and 
melting curve analysis to ensure the amplification of a single product and to ensure 
there was no primer-dimer formation during amplification. Examples of the standard 
curves and dissociation curves that resulted from qRT-PCR analysis of every gene 
tested are shown in this section. They are listed in the following order (housekeeping 
genes, followed by order of appearance in experimental chapters) 18S, GAPDH, 
GLUT2, SGLT1, DMT1, DCYTB, HFE, TfR1, FPN, HEPH, CTR1, HAH1, ATP7A 
and ATP7B.  
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9.2.1 Ribosomal RNA 18S 
Standard and melting curves were drawn for 18S to ensure efficiency and specificity 
of amplification. See figures below. 
 







9.2.2 Glyceraldehyde-3-monophosphate dehydrogenase (GAPDH) 
Standard and melting curves were drawn for GAPDH to ensure efficiency and 
specificity of amplification. See figures below. 
 
Efficiency: 110 %; slope: -3.1; R
2





9.2.3 Facilitative glucose transporter 2 (GLUT2) 
Standard and melting curves were drawn for GLUT2 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.4 Sodium/glucose cotransporter 1 (SGLT1) 
Standard and melting curves were drawn for GLUT2 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.5 Divalent metal ion transporter 1 (DMT1) 
Standard and melting curves were drawn for DMT1 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.6 Duodenal Cytochrome B reductase (DCYTB) 
Standard and melting curves were drawn for DCYTB to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.7 Haemochromatosis protein (HFE) 
Standard and melting curves were drawn for HFE to ensure efficiency and specificity 
of amplification. See figures below. 
 







9.2.8 Transferrin receptor 1 (TfR1) 
Standard and melting curves were drawn for TfR1 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.9 Ferroportin (FPN) 
Standard and melting curves were drawn for FPN to ensure efficiency and specificity 
of amplification. See figures below. 
 







9.2.10 Hephaestin (HEPH) 
Standard and melting curves were drawn for HEPH to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.11 Copper transporter 1 (CTR1) 
Standard and melting curves were drawn for CTR1 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.12 Human antioxidant protein homologue (HAH1) 
Standard and melting curves were drawn for HAH1 to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.13 Copper transporting ATPase α polypeptide (ATP7A) 
Standard and melting curves were drawn for ATP7A to ensure efficiency and 
specificity of amplification. See figures below. 
 







9.2.14 Copper transporting ATPase β polypeptide (ATP7B) 
Standard and melting curves were drawn for ATP7B to ensure efficiency and 
specificity of amplification. See figures below. 
 









9.3 Bioinformatics analysis 
Pathway analysis, ontological clustering and functional similarity clustering were 
applied, in Chapter 3, to transcriptome variation data from Caco-2 cells treated with 
a flavonoid-rich berry extract.  Ingenuity® Pathway Analysis (IPA) software was 
used for pathway analysis and The DAVID Bioinformatics Resources (Ver.  6.7) 
were used for GO term enrichment and to find genes with a similar function to an 
initial gene of interest (Maaser & Borlak, 2008; Huang da et al, 2009).  The 
following sections briefly describe the bioinformatics approaches applied with 
DAVID. 
9.3.1 Pathway analysis 
There are 6 steps involved in the generation of networks when using IPA software, 
these are described below briefly, and full descriptions are available from 
Ingenuity® user documentation: 
1. Focus genes selection: “focus genes” refers to genes and gene products that are c 
eligible for inclusion in a network. Focus genes are considered eligible for network 
inclusion when they form more than one connection to other genes in the list or in 
the Ingenuity® knowledgebase. Focus genes are determined and sorted in decreasing 
order of their triangle connectivity, which ensures that each gene forms a connection 
to two other genes. The highest ranked focus gene will be the gene forming the 
highest number of “triangles” with neighboring genes, either from the submitted data 
set or from the Ingenuity® knowledgebase. 
2. Networks constructed from focus genes: The highest ranked focus gene is 
removed to form a network, and is designated as a seed gene. Other focus genes are 
added until the maximum number of genes is included to form a network (default of 
35 genes per network). Networks are grown by the assumption that “biological 
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functions involve locally dense interactions”, thus genes are prioritised to grow a 
network when they form highest connections to the genes already present in the 
network. A metric called specific connectivity is applied to the genes prior to their 
addition to a network. Specific connectivity is the ratio between the number of genes 
intersecting an already present network and the total number of genes connected to 
the gene up for inclusion. 
3. Apply Linker genes between small networks: This step starts with the smallest 
networks; they are connected to each other by linker genes. Linker genes are those 
that form connections between both networks and are more likely to be chosen for 
inclusion when they form denser connections. Networks are grown this way until 
they contain up to 35 genes (default cap to network size). 
4. Introduce Neighborhood genes: Following network development and, where 
appropriate, the inclusion of linker genes; the networks are then grown by 
introducing neighborhood genes. Neighborhood genes are genes that form 2 or more 
connections to genes that are already on the periphery of the already present 
network. If no genes form 2 or more connections then genes that form a single 
connection are added. These neighborhood genes may be focus genes, but the 
probability is low, they are typically from the Ingenuity® global molecular network 
database. 
5. Forming all edges between genes: All the genes selected for network inclusion in 
the above steps 1 to 4 are brought together and updated with annotations from the 
Ingenuity® knowledgebase. Connections between genes are referred to as edges, 
these include any links between genes, without discriminating the type of interaction, 
these include: direct interactions, indirect interactions, inhibition, stimulation, 
unknown interactions, etc. 
259 
 
6. Compute p-value and network score: After the networks are grown and the 
edges are formed p-values and the network score are calculated. The p-value is 
derived using a Fisher’s exact test, where the number of focus genes in a given 
network is tested against the probability of finding the same number of “focus 
genes” when they are selected randomly from the global molecular network. The 
network score is then expressed as -log10 (p-value). 
 
9.3.2 Gene ontology analysis 
A Fisher’s exact test is used as the statistical basis to define GO term enrichment in a 
given gene list.  It is applied to determine if the number of genes from a GO term 
occurs disproportionately in one gene-list (i.e. experimental or user-submitted) 
relative to their occurrence in another gene-list (background) (Huang da et al, 2009).  
The example below shows a contingency table of the occurrence of kinases (example 
GO term) in an experimental gene-list, and their occurrence in a background gene 




User-submitted gene list 
Background / 
Human genome gene-list 
Kinases 3 40 
Not kinases 297 29 960 
 
 
The fisher’s exact p-value in this case would be 0.008.  As p ≤ 0.05, the experimental 




9.3.3 Functional similarity clustering and the Kappa score 
Gene functional similarity clustering with DAVID is calculated through their 
“related gene searching” algorithm.  This algorithm is based on the principle of 
overlapping GO terms between genes (Huang da et al, 2009).   
Every gene is associated with multiple terms.  If genes are associated with similar 
terms then they are involved in related biological mechanisms.  A Kappa score, or 
Kappa statistic, is the outcome of the algorithm used in DAVID and this score 
ranges from 0 to 1.  The higher the Kappa score, the stronger the agreement between 
the GO terms of those genes tested (Huang da et al, 2009).  Below is a worked 
example to calculating the Kappa score, this examples is derived from the DAVID 
user documation. 
 











ADAM23 1 1 0 0 1 0 
Itgb5 1 1 0 1 1 0 
 
 
In the above contingency table, the genes to be compared are on the left-hand-side.  
The GO terms that either of the genes is associated with are along the top row.  A 
binary code (1 or 0) is in place to identify if the GO term includes a gene of interest.  
A ‘1’ denotes presence of the gene in the GO term and a ‘0’ denotes its absence.  In 
the table below is a count of the binary code, it is used to derive numerical values for 







Row  totals 
1 0 
Itgb5 
1 3 (C1,1) 1 (C0,1) 4 (C1,*) 
0 0 (C0,1) 2 (C0,0) 2 (C0,*) 
Column totals 3 (C*,1) 3 (C*,0) 6 (Tab) 
 
The above values can be substituted into the following equations, where Kab is the 
Kappa score and the other alphabetical codes are represented in the contingency 
table above.   
 
Oab  =   C1,1 + C0,1   = 3 + 2   = 0.83 
         Tab            6 
 
Aab = C*,1 ● C1,* + C*,0 ● C0,* =  3 ● 4 + 3 ● 2  = 0.5 
              Tab ● Tab          6 ● 6 
 
Kab = Oab - Aab   = 0.83 - 0.5  = 0.66 
      1 - Aab          1 - 0.5  
 
 
If Kab < 0.25 then genes tested have low agreement; if Kab = 0.25 - 0.5 genes have 
moderate agreement; if Kab = 0.5 – 0.75 genes have high agreement; and if Kab = 
0.75 – 1 genes have very high agreement.  Therefore given the example above, Kab = 
0.66, this states that the functions of the genes ADAM23 and Itgb5 is in high 
agreement.   
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9.4 Differentially expressed genes 
Following microarray analysis of Caco-2 cell mRNA following treatment with a flavonoid rich berry extract, approximately 2400 genes were found 
to be differentially expressed. Below is a full list of the annotated genes organised in decreasing differential expression from the control, i.e. highest 
fold increase to lowest fold-decrease. 
Fold change Affymetrix ID Gene symbol Entrez gene name 
 102.329  205749_at  CYP1A1  cytochrome P450, family 1, subfamily A, polypeptide 1 
 29.512  202859_x_at  IL8  interleukin 8 
 27.542  204475_at  MMP1   matrix metallopeptidase 1 (interstitial collagenase) 
 27.542  212190_at  SERPINE2  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 
 23.988  211506_s_at  IL8  interleukin 8 
 23.988  210845_s_at  PLAUR  plasminogen activator, urokinase receptor 
 18.197  217678_at  SLC7A11  solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
 16.982  209457_at  DUSP5  dual specificity phosphatase 5 
 15.849  213895_at  EMP1  epithelial membrane protein 1 
 15.849  204420_at  FOSL1  FOS-like antigen 1 
 15.849  209921_at  SLC7A11  solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
 14.791  215034_s_at  TM4SF1  transmembrane 4 L six family member 1 
 13.804  207517_at  LAMC2  laminin, gamma 2 
 13.804  36711_at  MAFF  v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 
 12.882  206561_s_at  AKR1B10  aldo-keto reductase family 1, member B10 (aldose reductase) 
 12.882  201925_s_at  CD55  CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
 12.023  202672_s_at  ATF3  activating transcription factor 3 
 12.023  201325_s_at  EMP1  epithelial membrane protein 1 
 12.023  203108_at  GPRC5A  G protein-coupled receptor, family C, group 5, member A 
 12.023  218468_s_at  GREM1  gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 12.023  205032_at  ITGA2  integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
 11.220  218469_at  GREM1  gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
 11.220  217996_at  PHLDA1  pleckstrin homology-like domain, family A, member 1 
 11.220  214866_at  PLAUR  plasminogen activator, urokinase receptor 
 10.471  220468_at  ARL14  ADP-ribosylation factor-like 14 
 10.471  219799_s_at  DHRS9  dehydrogenase/reductase (SDR family) member 9 
 10.471  219508_at  GCNT3  glucosaminyl (N-acetyl) transferase 3, mucin type 
 10.471  204286_s_at  PMAIP1  phorbol-12-myristate-13-acetate-induced protein 1 
 10.471  209387_s_at  TM4SF1  transmembrane 4 L six family member 1 
 10.471  202241_at  TRIB1  tribbles homolog 1 (Drosophila) 
 9.772  201926_s_at  CD55  CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
 9.120  211889_x_at  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
 9.120  201884_at  CEACAM5   carcinoembryonic antigen-related cell adhesion molecule 5 
 9.120  203821_at  HBEGF  heparin-binding EGF-like growth factor 
 9.120  213953_at  KRT20  keratin 20 
 9.120  219557_s_at  NRIP3  nuclear receptor interacting protein 3 
 9.120  217997_at  PHLDA1  pleckstrin homology-like domain, family A, member 1 
 9.120  204285_s_at  PMAIP1  phorbol-12-myristate-13-acetate-induced protein 1 
 8.511  206576_s_at  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
 8.511  211883_x_at  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
 8.511  209803_s_at  PHLDA2  pleckstrin homology-like domain, family A, member 2 
 8.511  201266_at  TXNRD1  thioredoxin reductase 1 
 7.943  209498_at  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
 7.943  204698_at  ISG20  interferon stimulated exonuclease gene 20kDa 
 7.943  202267_at  LAMC2  laminin, gamma 2 
 7.413  201324_at  EMP1  epithelial membrane protein 1 
 7.413  203499_at  EPHA2  EPH receptor A2 
 7.413  206429_at  F2RL1  coagulation factor II (thrombin) receptor-like 1 
 7.413  221667_s_at  HSPB8  heat shock 22kDa protein 8 
 7.413  205302_at  IGFBP1  insulin-like growth factor binding protein 1 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 7.413  201466_s_at  JUN  jun oncogene 
 7.413  210665_at  TFPI  tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
 7.413  212665_at  TIPARP  TCDD-inducible poly(ADP-ribose) polymerase 
 7.413  202504_at  TRIM29  tripartite motif-containing 29 
 6.918  205014_at  FGFBP1  fibroblast growth factor binding protein 1 
 6.918  207574_s_at  GADD45B  growth arrest and DNA-damage-inducible, beta 
 6.918  202831_at  GPX2  glutathione peroxidase 2 (gastrointestinal) 
 6.918  214056_at  MCL1  myeloid cell leukaemia sequence 1 (BCL2-related) 
 6.918  217999_s_at  PHLDA1  pleckstrin homology-like domain, family A, member 1 
 6.918  33323_r_at  SFN  stratifin 
 6.457  210538_s_at  BIRC3  baculoviral IAP repeat-containing 3 
 6.457  209304_x_at  GADD45B  growth arrest and DNA-damage-inducible, beta 
 6.457  203925_at  GCLM  glutamate-cysteine ligase, modifier subunit 
 6.457  38037_at  HBEGF  heparin-binding EGF-like growth factor 
 6.457  33304_at  ISG20  interferon stimulated exonuclease gene 20kDa 
 6.457  208960_s_at  KLF6  Kruppel-like factor 6 
 6.457  216248_s_at  NR4A2  nuclear receptor subfamily 4, group A, member 2 
 6.457  210664_s_at  TFPI  tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
 6.457  218368_s_at  TNFRSF12A  tumor necrosis factor receptor superfamily, member 12A 
 6.457  221962_s_at  UBE2H  ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 
 6.026  201041_s_at  DUSP1  dual specificity phosphatase 1 
 6.026  215177_s_at  ITGA6  integrin, alpha 6 
 6.026  213281_at  JUN  jun oncogene 
 6.026  33322_i_at  SFN  stratifin 
 6.026  209386_at  TM4SF1  transmembrane 4 L six family member 1 
 5.623  209735_at  ABCG2  ATP-binding cassette, sub-family G (WHITE), member 2 
 5.623  215913_s_at  GULP1  GULP, engulfment adaptor PTB domain containing 1 
 5.623  200798_x_at  MCL1  myeloid cell leukaemia sequence 1 (BCL2-related) 
 5.623  201939_at  PLK2  polo-like kinase 2 (Drosophila) 
 5.623  217741_s_at  ZFAND5  zinc finger, AN1-type domain 5 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 5.248  204602_at  DKK1  dickkopf homolog 1 (Xenopus laevis) 
 5.248  221577_x_at  GDF15  growth differentiation factor 15 
 5.248  208961_s_at  KLF6  Kruppel-like factor 6 
 5.248  212099_at  RHOB  ras homolog gene family, member B 
 5.248  210260_s_at  TNFAIP8  tumor necrosis factor, alpha-induced protein 8 
 4.898  219474_at  C3ORF52  chromosome 3 open reading frame 52 
 4.898  207147_at  DLX2  distal-less homeobox 2 
 4.898  218498_s_at  ERO1L  ERO1-like (S. cerevisiae) 
 4.898  204472_at  GEM  GTP binding protein overexpressed in skeletal muscle 
 4.898  207160_at  IL12A  interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) 
 4.898  203144_s_at  KIAA0040  KIAA0040 
 4.898  204622_x_at  NR4A2  nuclear receptor subfamily 4, group A, member 2 
 4.898  204435_at  NUPL1  nucleoporin like 1 
 4.898  202627_s_at  SERPINE1  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 
 4.898  204011_at  SPRY2  sprouty homolog 2 (Drosophila) 
 4.898  208296_x_at  TNFAIP8  tumor necrosis factor, alpha-induced protein 8 
 4.898  214581_x_at  TNFRSF21  tumor necrosis factor receptor superfamily, member 21 
 4.898  221765_at  UGCG  UDP-glucose ceramide glucosyltransferase 
 4.898  204881_s_at  UGCG  UDP-glucose ceramide glucosyltransferase 
 4.571  218723_s_at  C13ORF15  chromosome 13 open reading frame 15 
 4.571  203757_s_at  CEACAM6   carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 
 4.571  219500_at  CLCF1  cardiotrophin-like cytokine factor 1 
 4.571  201428_at  CLDN4  claudin 4 
 4.571  209967_s_at  CREM  cAMP responsive element modulator 
 4.571  202669_s_at  EFNB2  ephrin-B2 
 4.571  202949_s_at  FHL2  four and a half LIM domains 2 
 4.571  209305_s_at  GADD45B  growth arrest and DNA-damage-inducible, beta 
 4.571  201464_x_at  JUN  jun oncogene 
 4.571  202067_s_at  LDLR  low density lipoprotein receptor 
 4.571  205479_s_at  PLAU  plasminogen activator, urokinase 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 4.571  202014_at  PPP1R15A  protein phosphatase 1, regulatory (inhibitor) subunit 15A 
 4.571  202786_at  STK39  serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 
 4.571  213258_at  TFPI  tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
 4.571  203167_at  TIMP2  TIMP metallopeptidase inhibitor 2 
 4.571  203234_at  UPP1  uridine phosphorylase 1 
 4.571  215150_at  YOD1  YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) 
 4.571  201531_at  ZFP36  zinc finger protein 36, C3H type, homolog (mouse) 
 4.266  205239_at  AREG  amphiregulin 
 4.266  211848_s_at  CEACAM7  carcinoembryonic antigen-related cell adhesion molecule 7 
 4.266  202668_at  EFNB2  ephrin-B2 
 4.266  210007_s_at  GPD2  glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
 4.266  204137_at  GPR137B  G protein-coupled receptor 137B 
 4.266  201656_at  ITGA6  integrin, alpha 6 
 4.266  201473_at  JUNB  jun B proto-oncogene 
 4.266  203143_s_at  KIAA0040  KIAA0040 
 4.266  210365_at  RUNX1  runt-related transcription factor 1 
 4.266  201249_at  SLC2A1  solute carrier family 2 (facilitated glucose transporter), member 1 
 4.266  204526_s_at  TBC1D8  TBC1 domain family, member 8 (with GRAM domain) 
 4.266  214168_s_at  TJP1  tight junction protein 1 (zona occludens 1) 
 4.266  218856_at  TNFRSF21  tumor necrosis factor receptor superfamily, member 21 
 3.981  205566_at  ABHD2  abhydrolase domain containing 2 
 3.981  214696_at  C17ORF91  chromosome 17 open reading frame 91 
 3.981  206199_at  CEACAM7  carcinoembryonic antigen-related cell adhesion molecule 7 
 3.981  207630_s_at  CREM  cAMP responsive element modulator 
 3.981  208893_s_at  DUSP6  dual specificity phosphatase 6 
 3.981  201313_at  ENO2  enolase 2 (gamma, neuronal) 
 3.981  209189_at  FOS  v-fos FBJ murine osteosarcoma viral oncogene homolog 
 3.981  208868_s_at  GABARAPL1  GABA(A) receptor-associated protein like 1 
 3.981  202923_s_at  GCLC  glutamate-cysteine ligase, catalytic subunit 
 3.981  214157_at  GNAS  GNAS complex locus 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 3.981  201389_at  ITGA5  integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
 3.981  217173_s_at  LDLR  low density lipoprotein receptor 
 3.981  202674_s_at  LMO7  LIM domain 7 
 3.981  213909_at  LRRC15  leucine rich repeat containing 15 
 3.981  214827_at  PARD6B  par-6 partitioning defective 6 homolog beta (C. elegans) 
 3.981  37028_at  PPP1R15A   protein phosphatase 1, regulatory (inhibitor) subunit 15A 
 3.981  202388_at  RGS2  regulator of G-protein signaling 2, 24kDa 
 3.981  202129_s_at  RIOK3  RIO kinase 3 (yeast) 
 3.981  219614_s_at  SLC6A20  solute carrier family 6 (proline IMINO transporter), member 20 
 3.981  204368_at  SLCO2A1  solute carrier organic anion transporter family, member 2A1 
 3.981  221489_s_at  SPRY4  sprouty homolog 4 (Drosophila) 
 3.715  213497_at  ABTB2  ankyrin repeat and BTB (POZ) domain containing 2 
 3.715  203065_s_at  CAV1  caveolin 1, caveolae protein, 22kDa 
 3.715  203324_s_at  CAV2  caveolin 2 
 3.715  211657_at  CEACAM6  carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 
 3.715  206198_s_at  CEACAM7  carcinoembryonic antigen-related cell adhesion molecule 7 
 3.715  203729_at  EMP3  epithelial membrane protein 3 
 3.715  220124_at  GAN  gigaxonin 
 3.715  220585_at  HKDC1  hexokinase domain containing 1 
 3.715  209185_s_at  IRS2  insulin receptor substrate 2 
 3.715  203068_at  KLHL21  kelch-like 21 (Drosophila) 
 3.715  208934_s_at  LGALS8  lectin, galactoside-binding, soluble, 8 
 3.715  213684_s_at  PDLIM5  PDZ and LIM domain 5 
 3.715  208300_at  PTPRH  protein tyrosine phosphatase, receptor type, H 
 3.715  210675_s_at  PTPRR  protein tyrosine phosphatase, receptor type, R 
 3.715  205205_at  RELB  v-rel reticuloendotheliosis viral oncogene homolog B 
 3.715  219710_at  SH3TC2  SH3 domain and tetratricopeptide repeats 2 
 3.715  219911_s_at  SLCO4A1  solute carrier organic anion transporter family, member 4A1 
 3.715  209676_at  TFPI  tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
 3.715  213349_at  TMCC1  transmembrane and coiled-coil domain family 1 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 3.715  218647_s_at  YRDC  yrdC domain containing (E. coli) 
 3.715  210275_s_at  ZFAND5  zinc finger, AN1-type domain 5 
 3.467  204455_at  DST  dystonin 
 3.467  208891_at  DUSP6  dual specificity phosphatase 6 
 3.467  210999_s_at  GRB10  growth factor receptor-bound protein 10 
 3.467  209098_s_at  JAG1  jagged 1 (Alagille syndrome) 
 3.467  204401_at  KCNN4  potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 
 3.467  210732_s_at  LGALS8  lectin, galactoside-binding, soluble, 8 
 3.467  221994_at  PDLIM5  PDZ and LIM domain 5 
 3.467  216804_s_at  PDLIM5  PDZ and LIM domain 5 
 3.467  202458_at  PRSS23  protease, serine, 23 
 3.467  212311_at  SERINC2  serine incorporator 2 
 3.467  219682_s_at  TBX3  T-box 3 
 3.467  219058_x_at  TINAGL1  tubulointerstitial nephritis antigen-like 1 
 3.467  218999_at  TMEM140  transmembrane protein 140 
 3.236  203946_s_at  ARG2  arginase, type II 
 3.236  206665_s_at  BCL2L1  BCL2-like 1 
 3.236  212097_at  CAV1  caveolin 1, caveolae protein, 22kDa 
 3.236  209850_s_at  CDC42EP2  CDC42 effector protein (Rho GTPase binding) 2 
 3.236  202284_s_at  CDKN1A  cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
 3.236  213554_s_at  CDV3  CDV3 homolog (mouse) 
 3.236  202536_at  CHMP2B  chromatin modifying protein 2B 
 3.236  201693_s_at  EGR1  early growth response 1 
 3.236  211603_s_at  ETV4  ets variant 4 
 3.236  213341_at  FEM1C  fem-1 homolog c (C. elegans) 
 3.236  211458_s_at  GABARAPL1  GABA(A) receptor-associated protein like 1 
 3.236  208138_at  GAST  gastrin 
 3.236  202922_at  GCLC  glutamate-cysteine ligase, catalytic subunit 
 3.236  209410_s_at  GRB10  growth factor receptor-bound protein 10 
 3.236  206342_x_at  IDS  iduronate 2-sulfatase 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 3.236  201631_s_at  IER3  immediate early response 3 
 3.236  202146_at  IFRD1  interferon-related developmental regulator 1 
 3.236  202147_s_at  IFRD1  interferon-related developmental regulator 1 
 3.236  209184_s_at  IRS2  insulin receptor substrate 2 
 3.236  218474_s_at  KCTD5  potassium channel tetramerisation domain containing 5 
 3.236  218823_s_at  KCTD9  potassium channel tetramerisation domain containing 9 
 3.236  203390_s_at  KIF3C  kinesin family member 3C 
 3.236  208785_s_at  MAP1LC3B  microtubule-associated protein 1 light chain 3 beta 
 3.236  212473_s_at  MICAL2  microtubule associated monooxygenase, calponin and LIM domain containing 2 
 3.236  212472_at  MICAL2  microtubule associated monooxygenase, calponin and LIM domain containing 2 
 3.236  200787_s_at  PEA15  phosphoprotein enriched in astrocytes 15 
 3.236  206636_at  RASA2  RAS p21 protein activator 2 
 3.236  212724_at  RND3  Rho family GTPase 3 
 3.236  202684_s_at  RNMT  RNA (guanine-7-) methyltransferase 
 3.236  204351_at  S100P  S100 calcium binding protein P 
 3.236  205691_at  SYNGR3  synaptogyrin 3 
 3.236  209191_at  TUBB6  tubulin, beta 6 
 3.236  211764_s_at  UBE2D1  ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) 
 3.020  218964_at  ARID3B  AT rich interactive domain 3B (BRIGHT-like) 
 3.020  205780_at  BIK  BCL2-interacting killer (apoptosis-inducing) 
 3.020  208653_s_at  CD164  CD164 molecule, sialomucin 
 3.020  201694_s_at  EGR1  early growth response 1 
 3.020  45297_at  EHD2  EH-domain containing 2 
 3.020  213506_at  F2RL1  coagulation factor II (thrombin) receptor-like 1 
 3.020  208869_s_at  GABARAPL1  GABA(A) receptor-associated protein like 1 
 3.020  202543_s_at  GMFB  glia maturation factor, beta 
 3.020  204235_s_at  GULP1  GULP, engulfment adaptor PTB domain containing 1 
 3.020  204237_at  GULP1  GULP, engulfment adaptor PTB domain containing 1 
 3.020  220266_s_at  KLF4  Kruppel-like factor 4 (gut) 
 3.020  202068_s_at  LDLR  low density lipoprotein receptor 
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 3.020  202679_at  NPC1  Niemann-Pick disease, type C1 
 3.020  213372_at  PAQR3  progestin and adipoQ receptor family member III 
 3.020  208383_s_at  PCK1  phosphoenolpyruvate carboxykinase 1 (soluble) 
 3.020  218951_s_at  PLCXD1  phosphatidylinositol-specific phospholipase C, X domain containing 1 
 3.020  207223_s_at  ROD1  ROD1 regulator of differentiation 1 (S. pombe) 
 3.020  218928_s_at  SLC37A1  solute carrier family 37 (glycerol-3-phosphate transporter), member 1 
 3.020  205016_at  TGFA  transforming growth factor, alpha 
 3.020  213191_at  TICAM1  toll-like receptor adaptor molecule 1 
 3.020  209118_s_at  TUBA1A  tubulin, alpha 1a 
 3.020  214590_s_at  UBE2D1  ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) 
 3.020  217785_s_at  YKT6  YKT6 v-SNARE homolog (S. cerevisiae) 
 2.818  200615_s_at  AP2B1  adaptor-related protein complex 2, beta 1 subunit 
 2.818  210896_s_at  ASPH  aspartate beta-hydroxylase 
 2.818  200921_s_at  BTG1  B-cell translocation gene 1, anti-proliferative 
 2.818  219720_s_at  C14ORF118  chromosome 14 open reading frame 118 
 2.818  213548_s_at  CDV3  CDV3 homolog (mouse) 
 2.818  217028_at  CXCR4  chemokine (C-X-C motif) receptor 4 
 2.818  208892_s_at  DUSP6  dual specificity phosphatase 6 
 2.818  213310_at  EIF2C2  eukaryotic translation initiation factor 2C, 2 
 2.818  211535_s_at  FGFR1  fibroblast growth factor receptor 1 
 2.818  206074_s_at  HMGA1  high mobility group AT-hook 1 
 2.818  218611_at  IER5  immediate early response 5 
 2.818  204990_s_at  ITGB4  integrin, beta 4 
 2.818  209099_x_at  JAG1  jagged 1 (Alagille syndrome) 
 2.818  216268_s_at  JAG1  jagged 1 (Alagille syndrome) 
 2.818  221841_s_at  KLF4  Kruppel-like factor 4 (gut) 
 2.818  208936_x_at  LGALS8  lectin, galactoside-binding, soluble, 8 
 2.818  208786_s_at  MAP1LC3B  microtubule-associated protein 1 light chain 3 beta 
 2.818  218295_s_at  NUP50  nucleoporin 50kDa 
 2.818  200788_s_at  PEA15  phosphoprotein enriched in astrocytes 15 
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 2.818  219045_at  RHOF  ras homolog gene family, member F (in filopodia) 
 2.818  221269_s_at  SH3BGRL3  SH3 domain binding glutamic acid-rich protein like 3 
 2.818  213843_x_at  SLC6A8  solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
 2.818  205547_s_at  TAGLN  transgelin 
 2.818  201208_s_at  TNFAIP1  tumor necrosis factor, alpha-induced protein 1 (endothelial) 
 2.818  202643_s_at  TNFAIP3  tumor necrosis factor, alpha-induced protein 3 
 2.818  203672_x_at  TPMT  thiopurine S-methyltransferase 
 2.818  204141_at  TUBB2A  tubulin, beta 2A 
 2.818  221291_at  ULBP2  UL16 binding protein 2 
 2.818  210935_s_at  WDR1  WD repeat domain 1 
 2.630  221927_s_at  ABHD11  abhydrolase domain containing 11 
 2.630  207992_s_at  AMPD3  adenosine monophosphate deaminase (isoform E) 
 2.630  201012_at  ANXA1  annexin A1 
 2.630  203910_at  ARHGAP29  Rho GTPase activating protein 29 
 2.630  211716_x_at  ARHGDIA  Rho GDP dissociation inhibitor (GDI) alpha 
 2.630  213606_s_at  ARHGDIA  Rho GDP dissociation inhibitor (GDI) alpha 
 2.630  201168_x_at  ARHGDIA  Rho GDP dissociation inhibitor (GDI) alpha 
 2.630  215037_s_at  BCL2L1  BCL2-like 1 
 2.630  200920_s_at  BTG1  B-cell translocation gene 1, anti-proliferative 
 2.630  213134_x_at  BTG3  BTG family, member 3 
 2.630  205548_s_at  BTG3  BTG family, member 3 
 2.630  200776_s_at  BZW1  basic leucine zipper and W2 domains 1 
 2.630  219856_at  C1ORF116  chromosome 1 open reading frame 116 
 2.630  202575_at  CRABP2  cellular retinoic acid binding protein 2 
 2.630  206374_at  DUSP8  dual specificity phosphatase 8 
 2.630  219207_at  EDC3  enhancer of mRNA decapping 3 homolog (S. cerevisiae) 
 2.630  205767_at  EREG  epiregulin 
 2.630  200859_x_at  FLNA  filamin A, alpha (actin binding protein 280) 
 2.630  213746_s_at  FLNA  filamin A, alpha (actin binding protein 280) 
 2.630  214752_x_at  FLNA  filamin A, alpha (actin binding protein 280) 
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 2.630  215243_s_at  GJB3  gap junction protein, beta 3, 31kDa 
 2.630  205770_at  GSR  glutathione reductase 
 2.630  202558_s_at  HSPA13  heat shock protein 70kDa family, member 13 
 2.630  202439_s_at  IDS  iduronate 2-sulfatase 
 2.630  203627_at  IGF1R  insulin-like growth factor 1 receptor 
 2.630  204116_at  IL2RG  interleukin 2 receptor, gamma (severe combined immunodeficiency) 
 2.630  208540_x_at  LOC729659  S100 calcium binding protein A11 pseudogene 
 2.630  214057_at  MCL1  myeloid cell leukaemia sequence 1 (BCL2-related) 
 2.630  207233_s_at  MITF  microphthalmia-associated transcription factor 
 2.630  211071_s_at  MLLT11  myeloid/lymphoid or mixed-lineage leukaemia (trithorax homolog, Drosophila); translocated to, 11 
 2.630  210048_at  NAPG  N-ethylmaleimide-sensitive factor attachment protein, gamma 
 2.630  207543_s_at  P4HA1  prolyl 4-hydroxylase, alpha polypeptide I 
 2.630  203242_s_at  PDLIM5  PDZ and LIM domain 5 
 2.630  209193_at  PIM1  pim-1 oncogene 
 2.630  635_s_at  PPP2R5B  protein phosphatase 2, regulatory subunit B', beta isoform 
 2.630  215707_s_at  PRNP  prion protein 
 2.630  206084_at  PTPRR  protein tyrosine phosphatase, receptor type, R 
 2.630  209882_at  RIT1  Ras-like without CAAX 1 
 2.630  204668_at  RNF24  ring finger protein 24 
 2.630  200660_at  S100A11  S100 calcium binding protein A11 
 2.630  201543_s_at  SAR1A  SAR1 homolog A (S. cerevisiae) 
 2.630  200958_s_at  SDCBP  syndecan binding protein (syntenin) 
 2.630  212314_at  SERINC2  serine incorporator 2 
 2.630  202856_s_at  SLC16A3  solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 
 2.630  202855_s_at  SLC16A3  solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 
 2.630  201250_s_at  SLC2A1  solute carrier family 2 (facilitated glucose transporter), member 1 
 2.630  216202_s_at  SPTLC2  serine palmitoyltransferase, long chain base subunit 2 
 2.630  201471_s_at  SQSTM1  sequestosome 1 
 2.630  208322_s_at  ST3GAL1  ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
 2.630  203439_s_at  STC2  stanniocalcin 2 
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 2.630  221592_at  TBC1D8  TBC1 domain family, member 8 (with GRAM domain) 
 2.630  203085_s_at  TGFB1  transforming growth factor, beta 1 
 2.630  217730_at  TMBIM1  transmembrane BAX inhibitor motif containing 1 
 2.630  208596_s_at  UGT1A7  UDP glucuronosyltransferase 1 family, polypeptide A7 
 2.630  210064_s_at  UPK1B  uroplakin 1B 
 2.630  212533_at  WEE1  WEE1 homolog (S. pombe) 
 2.630  212860_at  ZDHHC18  zinc finger, DHHC-type containing 18 
 2.455  209994_s_at  ABCB4  ATP-binding cassette, sub-family B (MDR/TAP), member 4 
 2.455  202912_at  ADM  adrenomedullin 
 2.455  205263_at  BCL10  B-cell CLL/lymphoma 10 
 2.455  212312_at  BCL2L1  BCL2-like 1 
 2.455  200985_s_at  CD59  CD59 molecule, complement regulatory protein 
 2.455  218178_s_at  CHMP1B  chromatin modifying protein 1B 
 2.455  208925_at  CLDND1  claudin domain containing 1 
 2.455  221676_s_at  CORO1C  coronin, actin binding protein, 1C 
 2.455  204751_x_at  DSC2  desmocollin 2 
 2.455  201538_s_at  DUSP3  dual specificity phosphatase 3 
 2.455  204540_at  EEF1A2  eukaryotic translation elongation factor 1 alpha 2 
 2.455  209037_s_at  EHD1  EH-domain containing 1 
 2.455  212527_at  FAM152B  family with sequence similarity 152, member B 
 2.455  208613_s_at  FLNB  filamin B, beta (actin binding protein 278) 
 2.455  207180_s_at  HTATIP2  HIV-1 Tat interactive protein 2, 30kDa 
 2.455  202637_s_at  ICAM1  intercellular adhesion molecule 1 
 2.455  205992_s_at  IL15  interleukin 15 
 2.455  201627_s_at  INSIG1  insulin induced gene 1 
 2.455  221877_at  IRGQ  immunity-related GTPase family, Q 
 2.455  64488_at  IRGQ  immunity-related GTPase family, Q 
 2.455  209743_s_at  ITCH  itchy E3 ubiquitin protein ligase homolog (mouse) 
 2.455  209653_at  KPNA4  karyopherin alpha 4 (importin alpha 3) 
 2.455  204734_at  KRT15  keratin 15 
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 2.455  208433_s_at  LRP8  low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 
 2.455  200797_s_at  MCL1  myeloid cell leukaemia sequence 1 (BCL2-related) 
 2.455  204702_s_at  NFE2L3  nuclear factor (erythroid-derived 2)-like 3 
 2.455  203918_at  PCDH1  protocadherin 1 
 2.455  218472_s_at  PELO  pelota homolog (Drosophila) 
 2.455  203879_at  PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide 
 2.455  207469_s_at  PIR  pirin (iron-binding nuclear protein) 
 2.455  217875_s_at  PMEPA1  prostate transmembrane protein, androgen induced 1 
 2.455  203997_at  PTPN3  protein tyrosine phosphatase, non-receptor type 3 
 2.455  210101_x_at  SH3GLB1  SH3-domain GRB2-like endophilin B1 
 2.455  210854_x_at  SLC6A8  solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
 2.455  215812_s_at  SLC6A8  solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
 2.455  210357_s_at  SMOX  spermine oxidase 
 2.455  203127_s_at  SPTLC2  serine palmitoyltransferase, long chain base subunit 2 
 2.455  202644_s_at  TNFAIP3  tumor necrosis factor, alpha-induced protein 3 
 2.455  212481_s_at  TPM4  tropomyosin 4 
 2.455  203343_at  UGDH  UDP-glucose dehydrogenase 
 2.455  221704_s_at  VPS37B  vacuolar protein sorting 37 homolog B (S. cerevisiae) 
 2.455  200611_s_at  WDR1  WD repeat domain 1 
 2.455  210812_at  XRCC4  X-ray repair complementing defective repair in Chinese hamster cells 4 
 2.455  211962_s_at  ZFP36L1  zinc finger protein 36, C3H type-like 1 
 2.291  209993_at  ABCB1  ATP-binding cassette, sub-family B (MDR/TAP), member 1 
 2.291  206155_at  ABCC2  ATP-binding cassette, sub-family C (CFTR/MRP), member 2 
 2.291  219496_at  ANKRD57  ankyrin repeat domain 57 
 2.291  205047_s_at  ASNS  asparagine synthetase 
 2.291  209135_at  ASPH  aspartate beta-hydroxylase 
 2.291  218608_at  ATP13A2  ATPase type 13A2 
 2.291  203612_at  BYSL  bystin-like 
 2.291  200777_s_at  BZW1  basic leucine zipper and W2 domains 1 
 2.291  219023_at  C4ORF16  chromosome 4 open reading frame 16 
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 2.291  218008_at  C7ORF42  chromosome 7 open reading frame 42 
 2.291  221040_at  CAPN10  calpain 10 
 2.291  204610_s_at  CCDC85B  coiled-coil domain containing 85B 
 2.291  208712_at  CCND1  cyclin D1 
 2.291  209772_s_at  CD24  CD24 molecule 
 2.291  208650_s_at  CD24  CD24 molecule 
 2.291  212463_at  CD59  CD59 molecule, complement regulatory protein 
 2.291  200984_s_at  CD59  CD59 molecule, complement regulatory protein 
 2.291  219492_at  CHIC2  cysteine-rich hydrophobic domain 2 
 2.291  202538_s_at  CHMP2B  chromatin modifying protein 2B 
 2.291  209156_s_at  COL6A2  collagen, type VI, alpha 2 
 2.291  222235_s_at  CSGALNACT2  chondroitin sulfate N-acetylgalactosaminyltransferase 2 
 2.291  209158_s_at  CYTH2  cytohesin 2 
 2.291  203367_at  DUSP14  dual specificity phosphatase 14 
 2.291  201537_s_at  DUSP3  dual specificity phosphatase 3 
 2.291  209536_s_at  EHD4  EH-domain containing 4 
 2.291  91826_at  EPS8L1  EPS8-like 1 
 2.291  208622_s_at  EZR  ezrin 
 2.291  212400_at  FAM102A  family with sequence similarity 102, member A 
 2.291  204232_at  FCER1G  Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 
 2.291  214240_at  GAL  galanin prepropeptide 
 2.291  214430_at  GLA  galactosidase, alpha 
 2.291  202755_s_at  GPC1  glypican 1 
 2.291  208308_s_at  GPI  glucose phosphate isomerase 
 2.291  219357_at  GTPBP1  GTP binding protein 1 
 2.291  202934_at  HK2  hexokinase 2 
 2.291  202557_at  HSPA13  heat shock protein 70kDa family, member 13 
 2.291  219998_at  HSPC159  galectin-related protein 
 2.291  211676_s_at  IFNGR1  interferon gamma receptor 1 
 2.291  203828_s_at  IL32  interleukin 32 
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 2.291  201625_s_at  INSIG1  insulin induced gene 1 
 2.291  209744_x_at  ITCH  itchy E3 ubiquitin protein ligase homolog (mouse) 
 2.291  217094_s_at  ITCH  itchy E3 ubiquitin protein ligase homolog (mouse) 
 2.291  201751_at  JOSD1  Josephin domain containing 1 
 2.291  215515_at  KIRREL  kin of IRRE like (Drosophila) 
 2.291  219399_at  LIN7C  lin-7 homolog C (C. elegans) 
 2.291  204970_s_at  MAFG  v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) 
 2.291  206247_at  MICB  MHC class I polypeptide-related sequence B 
 2.291  201297_s_at  MOBKL1B  MOB1, Mps One Binder kinase activator-like 1B (yeast) 
 2.291  201761_at  MTHFD2  methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase 
 2.291  37005_at  NBL1  neuroblastoma, suppression of tumorigenicity 1 
 2.291  211681_s_at  PDLIM5  PDZ and LIM domain 5 
 2.291  201037_at  PFKP  phosphofructokinase, platelet 
 2.291  213030_s_at  PLXNA2  plexin A2 
 2.291  205618_at  PRRG1  proline rich Gla (G-carboxyglutamic acid) 1 
 2.291  209885_at  RHOD  ras homolog gene family, member D 
 2.291  213038_at  RNF19B  ring finger protein 19B 
 2.291  36564_at  RNF19B  ring finger protein 19B 
 2.291  214697_s_at  ROD1  ROD1 regulator of differentiation 1 (S. pombe) 
 2.291  218209_s_at  RPRD1A  regulation of nuclear pre-mRNA domain containing 1A 
 2.291  204541_at  SEC14L2  SEC14-like 2 (S. cerevisiae) 
 2.291  208381_s_at  SGPL1  sphingosine-1-phosphate lyase 1 
 2.291  209091_s_at  SH3GLB1  SH3-domain GRB2-like endophilin B1 
 2.291  202234_s_at  SLC16A1  solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 
 2.291  202497_x_at  SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3 
 2.291  220123_at  SLC35F5  solute carrier family 35, member F5 
 2.291  212295_s_at  SLC7A1  solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 
 2.291  219677_at  SPSB1  splA/ryanodine receptor domain and SOCS box containing 1 
 2.291  40420_at  STK10  serine/threonine kinase 10 
 2.291  220800_s_at  TMOD3  tropomodulin 3 (ubiquitous) 
277 
 
Fold change Affymetrix ID Gene symbol Entrez gene name 
 2.291  210405_x_at  TNFRSF10B  tumor necrosis factor receptor superfamily, member 10b 
 2.291  209372_x_at  TUBB2B  tubulin, beta 2B 
 2.291  217799_x_at  UBE2H   ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 
 2.291  210065_s_at  UPK1B  uroplakin 1B 
 2.291  202205_at  VASP  vasodilator-stimulated phosphoprotein 
 2.291  211527_x_at  VEGFA  vascular endothelial growth factor A 
 2.291  209822_s_at  VLDLR  very low density lipoprotein receptor 
 2.291  209216_at  WDR45  WD repeat domain 45 
 2.291  219540_at  ZNF267  zinc finger protein 267 
 2.138  213017_at  ABHD3  abhydrolase domain containing 3 
 2.138  218581_at  ABHD4  abhydrolase domain containing 4 
 2.138  211653_x_at  AKR1C2  aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-
alpha hydroxysteroid dehydrogenase, type III) 
 2.138  222108_at  AMIGO2  adhesion molecule with Ig-like domain 2 
 2.138  206632_s_at  APOBEC3B  apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 
 2.138  221031_s_at  APOLD1  apolipoprotein L domain containing 1 
 2.138  201772_at  AZIN1  antizyme inhibitor 1 
 2.138  221190_s_at  C18ORF8  chromosome 18 open reading frame 8 
 2.138  221764_at  C19ORF22  chromosome 19 open reading frame 22 
 2.138  206788_s_at  CBFB  core-binding factor, beta subunit 
 2.138  202537_s_at  CHMP2B  chromatin modifying protein 2B 
 2.138  205474_at  CRLF3   cytokine receptor-like factor 3 
 2.138  202887_s_at  DDIT4  DNA-damage-inducible transcript 4 
 2.138  203810_at  DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4 
 2.138  208810_at  DNAJB6  DnaJ (Hsp40) homolog, subfamily B, member 6 
 2.138  203258_at  DRAP1  DR1-associated protein 1 (negative cofactor 2 alpha) 
 2.138  217901_at  DSG2  desmoglein 2 
 2.138  208708_x_at  EIF5  eukaryotic translation initiation factor 5 
 2.138  221665_s_at  EPS8L1  EPS8-like 1 
 2.138  221655_x_at  EPS8L1  EPS8-like 1 
 2.138  208621_s_at  EZR  ezrin 
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 2.138  218898_at  FAM57A  family with sequence similarity 57, member A 
 2.138  219901_at  FGD6  FYVE, RhoGEF and PH domain containing 6 
 2.138  210187_at  FKBP1A  FK506 binding protein 1A, 12kDa 
 2.138  207178_s_at  FRK  fyn-related kinase 
 2.138  218193_s_at  GOLT1B  Golgi transport 1 homolog B (S. cerevisiae) 
 2.138  209409_at  GRB10  growth factor receptor-bound protein 10 
 2.138  202042_at  HARS  histidyl-tRNA synthetase 
 2.138  221896_s_at  HIGD1A  HIG1 domain family, member 1A 
 2.138  205466_s_at  HS3ST1  heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
 2.138  202638_s_at  ICAM1  intercellular adhesion molecule 1 
 2.138  212223_at  IDS  iduronate 2-sulfatase 
 2.138  203233_at  IL4R  interleukin 4 receptor 
 2.138  202794_at  INPP1  inositol polyphosphate-1-phosphatase 
 2.138  201626_at  INSIG1  insulin induced gene 1 
 2.138  213076_at  ITPKC  inositol 1,4,5-trisphosphate 3-kinase C 
 2.138  217938_s_at  KCMF1  potassium channel modulatory factor 1 
 2.138  201776_s_at  KIAA0494  KIAA0494 
 2.138  221502_at  KPNA3  karyopherin alpha 3 (importin alpha 4) 
 2.138  218651_s_at  LARP6  La ribonucleoprotein domain family, member 6 
 2.138  218816_at  LRRC1  leucine rich repeat containing 1 
 2.138  200712_s_at  MAPRE1  microtubule-associated protein, RP/EB family, member 1 
 2.138  209200_at  MEF2C  myocyte enhancer factor 2C 
 2.138  209199_s_at  MEF2C  myocyte enhancer factor 2C 
 2.138  218853_s_at  MOSPD1   motile sperm domain containing 1 
 2.138  217739_s_at  NAMPT  nicotinamide phosphoribosyltransferase 
 2.138  217738_at  NAMPT  nicotinamide phosphoribosyltransferase 
 2.138  220731_s_at  NECAP2  NECAP endocytosis associated 2 
 2.138  201502_s_at  NFKBIA  nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
 2.138  218215_s_at  NR1H2  nuclear receptor subfamily 1, group H, member 2 
 2.138  208875_s_at  PAK2  p21 protein (Cdc42/Rac)-activated kinase 2 
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 2.138  204715_at  PANX1  pannexin 1 
 2.138  209552_at  PAX8  paired box 8 
 2.138  206686_at  PDK1  pyruvate dehydrogenase kinase, isozyme 1 
 2.138  203243_s_at  PDLIM5  PDZ and LIM domain 5 
 2.138  218644_at  PLEK2  pleckstrin 2 
 2.138  201490_s_at  PPIF  peptidylprolyl isomerase F 
 2.138  201489_at  PPIF  peptidylprolyl isomerase F 
 2.138  201375_s_at  PPP2CB  protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 
 2.138  201300_s_at  PRNP  prion protein 
 2.138  200833_s_at  RAP1B  RAP1B, member of RAS oncogene family 
 2.138  201783_s_at  RELA  v-rel reticuloendotheliosis viral oncogene homolog A (avian) 
 2.138  203175_at  RHOG  ras homolog gene family, member G (rho G) 
 2.138  212647_at  RRAS  related RAS viral (r-ras) oncogene homolog 
 2.138  210790_s_at  SAR1A  SAR1 homolog A (S. cerevisiae) 
 2.138  213988_s_at  SAT1  spermidine/spermine N1-acetyltransferase 1 
 2.138  202071_at  SDC4  syndecan 4 
 2.138  57703_at  SENP5   SUMO1/sentrin specific peptidase 5 
 2.138  201739_at  SGK1  serum/glucocorticoid regulated kinase 1 
 2.138  202236_s_at  SLC16A1  solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 
 2.138  216236_s_at  SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3 
 2.138  219409_at  SNIP1  Smad nuclear interacting protein 1 
 2.138  209481_at  SNRK  SNF related kinase 
 2.138  212458_at  SPRED2  sprouty-related, EVH1 domain containing 2 
 2.138  206907_at  TNFSF9  tumor necrosis factor (ligand) superfamily, member 9 
 2.138  203671_at  TPMT  thiopurine S-methyltransferase 
 2.138  215125_s_at  UGT1A7  UDP glucuronosyltransferase 1 family, polypeptide A7 
 2.138  210513_s_at  VEGFA  vascular endothelial growth factor A 
 2.138  209217_s_at  WDR45  WD repeat domain 45 
 2.138  222357_at  ZBTB20  zinc finger and BTB domain containing 20 
 2.138  204181_s_at  ZBTB43  zinc finger and BTB domain containing 43 
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 2.138  206683_at  ZNF165  zinc finger protein 165 
 2.138  219376_at  ZNF322B  zinc finger protein 322B 
 1.995  209380_s_at  ABCC5  ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
 1.995  217626_at  AKR1C1  aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) 
 1.995  209699_x_at  AKR1C2  aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-
alpha hydroxysteroid dehydrogenase, type III) 
 1.995  201096_s_at  ARF4  ADP-ribosylation factor 4 
 1.995  203945_at  ARG2  arginase, type II 
 1.995  219973_at  ARSJ  arylsulfatase family, member J 
 1.995  209186_at  ATP2A2  ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
 1.995  217835_x_at  C20ORF24  chromosome 20 open reading frame 24 
 1.995  213798_s_at  CAP1  CAP, adenylate cyclase-associated protein 1 (yeast) 
 1.995  211434_s_at  CCRL2  chemokine (C-C motif) receptor-like 2 
 1.995  200983_x_at  CD59  CD59 molecule, complement regulatory protein 
 1.995  205627_at  CDA  cytidine deaminase 
 1.995  209939_x_at  CFLAR  CASP8 and FADD-like apoptosis regulator 
 1.995  210563_x_at  CFLAR  CASP8 and FADD-like apoptosis regulator 
 1.995  218177_at  CHMP1B  chromatin modifying protein 1B 
 1.995  203954_x_at  CLDN3  claudin 3 
 1.995  203634_s_at  CPT1A  carnitine palmitoyltransferase 1A (liver) 
 1.995  208735_s_at  CTDSP2  CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 
 1.995  218260_at  DDA1  DET1 and DDB1 associated 1 
 1.995  203811_s_at  DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4 
 1.995  212792_at  DPY19L1  dpy-19-like 1 (C. elegans) 
 1.995  218995_s_at  EDN1  endothelin 1 
 1.995  201984_s_at  EGFR  epidermal growth factor receptor (erythroblastic leukaemia viral (v-erb-b) oncogene homolog, avian) 
 1.995  202021_x_at  EIF1  eukaryotic translation initiation factor 1 
 1.995  212227_x_at  EIF1  eukaryotic translation initiation factor 1 
 1.995  201144_s_at  EIF2S1  eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 
 1.995  208290_s_at  EIF5  eukaryotic translation initiation factor 5 
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 1.995  220198_s_at  EIF5A2  eukaryotic translation initiation factor 5A2 
 1.995  203349_s_at  ETV5  ets variant 5 
 1.995  208623_s_at  EZR  ezrin 
 1.995  219429_at  FA2H  fatty acid 2-hydroxylase 
 1.995  212373_at  FEM1B  fem-1 homolog b (C. elegans) 
 1.995  208840_s_at  G3BP2  GTPase activating protein (SH3 domain) binding protein 2 
 1.995  204224_s_at  GCH1  GTP cyclohydrolase 1 
 1.995  219473_at  GDAP2  ganglioside induced differentiation associated protein 2 
 1.995  218913_s_at  GMIP  GEM interacting protein 
 1.995  201179_s_at  GNAI3  guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 
 1.995  202756_s_at  GPC1  glypican 1 
 1.995  218238_at  GTPBP4  GTP binding protein 4 
 1.995  200800_s_at  HSPA1A  heat shock 70kDa protein 1A 
 1.995  209448_at  HTATIP2  HIV-1 Tat interactive protein 2, 30kDa 
 1.995  202081_at  IER2  immediate early response 2 
 1.995  217371_s_at  IL15  interleukin 15 
 1.995  200995_at  IPO7  importin 7 
 1.995  221503_s_at  KPNA3  karyopherin alpha 3 (importin alpha 4) 
 1.995  202651_at  LPGAT1  lysophosphatidylglycerol acyltransferase 1 
 1.995  201412_at  LRP10  low density lipoprotein receptor-related protein 10 
 1.995  212978_at  LRRC8B  leucine rich repeat containing 8 family, member B 
 1.995  211686_s_at  MAK16  MAK16 homolog (S. cerevisiae) 
 1.995  218522_s_at  MAP1S  microtubule-associated protein 1S 
 1.995  202670_at  MAP2K1  mitogen-activated protein kinase kinase 1 
 1.995  212497_at  MAPK1IP1L  mitogen-activated protein kinase 1 interacting protein 1-like 
 1.995  200898_s_at  MGEA5  meningioma expressed antigen 5 (hyaluronidase) 
 1.995  201298_s_at  MOBKL1B  MOB1, Mps One Binder kinase activator-like 1B (yeast) 
 1.995  218687_s_at  MUC13  mucin 13, cell surface associated 
 1.995  202431_s_at  MYC  v-myc myelocytomatosis viral oncogene homolog (avian) 
 1.995  222206_s_at  NCLN  nicalin homolog (zebrafish) 
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 1.995  218678_at  NES  nestin 
 1.995  219100_at  OBFC1  oligonucleotide/oligosaccharide-binding fold containing 1 
 1.995  218556_at  ORMDL2  ORM1-like 2 (S. cerevisiae) 
 1.995  218319_at  PELI1  pellino homolog 1 (Drosophila) 
 1.995  204369_at  PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide 
 1.995  211697_x_at  PNO1  partner of NOB1 homolog (S. cerevisiae) 
 1.995  218292_s_at  PRKAG2  protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
 1.995  203650_at  PROCR  protein C receptor, endothelial (EPCR) 
 1.995  209694_at  PTS  6-pyruvoyltetrahydropterin synthase 
 1.995  203885_at  RAB21  RAB21, member RAS oncogene family 
 1.995  205924_at  RAB3B  RAB3B, member RAS oncogene family 
 1.995  210127_at  RAB6B  RAB6B, member RAS oncogene family 
 1.995  214435_x_at  RALA  v-ral simian leukaemia viral oncogene homolog A (ras related) 
 1.995  213923_at  RAP2B  RAP2B, member of RAS oncogene family 
 1.995  209878_s_at  RELA  v-rel reticuloendotheliosis viral oncogene homolog A (avian) 
 1.995  202636_at  RNF103  ring finger protein 103 
 1.995  204665_at  RP5-1000E10.4  suppressor of IKK epsilon 
 1.995  212590_at  RRAS2  related RAS viral (r-ras) oncogene homolog 2 
 1.995  208456_s_at  RRAS2  related RAS viral (r-ras) oncogene homolog 2 
 1.995  214838_at  SFT2D2  SFT2 domain containing 2 
 1.995  209884_s_at  SLC4A7  solute carrier family 4, sodium bicarbonate cotransporter, member 7 
 1.995  208078_s_at  SNF1LK  salt-inducible kinase 1 
 1.995  220140_s_at  SNX11  sorting nexin 11 
 1.995  218817_at  SPCS3  signal peptidase complex subunit 3 homolog (S. cerevisiae) 
 1.995  219257_s_at  SPHK1  sphingosine kinase 1 
 1.995  202506_at  SSFA2  sperm specific antigen 2 
 1.995  201060_x_at  STOM  stomatin 
 1.995  220030_at  STYK1  serine/threonine/tyrosine kinase 1 
 1.995  212457_at  TFE3  transcription factor binding to IGHM enhancer 3 
 1.995  203313_s_at  TGIF1  TGFB-induced factor homeobox 1 
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 1.995  202011_at  TJP1  tight junction protein 1 (zona occludens 1) 
 1.995  213285_at  TMEM30B  transmembrane protein 30B 
 1.995  209294_x_at  TNFRSF10B  tumor necrosis factor receptor superfamily, member 10b 
 1.995  209295_at  TNFRSF10B  tumor necrosis factor receptor superfamily, member 10b 
 1.995  207536_s_at  TNFRSF9  tumor necrosis factor receptor superfamily, member 9 
 1.995  206911_at  TRIM25  tripartite motif-containing 25 
 1.995  210541_s_at  TRIM27  tripartite motif-containing 27 
 1.995  213476_x_at  TUBB3  tubulin, beta 3 
 1.995  218340_s_at  UBA6  ubiquitin-like modifier activating enzyme 6 
 1.995  201001_s_at  UBE2V1  ubiquitin-conjugating enzyme E2 variant 1 
 1.995  206094_x_at  UGT1A7  UDP glucuronosyltransferase 1 family, polypeptide A7 
 1.995  211662_s_at  VDAC2  voltage-dependent anion channel 2 
 1.995  204507_s_at  WDR92  WD repeat domain 92 
 1.995  201760_s_at  WSB2  WD repeat and SOCS box-containing 2 
 1.995  209551_at  YIPF4  Yip1 domain family, member 4 
 1.995  200640_at  YWHAZ  tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
 -1.995  214033_at  ABCC6  ATP-binding cassette, sub-family C (CFTR/MRP), member 6 
 -1.995  219986_s_at  ACAD10  acyl-Coenzyme A dehydrogenase family, member 10 
 -1.995  219413_at  ACBD4  acyl-Coenzyme A binding domain containing 4 
 -1.995  204393_s_at  ACPP  acid phosphatase, prostate 
 -1.995  208636_at  ACTN1  actinin, alpha 1 
 -1.995  208637_x_at  ACTN1  actinin, alpha 1 
 -1.995  203865_s_at  ADARB1  adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) 
 -1.995  218480_at  AGBL5  ATP/GTP binding protein-like 5 
 -1.995  212175_s_at  AK2  adenylate kinase 2 
 -1.995  218373_at  AKTIP  AKT interacting protein 
 -1.995  212798_s_at  ANKMY2  ankyrin repeat and MYND domain containing 2 
 -1.995  213035_at  ANKRD28  ankyrin repeat domain 28 
 -1.995  213419_at  APBB2  amyloid beta (A4) precursor protein-binding, family B, member 2 
 -1.995  212970_at  APBB2  amyloid beta (A4) precursor protein-binding, family B, member 2 
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 -1.995  206955_at  AQP7  aquaporin 7 
 -1.995  214102_at  ARAP2  ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 
 -1.995  212234_at  ASXL1  additional sex combs like 1 (Drosophila) 
 -1.995  203168_at  ATF6B  activating transcription factor 6 beta 
 -1.995  205052_at  AUH  AU RNA binding protein/enoyl-Coenzyme A hydratase 
 -1.995  210534_s_at  B9D1  B9 protein domain 1 
 -1.995  211947_s_at  BAT2D1  BAT2 domain containing 1 
 -1.995  221241_s_at  BCL2L14  BCL2-like 14 (apoptosis facilitator) 
 -1.995  210334_x_at  BIRC5  baculoviral IAP repeat-containing 5 
 -1.995  202179_at  BLMH  bleomycin hydrolase 
 -1.995  59644_at  BMP2K   BMP2 inducible kinase 
 -1.995  207186_s_at  BPTF  bromodomain PHD finger transcription factor 
 -1.995  209271_at  BPTF  bromodomain PHD finger transcription factor 
 -1.995  212645_x_at  BRE  brain and reproductive organ-expressed (TNFRSF1A modulator) 
 -1.995  211566_x_at  BRE  brain and reproductive organ-expressed (TNFRSF1A modulator) 
 -1.995  218024_at  BRP44L  brain protein 44-like 
 -1.995  220060_s_at  C12ORF48  chromosome 12 open reading frame 48 
 -1.995  219757_s_at  C14ORF101  chromosome 14 open reading frame 101 
 -1.995  219009_at  C14ORF93  chromosome 14 open reading frame 93 
 -1.995  217640_x_at  C18ORF24  chromosome 18 open reading frame 24 
 -1.995  218429_s_at  C19ORF66  chromosome 19 open reading frame 66 
 -1.995  218546_at  C1ORF115  chromosome 1 open reading frame 115 
 -1.995  207711_at  C20ORF117  chromosome 20 open reading frame 117 
 -1.995  219004_s_at  C21ORF45  chromosome 21 open reading frame 45 
 -1.995  201677_at  C3ORF37  chromosome 3 open reading frame 37 
 -1.995  219450_at  C4ORF19  chromosome 4 open reading frame 19 
 -1.995  39817_s_at  C6ORF108  chromosome 6 open reading frame 108 
 -1.995  213322_at  C6ORF130  chromosome 6 open reading frame 130 
 -1.995  213596_at  CASP4  caspase 4, apoptosis-related cysteine peptidase 
 -1.995  211464_x_at  CASP6  caspase 6, apoptosis-related cysteine peptidase 
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 -1.995  208908_s_at  CAST  calpastatin 
 -1.995  207467_x_at  CAST  calpastatin 
 -1.995  209682_at  CBLB  Cas-Br-M (murine) ecotropic retroviral transforming sequence b 
 -1.995  219130_at  CCDC76  coiled-coil domain containing 76 
 -1.995  205167_s_at  CDC25C  cell division cycle 25 homolog C (S. pombe) 
 -1.995  204126_s_at  CDC45L  CDC45 cell division cycle 45-like (S. cerevisiae) 
 -1.995  221436_s_at  CDCA3  cell division cycle associated 3 
 -1.995  210821_x_at  CENPA  centromere protein A 
 -1.995  203492_x_at  CEP57  centrosomal protein 57kDa 
 -1.995  203975_s_at  CHAF1A  chromatin assembly factor 1, subunit A (p150) 
 -1.995  204193_at  CHKB  choline kinase beta 
 -1.995  217501_at  CIAO1  cytosolic iron-sulfur protein assembly 1 homolog (S. cerevisiae) 
 -1.995  213839_at  CLMN  calmin (calponin-like, transmembrane) 
 -1.995  220739_s_at  CNNM3  cyclin M3 
 -1.995  219302_s_at  CNTNAP2  contactin associated protein-like 2 
 -1.995  218760_at  COQ6  coenzyme Q6 homolog, monooxygenase (S. cerevisiae) 
 -1.995  206256_at  CPN1  carboxypeptidase N, polypeptide 1 
 -1.995  215930_s_at  CTAGE5  CTAGE family, member 5 
 -1.995  201904_s_at  CTDSPL  CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like 
 -1.995  202613_at  CTPS  CTP synthase 
 -1.995  36084_at  CUL7   cullin 7 
 -1.995  823_at  CX3CL1  chemokine (C-X3-C motif) ligand 1 
 -1.995  207843_x_at  CYB5A  cytochrome b5 type A (microsomal) 
 -1.995  209366_x_at  CYB5A  cytochrome b5 type A (microsomal) 
 -1.995  39582_at  CYLD  cylindromatosis (turban tumor syndrome) 
 -1.995  205502_at  CYP17A1  cytochrome P450, family 17, subfamily A, polypeptide 1 
 -1.995  219664_s_at  DECR2  2,4-dienoyl CoA reductase 2, peroxisomal 
 -1.995  214079_at  DHRS2   dehydrogenase/reductase (SDR family) member 2 
 -1.995  212503_s_at  DIP2C  DIP2 disco-interacting protein 2 homolog C (Drosophila) 
 -1.995  201681_s_at  DLG5  discs, large homolog 5 (Drosophila) 
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 -1.995  222360_at  DPH5  DPH5 homolog (S. cerevisiae) 
 -1.995  208955_at  DUT   deoxyuridine triphosphatase 
 -1.995  209701_at  ERAP1  endoplasmic reticulum aminopeptidase 1 
 -1.995  204817_at  ESPL1  extra spindle pole bodies homolog 1 (S. cerevisiae) 
 -1.995  204231_s_at  FAAH  fatty acid amide hydrolase 
 -1.995  212981_s_at  FAM115A  family with sequence similarity 115, member A 
 -1.995  213463_s_at  FAM149B1  family with sequence similarity 149, member B1 
 -1.995  36612_at  FAM168A  family with sequence similarity 168, member A 
 -1.995  212357_at  FAM168A  family with sequence similarity 168, member A 
 -1.995  213689_x_at  FAM69A  family with sequence similarity 69, member A 
 -1.995  204283_at  FARS2  phenylalanyl-tRNA synthetase 2, mitochondrial 
 -1.995  210638_s_at  FBXO9  F-box protein 9 
 -1.995  203620_s_at  FCHSD2  FCH and double SH3 domains 2 
 -1.995  218454_at  FLJ22662  hypothetical protein FLJ22662 
 -1.995  218885_s_at  GALNT12  UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12 (GalNAc-
T12) 
 -1.995  213280_at  GARNL4  GTPase activating Rap/RanGAP domain-like 4 
 -1.995  204867_at  GCHFR  GTP cyclohydrolase I feedback regulator 
 -1.995  219078_at  GPATCH2  G patch domain containing 2 
 -1.995  212205_at  H2AFV  H2A histone family, member V 
 -1.995  205657_at  HAAO  3-hydroxyanthranilate 3,4-dioxygenase 
 -1.995  220801_s_at  HAO2   hydroxyacid oxidase 2 (long chain) 
 -1.995  219484_at  HCFC2  host cell factor C2 
 -1.995  218306_s_at  HERC1  hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain 
(RLD) 1 
 -1.995  217902_s_at  HERC2  hect domain and RLD 2 
 -1.995  211330_s_at  HFE  hemochromatosis 
 -1.995  203711_s_at  HIBCH  3-hydroxyisobutyryl-Coenzyme A hydrolase 
 -1.995  214472_at  HIST1H3D  histone cluster 1, H3d 
 -1.995  216548_x_at  HMG4L  high-mobility group (nonhistone chromosomal) protein 4-like 
 -1.995  219976_at  HOOK1  hook homolog 1 (Drosophila) 
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 -1.995  209844_at  HOXB13  homeobox B13 
 -1.995  216450_x_at  HSP90B1  heat shock protein 90kDa beta (Grp94), member 1 
 -1.995  201193_at  IDH1  isocitrate dehydrogenase 1 (NADP+), soluble 
 -1.995  205059_s_at  IDUA  iduronidase, alpha-L- 
 -1.995  218709_s_at  IFT52  intraflagellar transport 52 homolog (Chlamydomonas) 
 -1.995  218100_s_at  IFT57  intraflagellar transport 57 homolog (Chlamydomonas) 
 -1.995  202410_x_at  IGF2  insulin-like growth factor 2 (somatomedin A) 
 -1.995  205376_at  INPP4B  inositol polyphosphate-4-phosphatase, type II, 105kDa 
 -1.995  218905_at  INTS8  integrator complex subunit 8 
 -1.995  205176_s_at  ITGB3BP  integrin beta 3 binding protein (beta3-endonexin) 
 -1.995  217894_at  KCTD3  potassium channel tetramerisation domain containing 3 
 -1.995  202181_at  KIAA0247  KIAA0247 
 -1.995  212946_at  KIAA0564  KIAA0564 
 -1.995  36888_at  KIAA0841  KIAA0841 
 -1.995  204709_s_at  KIF23  kinesin family member 23 
 -1.995  209408_at  KIF2C  kinesin family member 2C 
 -1.995  221838_at  KLHL22  kelch-like 22 (Drosophila) 
 -1.995  201505_at  LAMB1  laminin, beta 1 
 -1.995  220158_at  LGALS14  lectin, galactoside-binding, soluble, 14 
 -1.995  209205_s_at  LMO4  LIM domain only 4 
 -1.995  213605_s_at  LOC100134401  hypothetical protein LOC100134401 
 -1.995  211996_s_at  LOC23117  PI-3-kinase-related kinase SMG-1 isoform 1 homolog 
 -1.995  220770_s_at  LOC63920  transposon-derived Buster3 transposase-like 
 -1.995  215123_at  LOC729602  NPIP-like protein ENSP00000283050 
 -1.995  215667_x_at  LOC730324  similar to postmeiotic segregation increased 2-like 2 
 -1.995  216908_x_at  LOC94431  RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) pseudogene 
 -1.995  212692_s_at  LRBA  LPS-responsive vesicle trafficking, beach and anchor containing 
 -1.995  214109_at  LRBA  LPS-responsive vesicle trafficking, beach and anchor containing 
 -1.995  219573_at  LRRC16A  leucine rich repeat containing 16A 
 -1.995  202245_at  LSS  lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 
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 -1.995  209014_at  MAGED1  melanoma antigen family D, 1 
 -1.995  65884_at  MAN1B1  mannosidase, alpha, class 1B, member 1 
 -1.995  219814_at  MBNL3  muscleblind-like 3 (Drosophila) 
 -1.995  209623_at  MCCC2  methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 
 -1.995  220651_s_at  MCM10  minichromosome maintenance complex component 10 
 -1.995  222037_at  MCM4  minichromosome maintenance complex component 4 
 -1.995  212945_s_at  MGA   MAX gene associated 
 -1.995  204918_s_at  MLLT3  myeloid/lymphoid or mixed-lineage leukaemia (trithorax homolog, Drosophila); translocated to, 3 
 -1.995  218773_s_at  MSRB2  methionine sulfoxide reductase B2 
 -1.995  204871_at  MTERF  mitochondrial transcription termination factor 
 -1.995  218506_x_at  N-PAC  cytokine-like nuclear factor n-pac 
 -1.995  219378_at  NARG1L  NMDA receptor regulated 1-like 
 -1.995  206453_s_at  NDRG2  NDRG family member 2 
 -1.995  213012_at  NEDD4  neural precursor cell expressed, developmentally down-regulated 4 
 -1.995  204641_at  NEK2  NIMA (never in mitosis gene a)-related kinase 2 
 -1.995  212299_at  NEK9   NIMA (never in mitosis gene a)- related kinase 9 
 -1.995  217527_s_at  NFATC2IP  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein 
 -1.995  215743_at  NMT2  N-myristoyltransferase 2 
 -1.995  202783_at  NNT  nicotinamide nucleotide transhydrogenase 
 -1.995  218244_at  NOL8  nucleolar protein 8 
 -1.995  207217_s_at  NOX1  NADPH oxidase 1 
 -1.995  206418_at  NOX1  NADPH oxidase 1 
 -1.995  200747_s_at  NUMA1  nuclear mitotic apparatus protein 1 
 -1.995  213599_at  OIP5  Opa interacting protein 5 
 -1.995  213204_at  PARC  p53-associated parkin-like cytoplasmic protein 
 -1.995  219639_x_at  PARP6  poly (ADP-ribose) polymerase family, member 6 
 -1.995  202876_s_at  PBX2  pre-B-cell leukaemia homeobox 2 
 -1.995  214177_s_at  PBXIP1  pre-B-cell leukaemia homeobox interacting protein 1 
 -1.995  204476_s_at  PC  pyruvate carboxylase 
 -1.995  39650_s_at  PCNXL2  pecanex-like 2 (Drosophila) 
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 -1.995  218953_s_at  PCYOX1L  prenylcysteine oxidase 1 like 
 -1.995  210825_s_at  PEBP1  phosphatidylethanolamine binding protein 1 
 -1.995  211941_s_at  PEBP1  phosphatidylethanolamine binding protein 1 
 -1.995  202108_at  PEPD  peptidase D 
 -1.995  55616_at  PERLD1  per1-like domain containing 1 
 -1.995  204873_at  PEX1  peroxisomal biogenesis factor 1 
 -1.995  205160_at  PEX11A  peroxisomal biogenesis factor 11 alpha 
 -1.995  204545_at  PEX6  peroxisomal biogenesis factor 6 
 -1.995  219235_s_at  PHACTR4  phosphatase and actin regulator 4 
 -1.995  217953_at  PHF3  PHD finger protein 3 
 -1.995  213407_at  PHLPPL  PH domain and leucine rich repeat protein phosphatase-like 
 -1.995  219093_at  PID1   phosphotyrosine interaction domain containing 1 
 -1.995  213889_at  PIGL  phosphatidylinositol glycan anchor biosynthesis, class L 
 -1.995  219048_at  PIGN  phosphatidylinositol glycan anchor biosynthesis, class N 
 -1.995  202732_at  PKIG  protein kinase (cAMP-dependent, catalytic) inhibitor gamma 
 -1.995  219702_at  PLAC1  placenta-specific 1 
 -1.995  220157_x_at  PLEKHA9  pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 9 
 -1.995  215412_x_at  PMS2L2  postmeiotic segregation increased 2-like 2 pseudogene 
 -1.995  216525_x_at  PMS2L3  postmeiotic segregation increased 2-like 3 
 -1.995  201578_at  PODXL  podocalyxin-like 
 -1.995  212836_at  POLD3  polymerase (DNA-directed), delta 3, accessory subunit 
 -1.995  207746_at  POLQ  polymerase (DNA directed), theta 
 -1.995  208469_s_at  PPT2  palmitoyl-protein thioesterase 2 
 -1.995  218009_s_at  PRC1  protein regulator of cytokinesis 1 
 -1.995  206346_at  PRLR  prolactin receptor 
 -1.995  219392_x_at  PRR11  proline rich 11 
 -1.995  207011_s_at  PTK7  PTK7 protein tyrosine kinase 7 
 -1.995  211737_x_at  PTN  pleiotrophin 
 -1.995  213313_at  RABGAP1  RAB GTPase activating protein 1 
 -1.995  204028_s_at  RABGAP1  RAB GTPase activating protein 1 
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 -1.995  204828_at  RAD9A  RAD9 homolog A (S. pombe) 
 -1.995  201394_s_at  RBM5  RNA binding motif protein 5 
 -1.995  216215_s_at  RBM9  RNA binding motif protein 9 
 -1.995  204969_s_at  RDX  radixin 
 -1.995  212398_at  RDX  radixin 
 -1.995  208021_s_at  RFC1  replication factor C (activator 1) 1, 145kDa 
 -1.995  203210_s_at  RFC5  replication factor C (activator 1) 5, 36.5kDa 
 -1.995  219154_at  RHOF  ras homolog gene family, member F (in filopodia) 
 -1.995  213397_x_at  RNASE4  ribonuclease, RNase A family, 4 
 -1.995  204040_at  RNF144A  ring finger protein 144A 
 -1.995  219739_at  RNF186  ring finger protein 186 
 -1.995  205806_at  ROM1  retinal outer segment membrane protein 1 
 -1.995  218307_at  RSAD1  radical S-adenosyl methionine domain containing 1 
 -1.995  204030_s_at  SCHIP1  schwannomin interacting protein 1 
 -1.995  221216_s_at  SCMH1  sex comb on midleg homolog 1 (Drosophila) 
 -1.995  200961_at  SEPHS2  selenophosphate synthetase 2 
 -1.995  212493_s_at  SETD2  SET domain containing 2 
 -1.995  210172_at  SF1  splicing factor 1 
 -1.995  215699_x_at  SFI1  Sfi1 homolog, spindle assembly associated (yeast) 
 -1.995  212721_at  SFRS12  splicing factor, arginine/serine-rich 12 
 -1.995  212266_s_at  SFRS5  splicing factor, arginine/serine-rich 5 
 -1.995  213649_at  SFRS7  splicing factor, arginine/serine-rich 7, 35kDa 
 -1.995  220038_at  SGK3  serum/glucocorticoid regulated kinase family, member 3 
 -1.995  203014_x_at  SGSM3  small G protein signaling modulator 3 
 -1.995  40149_at  SH2B1  SH2B adaptor protein 1 
 -1.995  204967_at  SHROOM2  shroom family member 2 
 -1.995  203125_x_at  SLC11A2  solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 
 -1.995  210686_x_at  SLC25A16  solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 
 -1.995  221920_s_at  SLC25A37  solute carrier family 25, member 37 
 -1.995  203164_at  SLC33A1  solute carrier family 33 (acetyl-CoA transporter), member 1 
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 -1.995  217828_at  SLTM  SAFB-like, transcription modulator 
 -1.995  210993_s_at  SMAD1  SMAD family member 1 
 -1.995  215294_s_at  SMARCA1  SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 
 -1.995  217792_at  SNX5  sorting nexin 5 
 -1.995  209437_s_at  SPON1  spondin 1, extracellular matrix protein 
 -1.995  208920_at  SRI  sorcin 
 -1.995  221554_at  STRADA  STE20-related kinase adaptor alpha 
 -1.995  203767_s_at  STS  steroid sulfatase (microsomal), isozyme S 
 -1.995  210612_s_at  SYNJ2  synaptojanin 2 
 -1.995  204045_at  TCEAL1  transcription elongation factor A (SII)-like 1 
 -1.995  209153_s_at  TCF3  transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) 
 -1.995  205210_at  TGFBRAP1  transforming growth factor, beta receptor associated protein 1 
 -1.995  216262_s_at  TGIF2  TGFB-induced factor homeobox 2 
 -1.995  204565_at  THEM2  thioesterase superfamily member 2 
 -1.995  204064_at  THOC1  THO complex 1 
 -1.995  222122_s_at  THOC2  THO complex 2 
 -1.995  205217_at  TIMM8A  translocase of inner mitochondrial membrane 8 homolog A (yeast) 
 -1.995  204340_at  TMEM187  transmembrane protein 187 
 -1.995  212621_at  TMEM194A  transmembrane protein 194A 
 -1.995  203050_at  TP53BP1  tumor protein p53 binding protein 1 
 -1.995  217914_at  TPCN1  two pore segment channel 1 
 -1.995  214196_s_at  TPP1  tripeptidyl peptidase I 
 -1.995  204352_at  TRAF5  TNF receptor-associated factor 5 
 -1.995  202368_s_at  TRAM2   translocation associated membrane protein 2 
 -1.995  221627_at  TRIM10  tripartite motif-containing 10 
 -1.995  203148_s_at  TRIM14  tripartite motif-containing 14 
 -1.995  203567_s_at  TRIM38  tripartite motif-containing 38 
 -1.995  221952_x_at  TRMT5  TRM5 tRNA methyltransferase 5 homolog (S. cerevisiae) 
 -1.995  208663_s_at  TTC3  tetratricopeptide repeat domain 3 
 -1.995  208664_s_at  TTC3  tetratricopeptide repeat domain 3 
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 -1.995  203584_at  TTC35  tetratricopeptide repeat domain 35 
 -1.995  203048_s_at  TTC37  tetratricopeptide repeat domain 37 
 -1.995  214672_at  TTLL5  tubulin tyrosine ligase-like family, member 5 
 -1.995  219948_x_at  UGT2A3  UDP glucuronosyltransferase 2 family, polypeptide A3 
 -1.995  206405_x_at  USP6  ubiquitin specific peptidase 6 (Tre-2 oncogene) 
 -1.995  211571_s_at  VCAN  versican 
 -1.995  203564_at  VCP  valosin-containing protein 
 -1.995  205019_s_at  VIPR1  vasoactive intestinal peptide receptor 1 
 -1.995  203106_s_at  VPS41  vacuolar protein sorting 41 homolog (S. cerevisiae) 
 -1.995  213031_s_at  WDR73  WD repeat domain 73 
 -1.995  203043_at  ZBED1  zinc finger, BED-type containing 1 
 -1.995  218348_s_at  ZC3H7A  zinc finger CCCH-type containing 7A 
 -1.995  222237_s_at  ZFP112  zinc finger protein 112 homolog (mouse) 
 -1.995  37943_at  ZFYVE26  zinc finger, FYVE domain containing 26 
 -1.995  214670_at  ZKSCAN1  zinc finger with KRAB and SCAN domains 1 
 -1.995  37254_at  ZNF133  zinc finger protein 133 
 -1.995  215359_x_at  ZNF44  zinc finger protein 44 
 -2.138  221669_s_at  ACAD8  acyl-Coenzyme A dehydrogenase family, member 8 
 -2.138  206833_s_at  ACYP2  acylphosphatase 2, muscle type 
 -2.138  201752_s_at  ADD3  adducin 3 (gamma) 
 -2.138  201924_at  AFF1  AF4/FMR2 family, member 1 
 -2.138  212543_at  AIM1   absent in melanoma 1 
 -2.138  218064_s_at  AKAP8L  A kinase (PRKA) anchor protein 8-like 
 -2.138  213591_at  ALDH7A1  aldehyde dehydrogenase 7 family, member A1 
 -2.138  204704_s_at  ALDOB  aldolase B, fructose-bisphosphate 
 -2.138  205583_s_at  ALG13   asparagine-linked glycosylation 13 homolog (S. cerevisiae) 
 -2.138  207140_at  ALPI  alkaline phosphatase, intestinal 
 -2.138  216550_x_at  ANKRD12  ankyrin repeat domain 12 
 -2.138  218950_at  ARAP3  ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 
 -2.138  211852_s_at  ATRN  attractin 
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 -2.138  208860_s_at  ATRX  alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) 
 -2.138  220580_at  BICC1  bicaudal C homolog 1 (Drosophila) 
 -2.138  202095_s_at  BIRC5  baculoviral IAP repeat-containing 5 
 -2.138  205750_at  BPHL  biphenyl hydrolase-like (serine hydrolase) 
 -2.138  38241_at  BTN3A3  butyrophilin, subfamily 3, member A3 
 -2.138  209642_at  BUB1  budding uninhibited by benzimidazoles 1 homolog (yeast) 
 -2.138  204073_s_at  C11ORF9  chromosome 11 open reading frame 9 
 -2.138  211034_s_at  C12ORF51  chromosome 12 open reading frame 51 
 -2.138  219617_at  C2ORF34  chromosome 2 open reading frame 34 
 -2.138  219455_at  C7ORF63  chromosome 7 open reading frame 63 
 -2.138  218168_s_at  CABC1  chaperone, ABC1 activity of bc1 complex homolog (S. pombe) 
 -2.138  222201_s_at  CASP8AP2  caspase 8 associated protein 2 
 -2.138  203799_at  CD302  CD302 molecule 
 -2.138  206387_at  CDX2  caudal type homeobox 2 
 -2.138  222151_s_at  CEP63  centrosomal protein 63kDa 
 -2.138  209194_at  CETN2  centrin, EF-hand protein, 2 
 -2.138  203950_s_at  CLCN6  chloride channel 6 
 -2.138  209164_s_at  CYB561  cytochrome b-561 
 -2.138  218021_at  DHRS4  dehydrogenase/reductase (SDR family) member 4 
 -2.138  209916_at  DHTKD1  dehydrogenase E1 and transketolase domain containing 1 
 -2.138  205726_at  DIAPH2  diaphanous homolog 2 (Drosophila) 
 -2.138  212504_at  DIP2C  DIP2 disco-interacting protein 2 homolog C (Drosophila) 
 -2.138  212611_at  DTX4  deltex 4 homolog (Drosophila) 
 -2.138  209932_s_at  DUT   deoxyuridine triphosphatase 
 -2.138  208956_x_at  DUT   deoxyuridine triphosphatase 
 -2.138  206101_at  ECM2  extracellular matrix protein 2, female organ and adipocyte specific 
 -2.138  217735_s_at  EIF2AK1  eukaryotic translation initiation factor 2-alpha kinase 1 
 -2.138  201935_s_at  EIF4G3  eukaryotic translation initiation factor 4 gamma, 3 
 -2.138  201027_s_at  EIF5B  eukaryotic translation initiation factor 5B 
 -2.138  202414_at  ERCC5  excision repair cross-complementing rodent repair deficiency, complementation group 5 
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 -2.138  212979_s_at  FAM115A  family with sequence similarity 115, member A 
 -2.138  218397_at  FANCL  Fanconi anemia, complementation group L 
 -2.138  203032_s_at  FH  fumarate hydratase 
 -2.138  206857_s_at  FKBP1B  FK506 binding protein 1B, 12.6 kDa 
 -2.138  215293_s_at  FRAG1  FGF receptor activating protein 1 
 -2.138  208475_at  FRMD4A  FERM domain containing 4A 
 -2.138  204374_s_at  GALK1  galactokinase 1 
 -2.138  209729_at  GAS2L1  growth arrest-specific 2 like 1 
 -2.138  213018_at  GATAD1  GATA zinc finger domain containing 1 
 -2.138  219722_s_at  GDPD3  glycerophosphodiester phosphodiesterase domain containing 3 
 -2.138  208914_at  GGA2  Golgi associated, gamma adaptin ear containing, ARF binding protein 2 
 -2.138  211767_at  GINS4  GINS complex subunit 4 (Sld5 homolog) 
 -2.138  218350_s_at  GMNN  geminin, DNA replication inhibitor 
 -2.138  201956_s_at  GNPAT  glyceronephosphate O-acyltransferase 
 -2.138  215470_at  GTF2H2B  general transcription factor IIH, polypeptide 2B 
 -2.138  218412_s_at  GTF2IRD1  GTF2I repeat domain containing 1 
 -2.138  204317_at  GTSE1  G-2 and S-phase expressed 1 
 -2.138  215942_s_at  GTSE1  G-2 and S-phase expressed 1 
 -2.138  212206_s_at  H2AFV   H2A histone family, member V 
 -2.138  218460_at  HEATR2  HEAT repeat containing 2 
 -2.138  205313_at  HNF1B  HNF1 homeobox B 
 -2.138  221919_at  HNRNPA1  heterogeneous nuclear ribonucleoprotein A1 
 -2.138  208814_at  HSPA4  heat shock 70kDa protein 4 
 -2.138  220322_at  IL1F9  interleukin 1 family, member 9 
 -2.138  214705_at  INADL   InaD-like (Drosophila) 
 -2.138  201124_at  ITGB5  integrin, beta 5 
 -2.138  202182_at  KAT2A  K(lysine) acetyltransferase 2A 
 -2.138  211713_x_at  KIAA0101  KIAA0101 
 -2.138  212943_at  KIAA0528  KIAA0528 
 -2.138  204155_s_at  KIAA0999  KIAA0999 protein 
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 -2.138  222039_at  KIF18B   kinesin family member 18B 
 -2.138  209680_s_at  KIFC1  kinesin family member C1 
 -2.138  206054_at  KNG1   kininogen 1 
 -2.138  212785_s_at  LARP7   La ribonucleoprotein domain family, member 7 
 -2.138  204016_at  LARS2  leucyl-tRNA synthetase 2, mitochondrial 
 -2.138  206606_at  LIPC  lipase, hepatic 
 -2.138  217506_at  LOC400642  hypothetical LOC400642 
 -2.138  204298_s_at  LOX  lysyl oxidase 
 -2.138  203495_at  LRRC14  leucine rich repeat containing 14 
 -2.138  222036_s_at  MCM4  minichromosome maintenance complex component 4 
 -2.138  216237_s_at  MCM5  minichromosome maintenance complex component 5 
 -2.138  203062_s_at  MDC1  mediator of DNA damage checkpoint 1 
 -2.138  212693_at  MDN1   MDN1, midasin homolog (yeast) 
 -2.138  204305_at  MIPEP  mitochondrial intermediate peptidase 
 -2.138  36830_at  MIPEP  mitochondrial intermediate peptidase 
 -2.138  211673_s_at  MOCS1  molybdenum cofactor synthesis 1 
 -2.138  213924_at  MPPE1  metallophosphoesterase 1 
 -2.138  218536_at  MRS2  MRS2 magnesium homeostasis factor homolog (S. cerevisiae) 
 -2.138  219451_at  MSRB2  methionine sulfoxide reductase B2 
 -2.138  216862_s_at  MTCP1  mature T-cell proliferation 1 
 -2.138  203037_s_at  MTSS1  metastasis suppressor 1 
 -2.138  212093_s_at  MTUS1  mitochondrial tumor suppressor 1 
 -2.138  204139_x_at  MZF1  myeloid zinc finger 1 
 -2.138  218330_s_at  NAV2   neuron navigator 2 
 -2.138  212854_x_at  NBPF10  neuroblastoma breakpoint family, member 10 
 -2.138  204321_at  NEO1  neogenin homolog 1 (chicken) 
 -2.138  212808_at  NFATC2IP  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein 
 -2.138  218318_s_at  NLK  nemo-like kinase 
 -2.138  209262_s_at  NR2F6  nuclear receptor subfamily 2, group F, member 6 
 -2.138  204105_s_at  NRCAM  neuronal cell adhesion molecule 
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 -2.138  217802_s_at  NUCKS1  nuclear casein kinase and cyclin-dependent kinase substrate 1 
 -2.138  213945_s_at  NUP210  nucleoporin 210kDa 
 -2.138  209240_at  OGT  O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
 -2.138  211778_s_at  OVOL2  ovo-like 2 (Drosophila) 
 -2.138  219461_at  PAK6  p21 protein (Cdc42/Rac)-activated kinase 6 
 -2.138  204752_x_at  PARP2  poly (ADP-ribose) polymerase 2 
 -2.138  203860_at  PCCA  propionyl Coenzyme A carboxylase, alpha polypeptide 
 -2.138  214797_s_at  PCTK3  PCTAIRE protein kinase 3 
 -2.138  203803_at  PCYOX1  prenylcysteine oxidase 1 
 -2.138  209577_at  PCYT2  phosphate cytidylyltransferase 2, ethanolamine 
 -2.138  219304_s_at  PDGFD  platelet derived growth factor D 
 -2.138  205353_s_at  PEBP1  phosphatidylethanolamine binding protein 1 
 -2.138  220576_at  PGAP1  post-GPI attachment to proteins 1 
 -2.138  219394_at  PGS1  phosphatidylglycerophosphate synthase 1 
 -2.138  203278_s_at  PHF21A  PHD finger protein 21A 
 -2.138  212719_at  PHLPP  PH domain and leucine rich repeat protein phosphatase 
 -2.138  201080_at  PIP4K2B  phosphatidylinositol-5-phosphate 4-kinase, type II, beta 
 -2.138  214874_at  PKP4  plakophilin 4 
 -2.138  220952_s_at  PLEKHA5  pleckstrin homology domain containing, family A member 5 
 -2.138  219510_at  POLQ  polymerase (DNA directed), theta 
 -2.138  209337_at  PSIP1  PC4 and SFRS1 interacting protein 1 
 -2.138  219938_s_at  PSTPIP2  proline-serine-threonine phosphatase interacting protein 2 
 -2.138  203038_at  PTPRK  protein tyrosine phosphatase, receptor type, K 
 -2.138  219428_s_at  PXMP4  peroxisomal membrane protein 4, 24kDa 
 -2.138  217597_x_at  RAB40B  RAB40B, member RAS oncogene family 
 -2.138  208393_s_at  RAD50  RAD50 homolog (S. cerevisiae) 
 -2.138  209849_s_at  RAD51C  RAD51 homolog C (S. cerevisiae) 
 -2.138  205647_at  RAD52  RAD52 homolog (S. cerevisiae) 
 -2.138  212031_at  RBM25   RNA binding motif protein 25 
 -2.138  204365_s_at  REEP1  receptor accessory protein 1 
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 -2.138  204023_at  RFC4  replication factor C (activator 1) 4, 37kDa 
 -2.138  209110_s_at  RGL2  ral guanine nucleotide dissociation stimulator-like 2 
 -2.138  220329_s_at  RMND1  required for meiotic nuclear division 1 homolog (S. cerevisiae) 
 -2.138  205158_at  RNASE4  ribonuclease, RNase A family, 4 
 -2.138  209111_at  RNF5   ring finger protein 5 
 -2.138  207624_s_at  RPGR   retinitis pigmentosa GTPase regulator 
 -2.138  221989_at  RPL10  ribosomal protein L10 
 -2.138  208607_s_at  SAA1  serum amyloid A1 
 -2.138  215848_at  SCAPER  S phase cyclin A-associated protein in the ER 
 -2.138  201427_s_at  SEPP1  selenoprotein P, plasma, 1 
 -2.138  212414_s_at  SEPT6  septin 6 
 -2.138  209443_at  SERPINA5  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 
 -2.138  218346_s_at  SESN1  sestrin 1 
 -2.138  215038_s_at  SETD2  SET domain containing 2 
 -2.138  219749_at  SH2D4A  SH2 domain containing 4A 
 -2.138  201311_s_at  SH3BGRL  SH3 domain binding glutamic acid-rich protein like 
 -2.138  213600_at  SIPA1L3   signal-induced proliferation-associated 1 like 3 
 -2.138  203761_at  SLA  Src-like-adaptor 
 -2.138  206081_at  SLC24A1  solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 
 -2.138  201349_at  SLC9A3R1  solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 
 -2.138  203875_at  SMARCA1  SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 
 -2.138  203874_s_at  SMARCA1  SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 
 -2.138  205658_s_at  SNAPC4  small nuclear RNA activating complex, polypeptide 4, 190kDa 
 -2.138  218324_s_at  SPATS2  spermatogenesis associated, serine-rich 2 
 -2.138  205185_at  SPINK5  serine peptidase inhibitor, Kazal type 5 
 -2.138  213355_at  ST3GAL6  ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
 -2.138  221191_at  STAG3L1  stromal antigen 3-like 1 
 -2.138  209969_s_at  STAT1  signal transducer and activator of transcription 1, 91kDa 
 -2.138  205339_at  STIL  SCL/TAL1 interrupting locus 
 -2.138  204287_at  SYNGR1  synaptogyrin 1 
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 -2.138  219992_at  TAC3  tachykinin 3 
 -2.138  219771_at  TBC1D8B  TBC1 domain family, member 8B (with GRAM domain) 
 -2.138  204731_at  TGFBR3  transforming growth factor, beta receptor III 
 -2.138  217974_at  TM7SF3  transmembrane 7 superfamily member 3 
 -2.138  218815_s_at  TMEM51  transmembrane protein 51 
 -2.138  217853_at  TNS3  tensin 3 
 -2.138  210052_s_at  TPX2  TPX2, microtubule-associated, homolog (Xenopus laevis) 
 -2.138  202369_s_at  TRAM2   translocation associated membrane protein 2 
 -2.138  219351_at  TRAPPC2  trafficking protein particle complex 2 
 -2.138  206308_at  TRDMT1  tRNA aspartic acid methyltransferase 1 
 -2.138  203049_s_at  TTC37  tetratricopeptide repeat domain 37 
 -2.138  202589_at  TYMS  thymidylate synthetase 
 -2.138  208760_at  UBE2I  ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 
 -2.138  212403_at  UBE3B  ubiquitin protein ligase E3B 
 -2.138  202317_s_at  UBE4B  ubiquitination factor E4B (UFD2 homolog, yeast) 
 -2.138  218108_at  UBR7  ubiquitin protein ligase E3 component n-recognin 7 (putative) 
 -2.138  220079_s_at  USP48  ubiquitin specific peptidase 48 
 -2.138  201886_at  WDR23  WD repeat domain 23 
 -2.138  202250_s_at  WDR42A  WD repeat domain 42A 
 -2.138  218505_at  WDR59  WD repeat domain 59 
 -2.138  219251_s_at  WDR60  WD repeat domain 60 
 -2.138  205340_at  ZBTB24   zinc finger and BTB domain containing 24 
 -2.138  213064_at  ZC3H14  zinc finger CCCH-type containing 14 
 -2.138  210281_s_at  ZMYM2  zinc finger, MYM-type 2 
 -2.138  202051_s_at  ZMYM4  zinc finger, MYM-type 4 
 -2.138  219854_at  ZNF14  zinc finger protein 14 
 -2.138  219314_s_at  ZNF219  zinc finger protein 219 
 -2.138  209538_at  ZNF32  zinc finger protein 32 
 -2.138  215012_at  ZNF451  zinc finger protein 451 
 -2.138  213775_x_at  ZNF638  zinc finger protein 638 
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 -2.138  205594_at  ZNF652  zinc finger protein 652 
 -2.138  219627_at  ZNF767  zinc finger family member 767 
 -2.138  204026_s_at  ZWINT   ZW10 interactor 
 -2.291  203196_at  ABCC4  ATP-binding cassette, sub-family C (CFTR/MRP), member 4 
 -2.291  212186_at  ACACA  acetyl-Coenzyme A carboxylase alpha 
 -2.291  215728_s_at  ACOT7  acyl-CoA thioesterase 7 
 -2.291  209195_s_at  ADCY6  adenylate cyclase 6 
 -2.291  205882_x_at  ADD3  adducin 3 (gamma) 
 -2.291  207544_s_at  ADH6  alcohol dehydrogenase 6 (class V) 
 -2.291  212174_at  AK2  adenylate kinase 2 
 -2.291  209424_s_at  AMACR  alpha-methylacyl-CoA racemase 
 -2.291  212289_at  ANKRD12  ankyrin repeat domain 12 
 -2.291  201613_s_at  AP1G2  adaptor-related protein complex 1, gamma 2 subunit 
 -2.291  40148_at  APBB2  amyloid beta (A4) precursor protein-binding, family B, member 2 
 -2.291  218917_s_at  ARID1A  AT rich interactive domain 1A (SWI-like) 
 -2.291  205865_at  ARID3A  AT rich interactive domain 3A (BRIGHT-like) 
 -2.291  212614_at  ARID5B  AT rich interactive domain 5B (MRF1-like) 
 -2.291  213587_s_at  ATP6V0E2  ATPase, H+ transporting V0 subunit e2 
 -2.291  204624_at  ATP7B  ATPase, Cu++ transporting, beta polypeptide 
 -2.291  213106_at  ATP8A1   ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 
 -2.291  214342_at  ATXN7L1  ataxin 7-like 1 
 -2.291  209464_at  AURKB  aurora kinase B 
 -2.291  202094_at  BIRC5  baculoviral IAP repeat-containing 5 
 -2.291  218789_s_at  C11ORF71  chromosome 11 open reading frame 71 
 -2.291  214264_s_at  C14ORF143  chromosome 14 open reading frame 143 
 -2.291  214357_at  C1ORF105  chromosome 1 open reading frame 105 
 -2.291  218646_at  C4ORF27  chromosome 4 open reading frame 27 
 -2.291  218179_s_at  C4ORF41  chromosome 4 open reading frame 41 
 -2.291  221879_at  CALML4  calmodulin-like 4 
 -2.291  222137_at  CC2D1A  coiled-coil and C2 domain containing 1A 
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 -2.291  218175_at  CCDC92   coiled-coil domain containing 92 
 -2.291  212899_at  CDC2L6  cell division cycle 2-like 6 (CDK8-like) 
 -2.291  204739_at  CENPC1  centromere protein C 1 
 -2.291  203491_s_at  CEP57  centrosomal protein 57kDa 
 -2.291  204266_s_at  CHKA  choline kinase alpha 
 -2.291  209571_at  CIR   CBF1 interacting corepressor 
 -2.291  213499_at  CLCN2  chloride channel 2 
 -2.291  213050_at  COBL  cordon-bleu homolog (mouse) 
 -2.291  208817_at  COMT  catechol-O-methyltransferase 
 -2.291  218328_at  COQ4  coenzyme Q4 homolog (S. cerevisiae) 
 -2.291  220044_x_at  CROP  cisplatin resistance-associated overexpressed protein 
 -2.291  220753_s_at  CRYL1  crystallin, lambda 1 
 -2.291  209163_at  CYB561  cytochrome b-561 
 -2.291  201279_s_at  DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
 -2.291  208718_at  DDX17  DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
 -2.291  218756_s_at  DHRS11  dehydrogenase/reductase (SDR family) member 11 
 -2.291  213647_at  DNA2  DNA replication helicase 2 homolog (yeast) 
 -2.291  205554_s_at  DNASE1L3  deoxyribonuclease I-like 3 
 -2.291  218457_s_at  DNMT3A  DNA (cytosine-5-)-methyltransferase 3 alpha 
 -2.291  213267_at  DOPEY1  dopey family member 1 
 -2.291  205248_at  DOPEY2  dopey family member 2 
 -2.291  203762_s_at  DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1 
 -2.291  207231_at  DZIP3  DAZ interacting protein 3, zinc finger 
 -2.291  221586_s_at  E2F5  E2F transcription factor 5, p130-binding 
 -2.291  202326_at  EHMT2  euchromatic histone-lysine N-methyltransferase 2 
 -2.291  201026_at  EIF5B  eukaryotic translation initiation factor 5B 
 -2.291  204142_at  ENOSF1  enolase superfamily member 1 
 -2.291  220524_at  EPB41L4B  erythrocyte membrane protein band 4.1 like 4B 
 -2.291  219905_at  ERMAP  erythroblast membrane-associated protein (Scianna blood group) 
 -2.291  214802_at  EXOC7  exocyst complex component 7 
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 -2.291  204714_s_at  F5  coagulation factor V (proaccelerin, labile factor) 
 -2.291  218518_at  FAM13B1  family with sequence similarity 13, member B1 
 -2.291  221591_s_at  FAM64A  family with sequence similarity 64, member A 
 -2.291  213007_at  FANCI  Fanconi anemia, complementation group I 
 -2.291  213008_at  FANCI  Fanconi anemia, complementation group I 
 -2.291  212987_at  FBXO9  F-box protein 9 
 -2.291  215645_at  FLCN  folliculin 
 -2.291  216442_x_at  FN1  fibronectin 1 
 -2.291  212464_s_at  FN1  fibronectin 1 
 -2.291  210495_x_at  FN1  fibronectin 1 
 -2.291  211719_x_at  FN1  fibronectin 1 
 -2.291  207014_at  GABRA2  gamma-aminobutyric acid (GABA) A receptor, alpha 2 
 -2.291  216411_s_at  GALK2  galactokinase 2 
 -2.291  205354_at  GAMT  guanidinoacetate N-methyltransferase 
 -2.291  209604_s_at  GATA3  GATA binding protein 3 
 -2.291  206102_at  GINS1  GINS complex subunit 1 (Psf1 homolog) 
 -2.291  222034_at  GNB2L1  guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 
 -2.291  222102_at  GSTA3  glutathione S-transferase alpha 3 
 -2.291  202967_at  GSTA4  glutathione S-transferase alpha 4 
 -2.291  215333_x_at  GSTM1  glutathione S-transferase mu 1 
 -2.291  204550_x_at  GSTM1  glutathione S-transferase mu 1 
 -2.291  205439_at  GSTT2  glutathione S-transferase theta 2 
 -2.291  206312_at  GUCY2C  guanylate cyclase 2C (heat stable enterotoxin receptor) 
 -2.291  219352_at  HERC6  hect domain and RLD 6 
 -2.291  204578_at  HISPPD2A  histidine acid phosphatase domain containing 2A 
 -2.291  215071_s_at  HIST1H2AC  histone cluster 1, H2ac 
 -2.291  208025_s_at  HMGA2  high mobility group AT-hook 2 
 -2.291  207165_at  HMMR  hyaluronan-mediated motility receptor (RHAMM) 
 -2.291  211930_at  HNRNPA3  heterogeneous nuclear ribonucleoprotein A3 
 -2.291  212203_x_at  IFITM3  interferon induced transmembrane protein 3 (1-8U) 
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 -2.291  209342_s_at  IKBKB  inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
 -2.291  213447_at  IPW  imprinted in Prader-Willi syndrome (non-protein coding) 
 -2.291  205874_at  ITPKA  inositol 1,4,5-trisphosphate 3-kinase A 
 -2.291  213005_s_at  KANK1  KN motif and ankyrin repeat domains 1 
 -2.291  203845_at  KAT2B  K(lysine) acetyltransferase 2B 
 -2.291  213034_at  KIAA0999  KIAA0999 protein 
 -2.291  212779_at  KIAA1109  KIAA1109 
 -2.291  220777_at  KIF13A  kinesin family member 13A 
 -2.291  203943_at  KIF3B  kinesin family member 3B 
 -2.291  205306_x_at  KMO  kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
 -2.291  206316_s_at  KNTC1  kinetochore associated 1 
 -2.291  34764_at  LARS2  leucyl-tRNA synthetase 2, mitochondrial 
 -2.291  213195_at  LOC201229  hypothetical protein LOC201229 
 -2.291  213510_x_at  LOC220594  TL132 protein 
 -2.291  215247_at  LOC440895  LIM and senescent cell antigen-like domains 3-like 
 -2.291  221640_s_at  LRDD  leucine-rich repeats and death domain containing 
 -2.291  205606_at  LRP6  low density lipoprotein receptor-related protein 6 
 -2.291  220143_x_at  LUC7L  LUC7-like (S. cerevisiae) 
 -2.291  203778_at  MANBA  mannosidase, beta A, lysosomal 
 -2.291  206249_at  MAP3K13  mitogen-activated protein kinase kinase kinase 13 
 -2.291  221824_s_at  MARCH8  membrane-associated ring finger (C3HC4) 8 
 -2.291  202350_s_at  MATN2  matrilin 2 
 -2.291  201555_at  MCM3  minichromosome maintenance complex component 3 
 -2.291  219673_at  MCM9  minichromosome maintenance complex component 9 
 -2.291  218883_s_at  MLF1IP  MLF1 interacting protein 
 -2.291  212079_s_at  MLL  myeloid/lymphoid or mixed-lineage leukaemia (trithorax homolog, Drosophila) 
 -2.291  210212_x_at  MTCP1  mature T-cell proliferation 1 
 -2.291  218663_at  NCAPG   non-SMC condensin I complex, subunit G 
 -2.291  219588_s_at  NCAPG2  non-SMC condensin II complex, subunit G2 
 -2.291  209105_at  NCOA1  nuclear receptor coactivator 1 
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 -2.291  209107_x_at  NCOA1  nuclear receptor coactivator 1 
 -2.291  214657_s_at  NCRNA00084  non-protein coding RNA 84 
 -2.291  219961_s_at  NCRNA00153  non-protein coding RNA 153 
 -2.291  202607_at  NDST1  N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 
 -2.291  213331_s_at  NEK1  NIMA (never in mitosis gene a)-related kinase 1 
 -2.291  217526_at  NFATC2IP  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein 
 -2.291  201708_s_at  NIPSNAP1  nipsnap homolog 1 (C. elegans) 
 -2.291  206340_at  NR1H4  nuclear receptor subfamily 1, group H, member 4 
 -2.291  201865_x_at  NR3C1  nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 
 -2.291  219067_s_at  NSMCE4A  non-SMC element 4 homolog A (S. cerevisiae) 
 -2.291  211376_s_at  NSMCE4A  non-SMC element 4 homolog A (S. cerevisiae) 
 -2.291  203675_at  NUCB2  nucleobindin 2 
 -2.291  204766_s_at  NUDT1  nudix (nucleoside diphosphate linked moiety X)-type motif 1 
 -2.291  214136_at  NUDT13   nudix (nucleoside diphosphate linked moiety X)-type motif 13 
 -2.291  220035_at  NUP210  nucleoporin 210kDa 
 -2.291  218162_at  OLFML3  olfactomedin-like 3 
 -2.291  207576_x_at  OXT  oxytocin, prepropeptide 
 -2.291  222317_at  PDE3B  phosphodiesterase 3B, cGMP-inhibited 
 -2.291  205251_at  PER2  period homolog 2 (Drosophila) 
 -2.291  218410_s_at  PGP  phosphoglycolate phosphatase 
 -2.291  218517_at  PHF17  PHD finger protein 17 
 -2.291  209438_at  PHKA2  phosphorylase kinase, alpha 2 (liver) 
 -2.291  202738_s_at  PHKB  phosphorylase kinase, beta 
 -2.291  209780_at  PHTF2  putative homeodomain transcription factor 2 
 -2.291  212239_at  PIK3R1  phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
 -2.291  212249_at  PIK3R1  phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
 -2.291  212240_s_at  PIK3R1  phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
 -2.291  204572_s_at  PIN4  protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 
 -2.291  220686_s_at  PIWIL2  piwi-like 2 (Drosophila) 
 -2.291  213222_at  PLCB1  phospholipase C, beta 1 (phosphoinositide-specific) 
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 -2.291  202789_at  PLCG1  phospholipase C, gamma 1 
 -2.291  204887_s_at  PLK4  polo-like kinase 4 (Drosophila) 
 -2.291  204519_s_at  PLLP  plasma membrane proteolipid (plasmolipin) 
 -2.291  206956_at  PMF1  polyamine-modulated factor 1 
 -2.291  203515_s_at  PMVK  phosphomevalonate kinase 
 -2.291  212349_at  POFUT1  protein O-fucosyltransferase 1 
 -2.291  204835_at  POLA1  polymerase (DNA directed), alpha 1, catalytic subunit 
 -2.291  216026_s_at  POLE  polymerase (DNA directed), epsilon 
 -2.291  205909_at  POLE2  polymerase (DNA directed), epsilon 2 (p59 subunit) 
 -2.291  219317_at  POLI  polymerase (DNA directed) iota 
 -2.291  214144_at  POLR2D  polymerase (RNA) II (DNA directed) polypeptide D 
 -2.291  212686_at  PPM1H  protein phosphatase 1H (PP2C domain containing) 
 -2.291  218045_x_at  PTMS  parathymosin 
 -2.291  209515_s_at  RAB27A  RAB27A, member RAS oncogene family 
 -2.291  206066_s_at  RAD51C  RAD51 homolog C (S. cerevisiae) 
 -2.291  204558_at  RAD54L  RAD54-like (S. cerevisiae) 
 -2.291  210552_s_at  RALGPS1  Ral GEF with PH domain and SH3 binding motif 1 
 -2.291  221872_at  RARRES1  retinoic acid receptor responder (tazarotene induced) 1 
 -2.291  212783_at  RBBP6   retinoblastoma binding protein 6 
 -2.291  212027_at  RBM25   RNA binding motif protein 25 
 -2.291  212030_at  RBM25   RNA binding motif protein 25 
 -2.291  212033_at  RBM25   RNA binding motif protein 25 
 -2.291  203696_s_at  RFC2  replication factor C (activator 1) 2, 40kDa 
 -2.291  60471_at  RIN3  Ras and Rab interactor 3 
 -2.291  219457_s_at  RIN3  Ras and Rab interactor 3 
 -2.291  219263_at  RNF128  ring finger protein 128 
 -2.291  220991_s_at  RNF32  ring finger protein 32 
 -2.291  213973_at  RRBP1  ribosome binding protein 1 homolog 180kDa (dog) 
 -2.291  212301_at  RTF1  Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 
 -2.291  218243_at  RUFY1  RUN and FYVE domain containing 1 
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 -2.291  202792_s_at  SAPS2  SAPS domain family, member 2 
 -2.291  213874_at  SERPINA4  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 
 -2.291  221562_s_at  SIRT3  sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) 
 -2.291  221913_at  SIRT3  sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) 
 -2.291  210047_at  SLC11A2  solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 
 -2.291  205074_at  SLC22A5  solute carrier family 22 (organic cation/carnitine transporter), member 5 
 -2.291  218136_s_at  SLC25A37  solute carrier family 25, member 37 
 -2.291  212890_at  SLC38A10  solute carrier family 38, member 10 
 -2.291  222364_at  SLC44A1  solute carrier family 44, member 1 
 -2.291  215623_x_at  SMC4  structural maintenance of chromosomes 4 
 -2.291  214494_s_at  SPG7  spastic paraplegia 7 (pure and complicated autosomal recessive) 
 -2.291  202104_s_at  SPG7  spastic paraplegia 7 (pure and complicated autosomal recessive) 
 -2.291  213329_at  SRGAP2  SLIT-ROBO Rho GTPase activating protein 2 
 -2.291  212625_at  STX10  syntaxin 10 
 -2.291  207601_at  SULT1B1  sulfotransferase family, cytosolic, 1B, member 1 
 -2.291  218308_at  TACC3  transforming, acidic coiled-coil containing protein 3 
 -2.291  201814_at  TBC1D5  TBC1 domain family, member 5 
 -2.291  202371_at  TCEAL4  transcription elongation factor A (SII)-like 4 
 -2.291  212387_at  TCF4  transcription factor 4 
 -2.291  212382_at  TCF4  transcription factor 4 
 -2.291  219800_s_at  THNSL1  threonine synthase-like 1 (S. cerevisiae) 
 -2.291  212994_at  THOC2  THO complex 2 
 -2.291  213135_at  TIAM1  T-cell lymphoma invasion and metastasis 1 
 -2.291  212770_at  TLE3  transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) 
 -2.291  203839_s_at  TNK2  tyrosine kinase, non-receptor, 2 
 -2.291  219587_at  TTC12  tetratricopeptide repeat domain 12 
 -2.291  219481_at  TTC13  tetratricopeptide repeat domain 13 
 -2.291  218838_s_at  TTC31  tetratricopeptide repeat domain 31 
 -2.291  204822_at  TTK  TTK protein kinase 
 -2.291  205854_at  TULP3  tubby like protein 3 
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 -2.291  202365_at  UNC119B  unc-119 homolog B (C. elegans) 
 -2.291  203519_s_at  UPF2  UPF2 regulator of nonsense transcripts homolog (yeast) 
 -2.291  214323_s_at  UPF3A  UPF3 regulator of nonsense transcripts homolog A (yeast) 
 -2.291  203241_at  UVRAG  UV radiation resistance associated gene 
 -2.291  219538_at  WDR5B  WD repeat domain 5B 
 -2.291  203958_s_at  ZBTB40  zinc finger and BTB domain containing 40 
 -2.291  213063_at  ZC3H14  zinc finger CCCH-type containing 14 
 -2.291  201368_at  ZFP36L2  zinc finger protein 36, C3H type-like 2 
 -2.291  203556_at  ZHX2  zinc fingers and homeoboxes 2 
 -2.291  207394_at  ZNF137  zinc finger protein 137 
 -2.291  207513_s_at  ZNF189  zinc finger protein 189 
 -2.291  219228_at  ZNF331  zinc finger protein 331 
 -2.291  215358_x_at  ZNF37B  zinc finger protein 37B 
 -2.291  211257_x_at  ZNF638  zinc finger protein 638 
 -2.291  222120_at  ZNF764  zinc finger protein 764 
 -2.455  203981_s_at  ABCD4  ATP-binding cassette, sub-family D (ALD), member 4 
 -2.455  213198_at  ACVR1B  activin A receptor, type IB 
 -2.455  213245_at  ADCY1  adenylate cyclase 1 (brain) 
 -2.455  205996_s_at  AK2  adenylate kinase 2 
 -2.455  211004_s_at  ALDH3B1  aldehyde dehydrogenase 3 family, member B1 
 -2.455  209426_s_at  AMACR  alpha-methylacyl-CoA racemase 
 -2.455  204294_at  AMT   aminomethyltransferase 
 -2.455  216195_at  ANK2  ankyrin 2, neuronal 
 -2.455  214723_x_at  ANKRD36B  ankyrin repeat domain 36B 
 -2.455  208861_s_at  ATRX  alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) 
 -2.455  205363_at  BBOX1  butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 
 -2.455  214452_at  BCAT1  branched chain aminotransferase 1, cytosolic 
 -2.455  213709_at  BHLHB9  basic helix-loop-helix domain containing, class B, 9 
 -2.455  216521_s_at  BRCC3  BRCA1/BRCA2-containing complex, subunit 3 
 -2.455  221196_x_at  BRCC3  BRCA1/BRCA2-containing complex, subunit 3 
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 -2.455  218983_at  C1RL  complement component 1, r subcomponent-like 
 -2.455  220943_s_at  C2ORF56  chromosome 2 open reading frame 56 
 -2.455  204238_s_at  C6ORF108  chromosome 6 open reading frame 108 
 -2.455  64408_s_at  CALML4  calmodulin-like 4 
 -2.455  214322_at  CAMK2G  calcium/calmodulin-dependent protein kinase II gamma 
 -2.455  212554_at  CAP2  CAP, adenylate cyclase-associated protein, 2 (yeast) 
 -2.455  212551_at  CAP2  CAP, adenylate cyclase-associated protein, 2 (yeast) 
 -2.455  210944_s_at  CAPN3  calpain 3, (p94) 
 -2.455  209790_s_at  CASP6  caspase 6, apoptosis-related cysteine peptidase 
 -2.455  201432_at  CAT  catalase 
 -2.455  207625_s_at  CBFA2T2  core-binding factor, runt domain, alpha subunit 2; translocated to, 2 
 -2.455  219644_at  CCDC41  coiled-coil domain containing 41 
 -2.455  214710_s_at  CCNB1  cyclin B1 
 -2.455  205271_s_at  CCRK  cell cycle related kinase 
 -2.455  204962_s_at  CENPA  centromere protein A 
 -2.455  207590_s_at  CENPI  centromere protein I 
 -2.455  206003_at  CEP135  centrosomal protein 135kDa 
 -2.455  204251_s_at  CEP164  centrosomal protein 164kDa 
 -2.455  210859_x_at  CLN3  ceroid-lipofuscinosis, neuronal 3 
 -2.455  204576_s_at  CLUAP1  clusterin associated protein 1 
 -2.455  219300_s_at  CNTNAP2  contactin associated protein-like 2 
 -2.455  212228_s_at  COQ9  coenzyme Q9 homolog (S. cerevisiae) 
 -2.455  205538_at  CORO2A  coronin, actin binding protein, 2A 
 -2.455  204662_at  CP110  CP110 protein 
 -2.455  207030_s_at  CSRP2  cysteine and glycine-rich protein 2 
 -2.455  201906_s_at  CTDSPL  CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like 
 -2.455  221850_x_at  CTGLF1  centaurin, gamma-like family, member 1 
 -2.455  203979_at  CYP27A1  cytochrome P450, family 27, subfamily A, polypeptide 1 
 -2.455  212855_at  DCUN1D4  DCN1, defective in cullin neddylation 1, domain containing 4 (S. cerevisiae) 
 -2.455  208149_x_at  DDX11  DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) 
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 -2.455  213998_s_at  DDX17  DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
 -2.455  48808_at  DHFR  dihydrofolate reductase 
 -2.455  202532_s_at  DHFR  dihydrofolate reductase 
 -2.455  202534_x_at  DHFR  dihydrofolate reductase 
 -2.455  208216_at  DLX4  distal-less homeobox 4 
 -2.455  220372_at  DNAJC28  DnaJ (Hsp40) homolog, subfamily C, member 28 
 -2.455  201431_s_at  DPYSL3  dihydropyrimidinase-like 3 
 -2.455  218854_at  DSE  dermatan sulfate epimerase 
 -2.455  207232_s_at  DZIP3  DAZ interacting protein 3, zinc finger 
 -2.455  209963_s_at  EPOR  erythropoietin receptor 
 -2.455  218180_s_at  EPS8L2  EPS8-like 2 
 -2.455  219629_at  FAM118A  family with sequence similarity 118, member A 
 -2.455  222245_s_at  FER1L4   fer-1-like 4 (C. elegans) 
 -2.455  213737_x_at  FLJ35785  Golgi autoantigen, golgin subfamily a, 9 pseudogene 
 -2.455  203146_s_at  GABBR1  gamma-aminobutyric acid (GABA) B receptor, 1 
 -2.455  210002_at  GATA6  GATA binding protein 6 
 -2.455  221521_s_at  GINS2  GINS complex subunit 2 (Psf2 homolog) 
 -2.455  218146_at  GLT8D1  glycosyltransferase 8 domain containing 1 
 -2.455  220773_s_at  GPHN  gephyrin 
 -2.455  219313_at  GRAMD1C  GRAM domain containing 1C 
 -2.455  206712_at  GRTP1  growth hormone regulated TBC protein 1 
 -2.455  204418_x_at  GSTM2  glutathione S-transferase mu 2 (muscle) 
 -2.455  204318_s_at  GTSE1  G-2 and S-phase expressed 1 
 -2.455  204315_s_at  GTSE1  G-2 and S-phase expressed 1 
 -2.455  210387_at  HIST1H2BG  histone cluster 1, H2bg 
 -2.455  209709_s_at  HMMR  hyaluronan-mediated motility receptor (RHAMM) 
 -2.455  210881_s_at  IGF2  insulin-like growth factor 2 (somatomedin A) 
 -2.455  212813_at  JAM3  junctional adhesion molecule 3 
 -2.455  214861_at  JMJD2C  jumonji domain containing 2C 
 -2.455  216762_at  KANK1  KN motif and ankyrin repeat domains 1 
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 -2.455  213358_at  KIAA0802  KIAA0802 
 -2.455  209760_at  KIAA0922  KIAA0922 
 -2.455  204444_at  KIF11  kinesin family member 11 
 -2.455  221258_s_at  KIF18A  kinesin family member 18A 
 -2.455  217906_at  KLHDC2  kelch domain containing 2 
 -2.455  214045_at  LIAS  lipoic acid synthetase 
 -2.455  202193_at  LIMK2  LIM domain kinase 2 
 -2.455  209204_at  LMO4  LIM domain only 4 
 -2.455  212850_s_at  LRP4  low density lipoprotein receptor-related protein 4 
 -2.455  221740_x_at  LRRC37A2  leucine rich repeat containing 37, member A2 
 -2.455  211018_at  LSS  lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 
 -2.455  204069_at  MEIS1  Meis homeobox 1 
 -2.455  218251_at  MID1IP1  MID1 interacting protein 1 (gastrulation specific G12 homolog (zebrafish)) 
 -2.455  218630_at  MKS1  Meckel syndrome, type 1 
 -2.455  219527_at  MOSC2  MOCO sulphurase C-terminal domain containing 2 
 -2.455  202974_at  MPP1  membrane protein, palmitoylated 1, 55kDa 
 -2.455  214268_s_at  MTMR4  myotubularin related protein 4 
 -2.455  212372_at  MYH10  myosin, heavy chain 10, non-muscle 
 -2.455  220319_s_at  MYLIP  myosin regulatory light chain interacting protein 
 -2.455  213375_s_at  N4BP2L1  NEDD4 binding protein 2-like 1 
 -2.455  221899_at  N4BP2L2  NEDD4 binding protein 2-like 2 
 -2.455  204162_at  NDC80  NDC80 homolog, kinetochore complex component (S. cerevisiae) 
 -2.455  212448_at  NEDD4L  neural precursor cell expressed, developmentally down-regulated 4-like 
 -2.455  219542_at  NEK11  NIMA (never in mitosis gene a)- related kinase 11 
 -2.455  202007_at  NID1  nidogen 1 
 -2.455  214722_at  NOTCH2NL  Notch homolog 2 (Drosophila) N-terminal like 
 -2.455  214870_x_at  NPIP  nuclear pore complex interacting protein 
 -2.455  211671_s_at  NR3C1  nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 
 -2.455  220176_at  NUBPL  nucleotide binding protein-like 
 -2.455  222027_at  NUCKS1  nuclear casein kinase and cyclin-dependent kinase substrate 1 
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 -2.455  212775_at  OBSL1  obscurin-like 1 
 -2.455  202780_at  OXCT1  3-oxoacid CoA transferase 1 
 -2.455  214086_s_at  PARP2  poly (ADP-ribose) polymerase 2 
 -2.455  214239_x_at  PCGF2  polycomb group ring finger 2 
 -2.455  214937_x_at  PCM1  pericentriolar material 1 
 -2.455  214118_x_at  PCM1  pericentriolar material 1 
 -2.455  212594_at  PDCD4  programmed cell death 4 (neoplastic transformation inhibitor) 
 -2.455  214582_at  PDE3B  phosphodiesterase 3B, cGMP-inhibited 
 -2.455  212092_at  PEG10  paternally expressed 10 
 -2.455  212660_at  PHF15  PHD finger protein 15 
 -2.455  203688_at  PKD2   polycystic kidney disease 2 (autosomal dominant) 
 -2.455  201928_at  PKP4  plakophilin 4 
 -2.455  209504_s_at  PLEKHB1  pleckstrin homology domain containing, family B (evectins) member 1 
 -2.455  218901_at  PLSCR4  phospholipid scramblase 4 
 -2.455  212036_s_at  PNN  pinin, desmosome associated protein 
 -2.455  220675_s_at  PNPLA3  patatin-like phospholipase domain containing 3 
 -2.455  210433_at  POFUT1  protein O-fucosyltransferase 1 
 -2.455  203422_at  POLD1  polymerase (DNA directed), delta 1, catalytic subunit 125kDa 
 -2.455  209355_s_at  PPAP2B  phosphatidic acid phosphatase type 2B 
 -2.455  213849_s_at  PPP2R2B  protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform 
 -2.455  213483_at  PPWD1  peptidylprolyl isomerase domain and WD repeat containing 1 
 -2.455  205194_at  PSPH  phosphoserine phosphatase 
 -2.455  209815_at  PTCH1  patched homolog 1 (Drosophila) 
 -2.455  219076_s_at  PXMP2  peroxisomal membrane protein 2, 22kDa 
 -2.455  203933_at  RAB11FIP3  RAB11 family interacting protein 3 (class II) 
 -2.455  212781_at  RBBP6  retinoblastoma binding protein 6 
 -2.455  212028_at  RBM25   RNA binding motif protein 25 
 -2.455  218352_at  RCBTB1  regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 1 
 -2.455  214433_s_at  SELENBP1  selenium binding protein 1 
 -2.455  219194_at  SEMA4G  sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4G 
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 -2.455  220626_at  SERPINA10  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10 
 -2.455  214092_x_at  SFRS14  splicing factor, arginine/serine-rich 14 
 -2.455  220974_x_at  SFXN3  sideroflexin 3 
 -2.455  219493_at  SHCBP1  SHC SH2-domain binding protein 1 
 -2.455  207095_at  SLC10A2  solute carrier family 10 (sodium/bile acid cotransporter family), member 2 
 -2.455  202800_at  SLC1A3  solute carrier family 1 (glial high affinity glutamate transporter), member 3 
 -2.455  204587_at  SLC25A14  solute carrier family 25 (mitochondrial carrier, brain), member 14 
 -2.455  214140_at  SLC25A16  solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 
 -2.455  203658_at  SLC25A20  solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
 -2.455  218494_s_at  SLC2A4RG  SLC2A4 regulator 
 -2.455  205799_s_at  SLC3A1  solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, 
dibasic and neutral amino acid transport), member 1 
 -2.455  206565_x_at  SMA4  glucuronidase, beta pseudogene 
 -2.455  213253_at  SMC2  structural maintenance of chromosomes 2 
 -2.455  219583_s_at  SPATA7  spermatogenesis associated 7 
 -2.455  217813_s_at  SPIN1  spindlin 1 
 -2.455  211704_s_at  SPIN2B  spindlin family, member 2B 
 -2.455  222173_s_at  TBC1D2  TBC1 domain family, member 2 
 -2.455  212796_s_at  TBC1D2B  TBC1 domain family, member 2B 
 -2.455  201813_s_at  TBC1D5  TBC1 domain family, member 5 
 -2.455  203753_at  TCF4  transcription factor 4 
 -2.455  218584_at  TCTN1  tectonic family member 1 
 -2.455  218724_s_at  TGIF2  TGFB-induced factor homeobox 2 
 -2.455  219423_x_at  TNFRSF25  tumor necrosis factor receptor superfamily, member 25 
 -2.455  210372_s_at  TPD52L1  tumor protein D52-like 1 
 -2.455  201731_s_at  TPR  translocated promoter region (to activated MET oncogene) 
 -2.455  213679_at  TTC30A  tetratricopeptide repeat domain 30A 
 -2.455  220507_s_at  UPB1  ureidopropionase, beta 
 -2.455  206958_s_at  UPF3A  UPF3 regulator of nonsense transcripts homolog A (yeast) 
 -2.455  212606_at  WDFY3  WD repeat and FYVE domain containing 3 
 -2.455  209053_s_at  WHSC1  Wolf-Hirschhorn syndrome candidate 1 
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 -2.455  209375_at  XPC  xeroderma pigmentosum, complementation group C 
 -2.455  201369_s_at  ZFP36L2  zinc finger protein 36, C3H type-like 2 
 -2.455  213073_at  ZFYVE26  zinc finger, FYVE domain containing 26 
 -2.455  205739_x_at  ZNF107  zinc finger protein 107 
 -2.455  205514_at  ZNF415  zinc finger protein 415 
 -2.455  221625_at  ZNF506  zinc finger protein 506 
 -2.455  220617_s_at  ZNF532  zinc finger protein 532 
 -2.455  220661_s_at  ZNF692  zinc finger protein 692 
 -2.455  57516_at  ZNF764  zinc finger protein 764 
 -2.455  219676_at  ZSCAN16  zinc finger and SCAN domain containing 16 
 -2.630  205512_s_at  AIFM1  apoptosis-inducing factor, mitochondrion-associated, 1 
 -2.630  208950_s_at  ALDH7A1  aldehyde dehydrogenase 7 family, member A1 
 -2.630  214221_at  ALMS1  Alstrom syndrome 1 
 -2.630  212985_at  APBB2  amyloid beta (A4) precursor protein-binding, family B, member 2 
 -2.630  201288_at  ARHGDIB  Rho GDP dissociation inhibitor (GDI) beta 
 -2.630  203264_s_at  ARHGEF9  Cdc42 guanine nucleotide exchange factor (GEF) 9 
 -2.630  210649_s_at  ARID1A  AT rich interactive domain 1A (SWI-like) 
 -2.630  219218_at  BAHCC1  BAH domain and coiled-coil containing 1 
 -2.630  212745_s_at  BBS4  Bardet-Biedl syndrome 4 
 -2.630  218285_s_at  BDH2  3-hydroxybutyrate dehydrogenase, type 2 
 -2.630  217207_s_at  BTNL3  butyrophilin-like 3 
 -2.630  203257_s_at  C11ORF49  chromosome 11 open reading frame 49 
 -2.630  203173_s_at  C16ORF62  chromosome 16 open reading frame 62 
 -2.630  209007_s_at  C1ORF63  chromosome 1 open reading frame 63 
 -2.630  65472_at  C2ORF68  chromosome 2 open reading frame 68 
 -2.630  209030_s_at  CADM1  cell adhesion molecule 1 
 -2.630  201617_x_at  CALD1  caldesmon 1 
 -2.630  201616_s_at  CALD1  caldesmon 1 
 -2.630  212077_at  CALD1  caldesmon 1 
 -2.630  216598_s_at  CCL2  chemokine (C-C motif) ligand 2 
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 -2.630  212897_at  CDC2L6  cell division cycle 2-like 6 (CDK8-like) 
 -2.630  210622_x_at  CDK10  cyclin-dependent kinase 10 
 -2.630  218740_s_at  CDK5RAP3   CDK5 regulatory subunit associated protein 3 
 -2.630  213492_at  COL2A1  collagen, type II, alpha 1 
 -2.630  210070_s_at  CPT1B  carnitine palmitoyltransferase 1B (muscle) 
 -2.630  210757_x_at  DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
 -2.630  205472_s_at  DACH1  dachshund homolog 1 (Drosophila) 
 -2.630  210397_at  DEFB1  defensin, beta 1 
 -2.630  215058_at  DENND5B  DENN/MADD domain containing 5B 
 -2.630  220295_x_at  DEPDC1  DEP domain containing 1 
 -2.630  205223_at  DEPDC5  DEP domain containing 5 
 -2.630  206752_s_at  DFFB  DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase) 
 -2.630  205744_at  DOC2A  double C2-like domains, alpha 
 -2.630  203358_s_at  EZH2  enhancer of zeste homolog 2 (Drosophila) 
 -2.630  210445_at  FABP6  fatty acid binding protein 6, ileal 
 -2.630  203482_at  FAM178A  family with sequence similarity 178, member A 
 -2.630  216044_x_at  FAM69A  family with sequence similarity 69, member A 
 -2.630  203806_s_at  FANCA  Fanconi anemia, complementation group A 
 -2.630  58780_s_at  FLJ10357  hypothetical protein FLJ10357 
 -2.630  219316_s_at  FLVCR2  feline leukaemia virus subgroup C cellular receptor family, member 2 
 -2.630  202580_x_at  FOXM1  forkhead box M1 
 -2.630  41858_at  FRAG1  FGF receptor activating protein 1 
 -2.630  1598_g_at  GAS6  growth arrest-specific 6 
 -2.630  205498_at  GHR  growth hormone receptor 
 -2.630  203384_s_at  GOLGA1  Golgi autoantigen, golgin subfamily a, 1 
 -2.630  201057_s_at  GOLGB1  golgin B1, Golgi integral membrane protein 
 -2.630  215554_at  GPLD1  glycosylphosphatidylinositol specific phospholipase D1 
 -2.630  206204_at  GRB14  growth factor receptor-bound protein 14 
 -2.630  219233_s_at  GSDMB  gasdermin B 
 -2.630  215659_at  GSDMB  gasdermin B 
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 -2.630  201035_s_at  HADH  hydroxyacyl-Coenzyme A dehydrogenase 
 -2.630  206846_s_at  HDAC6  histone deacetylase 6 
 -2.630  203744_at  HMGB3  high-mobility group box 3 
 -2.630  214434_at  HSPA12A  heat shock 70kDa protein 12A 
 -2.630  219284_at  HSPBAP1  HSPB (heat shock 27kDa) associated protein 1 
 -2.630  201163_s_at  IGFBP7  insulin-like growth factor binding protein 7 
 -2.630  201162_at  IGFBP7  insulin-like growth factor binding protein 7 
 -2.630  221974_at  IPW  imprinted in Prader-Willi syndrome (non-protein coding) 
 -2.630  213392_at  IQCK  IQ motif containing K 
 -2.630  216958_s_at  IVD  isovaleryl Coenzyme A dehydrogenase 
 -2.630  212523_s_at  KIAA0146  KIAA0146 
 -2.630  204156_at  KIAA0999  KIAA0999 protein 
 -2.630  218355_at  KIF4A  kinesin family member 4A 
 -2.630  211651_s_at  LAMB1  laminin, beta 1 
 -2.630  214035_x_at  LOC399491  LOC399491 protein 
 -2.630  211596_s_at  LRIG1  leucine-rich repeats and immunoglobulin-like domains 1 
 -2.630  203668_at  MAN2C1  mannosidase, alpha, class 2C, member 1 
 -2.630  218366_x_at  METT11D1  methyltransferase 11 domain containing 1 
 -2.630  205442_at  MFAP3L  microfibrillar-associated protein 3-like 
 -2.630  211038_s_at  MGC12760  ciliary rootlet coiled-coil, rootletin-like 1 
 -2.630  221771_s_at  MPHOSPH8  M-phase phosphoprotein 8 
 -2.630  214071_at  MPPE1  metallophosphoesterase 1 
 -2.630  203678_at  MTMR15  myotubularin related protein 15 
 -2.630  212277_at  MTMR4  myotubularin related protein 4 
 -2.630  212096_s_at  MTUS1  mitochondrial tumor suppressor 1 
 -2.630  210778_s_at  MXD4  MAX dimerisation protein 4 
 -2.630  214765_s_at  NAAA  N-acylethanolamine acid amidase 
 -2.630  201970_s_at  NASP  nuclear autoantigenic sperm protein (histone-binding) 
 -2.630  214693_x_at  NBPF8  neuroblastoma breakpoint family, member 8 
 -2.630  201774_s_at  NCAPD2  non-SMC condensin I complex, subunit D2 
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 -2.630  212789_at  NCAPD3  non-SMC condensin II complex, subunit D3 
 -2.630  212949_at  NCAPH  non-SMC condensin I complex, subunit H 
 -2.630  210249_s_at  NCOA1  nuclear receptor coactivator 1 
 -2.630  210174_at  NR5A2  nuclear receptor subfamily 5, group A, member 2 
 -2.630  207877_s_at  NVL  nuclear VCP-like 
 -2.630  201599_at  OAT  ornithine aminotransferase (gyrate atrophy) 
 -2.630  212307_s_at  OGT  O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
 -2.630  207564_x_at  OGT  O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
 -2.630  205040_at  ORM1  orosomucoid 1 
 -2.630  207838_x_at  PBXIP1  pre-B-cell leukaemia homeobox interacting protein 1 
 -2.630  213517_at  PCBP2  poly(rC) binding protein 2 
 -2.630  202174_s_at  PCM1  pericentriolar material 1 
 -2.630  221142_s_at  PECR  peroxisomal trans-2-enoyl-CoA reductase 
 -2.630  201701_s_at  PGRMC2  progesterone receptor membrane component 2 
 -2.630  222150_s_at  PION  pigeon homolog (Drosophila) 
 -2.630  177_at  PLD1  phospholipase D1, phosphatidylcholine-specific 
 -2.630  212841_s_at  PPFIBP2  PTPRF interacting protein, binding protein 2 (liprin beta 2) 
 -2.630  204788_s_at  PPOX  protoporphyrinogen oxidase 
 -2.630  216347_s_at  PPP1R13B  protein phosphatase 1, regulatory (inhibitor) subunit 13B 
 -2.630  211090_s_at  PRPF4B  PRP4 pre-mRNA processing factor 4 homolog B (yeast) 
 -2.630  208165_s_at  PRSS16  protease, serine, 16 (thymus) 
 -2.630  205961_s_at  PSIP1  PC4 and SFRS1 interacting protein 1 
 -2.630  205048_s_at  PSPH  phosphoserine phosphatase 
 -2.630  220500_s_at  RABL2A  RAB, member of RAS oncogene family-like 2A 
 -2.630  209349_at  RAD50  RAD50 homolog (S. cerevisiae) 
 -2.630  219494_at  RAD54B  RAD54 homolog B (S. cerevisiae) 
 -2.630  210106_at  RDH5  retinol dehydrogenase 5 (11-cis/9-cis) 
 -2.630  215201_at  REPS1  RALBP1 associated Eps domain containing 1 
 -2.630  218370_s_at  S100PBP  S100P binding protein 
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 -2.630  209741_x_at  SCAPER  S phase cyclin A-associated protein in the ER 
 -2.630  216399_s_at  SCAPER  S phase cyclin A-associated protein in the ER 
 -2.630  212158_at  SDC2  syndecan 2 
 -2.630  218649_x_at  SDCCAG1  serologically defined colon cancer antigen 1 
 -2.630  219751_at  SETD6  SET domain containing 6 
 -2.630  36129_at  SGSM2  small G protein signaling modulator 2 
 -2.630  213308_at  SHANK2  SH3 and multiple ankyrin repeat domains 2 
 -2.630  206664_at  SI  sucrase-isomaltase (alpha-glucosidase) 
 -2.630  202254_at  SIPA1L1  signal-induced proliferation-associated 1 like 1 
 -2.630  204404_at  SLC12A2  solute carrier family 12 (sodium/potassium/chloride transporters), member 2 
 -2.630  211855_s_at  SLC25A14  solute carrier family 25 (mitochondrial carrier, brain), member 14 
 -2.630  218978_s_at  SLC25A37  solute carrier family 25, member 37 
 -2.630  222217_s_at  SLC27A3  solute carrier family 27 (fatty acid transporter), member 3 
 -2.630  217122_s_at  SLC35E2  solute carrier family 35, member E2 
 -2.630  202830_s_at  SLC37A4  solute carrier family 37 (glucose-6-phosphate transporter), member 4 
 -2.630  204240_s_at  SMC2  structural maintenance of chromosomes 2 
 -2.630  219109_at  SPAG16  sperm associated antigen 16 
 -2.630  203145_at  SPAG5  sperm associated antigen 5 
 -2.630  202440_s_at  ST5  suppression of tumorigenicity 5 
 -2.630  221264_s_at  TARDBP  TAR DNA binding protein 
 -2.630  222116_s_at  TBC1D16  TBC1 domain family, member 16 
 -2.630  211052_s_at  TBCD  tubulin folding cofactor D 
 -2.630  221016_s_at  TCF7L1  transcription factor 7-like 1 (T-cell specific, HMG-box) 
 -2.630  201042_at  TGM2  transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 
 -2.630  54632_at  THADA  thyroid adenoma associated 
 -2.630  201450_s_at  TIA1  TIA1 cytotoxic granule-associated RNA binding protein 
 -2.630  210166_at  TLR5  toll-like receptor 5 
 -2.630  219410_at  TMEM45A  transmembrane protein 45A 
 -2.630  210886_x_at  TP53TG1  TP53 target 1 (non-protein coding) 
 -2.630  201730_s_at  TPR  translocated promoter region (to activated MET oncogene) 
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 -2.630  209660_at  TTR  transthyretin 
 -2.630  218289_s_at  UBA5  ubiquitin-like modifier activating enzyme 5 
 -2.630  206959_s_at  UPF3A  UPF3 regulator of nonsense transcripts homolog A (yeast) 
 -2.630  212980_at  USP34   ubiquitin specific peptidase 34 
 -2.630  204255_s_at  VDR  vitamin D (1,25- dihydroxyvitamin D3) receptor 
 -2.630  204254_s_at  VDR  vitamin D (1,25- dihydroxyvitamin D3) receptor 
 -2.630  218396_at  VPS13C  vacuolar protein sorting 13 homolog C (S. cerevisiae) 
 -2.630  221103_s_at  WDR52  WD repeat domain 52 
 -2.630  209054_s_at  WHSC1  Wolf-Hirschhorn syndrome candidate 1 
 -2.630  201294_s_at  WSB1  WD repeat and SOCS box-containing 1 
 -2.630  203959_s_at  ZBTB40  zinc finger and BTB domain containing 40 
 -2.630  222186_at  ZFAND6  zinc finger, AN1-type domain 6 
 -2.630  201367_s_at  ZFP36L2  zinc finger protein 36, C3H type-like 2 
 -2.630  207605_x_at  ZNF117  zinc finger protein 117 
 -2.630  221645_s_at  ZNF83  zinc finger protein 83 
 -2.818  220841_s_at  AHI1  Abelson helper integration site 1 
 -2.818  205640_at  ALDH3B1  aldehyde dehydrogenase 3 family, member B1 
 -2.818  208951_at  ALDH7A1  aldehyde dehydrogenase 7 family, member A1 
 -2.818  216563_at  ANKRD12  ankyrin repeat domain 12 
 -2.818  220940_at  ANKRD36B  ankyrin repeat domain 36B 
 -2.818  219842_at  ARL15  ADP-ribosylation factor-like 15 
 -2.818  219164_s_at  ATG2B  ATG2 autophagy related 2 homolog B (S. cerevisiae) 
 -2.818  210858_x_at  ATM  ataxia telangiectasia mutated 
 -2.818  214132_at  ATP5C1  ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 
 -2.818  214742_at  AZI1  5-azacytidine induced 1 
 -2.818  211715_s_at  BDH1  3-hydroxybutyrate dehydrogenase, type 1 
 -2.818  204531_s_at  BRCA1  breast cancer 1, early onset 
 -2.818  221208_s_at  C11ORF61  chromosome 11 open reading frame 61 
 -2.818  53720_at  C19ORF66  chromosome 19 open reading frame 66 
 -2.818  220149_at  C2ORF54  chromosome 2 open reading frame 54 
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 -2.818  209285_s_at  C3ORF63  chromosome 3 open reading frame 63 
 -2.818  220234_at  CA8  carbonic anhydrase VIII 
 -2.818  218456_at  CAPRIN2  caprin family member 2 
 -2.818  211922_s_at  CAT  catalase 
 -2.818  203469_s_at  CDK10  cyclin-dependent kinase 10 
 -2.818  209172_s_at  CENPF  centromere protein F, 350/400ka (mitosin) 
 -2.818  219242_at  CEP63  centrosomal protein 63kDa 
 -2.818  219301_s_at  CNTNAP2  contactin associated protein-like 2 
 -2.818  221971_x_at  CTGLF1  centaurin, gamma-like family, member 1 
 -2.818  216058_s_at  CYP2C19  cytochrome P450, family 2, subfamily C, polypeptide 19 
 -2.818  220562_at  CYP2W1  cytochrome P450, family 2, subfamily W, polypeptide 1 
 -2.818  203409_at  DDB2  damage-specific DNA binding protein 2, 48kDa 
 -2.818  206457_s_at  DIO1  deiodinase, iodothyronine, type I 
 -2.818  220572_at  DKFZP547G183  hypothetical LOC55525 
 -2.818  203764_at  DLGAP5  discs, large (Drosophila) homolog-associated protein 5 
 -2.818  203763_at  DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1 
 -2.818  219990_at  E2F8  E2F transcription factor 8 
 -2.818  209696_at  FBP1  fructose-1,6-bisphosphatase 1 
 -2.818  218920_at  FLJ10404  hypothetical protein FLJ10404 
 -2.818  214093_s_at  FUBP1  far upstream element (FUSE) binding protein 1 
 -2.818  203179_at  GALT  galactose-1-phosphate uridylyltransferase 
 -2.818  213552_at  GLCE  glucuronic acid epimerase 
 -2.818  205531_s_at  GLS2  glutaminase 2 (liver, mitochondrial) 
 -2.818  218147_s_at  GLT8D1  glycosyltransferase 8 domain containing 1 
 -2.818  201567_s_at  GOLGA4  Golgi autoantigen, golgin subfamily a, 4 
 -2.818  213706_at  GPD1  glycerol-3-phosphate dehydrogenase 1 (soluble) 
 -2.818  212070_at  GPR56  G protein-coupled receptor 56 
 -2.818  204793_at  GPRASP1  G protein-coupled receptor associated sorting protein 1 
 -2.818  209377_s_at  HMGN3  high mobility group nucleosomal binding domain 3 
 -2.818  218780_at  HOOK2  hook homolog 2 (Drosophila) 
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 -2.818  204792_s_at  IFT140  intraflagellar transport 140 homolog (Chlamydomonas) 
 -2.818  204703_at  IFT88  intraflagellar transport 88 homolog (Chlamydomonas) 
 -2.818  213804_at  INPP5B  inositol polyphosphate-5-phosphatase, 75kDa 
 -2.818  203906_at  IQSEC1  IQ motif and Sec7 domain 1 
 -2.818  221125_s_at  KCNMB3  potassium large conductance calcium-activated channel, subfamily M beta member 3 
 -2.818  219479_at  KDELC1  KDEL (Lys-Asp-Glu-Leu) containing 1 
 -2.818  216969_s_at  KIF22  kinesin family member 22 
 -2.818  208450_at  LGALS2  lectin, galactoside-binding, soluble, 2 
 -2.818  202726_at  LIG1  ligase I, DNA, ATP-dependent 
 -2.818  221501_x_at  LOC339047  hypothetical protein LOC339047 
 -2.818  215920_s_at  LOC440350  similar to nuclear pore complex interacting protein 
 -2.818  37796_at  LRCH4  leucine-rich repeats and calponin homology (CH) domain containing 4 
 -2.818  219999_at  MAN2A2  mannosidase, alpha, class 2A, member 2 
 -2.818  204041_at  MAOB  monoamine oxidase B 
 -2.818  35147_at  MCF2L  MCF.2 cell line derived transforming sequence-like 
 -2.818  221636_s_at  MOSC2  MOCO sulphurase C-terminal domain containing 2 
 -2.818  222369_at  NAT11  N-acetyltransferase 11 (GCN5-related, putative) 
 -2.818  207631_at  NBR2  neighbor of BRCA1 gene 2 
 -2.818  218662_s_at  NCAPG  non-SMC condensin I complex, subunit G 
 -2.818  209106_at  NCOA1  nuclear receptor coactivator 1 
 -2.818  209289_at  NFIB  nuclear factor I/B 
 -2.818  201591_s_at  NISCH  nischarin 
 -2.818  219553_at  NME7  non-metastatic cells 7, protein expressed in (nucleoside-diphosphate kinase) 
 -2.818  213471_at  NPHP4  nephronophthisis 4 
 -2.818  204538_x_at  NPIP  nuclear pore complex interacting protein 
 -2.818  216321_s_at  NR3C1  nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 
 -2.818  212776_s_at  OBSL1  obscurin-like 1 
 -2.818  220133_at  ODAM  odontogenic, ameloblast asssociated 
 -2.818  205564_at  PAGE4  P antigen family, member 4 (prostate associated) 
 -2.818  203117_s_at  PAN2   PAN2 polyA specific ribonuclease subunit homolog (S. cerevisiae) 
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 -2.818  209439_s_at  PHKA2  phosphorylase kinase, alpha 2 (liver) 
 -2.818  207081_s_at  PI4KA  phosphatidylinositol 4-kinase, catalytic, alpha 
 -2.818  201929_s_at  PKP4  plakophilin 4 
 -2.818  221088_s_at  PPP1R9A  protein phosphatase 1, regulatory (inhibitor) subunit 9A 
 -2.818  205037_at  RABL4  RAB, member of RAS oncogene family-like 4 
 -2.818  205178_s_at  RBBP6   retinoblastoma binding protein 6 
 -2.818  219754_at  RBM41  RNA binding motif protein 41 
 -2.818  209497_s_at  RBM4B  RNA binding motif protein 4B 
 -2.818  204364_s_at  REEP1  receptor accessory protein 1 
 -2.818  219610_at  RGNEF  Rho-guanine nucleotide exchange factor 
 -2.818  213555_at  RWDD2A  RWD domain containing 2A 
 -2.818  206325_at  SERPINA6  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 
 -2.818  212000_at  SFRS14  splicing factor, arginine/serine-rich 14 
 -2.818  217289_s_at  SLC37A4  solute carrier family 37 (glucose-6-phosphate transporter), member 4 
 -2.818  214850_at  SMA4  glucuronidase, beta pseudogene 
 -2.818  207069_s_at  SMAD6  SMAD family member 6 
 -2.818  201664_at  SMC4  structural maintenance of chromosomes 4 
 -2.818  218087_s_at  SORBS1  sorbin and SH3 domain containing 1 
 -2.818  213994_s_at  SPON1  spondin 1, extracellular matrix protein 
 -2.818  213993_at  SPON1  spondin 1, extracellular matrix protein 
 -2.818  209436_at  SPON1  spondin 1, extracellular matrix protein 
 -2.818  203769_s_at  STS  steroid sulfatase (microsomal), isozyme S 
 -2.818  213971_s_at  SUZ12  suppressor of zeste 12 homolog (Drosophila) 
 -2.818  213913_s_at  TBC1D30  TBC1 domain family, member 30 
 -2.818  201447_at  TIA1  TIA1 cytotoxic granule-associated RNA binding protein 
 -2.818  221951_at  TMEM80  transmembrane protein 80 
 -2.818  209354_at  TNFRSF14  tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) 
 -2.818  201292_at  TOP2A  topoisomerase (DNA) II alpha 170kDa 
 -2.818  210241_s_at  TP53TG1  TP53 target 1 (non-protein coding) 
 -2.818  213266_at  TUBGCP4  tubulin, gamma complex associated protein 4 
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 -2.818  207559_s_at  ZMYM3   zinc finger, MYM-type 3 
 -2.818  213269_at  ZNF248  zinc finger protein 248 
 -2.818  221213_s_at  ZNF280D  zinc finger protein 280D 
 -2.818  214813_at  ZNF75D  zinc finger protein 75D 
 -3.020  205969_at  AADAC  arylacetamide deacetylase (esterase) 
 -3.020  205209_at  ACVR1B  activin A receptor, type IB 
 -3.020  203609_s_at  ALDH5A1  aldehyde dehydrogenase 5 family, member A1 
 -3.020  221588_x_at  ALDH6A1  aldehyde dehydrogenase 6 family, member A1 
 -3.020  211712_s_at  ANXA9  annexin A9 
 -3.020  218067_s_at  ARGLU1  arginine and glutamate rich 1 
 -3.020  221656_s_at  ARHGEF10L  Rho guanine nucleotide exchange factor (GEF) 10-like 
 -3.020  205673_s_at  ASB9  ankyrin repeat and SOCS box-containing 9 
 -3.020  218857_s_at  ASRGL1  asparaginase like 1 
 -3.020  203188_at  B3GNT1  UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 
 -3.020  203755_at  BUB1B  budding uninhibited by benzimidazoles 1 homolog beta (yeast) 
 -3.020  221878_at  C2ORF68  chromosome 2 open reading frame 68 
 -3.020  214475_x_at  CAPN3  calpain 3, (p94) 
 -3.020  212886_at  CCDC69  coiled-coil domain containing 69 
 -3.020  207173_x_at  CDH11  cadherin 11, type 2, OB-cadherin (osteoblast) 
 -3.020  218827_s_at  CEP192  centrosomal protein 192kDa 
 -3.020  202310_s_at  COL1A1  collagen, type I, alpha 1 
 -3.020  204136_at  COL7A1  collagen, type VII, alpha 1 
 -3.020  208835_s_at  CROP  cisplatin resistance-associated overexpressed protein 
 -3.020  203804_s_at  CROP  cisplatin resistance-associated overexpressed protein 
 -3.020  204055_s_at  CTAGE5  CTAGE family, member 5 
 -3.020  219355_at  CXORF57  chromosome X open reading frame 57 
 -3.020  213378_s_at  DDX11  DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) 
 -3.020  208159_x_at  DDX11  DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) 
 -3.020  213279_at  DHRS1  dehydrogenase/reductase (SDR family) member 1 
 -3.020  213271_s_at  DOPEY1  dopey family member 1 
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 -3.020  201025_at  EIF5B  eukaryotic translation initiation factor 5B 
 -3.020  204143_s_at  ENOSF1  enolase superfamily member 1 
 -3.020  221884_at  EVI1  ecotropic viral integration site 1 
 -3.020  204379_s_at  FGFR3  fibroblast growth factor receptor 3 
 -3.020  222018_at  FKSG17  nascent-polypeptide-associated complex alpha polypeptide pseudogene 1 
 -3.020  203178_at  GATM  glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
 -3.020  204836_at  GLDC  glycine dehydrogenase (decarboxylating) 
 -3.020  204324_s_at  GOLIM4  Golgi integral membrane protein 4 
 -3.020  210912_x_at  GSTM4  glutathione S-transferase mu 4 
 -3.020  201036_s_at  HADH  hydroxyacyl-Coenzyme A dehydrogenase 
 -3.020  207156_at  HIST1H2AK  histone cluster 1, H2ak 
 -3.020  213931_at  ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
 -3.020  205304_s_at  KCNJ8  potassium inwardly-rectifying channel, subfamily J, member 8 
 -3.020  218755_at  KIF20A  kinesin family member 20A 
 -3.020  205235_s_at  KIF20B  kinesin family member 20B 
 -3.020  205668_at  LY75  lymphocyte antigen 75 
 -3.020  211042_x_at  MCAM  melanoma cell adhesion molecule 
 -3.020  206522_at  MGAM  maltase-glucoamylase (alpha-glucosidase) 
 -3.020  213181_s_at  MOCS1  molybdenum cofactor synthesis 1 
 -3.020  221965_at  MPHOSPH9  M-phase phosphoprotein 9 
 -3.020  212095_s_at  MTUS1  mitochondrial tumor suppressor 1 
 -3.020  213067_at  MYH10  myosin, heavy chain 10, non-muscle 
 -3.020  210336_x_at  MZF1  myeloid zinc finger 1 
 -3.020  40569_at  MZF1  myeloid zinc finger 1 
 -3.020  215434_x_at  NBPF8  neuroblastoma breakpoint family, member 8 
 -3.020  203245_s_at  NCRNA00094  non-protein coding RNA 94 
 -3.020  215338_s_at  NKTR  natural killer-tumor recognition sequence 
 -3.020  202379_s_at  NKTR  natural killer-tumor recognition sequence 
 -3.020  208343_s_at  NR5A2  nuclear receptor subfamily 5, group A, member 2 
 -3.020  214130_s_at  PDE4DIP  phosphodiesterase 4D interacting protein 
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 -3.020  214129_at  PDE4DIP  phosphodiesterase 4D interacting protein 
 -3.020  212094_at  PEG10  paternally expressed 10 
 -3.020  219225_at  PGBD5  piggyBac transposable element derived 5 
 -3.020  213408_s_at  PI4KA  phosphatidylinositol 4-kinase, catalytic, alpha 
 -3.020  201927_s_at  PKP4  plakophilin 4 
 -3.020  205203_at  PLD1  phospholipase D1, phosphatidylcholine-specific 
 -3.020  206940_s_at  POU4F1  POU class 4 homeobox 1 
 -3.020  208993_s_at  PPIG  peptidylprolyl isomerase G (cyclophilin G) 
 -3.020  201213_at  PPP1R7  protein phosphatase 1, regulatory (inhibitor) subunit 7 
 -3.020  202127_at  PRPF4B  PRP4 pre-mRNA processing factor 4 homolog B (yeast) 
 -3.020  213521_at  PTPN18  protein tyrosine phosphatase, non-receptor type 18 (brain-derived) 
 -3.020  204547_at  RAB40B  RAB40B, member RAS oncogene family 
 -3.020  219222_at  RBKS  ribokinase 
 -3.020  57540_at  RBKS  ribokinase 
 -3.020  202449_s_at  RXRA  retinoid X receptor, alpha 
 -3.020  214402_s_at  SFI1  Sfi1 homolog, spindle assembly associated (yeast) 
 -3.020  36545_s_at  SFI1  Sfi1 homolog, spindle assembly associated (yeast) 
 -3.020  214016_s_at  SFPQ  splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated) 
 -3.020  64371_at  SFRS14  splicing factor, arginine/serine-rich 14 
 -3.020  221010_s_at  SIRT5  sirtuin (silent mating type information regulation 2 homolog) 5 (S. cerevisiae) 
 -3.020  210567_s_at  SKP2  S-phase kinase-associated protein 2 (p45) 
 -3.020  221572_s_at  SLC26A6  solute carrier family 26, member 6 
 -3.020  220435_at  SLC30A10  solute carrier family 30, member 10 
 -3.020  213721_at  SOX2  SRY (sex determining region Y)-box 2 
 -3.020  213103_at  STARD13  StAR-related lipid transfer (START) domain containing 13 
 -3.020  222146_s_at  TCF4  transcription factor 4 
 -3.020  218491_s_at  THYN1  thymocyte nuclear protein 1 
 -3.020  201446_s_at  TIA1  TIA1 cytotoxic granule-associated RNA binding protein 
 -3.020  214833_at  TMEM63A  transmembrane protein 63A 
 -3.020  209917_s_at  TP53TG1  TP53 target 1 (non-protein coding) 
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 -3.020  203568_s_at  TRIM38  tripartite motif-containing 38 
 -3.020  221897_at  TRIM52  tripartite motif-containing 52 
 -3.020  202242_at  TSPAN7  tetraspanin 7 
 -3.020  217684_at  TYMS  thymidylate synthetase 
 -3.020  207245_at  UGT2B17  UDP glucuronosyltransferase 2 family, polypeptide B17 
 -3.020  218806_s_at  VAV3  vav 3 guanine nucleotide exchange factor 
 -3.020  212326_at  VPS13D  vacuolar protein sorting 13 homolog D (S. cerevisiae) 
 -3.020  214567_s_at  XCL2  chemokine (C motif) ligand 2 
 -3.020  205672_at  XPA  xeroderma pigmentosum, complementation group A 
 -3.020  203521_s_at  ZNF318   zinc finger protein 318 
 -3.236  209459_s_at  ABAT  4-aminobutyrate aminotransferase 
 -3.236  213353_at  ABCA5  ATP-binding cassette, sub-family A (ABC1), member 5 
 -3.236  218844_at  ACSF2  acyl-CoA synthetase family member 2 
 -3.236  214261_s_at  ADH6  alcohol dehydrogenase 6 (class V) 
 -3.236  221569_at  AHI1  Abelson helper integration site 1 
 -3.236  204551_s_at  AHSG  alpha-2-HS-glycoprotein 
 -3.236  221589_s_at  ALDH6A1  aldehyde dehydrogenase 6 family, member A1 
 -3.236  214220_s_at  ALMS1  Alstrom syndrome 1 
 -3.236  208323_s_at  ANXA13  annexin A13 
 -3.236  210085_s_at  ANXA9  annexin A9 
 -3.236  205216_s_at  APOH  apolipoprotein H (beta-2-glycoprotein I) 
 -3.236  203747_at  AQP3  aquaporin 3 (Gill blood group) 
 -3.236  221135_s_at  ASTE1  asteroid homolog 1 (Drosophila) 
 -3.236  208859_s_at  ATRX  alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) 
 -3.236  37547_at  BBS9  Bardet-Biedl syndrome 9 
 -3.236  214727_at  BRCA2  breast cancer 2, early onset 
 -3.236  207259_at  C17ORF73  chromosome 17 open reading frame 73 
 -3.236  219381_at  C5ORF42  chromosome 5 open reading frame 42 
 -3.236  221427_s_at  CCNL2  cyclin L2 
 -3.236  202870_s_at  CDC20  cell division cycle 20 homolog (S. cerevisiae) 
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 -3.236  205250_s_at  CEP290  centrosomal protein 290kDa 
 -3.236  219036_at  CEP70  centrosomal protein 70kDa 
 -3.236  203854_at  CFI  complement factor I 
 -3.236  215318_at  CG012  hypothetical gene CG012 
 -3.236  203641_s_at  COBLL1  COBL-like 1 
 -3.236  220072_at  CSPP1  centrosome and spindle pole associated protein 1 
 -3.236  211126_s_at  CSRP2  cysteine and glycine-rich protein 2 
 -3.236  206775_at  CUBN  cubilin (intrinsic factor-cobalamin receptor) 
 -3.236  212820_at  DMXL2  Dmx-like 2 
 -3.236  213186_at  DZIP3  DAZ interacting protein 3, zinc finger 
 -3.236  219833_s_at  EFHC1  EF-hand domain (C-terminal) containing 1 
 -3.236  201936_s_at  EIF4G3  eukaryotic translation initiation factor 4 gamma, 3 
 -3.236  214313_s_at  EIF5B  eukaryotic translation initiation factor 5B 
 -3.236  201024_x_at  EIF5B  eukaryotic translation initiation factor 5B 
 -3.236  214314_s_at  EIF5B  eukaryotic translation initiation factor 5B 
 -3.236  216836_s_at  ERBB2  v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian) 
 -3.236  207300_s_at  F7  coagulation factor VII (serum prothrombin conversion accelerator) 
 -3.236  218248_at  FAM111A  family with sequence similarity 111, member A 
 -3.236  212991_at  FBXO9  F-box protein 9 
 -3.236  204988_at  FGB  fibrinogen beta chain 
 -3.236  205022_s_at  FOXN3  forkhead box N3 
 -3.236  216733_s_at  GATM  glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
 -3.236  205505_at  GCNT1  glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) 
 -3.236  201056_at  GOLGB1  golgin B1, Golgi integral membrane protein 
 -3.236  204149_s_at  GSTM4  glutathione S-transferase mu 4 
 -3.236  210964_s_at  GYG2  glycogenin 2 
 -3.236  213069_at  HEG1  HEG homolog 1 (zebrafish) 
 -3.236  201565_s_at  ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
 -3.236  209341_s_at  IKBKB  inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
 -3.236  48825_at  ING4  inhibitor of growth family, member 4 
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 -3.236  219095_at  JMJD7-PLA2G4B  JMJD7-PLA2G4B readthrough transcript 
 -3.236  211028_s_at  KHK  ketohexokinase (fructokinase) 
 -3.236  203276_at  LMNB1  lamin B1 
 -3.236  215283_at  LOC400642  hypothetical LOC400642 
 -3.236  200785_s_at  LRP1  low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
 -3.236  205698_s_at  MAP2K6  mitogen-activated protein kinase kinase 6 
 -3.236  214778_at  MEGF8  multiple EGF-like-domains 8 
 -3.236  217610_at  MGC13098  polymerase (RNA) II (DNA directed) polypeptide J4, pseudogene 
 -3.236  212023_s_at  MKI67  antigen identified by monoclonal antibody Ki-67 
 -3.236  212021_s_at  MKI67  antigen identified by monoclonal antibody Ki-67 
 -3.236  221163_s_at  MLXIPL  MLX interacting protein-like 
 -3.236  204861_s_at  NAIP  NLR family, apoptosis inhibitory protein 
 -3.236  201969_at  NASP  nuclear autoantigenic sperm protein (histone-binding) 
 -3.236  213328_at  NEK1  NIMA (never in mitosis gene a)-related kinase 1 
 -3.236  213029_at  NFIB  nuclear factor I/B 
 -3.236  202380_s_at  NKTR  natural killer-tumor recognition sequence 
 -3.236  208337_s_at  NR5A2  nuclear receptor subfamily 5, group A, member 2 
 -3.236  219277_s_at  OGDHL  oxoglutarate dehydrogenase-like 
 -3.236  219236_at  PAQR6  progestin and adipoQ receptor family member VI 
 -3.236  213227_at  PGRMC2  progesterone receptor membrane component 2 
 -3.236  209740_s_at  PNPLA4  patatin-like phospholipase domain containing 4 
 -3.236  210499_s_at  PQBP1  polyglutamine binding protein 1 
 -3.236  216048_s_at  RHOBTB3  Rho-related BTB domain containing 3 
 -3.236  212001_at  SFRS14  splicing factor, arginine/serine-rich 14 
 -3.236  222248_s_at  SIRT4  sirtuin (silent mating type information regulation 2 homolog) 4 (S. cerevisiae) 
 -3.236  213119_at  SLC36A1  solute carrier family 36 (proton/amino acid symporter), member 1 
 -3.236  201663_s_at  SMC4  structural maintenance of chromosomes 4 
 -3.236  213221_s_at  SNF1LK2  salt-inducible kinase 2 
 -3.236  204067_at  SUOX  sulfite oxidase 
 -3.236  206546_at  SYCP2  synaptonemal complex protein 2 
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 -3.236  213891_s_at  TCF4  transcription factor 4 
 -3.236  220212_s_at  THADA  thyroid adenoma associated 
 -3.236  203046_s_at  TIMELESS  timeless homolog (Drosophila) 
 -3.236  201291_s_at  TOP2A  topoisomerase (DNA) II alpha 170kDa 
 -3.236  214755_at  UAP1L1  UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 
 -3.236  213243_at  VPS13B  vacuolar protein sorting 13 homolog B (yeast) 
 -3.236  201295_s_at  WSB1  WD repeat and SOCS box-containing 1 
 -3.236  214776_x_at  XYLB  xylulokinase homolog (H. influenzae) 
 -3.236  212704_at  ZCCHC11  zinc finger, CCHC domain containing 11 
 -3.236  212655_at  ZCCHC14  zinc finger, CCHC domain containing 14 
 -3.236  212601_at  ZZEF1  zinc finger, ZZ-type with EF-hand domain 1 
 -3.467  210377_at  ACSM3  acyl-CoA synthetase medium-chain family member 3 
 -3.467  209425_at  AMACR  alpha-methylacyl-CoA racemase 
 -3.467  209521_s_at  AMOT  angiomotin 
 -3.467  202921_s_at  ANK2  ankyrin 2, neuronal 
 -3.467  212517_at  ATRN  attractin 
 -3.467  206913_at  BAAT  bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase) 
 -3.467  218471_s_at  BBS1  Bardet-Biedl syndrome 1 
 -3.467  212744_at  BBS4  Bardet-Biedl syndrome 4 
 -3.467  207655_s_at  BLNK  B-cell linker 
 -3.467  218298_s_at  C14ORF159  chromosome 14 open reading frame 159 
 -3.467  213148_at  C2ORF72  chromosome 2 open reading frame 72 
 -3.467  220751_s_at  C5ORF4  chromosome 5 open reading frame 4 
 -3.467  215985_at  C6ORF12  chromosome 6 open reading frame 12 
 -3.467  210409_at  C6ORF124  chromosome 6 open reading frame 124 
 -3.467  209031_at  CADM1  cell adhesion molecule 1 
 -3.467  211890_x_at  CAPN3  calpain 3, (p94) 
 -3.467  212586_at  CAST  calpastatin 
 -3.467  220307_at  CD244  CD244 molecule, natural killer cell receptor 2B4 
 -3.467  203468_at  CDK10  cyclin-dependent kinase 10 
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 -3.467  221683_s_at  CEP290  centrosomal protein 290kDa 
 -3.467  206633_at  CHRNA1  cholinergic receptor, nicotinic, alpha 1 (muscle) 
 -3.467  206224_at  CST1  cystatin SN 
 -3.467  203558_at  CUL7  cullin 7 
 -3.467  205311_at  DDC  dopa decarboxylase (aromatic L-amino acid decarboxylase) 
 -3.467  220668_s_at  DNMT3B  DNA (cytosine-5-)-methyltransferase 3 beta 
 -3.467  210656_at  EED  embryonic ectoderm development 
 -3.467  204797_s_at  EML1   echinoderm microtubule associated protein like 1 
 -3.467  202177_at  GAS6  growth arrest-specific 6 
 -3.467  211569_s_at  HADH  hydroxyacyl-Coenzyme A dehydrogenase 
 -3.467  206194_at  HOXC4  homeobox C4 
 -3.467  206858_s_at  HOXC6  homeobox C6 
 -3.467  202390_s_at  HTT  huntingtin 
 -3.467  207194_s_at  ICAM4  intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) 
 -3.467  206364_at  KIF14  kinesin family member 14 
 -3.467  215446_s_at  LOX  lysyl oxidase 
 -3.467  218437_s_at  LZTFL1  leucine zipper transcription factor-like 1 
 -3.467  213761_at  MDM1  Mdm1 nuclear protein homolog (mouse) 
 -3.467  212020_s_at  MKI67  antigen identified by monoclonal antibody Ki-67 
 -3.467  219703_at  MNS1  meiosis-specific nuclear structural 1 
 -3.467  218865_at  MOSC1  MOCO sulphurase C-terminal domain containing 1 
 -3.467  210410_s_at  MSH5  mutS homolog 5 (E. coli) 
 -3.467  211916_s_at  MYO1A  myosin IA 
 -3.467  222161_at  NAALAD2  N-acetylated alpha-linked acidic dipeptidase 2 
 -3.467  209290_s_at  NFIB  nuclear factor I/B 
 -3.467  209119_x_at  NR2F2  nuclear receptor subfamily 2, group F, member 2 
 -3.467  222128_at  NSUN6  NOL1/NOP2/Sun domain family, member 6 
 -3.467  219630_at  PDZK1IP1  PDZK1 interacting protein 1 
 -3.467  220041_at  PIGZ  phosphatidylinositol glycan anchor biosynthesis, class Z 
 -3.467  208994_s_at  PPIG  peptidylprolyl isomerase G (cyclophilin G) 
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 -3.467  213093_at  PRKCA  protein kinase C, alpha 
 -3.467  214203_s_at  PRODH  proline dehydrogenase (oxidase) 1 
 -3.467  201896_s_at  PSRC1  proline/serine-rich coiled-coil 1 
 -3.467  218700_s_at  RAB7L1  RAB7, member RAS oncogene family-like 1 
 -3.467  218699_at  RAB7L1  RAB7, member RAS oncogene family-like 1 
 -3.467  205075_at  SERPINF2  serpin peptidase inhibitor, clade F (alpha-2 antiplasmin,pigment epithelium derived factor), member 2 
 -3.467  212179_at  SFRS18  splicing factor, arginine/serine-rich 18 
 -3.467  217226_s_at  SFXN3  sideroflexin 3 
 -3.467  217538_at  SGSM2  small G protein signaling modulator 2 
 -3.467  209980_s_at  SHMT1  serine hydroxymethyltransferase 1 (soluble) 
 -3.467  203625_x_at  SKP2  S-phase kinase-associated protein 2 (p45) 
 -3.467  205896_at  SLC22A4  solute carrier family 22 (organic cation/ergothioneine transporter), member 4 
 -3.467  206143_at  SLC26A3  solute carrier family 26, member 3 
 -3.467  207519_at  SLC6A4  solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 
 -3.467  215043_s_at  SMA5  glucuronidase, beta pseudogene 
 -3.467  219695_at  SMPD3  sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 
 -3.467  204288_s_at  SORBS2  sorbin and SH3 domain containing 2 
 -3.467  202813_at  TARBP1  TAR (HIV-1) RNA binding protein 1 
 -3.467  209403_at  TBC1D3  TBC1 domain family, member 3 
 -3.467  201448_at  TIA1  TIA1 cytotoxic granule-associated RNA binding protein 
 -3.467  204649_at  TROAP  trophinin associated protein (tastin) 
 -3.467  211682_x_at  UGT2B28  UDP glucuronosyltransferase 2 family, polypeptide B28 
 -3.467  218757_s_at  UPF3B  UPF3 regulator of nonsense transcripts homolog B (yeast) 
 -3.467  222072_at  XPNPEP1  X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 
 -3.467  221869_at  ZNF512B  zinc finger protein 512B 
 -3.467  207933_at  ZP2  zona pellucida glycoprotein 2 (sperm receptor) 
 -3.715  220951_s_at  A1CF  APOBEC1 complementation factor 
 -3.715  214829_at  AASS  aminoadipate-semialdehyde synthase 
 -3.715  43427_at  ACACB  acetyl-Coenzyme A carboxylase beta 
 -3.715  49452_at  ACACB  acetyl-Coenzyme A carboxylase beta 
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 -3.715  205364_at  ACOX2  acyl-Coenzyme A oxidase 2, branched chain 
 -3.715  205942_s_at  ACSM3  acyl-CoA synthetase medium-chain family member 3 
 -3.715  204694_at  AFP  alpha-fetoprotein 
 -3.715  204290_s_at  ALDH6A1  aldehyde dehydrogenase 6 family, member A1 
 -3.715  202888_s_at  ANPEP  alanyl (membrane) aminopeptidase 
 -3.715  213454_at  APITD1  apoptosis-inducing, TAF9-like domain 1 
 -3.715  39249_at  AQP3  aquaporin 3 (Gill blood group) 
 -3.715  210653_s_at  BCKDHB  branched chain keto acid dehydrogenase E1, beta polypeptide 
 -3.715  220421_at  BTNL8  butyrophilin-like 8 
 -3.715  219655_at  C7ORF10  chromosome 7 open reading frame 10 
 -3.715  209032_s_at  CADM1  cell adhesion molecule 1 
 -3.715  215145_s_at  CNTNAP2  contactin associated protein-like 2 
 -3.715  213110_s_at  COL4A5  collagen, type IV, alpha 5 
 -3.715  203139_at  DAPK1  death-associated protein kinase 1 
 -3.715  205777_at  DUSP9  dual specificity phosphatase 9 
 -3.715  217838_s_at  EVL  Enah/Vasp-like 
 -3.715  220326_s_at  FLJ10357  hypothetical protein FLJ10357 
 -3.715  222274_at  FLJ31568  zinc finger, DHHC-type containing 8 pseudogene 
 -3.715  213212_x_at  FLJ40113  Golgi autoantigen, golgin subfamily a-like pseudogene 
 -3.715  218031_s_at  FOXN3  forkhead box N3 
 -3.715  220506_at  GUCY1B2  guanylate cyclase 1, soluble, beta 2 
 -3.715  215695_s_at  GYG2  glycogenin 2 
 -3.715  204569_at  ICK  intestinal cell (MAK-like) kinase 
 -3.715  201566_x_at  ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
 -3.715  219306_at  KIF15  kinesin family member 15 
 -3.715  202183_s_at  KIF22  kinesin family member 22 
 -3.715  213880_at  LGR5  leucine-rich repeat-containing G protein-coupled receptor 5 
 -3.715  213502_x_at  LOC91316  glucuronidase, beta/ immunoglobulin lambda-like polypeptide 1 pseudogene 
 -3.715  221834_at  LONP2  lon peptidase 2, peroxisomal 
 -3.715  203570_at  LOXL1  lysyl oxidase-like 1 
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 -3.715  210528_at  MR1  major histocompatibility complex, class I-related 
 -3.715  203801_at  MRPS14  mitochondrial ribosomal protein S14 
 -3.715  209120_at  NR2F2  nuclear receptor subfamily 2, group F, member 2 
 -3.715  220183_s_at  NUDT6  nudix (nucleoside diphosphate linked moiety X)-type motif 6 
 -3.715  209826_at  PPT2  palmitoyl-protein thioesterase 2 
 -3.715  220510_at  RHBG  Rh family, B glycoprotein 
 -3.715  221909_at  RNFT2  ring finger protein, transmembrane 2 
 -3.715  219482_at  SETD4  SET domain containing 4 
 -3.715  220736_at  SLC19A3  solute carrier family 19, member 3 
 -3.715  210677_at  SOAT2  sterol O-acyltransferase 2 
 -3.715  212386_at  TCF4  transcription factor 4 
 -3.715  65630_at  TMEM80  transmembrane protein 80 
 -3.715  221173_at  USH1C  Usher syndrome 1C (autosomal recessive, severe) 
 -3.715  206366_x_at  XCL1  chemokine (C motif) ligand 1 
 -3.981  209460_at  ABAT  4-aminobutyrate aminotransferase 
 -3.981  222362_at  AGFG2  ArfGAP with FG repeats 2 
 -3.981  222126_at  AGFG2  ArfGAP with FG repeats 2 
 -3.981  212173_at  AK2  adenylate kinase 2 
 -3.981  203074_at  ANXA8L2  annexin A8-like 2 
 -3.981  205108_s_at  APOB  apolipoprotein B (including Ag(x) antigen) 
 -3.981  209006_s_at  C1ORF63  chromosome 1 open reading frame 63 
 -3.981  201615_x_at  CALD1  caldesmon 1 
 -3.981  206878_at  DAO  D-amino-acid oxidase 
 -3.981  219469_at  DYNC2H1  dynein, cytoplasmic 2, heavy chain 1 
 -3.981  210220_at  FZD2  frizzled homolog 2 (Drosophila) 
 -3.981  204973_at  GJB1  gap junction protein, beta 1, 32kDa 
 -3.981  220085_at  HELLS  helicase, lymphoid-specific 
 -3.981  217317_s_at  LOC283755  hect domain and RLD 2 pseudogene 3 
 -3.981  221833_at  LONP2  lon peptidase 2, peroxisomal 
 -3.981  209348_s_at  MAF  v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
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 -3.981  218440_at  MCCC1  methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 
 -3.981  218641_at  MGC3032  hypothetical protein MGC3032 
 -3.981  210694_s_at  MID1  midline 1 (Opitz/BBB syndrome) 
 -3.981  215731_s_at  MPHOSPH9  M-phase phosphoprotein 9 
 -3.981  206964_at  NAT8B  N-acetyltransferase 8B (GCN5-related, putative, gene/pseudogene) 
 -3.981  213033_s_at  NFIB  nuclear factor I/B 
 -3.981  214632_at  NRP2  neuropilin 2 
 -3.981  206623_at  PDE6A  phosphodiesterase 6A, cGMP-specific, rod, alpha 
 -3.981  205111_s_at  PLCE1  phospholipase C, epsilon 1 
 -3.981  211341_at  POU4F1  POU class 4 homeobox 1 
 -3.981  208995_s_at  PPIG  peptidylprolyl isomerase G (cyclophilin G) 
 -3.981  212805_at  PRUNE2  prune homolog 2 (Drosophila) 
 -3.981  50965_at  RAB26  RAB26, member RAS oncogene family 
 -3.981  219864_s_at  RCAN3  RCAN family member 3 
 -3.981  209441_at  RHOBTB2  Rho-related BTB domain containing 2 
 -3.981  202976_s_at  RHOBTB3  Rho-related BTB domain containing 3 
 -3.981  202975_s_at  RHOBTB3  Rho-related BTB domain containing 3 
 -3.981  221768_at  SFPQ  splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated) 
 -3.981  212176_at  SFRS18  splicing factor, arginine/serine-rich 18 
 -3.981  205097_at  SLC26A2  solute carrier family 26 (sulfate transporter), member 2 
 -3.981  206535_at  SLC2A2  solute carrier family 2 (facilitated glucose transporter), member 2 
 -3.981  213364_s_at  SNX1  sorting nexin 1 
 -3.981  201449_at  TIA1  TIA1 cytotoxic granule-associated RNA binding protein 
 -3.981  202688_at  TNFSF10  tumor necrosis factor (ligand) superfamily, member 10 
 -3.981  214329_x_at  TNFSF10  tumor necrosis factor (ligand) superfamily, member 10 
 -3.981  204391_x_at  TRIM24  tripartite motif-containing 24 
 -3.981  213301_x_at  TRIM24  tripartite motif-containing 24 
 -3.981  219632_s_at  TRPV1  transient receptor potential cation channel, subfamily V, member 1 
 -3.981  212928_at  TSPYL4  TSPY-like 4 
 -3.981  219740_at  VASH2  vasohibin 2 
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 -3.981  211064_at  ZNF493  zinc finger protein 493 
 -3.981  213659_at  ZNF75D  zinc finger protein 75D 
 -4.266  213095_x_at  AIF1  allograft inflammatory factor 1 
 -4.266  218487_at  ALAD  aminolevulinate, delta-, dehydratase 
 -4.266  203608_at  ALDH5A1  aldehyde dehydrogenase 5 family, member A1 
 -4.266  219918_s_at  ASPM  asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 
 -4.266  213143_at  C2ORF72  chromosome 2 open reading frame 72 
 -4.266  207828_s_at  CENPF  centromere protein F, 350/400ka (mitosin) 
 -4.266  203642_s_at  COBLL1  COBL-like 1 
 -4.266  210069_at  CPT1B  carnitine palmitoyltransferase 1B (muscle) 
 -4.266  206424_at  CYP26A1  cytochrome P450, family 26, subfamily A, polypeptide 1 
 -4.266  201278_at  DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
 -4.266  214347_s_at  DDC  dopa decarboxylase (aromatic L-amino acid decarboxylase) 
 -4.266  213645_at  ENOSF1  enolase superfamily member 1 
 -4.266  220150_s_at  FAM184A  family with sequence similarity 184, member A 
 -4.266  216238_s_at  FGB  fibrinogen beta chain 
 -4.266  203632_s_at  GPRC5B  G protein-coupled receptor, family C, group 5, member B 
 -4.266  204607_at  HMGCS2  3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
 -4.266  219174_at  IFT74  intraflagellar transport 74 homolog (Chlamydomonas) 
 -4.266  204987_at  ITIH2  inter-alpha (globulin) inhibitor H2 
 -4.266  205303_at  KCNJ8  potassium inwardly-rectifying channel, subfamily J, member 8 
 -4.266  203637_s_at  MID1  midline 1 (Opitz/BBB syndrome) 
 -4.266  214770_at  MSR1  macrophage scavenger receptor 1 
 -4.266  218966_at  MYO5C  myosin VC 
 -4.266  209121_x_at  NR2F2  nuclear receptor subfamily 2, group F, member 2 
 -4.266  215073_s_at  NR2F2  nuclear receptor subfamily 2, group F, member 2 
 -4.266  213947_s_at  NUP210  nucleoporin 210kDa 
 -4.266  216945_x_at  PASK  PAS domain containing serine/threonine kinase 
 -4.266  220954_s_at  PILRB   paired immunoglobin-like type 2 receptor beta 
 -4.266  205112_at  PLCE1  phospholipase C, epsilon 1 
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 -4.266  215807_s_at  PLXNB1  plexin B1 
 -4.266  218931_at  RAB17  RAB17, member RAS oncogene family 
 -4.266  219151_s_at  RABL2A  RAB, member of RAS oncogene family-like 2A 
 -4.266  49306_at  RASSF4  Ras association (RalGDS/AF-6) domain family member 4 
 -4.266  205933_at  SETBP1  SET binding protein 1 
 -4.266  212177_at  SFRS18  splicing factor, arginine/serine-rich 18 
 -4.266  213307_at  SHANK2  SH3 and multiple ankyrin repeat domains 2 
 -4.266  220413_at  SLC39A2  solute carrier family 39 (zinc transporter), member 2 
 -4.266  205342_s_at  SULT1C2  sulfotransferase family, cytosolic, 1C, member 2 
 -4.266  207392_x_at  UGT2B15  UDP glucuronosyltransferase 2 family, polypeptide B15 
 -4.266  219077_s_at  WWOX  WW domain containing oxidoreductase 
 -4.266  214823_at  ZNF204  zinc finger protein 204 pseudogene 
 -4.571  203504_s_at  ABCA1  ATP-binding cassette, sub-family A (ABC1), member 1 
 -4.571  203756_at  ARHGEF17  Rho guanine nucleotide exchange factor (GEF) 17 
 -4.571  209693_at  ASTN2   astrotactin 2 
 -4.571  212672_at  ATM  ataxia telangiectasia mutated 
 -4.571  222336_at  C4ORF34  chromosome 4 open reading frame 34 
 -4.571  215785_s_at  CYFIP2   cytoplasmic FMR1 interacting protein 2 
 -4.571  201280_s_at  DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
 -4.571  220233_at  FBXO17  F-box protein 17 
 -4.571  214701_s_at  FN1  fibronectin 1 
 -4.571  213524_s_at  G0S2  G0/G1switch 2 
 -4.571  219954_s_at  GBA3  glucosidase, beta, acid 3 (cytosolic) 
 -4.571  219876_s_at  GOLGA2L1  Golgi autoantigen, golgin subfamily a, 2-like 1 
 -4.571  208798_x_at  GOLGA8A  Golgi autoantigen, golgin subfamily a, 8A 
 -4.571  220744_s_at  IFT122  intraflagellar transport 122 homolog (Chlamydomonas) 
 -4.571  204202_at  IQCE  IQ motif containing E 
 -4.571  206006_s_at  KIAA1009  KIAA1009 
 -4.571  220393_at  LGSN  lengsin, lens protein with glutamine synthetase domain 
 -4.571  32062_at  LRRC14  leucine rich repeat containing 14 
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 -4.571  210128_s_at  LTB4R  leukotriene B4 receptor 
 -4.571  212022_s_at  MKI67  antigen identified by monoclonal antibody Ki-67 
 -4.571  221606_s_at  NSBP1  nucleosomal binding protein 1 
 -4.571  213046_at  PABPN1  poly(A) binding protein, nuclear 1 
 -4.571  205380_at  PDZK1  PDZ domain containing 1 
 -4.571  205697_at  SCGN  secretagogin, EF-hand calcium binding protein 
 -4.571  212319_at  SGSM2  small G protein signaling modulator 2 
 -4.571  214719_at  SLC46A3  solute carrier family 46, member 3 
 -4.571  202761_s_at  SYNE2  spectrin repeat containing, nuclear envelope 2 
 -4.571  220639_at  TM4SF20  transmembrane 4 L six family member 20 
 -4.571  218807_at  VAV3  vav 3 guanine nucleotide exchange factor 
 -4.571  217367_s_at  ZHX3  zinc fingers and homeoboxes 3 
 -4.898  210962_s_at  AKAP9  A kinase (PRKA) anchor protein (yotiao) 9 
 -4.898  211298_s_at  ALB  albumin 
 -4.898  39248_at  AQP3  aquaporin 3 (Gill blood group) 
 -4.898  219870_at  ATF7IP2  activating transcription factor 7 interacting protein 2 
 -4.898  210168_at  C6  complement component 6 
 -4.898  206866_at  CDH4   cadherin 4, type 1, R-cadherin (retinal) 
 -4.898  205642_at  CEP110  centrosomal protein 110kDa 
 -4.898  217690_at  ENOSF1  enolase superfamily member 1 
 -4.898  207981_s_at  ESRRG  estrogen-related receptor gamma 
 -4.898  208228_s_at  FGFR2  fibroblast growth factor receptor 2 
 -4.898  213650_at  GOLGA8A  Golgi autoantigen, golgin subfamily a, 8A 
 -4.898  212906_at  GRAMD1B  GRAM domain containing 1B 
 -4.898  213359_at  HNRNPD  heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) 
 -4.898  205522_at  HOXD4  homeobox D4 
 -4.898  203153_at  IFIT1  interferon-induced protein with tetratricopeptide repeats 1 
 -4.898  213832_at  KCND3  potassium voltage-gated channel, Shal-related subfamily, member 3 
 -4.898  220911_s_at  KIAA1305  KIAA1305 
 -4.898  209757_s_at  MYCN  v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 
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 -4.898  221207_s_at  NBEA   neurobeachin 
 -4.898  212151_at  PBX1  pre-B-cell leukaemia homeobox 1 
 -4.898  213388_at  PDE4DIP  phosphodiesterase 4D interacting protein 
 -4.898  213431_x_at  SFI1  Sfi1 homolog, spindle assembly associated (yeast) 
 -5.248  215407_s_at  ASTN2   astrotactin 2 
 -5.248  220227_at  CDH4   cadherin 4, type 1, R-cadherin (retinal) 
 -5.248  205046_at  CENPE  centromere protein E, 312kDa 
 -5.248  205222_at  EHHADH  enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 
 -5.248  210425_x_at  GOLGA8A  Golgi autoantigen, golgin subfamily a, 8A 
 -5.248  204997_at  GPD1  glycerol-3-phosphate dehydrogenase 1 (soluble) 
 -5.248  219936_s_at  GPR87  G protein-coupled receptor 87 
 -5.248  213248_at  LOC730101  hypothetical LOC730101 
 -5.248  206363_at  MAF  v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
 -5.248  203636_at  MID1  midline 1 (Opitz/BBB syndrome) 
 -5.248  212913_at  MSH5  mutS homolog 5 (E. coli) 
 -5.248  208189_s_at  MYO7A  myosin VIIA 
 -5.248  209322_s_at  SH2B1  SH2B adaptor protein 1 
 -5.248  206529_x_at  SLC26A4  solute carrier family 26, member 4 
 -5.248  215169_at  SLC35E2  solute carrier family 35, member E2 
 -5.248  206715_at  TFEC  transcription factor EC 
 -5.248  202687_s_at  TNFSF10  tumor necrosis factor (ligand) superfamily, member 10 
 -5.623  205043_at  CFTR  cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C,member 7) 
 -5.623  221729_at  COL5A2  collagen, type V, alpha 2 
 -5.623  221730_at  COL5A2  collagen, type V, alpha 2 
 -5.623  207174_at  GPC5  glypican 5 
 -5.623  203474_at  IQGAP2  IQ motif containing GTPase activating protein 2 
 -5.623  217512_at  KNG1   kininogen 1 
 -5.623  213653_at  METTL3  methyltransferase like 3 
 -5.623  214241_at  NDUFB8  NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa 
 -5.623  213032_at  NFIB  nuclear factor I/B 
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 -5.623  205259_at  NR3C2  nuclear receptor subfamily 3, group C, member 2 
 -5.623  206498_at  OCA2  oculocutaneous albinism II 
 -5.623  205041_s_at  ORM1  orosomucoid 1 
 -5.623  205719_s_at  PAH  phenylalanine hydroxylase 
 -5.623  212148_at  PBX1  pre-B-cell leukaemia homeobox 1 
 -5.623  210451_at  PKLR  pyruvate kinase, liver and RBC 
 -5.623  205414_s_at  RICH2  Rho-type GTPase-activating protein RICH2 
 -5.623  219604_s_at  ZNF3  zinc finger protein 3 
 -5.623  55872_at  ZNF512B  zinc finger protein 512B 
 -6.026  206030_at  ASPA  aspartoacylase (Canavan disease) 
 -6.026  204573_at  CROT  carnitine O-octanoyltransferase 
 -6.026  221139_s_at  CSAD  cysteine sulfinic acid decarboxylase 
 -6.026  218858_at  DEPDC6   DEP domain containing 6 
 -6.026  219612_s_at  FGG  fibrinogen gamma chain 
 -6.026  207761_s_at  METTL7A  methyltransferase like 7A 
 -6.026  213040_s_at  NPTXR  neuronal pentraxin receptor 
 -6.026  222078_at  PKLR  pyruvate kinase, liver and RBC 
 -6.026  213520_at  RECQL4  RecQ protein-like 4 
 -6.026  202133_at  WWTR1  WW domain containing transcription regulator 1 
 -6.457  203505_at  ABCA1  ATP-binding cassette, sub-family A (ABC1), member 1 
 -6.457  215483_at  AKAP9  A kinase (PRKA) anchor protein (yotiao) 9 
 -6.457  202920_at  ANK2  ankyrin 2, neuronal 
 -6.457  201679_at  ARS2  arsenate resistance protein 2 
 -6.457  214419_s_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -6.457  203638_s_at  FGFR2  fibroblast growth factor receptor 2 
 -6.457  220609_at  LOC202181  hypothetical protein LOC202181 
 -6.457  209519_at  NCBP1   nuclear cap binding protein subunit 1, 80kDa 
 -6.457  210751_s_at  RGN  regucalcin (senescence marker protein-30) 
 -6.457  213666_at  SEPT6  septin 6 
 -6.457  215657_at  SLC26A3  solute carrier family 26, member 3 
338 
 
Fold change Affymetrix ID Gene symbol Entrez gene name 
 -6.457  205343_at  SULT1C2  sulfotransferase family, cytosolic, 1C, member 2 
 -6.457  214382_at  UNC93A  unc-93 homolog A (C. elegans) 
 -6.457  206771_at  UPK3A  uroplakin 3A 
 -6.918  213411_at  ADAM22  ADAM metallopeptidase domain 22 
 -6.918  207102_at  AKR1D1  aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-reductase) 
 -6.918  213213_at  DIDO1  death inducer-obliterator 1 
 -6.918  209368_at  EPHX2  epoxide hydrolase 2, cytoplasmic 
 -6.918  205649_s_at  FGA  fibrinogen alpha chain 
 -6.918  204515_at  HSD3B1  hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 
 -6.918  219543_at  PBLD  phenazine biosynthesis-like protein domain containing 
 -6.918  203895_at  PLCB4  phospholipase C, beta 4 
 -6.918  204199_at  RALGPS1  Ral GEF with PH domain and SH3 binding motif 1 
 -6.918  221908_at  RNFT2  ring finger protein, transmembrane 2 
 -6.918  211470_s_at  SULT1C2  sulfotransferase family, cytosolic, 1C, member 2 
 -7.413  216661_x_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -7.413  205650_s_at  FGA  fibrinogen alpha chain 
 -7.413  220349_s_at  FLJ21865  endo-beta-N-acetylglucosaminidase 
 -7.413  208476_s_at  FRMD4A  FERM domain containing 4A 
 -7.413  206005_s_at  KIAA1009  KIAA1009 
 -7.413  208434_at  MDS1  myelodysplasia syndrome 1 
 -7.413  209926_at  MEF2B   myocyte enhancer factor 2B 
 -7.413  210289_at  NAT8  N-acetyltransferase 8 (GCN5-related, putative) 
 -7.413  217583_at  PAH  phenylalanine hydroxylase 
 -7.413  212915_at  PDZRN3  PDZ domain containing ring finger 3 
 -7.413  209568_s_at  RGL1  ral guanine nucleotide dissociation stimulator-like 1 
 -7.413  215146_s_at  TTC28  tetratricopeptide repeat domain 28 
 -7.413  215729_s_at  VGLL1  vestigial like 1 (Drosophila) 
 -7.413  220917_s_at  WDR19  WD repeat domain 19 
 -7.943  215559_at  ABCC6  ATP-binding cassette, sub-family C (CFTR/MRP), member 6 
 -7.943  206149_at  CHP2  calcineurin B homologous protein 2 
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 -7.943  220999_s_at  CYFIP2   cytoplasmic FMR1 interacting protein 2 
 -7.943  215014_at  KCND3  potassium voltage-gated channel, Shal-related subfamily, member 3 
 -7.943  214180_at  MAN1C1  mannosidase, alpha, class 1C, member 1 
 -7.943  220303_at  PDZD3  PDZ domain containing 3 
 -7.943  209561_at  THBS3   thrombospondin 3 
 -7.943  207426_s_at  TNFSF4  tumor necrosis factor (ligand) superfamily, member 4 
 -8.511  220148_at  ALDH8A1  aldehyde dehydrogenase 8 family, member A1 
 -8.511  206500_s_at  C14ORF106  chromosome 14 open reading frame 106 
 -8.511  217558_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -8.511  214421_x_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -8.511  220017_x_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -8.511  216687_x_at  UGT2B15  UDP glucuronosyltransferase 2 family, polypeptide B15 
 -9.120  220390_at  AGBL2  ATP/GTP binding protein-like 2 
 -9.120  220084_at  C14ORF105  chromosome 14 open reading frame 105 
 -9.120  216025_x_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -9.120  214163_at  HSPB11  heat shock protein family B (small), member 11 
 -9.772  214420_s_at  CYP2C9  cytochrome P450, family 2, subfamily C, polypeptide 9 
 -9.772  206643_at  HAL  histidine ammonia-lyase 
 -9.772  213703_at  LOC150759  hypothetical protein LOC150759 
 -9.772  205710_at  LRP2  low density lipoprotein-related protein 2 
 -9.772  214881_s_at  UBTF  upstream binding transcription factor, RNA polymerase I 
 -10.471  219850_s_at  EHF  ets homologous factor 
 -10.471  203896_s_at  PLCB4  phospholipase C, beta 4 
 -10.471  219511_s_at  SNCAIP  synuclein, alpha interacting protein 
 -10.471  206292_s_at  SULT2A1  sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 
 -11.220  220622_at  LRRC31  leucine rich repeat containing 31 
 -11.220  201998_at  ST6GAL1  ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
 -11.220  219934_s_at  SULT1E1  sulfotransferase family 1E, estrogen-preferring, member 1 
 -12.023  210108_at  CACNA1D  calcium channel, voltage-dependent, L type, alpha 1D subunit 
 -12.023  204307_at  KIAA0329  KIAA0329 
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Fold change Affymetrix ID Gene symbol Entrez gene name 
 -12.023  207051_at  SLC17A4  solute carrier family 17 (sodium phosphate), member 4 
 -12.882  212392_s_at  PDE4DIP  phosphodiesterase 4D interacting protein 
 -12.882  216228_s_at  WDHD1  WD repeat and HMG-box DNA binding protein 1 
 -13.804  217904_s_at  BACE1  beta-site APP-cleaving enzyme 1 
 -13.804  210424_s_at  GOLGA8A  Golgi autoantigen, golgin subfamily a, 8A 
 -13.804  220385_at  JPH2  junctophilin 2 
 -13.804  205054_at  NEB  nebulin 
 -13.804  206293_at  SULT2A1  sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 
 -14.791  220456_at  SPTLC3  serine palmitoyltransferase, long chain base subunit 3 
 -15.849  1431_at  CYP2E1  cytochrome P450, family 2, subfamily E, polypeptide 1 
 -15.849  206963_s_at  NAT8B  N-acetyltransferase 8B (GCN5-related, putative, gene/pseudogene) 
 -16.982  220679_s_at  CDH7  cadherin 7, type 2 
 -16.982  204713_s_at  F5  coagulation factor V (proaccelerin, labile factor) 
 -16.982  40665_at  FMO3  flavin containing monooxygenase 3 
 -16.982  213241_at  PLXNC1  plexin C1 
 -18.197  208480_s_at  ABCC6  ATP-binding cassette, sub-family C (CFTR/MRP), member 6 
 -18.197  211526_s_at  TNFRSF6B  tumor necrosis factor receptor superfamily, member 6b, decoy 
 -19.498  207487_at  FLJ11996  hypothetical protein FLJ11996 
 -20.893  218918_at  MAN1C1  mannosidase, alpha, class 1C, member 1 
 -22.387  208498_s_at  AMY1B  amylase, alpha 1B (salivary) 
 -23.988  212935_at  MCF2L  MCF.2 cell line derived transforming sequence-like 
 -25.704  206265_s_at  GPLD1  glycosylphosphatidylinositol specific phospholipase D1 
 -29.512  220095_at  CNTLN  centlein, centrosomal protein 
 -29.512  212385_at  TCF4  transcription factor 4 





9.5 Gene ontology analysis 
9.5.1 Down-regulated genes 
In the following tables are GO terms, enriched in down-regulated gene list in Caco-2 
cells following berry extract treatment.  The terms listed are all significantly 
enriched p ≤ 0.05 in our gene-list.  The tables are organised by GO term categories 
(i.e. Molecular function – biological process – cellular component). 
GO term: Molecular function p-value 
ion binding 7.6*10
-124 




transition metal ion binding 5.5*10
-69 
zinc ion binding 2.3*10
-47 
calcium ion binding 1.1*10
-17 
transferase activity, transferring one-carbon groups 7.5*10
-10 




magnesium ion binding 3.5*10
-9 




S-adenosylmethionine-dependent methyltransferase activity 4.8*10
-6 
hydrolase activity, hydrolyzing O-glycosyl compounds 5.3*10
-6 
lipid transporter activity 9.2*10
-6 
steroid hormone receptor activity 1.2*10
-5 
ligand-dependent nuclear receptor activity 3.9*10
-5 
hydrolase activity, acting on glycosyl bonds 4.5*10
-5 




















protein methyltransferase activity 2*10
-3 








carbohydrate kinase activity 6.2*10
-3 









GO Term: Biological Process p-value 
carbohydrate metabolic process 2.6*10
-14 
cellular carbohydrate metabolic process 2.5*10
-11 




metal ion homeostasis 1*10
-7 
cellular metal ion homeostasis 1*10
-7 




monosaccharide metabolic process 8.2*10
-7 
calcium ion homeostasis 1.4*10
-6 
cellular calcium ion homeostasis 1.4*10
-6 




di-, tri-valent inorganic cation homeostasis 1.9*10
-6 
alcohol metabolic process 3.9*10
-6 
cellular chemical homeostasis 4.8*10
-6 
cellular ion homeostasis 4.8*10
-6 
GO term: Molecular Function p-value 
RNA methyltransferase activity 8.6*10
-3 
calcium-dependent phospholipid binding 8.6*10
-3 
histone deacetylase activity 1*10
-2 
protein deacetylase activity 1*10
-2 
ligase activity, forming carbon-carbon bonds 1.1*10
-2 














ligase activity, forming carbon-nitrogen bonds 1.9*10
-2 












small protein conjugating enzyme activity 3.6*10
-2 
mannosyl-oligosaccharide mannosidase activity 3.8*10
-2 
phospholipase C activity 3.8*10
-2 
oxidoreductase activity, acting on paired donors, with incorporation or reduction of 
molecular oxygen 
3.9*10-2 
DNA-directed DNA polymerase activity 4.1*10
-2 
small conjugating protein ligase activity 4.2*10
-2 
cobalt ion binding 4.3*10
-2 
3'-5' exonuclease activity 4.4*10
-2 
acetyl-CoA carboxylase activity 4.8*10
-2 
(S)-limonene 7-monooxygenase activity 4.8*10
-2 
(S)-limonene 6-monooxygenase activity 4.8*10
-2 










GO Term: Biological Process p-value 




carboxylic acid metabolic process 2.5*10
-5 




regulation of biological quality 4.5*10
-5 




cell cycle phase 1.7*10
-4 










one-carbon compound metabolic process 4.5*10
-4 
M phase of mitotic cell cycle 4.8*10
-4 




regulation of body fluid levels 8.2*10
-4 
monocarboxylic acid metabolic process 9.2*10
-4 












carbohydrate biosynthetic process 2.2*10
-3 










di-, tri-valent inorganic cation transport 4.3*10
-3 
regulation of ARF GTPase activity 5.6*10
-3 






glucose metabolic process 8*10
-3 
DNA synthesis during DNA repair 1.1*10
-2 
galactose metabolic process 1.1*10
-2 










protein modification by small protein conjugation 1.5*10
-2 
glucan metabolic process 1.6*10
-2 
lipid catabolic process 1.6*10
-2 
cellular carbohydrate catabolic process 1.8*10
-2 




cellular polysaccharide metabolic process 2.2*10
-2 




GO Term: Biological Process p-value 
regulation of cell adhesion 2.4*10
-2 
polysaccharide metabolic process 2.4*10
-2 
carbohydrate catabolic process 2.4*10
-2 
sequestering of metal ion 2.8*10
-2 
cofactor metabolic process 2.9*10
-2 
tricarboxylic acid cycle intermediate metabolic process 3*10
-2 
pyruvate metabolic process 3*10
-2 
regulation of ARF protein signal transduction 3.1*10
-2 
vitamin metabolic process 3.2*10
-2 
heparan sulfate proteoglycan biosynthetic process 3.3*10
-2 
ARF protein signal transduction 3.3*10
-2 








monosaccharide biosynthetic process 3.8*10
-2 
alcohol biosynthetic process 3.8*10
-2 
iron ion transport 3.8*10
-2 
hexose biosynthetic process 3.8*10
-2 




axon cargo transport 4.4*10
-2 
glycoprotein metabolic process 4.6*10
-2 
creatine biosynthetic process 4.8*10
-2 
amino acid derivative biosynthetic process 4.8*10
-2 
cyclic nucleotide biosynthetic process 4.8*10
-2 
glycoprotein biosynthetic process 4.9*10
-2 
heparan sulfate proteoglycan metabolic process 5*10
-2 
 
GO term: Cellular Components p-value 


















histone methyltransferase complex 1.3*10
-2 












apical plasma membrane 3.2*10
-2 






plus-end kinesin complex 4.5*10
-2 






9.5.2 Up-regulated genes 
In the following tables are GO terms, enriched in up-regulated gene list in Caco-2 
cells following berry extract treatment.  The terms listed are all significantly 
enriched p ≤ 0.05 in our gene-list.  The tables are organised by GO term categories 
(Molecular function – biological process – cellular component). 
 
GO term: Molecular Function p- value 








transmembrane transporter activity 3.6*10-
10 
transferase activity, transferring hexosyl groups 4.9*10-
10 
active transmembrane transporter activity 7.6*10-
10 




substrate-specific transmembrane transporter activity 1.3*10
-7 










hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 5*10
-6 




guanyl ribonucleotide binding 9*10
-6 
guanyl nucleotide binding 9.2*10
-6 
xenobiotic-transporting ATPase activity 2.6*10
-4 
xenobiotic transporter activity 2.6*10
-4 
drug transporter activity 6.1*10
-4 
sugar:hydrogen ion symporter activity 1.1*10
-3 
sugar transmembrane transporter activity 1.3*10
-3 




ATPase activity, coupled to transmembrane movement of substances 2.3*10
-3 
ATPase activity, coupled to movement of substances 2.4*10
-3 
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of 
substances 
3*10-3 
P-P-bond-hydrolysis-driven transmembrane transporter activity 3.5*10
-3 
primary active transmembrane transporter activity 3.5*10
-3 
ion transmembrane transporter activity 3.7*10
-3 
low-density lipoprotein receptor activity 4.6*10
-3 
lipoprotein receptor activity 4.6*10
-3 
actin filament binding 5.1*10
-3 
solute:cation symporter activity 5.5*10
-3 
carboxylic acid transmembrane transporter activity 5.8*10
-3 




GO term: Molecular Function p- value 
anion transmembrane transporter activity 9.1*10
-3 
glucose transmembrane transporter activity 9.7*10
-3 
low-density lipoprotein binding 9.7*10
-3 
hexose transmembrane transporter activity 1.1*10
-2 
monosaccharide transmembrane transporter activity 1.1*10
-2 
voltage-gated ion channel activity 1.2*10
-2 
voltage-gated channel activity 1.2*10
-2 






neurotransmitter:sodium symporter activity 1.8*10
-2 
glutamate-cysteine ligase activity 1.9*10
-2 
voltage-gated potassium channel activity 1.9*10
-2 
protein heterodimerisation activity 2*10
-2 
protein domain specific binding 2*10
-2 
neurotransmitter transporter activity 2.3*10
-2 








carbohydrate kinase activity 3.4*10
-2 




potassium channel activity 4.2*10
-2 
wide pore channel activity 4.3*10
-2 
secondary active monocarboxylate transmembrane transporter activity 4.6*10
-2 
protein kinase binding 4.6*10
-2 
cation transmembrane transporter activity 4.8*10
-2 
 
GO term: Biological Process p-value 

































cellular component organisation and biogenesis 3.7*10-
12
 
negative regulation of catalytic activity 1.2*10-
10
 
membrane organisation and biogenesis 4.1*10-
10
 
negative regulation of kinase activity 5.2*10-
10
 
negative regulation of protein kinase activity 5.2*10-
10
 









glucose metabolic process 5*10
-9
 
carbohydrate metabolic process 1.9*10
-8
 





GO term: Biological Process p-value 
regulation of protein kinase activity 2.7*10
-8
 
regulation of a molecular function 2.7*10
-8
 
monosaccharide metabolic process 3.6*10
-8
 
regulation of kinase activity 3.8*10
-8
 
regulation of transferase activity 5*10
-8
 
alcohol metabolic process 6.9*10
-8
 
response to drug 2.4*10
-7
 
regulation of catalytic activity 2.9*10
-7
 
negative regulation of MAP kinase activity 3.4*10
-7
 
intracellular protein transport 3.7*10
-7
 
regulation of transport 7.1*10
-7
 
regulation of MAP kinase activity 1.1*10
-6
 
cellular carbohydrate metabolic process 1.2*10
-6
 


















negative regulation of transport 2.1*10
-5
 



























protein kinase cascade 8.9*10
-5
 
regulation of protein import into nucleus 1.2*10
-4
 





















intracellular signaling cascade 2.6*10
-4
 
regulation of protein transport 3.2*10
-4
 
regulation of nucleocytoplasmic transport 3.7*10
-4
 
monocarboxylic acid transport 5*10
-4
 
cytoskeleton-dependent intracellular transport 5.3*10
-4
 
cytoskeleton organisation and biogenesis 5.5*10
-4
 
lipid metabolic process 5.6*10
-4
 






























negative regulation of biological process 8.2*10
-4
 
negative regulation of apoptosis 8.6*10
-4
 






regulation of blood vessel size 1*10
-3
 
regulation of tube size 1*10
-3
 
vascular process in circulatory system 1.1*10
-3
 









secretion by cell 1.1*10
-3
 
response to hormone stimulus 1.3*10
-3
 






carboxylic acid transport 1.5*10
-3
 
organic acid transport 1.6*10
-3
 
carbohydrate biosynthetic process 1.6*10
-3
 
transcription factor import into nucleus 1.8*10
-3
 















localisation of cell 2*10
-3
 
monosaccharide catabolic process 2.1*10
-3
 
alcohol catabolic process 2.3*10
-3
 









regulation of membrane potential 2.9*10
-3
 
regulation of biological quality 2.9*10
-3
 
cellular lipid metabolic process 3*10
-3
 
pyruvate metabolic process 3.3*10
-3
 
peptidoglycan metabolic process 3.3*10
-3
 
carboxylic acid metabolic process 3.5*10
-3
 






steroid metabolic process 4.1*10
-3
 
positive regulation of catalytic activity 4.3*10
-3
 
monosaccharide biosynthetic process 4.4*10
-3
 
alcohol biosynthetic process 4.4*10
-3
 












regulation of mitochondrial membrane potential 4.9*10
-3
 
cytoplasmic sequestering of transcription factor 4.9*10
-3
 





















cellular carbohydrate catabolic process 6.7*10
-3
 
Golgi vesicle transport 6.7*10
-3
 
regulation of nitric oxide biosynthetic process 7.1*10
-3
 
response to steroid hormone stimulus 7.2*10
-3
 
regulation of cell proliferation 7.7*10
-3
 
negative regulation of protein import into nucleus 8.3*10
-3
 
negative regulation of transcription factor import into nucleus 8.3*10
-3
 






maintenance of localisation 9*10
-3
 












generation of a signal involved in cell-cell signaling 1*10
-2
 
negative regulation of protein transport 1.1*10
-2
 
protein amino acid glycosylation 1.3*10
-2
 






positive regulation of protein kinase activity 1.5*10
-2
 









glycoprotein biosynthetic process 1.6*10
-2
 
positive regulation of kinase activity 1.7*10
-2
 






glycosphingolipid metabolic process 1.9*10
-2
 
regulation of exocytosis 1.9*10
-2
 
protein amino acid autophosphorylation 1.9*10
-2
 
positive regulation of apoptosis 2*10
-2
 
multicellular organismal protein metabolic process 2.1*10
-2
 
multicellular organismal macromolecule catabolic process 2.1*10
-2
 






multicellular organismal protein catabolic process 2.1*10
-2
 
positive regulation of epithelial cell proliferation 2.1*10
-2
 






positive regulation of programmed cell death 2.1*10
-2
 
macromolecule catabolic process 2.1*10
-2
 
regulation of hormone secretion 2.3*10
-2
 
digestive system process 2.3*10
-2
 
multicellular organismal catabolic process 2.3*10
-2
 
response to estrogen stimulus 2.3*10
-2
 
response to peptide hormone stimulus 2.3*10
-2
 









maintenance of cellular protein localisation 2.7*10
-2
 
actin cytoskeleton organisation and biogenesis 2.7*10
-2
 





GO term: Biological Process p-value 
cellular chemical homeostasis 2.8*10
-2
 
cellular ion homeostasis 2.8*10
-2
 
multicellular organismal metabolic process 2.9*10
-2
 






regulation of secretion 3*10
-2
 
maintenance of protein localisation 3.1*10
-2
 
nitric oxide metabolic process 3.1*10
-2
 
nitric oxide biosynthetic process 3.1*10
-2
 
inorganic anion transport 3.1*10
-2
 
negative regulation of nitric oxide biosynthetic process 3.2*10
-2
 
glycoprotein metabolic process 3.2*10
-2
 
monovalent inorganic cation transport 3.2*10
-2
 
negative regulation of multicellular organismal process 3.6*10
-2
 
actin filament-based process 3.6*10
-2
 
regulation of multicellular organismal process 3.8*10
-2
 
glycolipid metabolic process 3.9*10
-2
 
cytoplasmic sequestering of NF-KappaB 4.2*10
-2
 
regulation of mitochondrial depolarisation 4.2*10
-2
 
multicellular organism reproduction 4.2*10
-2
 






regulation of phosphorylation 4.5*10
-2
 
ceramide metabolic process 4.6*10
-2
 































































































cytoplasmic vesicle membrane 5.3*10
-3
 


















basal plasma membrane 1.2*10
-2
 
voltage-gated potassium channel complex 1.3*10
-2
 
basal part of cell 1.4*10
-2
 
























mitochondrial outer membrane 3.3*10
-2
 
late endosome membrane 3.4*10
-2
 












apical plasma membrane 4.2*10
-2
 
organelle outer membrane 4.7*10
-2
 
nuclear membrane 4.7*10
-2
 
 
 
